NCT#,phase,condition,sponsor,start_date,mesh_list,criterion
NCT00000172,Phase 3,Alzheimer Disease,"Janssen, LP",unknown,Alzheimer Disease;Galantamine, Probable Alzheimer's disease
NCT00000172,Phase 3,Alzheimer Disease,"Janssen, LP",unknown,Alzheimer Disease;Galantamine, Mini-Mental State Examination (MMSE) 10-22 and ADAS greater than or equal to 18
NCT00000172,Phase 3,Alzheimer Disease,"Janssen, LP",unknown,Alzheimer Disease;Galantamine, Alzheimer's Disease Assessment Scale cognitive portion (ADAS-cog-11) score of at least 18
NCT00000172,Phase 3,Alzheimer Disease,"Janssen, LP",unknown,Alzheimer Disease;Galantamine, Opportunity for Activities of Daily Living
NCT00000172,Phase 3,Alzheimer Disease,"Janssen, LP",unknown,Alzheimer Disease;Galantamine, Caregiver
NCT00000172,Phase 3,Alzheimer Disease,"Janssen, LP",unknown,Alzheimer Disease;Galantamine," Subjects who live with or have regular daily visits from a responsible caregiver (visit frequency: preferably daily but at least 5 days/week). This includes a friend or relative or paid personnel. The caregiver should be capable of assisting with the subject's medication, prepared to attend with the subject for assessments, and willing to provide information about the subject."
NCT00000173,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),Mar-99,Alzheimer Disease;Cognitive Dysfunction;Vitamin E;Donepezil, Memory complaints and memory difficulties which are verified by an informant.
NCT00000173,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),Mar-99,Alzheimer Disease;Cognitive Dysfunction;Vitamin E;Donepezil," Abnormal memory function documented by scoring below the education adjusted cutoff on the Logical Memory II subscale (Delayed Paragraph Recall) from the Wechsler Memory Scale - Revised (the maximum score is 25): a) less than or equal to 8 for 16 or more years of education, b) less than or equal to 4 for 8-15 years of education, c) less than or equal to 2 for 0-7 years of education."
NCT00000173,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),Mar-99,Alzheimer Disease;Cognitive Dysfunction;Vitamin E;Donepezil, Mini-Mental Exam score between 24 and 30 (inclusive) (Exceptions may be made for subjects with less than 8 years of education at the discretion of the project director.).
NCT00000173,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),Mar-99,Alzheimer Disease;Cognitive Dysfunction;Vitamin E;Donepezil, Clinical Dementia Rating = 0.5. Memory Box score must be at least 0.5.
NCT00000173,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),Mar-99,Alzheimer Disease;Cognitive Dysfunction;Vitamin E;Donepezil, General cognition and functional performance sufficiently preserved such that a diagnosis of Alzheimer's disease cannot be made by the site physician at the time of the screening visit.
NCT00000173,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),Mar-99,Alzheimer Disease;Cognitive Dysfunction;Vitamin E;Donepezil, No significant cerebrovascular disease: Modified Hachinski score of less than or equal to 4.
NCT00000173,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),Mar-99,Alzheimer Disease;Cognitive Dysfunction;Vitamin E;Donepezil, Age between 55 and 90 (inclusive).
NCT00000173,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),Mar-99,Alzheimer Disease;Cognitive Dysfunction;Vitamin E;Donepezil," Permitted medications stable for at least 1 month prior to screening. In particular: a) Subjects may take stable doses of antidepressants lacking significant anticholinergic side effects (if they are not currently depressed and do not have a history of major depression within the past 2 years). b) Estrogen replacement therapy is permissible. c) Ginkgo biloba is permissible, but discouraged."
NCT00000173,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),Mar-99,Alzheimer Disease;Cognitive Dysfunction;Vitamin E;Donepezil, Hamilton Depression rating scale score of less than or equal to 12 on the 17-item scale.
NCT00000173,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),Mar-99,Alzheimer Disease;Cognitive Dysfunction;Vitamin E;Donepezil," Informant is available who has frequent contact with the subject (e.g. an average of 10 hours per week or more), agrees to monitor administration of study drug, observe for adverse events, and accompany the subject to all clinic visits for the duration of the protocol."
NCT00000173,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),Mar-99,Alzheimer Disease;Cognitive Dysfunction;Vitamin E;Donepezil," CT or MRI scans within 12 months prior to screening without evidence of infection, infarction, or other focal lesions and without clinical symptoms suggestive of intervening neurological disease. A lacune in a non-critical brain area which is not believed to contribute to the subject's cognitive impairment is permissible."
NCT00000173,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),Mar-99,Alzheimer Disease;Cognitive Dysfunction;Vitamin E;Donepezil, Adequate visual and auditory acuity to allow neuropsychological testing.
NCT00000173,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),Mar-99,Alzheimer Disease;Cognitive Dysfunction;Vitamin E;Donepezil, Good general health with no additional diseases expected to interfere with the study.
NCT00000173,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),Mar-99,Alzheimer Disease;Cognitive Dysfunction;Vitamin E;Donepezil," Normal B12, RPR, and Thyroid Function Tests or without any clinically significant abnormalities that would be expected to interfere with the study."
NCT00000173,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),Mar-99,Alzheimer Disease;Cognitive Dysfunction;Vitamin E;Donepezil, ECG without clinically significant abnormalities that would be expected to interfere with the study.
NCT00000173,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),Mar-99,Alzheimer Disease;Cognitive Dysfunction;Vitamin E;Donepezil," Subject is not pregnant, lactating, or of childbearing potential (i.e. women must be two years post-menopausal or surgically sterile)."
NCT00000173,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),Mar-99,Alzheimer Disease;Cognitive Dysfunction;Vitamin E;Donepezil," Agreement not to take other vitamin supplements (including Vitamin E), multivitamins, other than those provided by the study."
NCT00000177,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),Oct-95,Alzheimer Disease;Estrogens," Women with a diagnosis of Alzheimer's disease who currently are not taking estrogen replacement therapy, who have had a hysterectomy, and who are in stable general health."
NCT00000178,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),unknown,Alzheimer Disease;Prednisone, Patients with Alzheimer's disease who are in stable medical condition
NCT00000179,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),unknown,Alzheimer Disease;Haloperidol;Haloperidol decanoate;Trazodone, Memory problem consistent with a probable diagnosis of Alzheimer's disease (AD)
NCT00000179,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),unknown,Alzheimer Disease;Haloperidol;Haloperidol decanoate;Trazodone, Agitation symptoms for at least the past 2 weeks
NCT00000179,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),unknown,Alzheimer Disease;Haloperidol;Haloperidol decanoate;Trazodone, Patient has caregiver who can participate
NCT00000179,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),unknown,Alzheimer Disease;Haloperidol;Haloperidol decanoate;Trazodone, Patient lives in the same household as the caregiver
NCT00004845,Phase 2/Phase 3,Alzheimer Disease,National Institute on Aging (NIA),unknown,Alzheimer Disease;Naproxen;Rofecoxib, NINCDS/ADRDA criteria for probable AD
NCT00004845,Phase 2/Phase 3,Alzheimer Disease,National Institute on Aging (NIA),unknown,Alzheimer Disease;Naproxen;Rofecoxib," MMSE between 13 and 26, inclusive"
NCT00004845,Phase 2/Phase 3,Alzheimer Disease,National Institute on Aging (NIA),unknown,Alzheimer Disease;Naproxen;Rofecoxib, Stable medical condition for 3 months
NCT00004845,Phase 2/Phase 3,Alzheimer Disease,National Institute on Aging (NIA),unknown,Alzheimer Disease;Naproxen;Rofecoxib, Screening visit
NCT00004845,Phase 2/Phase 3,Alzheimer Disease,National Institute on Aging (NIA),unknown,Alzheimer Disease;Naproxen;Rofecoxib," Physically acceptable for this study as confirmed by medical history, physical exam, neurologic exam, and clinical laboratory tests"
NCT00004845,Phase 2/Phase 3,Alzheimer Disease,National Institute on Aging (NIA),unknown,Alzheimer Disease;Naproxen;Rofecoxib, Supervision available for administration of study medications; caregiver/informant to accompany patient to all scheduled visits
NCT00004845,Phase 2/Phase 3,Alzheimer Disease,National Institute on Aging (NIA),unknown,Alzheimer Disease;Naproxen;Rofecoxib, Fluent in English or Spanish
NCT00004845,Phase 2/Phase 3,Alzheimer Disease,National Institute on Aging (NIA),unknown,Alzheimer Disease;Naproxen;Rofecoxib, Age greater than or equal to 55 years old
NCT00004845,Phase 2/Phase 3,Alzheimer Disease,National Institute on Aging (NIA),unknown,Alzheimer Disease;Naproxen;Rofecoxib, Modified Hachinski of less than or equal to 4
NCT00004845,Phase 2/Phase 3,Alzheimer Disease,National Institute on Aging (NIA),unknown,Alzheimer Disease;Naproxen;Rofecoxib, CT or MRI since onset of memory impairment demonstrating absence of clinically significant focal lesion
NCT00004845,Phase 2/Phase 3,Alzheimer Disease,National Institute on Aging (NIA),unknown,Alzheimer Disease;Naproxen;Rofecoxib, Able to complete baseline assessments
NCT00004845,Phase 2/Phase 3,Alzheimer Disease,National Institute on Aging (NIA),unknown,Alzheimer Disease;Naproxen;Rofecoxib, 6 years of education or work history sufficient to exclude mental retardation
NCT00004845,Phase 2/Phase 3,Alzheimer Disease,National Institute on Aging (NIA),unknown,Alzheimer Disease;Naproxen;Rofecoxib, Able to ingest oral medication
NCT00006187,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease, Patient is male or female and at least 50 years of age or older
NCT00006187,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease, Female patients must be postmenopausal or surgically sterilized
NCT00006187,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease, Clinical diagnosis of AD
NCT00006187,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease, Patient must be in good health except for AD diagnosis
NCT00006187,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease, Patient must have informant/caregiver who can monitor and assist patient during the study
NCT00006399,Phase 2,Alzheimer Disease,National Center for Research Resources (NCRR),Sep-99,Alzheimer Disease;Donepezil;Progesterone;Estrogens, Normal volunteers and women with mild Alzheimer's disease:
NCT00006399,Phase 2,Alzheimer Disease,National Center for Research Resources (NCRR),Sep-99,Alzheimer Disease;Donepezil;Progesterone;Estrogens, Non-smoker
NCT00006399,Phase 2,Alzheimer Disease,National Center for Research Resources (NCRR),Sep-99,Alzheimer Disease;Donepezil;Progesterone;Estrogens, No use of Hormone Replacement Therapy for at least one year
NCT00006399,Phase 2,Alzheimer Disease,National Center for Research Resources (NCRR),Sep-99,Alzheimer Disease;Donepezil;Progesterone;Estrogens, No menses for at least one year
NCT00006399,Phase 2,Alzheimer Disease,National Center for Research Resources (NCRR),Sep-99,Alzheimer Disease;Donepezil;Progesterone;Estrogens, Normal mammogram within the last year
NCT00006399,Phase 2,Alzheimer Disease,National Center for Research Resources (NCRR),Sep-99,Alzheimer Disease;Donepezil;Progesterone;Estrogens, minimum age is 45 for patients with Alzheimer's disease; 50 for normal volunteers
NCT00006399,Phase 2,Alzheimer Disease,National Center for Research Resources (NCRR),Sep-99,Alzheimer Disease;Donepezil;Progesterone;Estrogens, Maximum age is 85 for patients with Alzheimer's disease; there is no maximum age for normal volunteers.
NCT00007189,Phase 3,Alzheimer Disease,Seattle Institute for Biomedical and Clinical Research,Jan-01,Alzheimer Disease;Celecoxib;Naproxen, Aged 70 years or older.
NCT00007189,Phase 3,Alzheimer Disease,Seattle Institute for Biomedical and Clinical Research,Jan-01,Alzheimer Disease;Celecoxib;Naproxen," Family history of parent, brother, or sister who has, or had, serious age-related memory loss, senility, dementia, or Alzheimer's disease."
NCT00007189,Phase 3,Alzheimer Disease,Seattle Institute for Biomedical and Clinical Research,Jan-01,Alzheimer Disease;Celecoxib;Naproxen," Study partner available to provide information on the cognitive status of the participant and to assist with monitoring of trial medications, if needed."
NCT00007189,Phase 3,Alzheimer Disease,Seattle Institute for Biomedical and Clinical Research,Jan-01,Alzheimer Disease;Celecoxib;Naproxen, Sufficient fluency in written and spoken English to participate in study visits and neuropsychological testing.
NCT00007189,Phase 3,Alzheimer Disease,Seattle Institute for Biomedical and Clinical Research,Jan-01,Alzheimer Disease;Celecoxib;Naproxen," Willingness to limit use of the following for the duration of the study: vitamin E (at doses greater than 400 IU per day), non-aspirin NSAIDs, histamine H2 receptor antagonists (Tagamet, for example), corticosteroids, anti-inflammatory or analgesic doses of aspirin (greater than 81 mg per day), Ginkgo biloba extracts"
NCT00007189,Phase 3,Alzheimer Disease,Seattle Institute for Biomedical and Clinical Research,Jan-01,Alzheimer Disease;Celecoxib;Naproxen," Ability and intention to participate in regular study visits, in the opinion of the study physician."
NCT00007189,Phase 3,Alzheimer Disease,Seattle Institute for Biomedical and Clinical Research,Jan-01,Alzheimer Disease;Celecoxib;Naproxen, Provision of informed consent.
NCT00010803,Phase 3,Alzheimer's Disease,National Center for Complementary and Integrative Health (NCCIH),Oct-00,Alzheimer Disease, Non-demented participants
NCT00010803,Phase 3,Alzheimer's Disease,National Center for Complementary and Integrative Health (NCCIH),Oct-00,Alzheimer Disease, Willing to participate in a seven-year follow-up trial of Ginkgo Biloba
NCT00010803,Phase 3,Alzheimer's Disease,National Center for Complementary and Integrative Health (NCCIH),Oct-00,Alzheimer Disease, English is their usual language
NCT00010803,Phase 3,Alzheimer's Disease,National Center for Complementary and Integrative Health (NCCIH),Oct-00,Alzheimer Disease, Willing informant who has frequent contact with the participant
NCT00024531,Phase 2,Alzheimer Disease,Institute for the Study of Aging (ISOA),Oct-00,Alzheimer Disease;Atorvastatin;Calcium," Prior to participation in this study, each prospective study individual must sign an informed consent form."
NCT00024531,Phase 2,Alzheimer Disease,Institute for the Study of Aging (ISOA),Oct-00,Alzheimer Disease;Atorvastatin;Calcium, Diagnosis of probable or possible Alzheimer's disease according to NINDS-ADRDA and DSM-IV criteria.
NCT00024531,Phase 2,Alzheimer Disease,Institute for the Study of Aging (ISOA),Oct-00,Alzheimer Disease;Atorvastatin;Calcium, Not actively participating in another clinical drug trial.
NCT00024531,Phase 2,Alzheimer Disease,Institute for the Study of Aging (ISOA),Oct-00,Alzheimer Disease;Atorvastatin;Calcium, MMSE range 12-28 at entry.
NCT00024531,Phase 2,Alzheimer Disease,Institute for the Study of Aging (ISOA),Oct-00,Alzheimer Disease;Atorvastatin;Calcium, Hachinski Modified Ischemic score less than  or =4.
NCT00024531,Phase 2,Alzheimer Disease,Institute for the Study of Aging (ISOA),Oct-00,Alzheimer Disease;Atorvastatin;Calcium, Accompanied by appropriate caregiver who can aid in administration of medication and make assessments.
NCT00024531,Phase 2,Alzheimer Disease,Institute for the Study of Aging (ISOA),Oct-00,Alzheimer Disease;Atorvastatin;Calcium," Good general health as evidenced by physical, neurological and clinical laboratory examination."
NCT00024531,Phase 2,Alzheimer Disease,Institute for the Study of Aging (ISOA),Oct-00,Alzheimer Disease;Atorvastatin;Calcium, Education level greater than  or = 9th grade or equivalent.
NCT00024531,Phase 2,Alzheimer Disease,Institute for the Study of Aging (ISOA),Oct-00,Alzheimer Disease;Atorvastatin;Calcium, Fluent in the English language.
NCT00024531,Phase 2,Alzheimer Disease,Institute for the Study of Aging (ISOA),Oct-00,Alzheimer Disease;Atorvastatin;Calcium, Reliable caregiver.
NCT00024531,Phase 2,Alzheimer Disease,Institute for the Study of Aging (ISOA),Oct-00,Alzheimer Disease;Atorvastatin;Calcium, Able to complete neuropsychological tests.
NCT00024531,Phase 2,Alzheimer Disease,Institute for the Study of Aging (ISOA),Oct-00,Alzheimer Disease;Atorvastatin;Calcium, Ambulatory.
NCT00024531,Phase 2,Alzheimer Disease,Institute for the Study of Aging (ISOA),Oct-00,Alzheimer Disease;Atorvastatin;Calcium, On stable doses of medications for the treatment of non-excluded medical conditions for four weeks prior to screening.
NCT00024531,Phase 2,Alzheimer Disease,Institute for the Study of Aging (ISOA),Oct-00,Alzheimer Disease;Atorvastatin;Calcium, Able to participate in all scheduled evaluations.
NCT00024531,Phase 2,Alzheimer Disease,Institute for the Study of Aging (ISOA),Oct-00,Alzheimer Disease;Atorvastatin;Calcium, Geriatric Depression Scale less than  or = 20.
NCT00024531,Phase 2,Alzheimer Disease,Institute for the Study of Aging (ISOA),Oct-00,Alzheimer Disease;Atorvastatin;Calcium, Not exceeding 400 IU of Vitamin E for 30 days.
NCT00024531,Phase 2,Alzheimer Disease,Institute for the Study of Aging (ISOA),Oct-00,Alzheimer Disease;Atorvastatin;Calcium," For patients currently taking donepezil, they must remain on a stable dose for at least three months. Individuals taking stable doses of other cholinesterase inhibitors can be included, but no study subject may initiate use of any cholinesterase inhibitor after entrance to trial."
NCT00024531,Phase 2,Alzheimer Disease,Institute for the Study of Aging (ISOA),Oct-00,Alzheimer Disease;Atorvastatin;Calcium, Individuals of both sexes over 50 years of age will be eligible.
NCT00024531,Phase 2,Alzheimer Disease,Institute for the Study of Aging (ISOA),Oct-00,Alzheimer Disease;Atorvastatin;Calcium, Exclusion criteria:
NCT00024531,Phase 2,Alzheimer Disease,Institute for the Study of Aging (ISOA),Oct-00,Alzheimer Disease;Atorvastatin;Calcium, Significant neurological or psychiatric disease other than Alzheimer's disease.
NCT00024531,Phase 2,Alzheimer Disease,Institute for the Study of Aging (ISOA),Oct-00,Alzheimer Disease;Atorvastatin;Calcium, Patients with known or suspected Parkinsons's disease or dementia with Lewy bodies.
NCT00024531,Phase 2,Alzheimer Disease,Institute for the Study of Aging (ISOA),Oct-00,Alzheimer Disease;Atorvastatin;Calcium, Significant systemic illness (including uncontrolled hypertension) or organ failure.
NCT00024531,Phase 2,Alzheimer Disease,Institute for the Study of Aging (ISOA),Oct-00,Alzheimer Disease;Atorvastatin;Calcium," History of mental illness within one year or history of significant untreated cardiac or thromboembolic vascular disease (arrythmias, unstable angina, CVA, deep venous thrombosis, or pulmonary embolus)."
NCT00024531,Phase 2,Alzheimer Disease,Institute for the Study of Aging (ISOA),Oct-00,Alzheimer Disease;Atorvastatin;Calcium," Current chronic use of anti-cholinergic medications (anti-histamines, and Artane or Cogentin). Stable doses of anxiolytics, sedatives, hypnotics, antipsychotics and SSRI antidepressants are acceptable. The use of any antipsychotics or tricyclic anti-depressants must be reviewed prior to entry."
NCT00024531,Phase 2,Alzheimer Disease,Institute for the Study of Aging (ISOA),Oct-00,Alzheimer Disease;Atorvastatin;Calcium, Diagnosis of major depression according to DSM-IV criteria in the last two years.
NCT00024531,Phase 2,Alzheimer Disease,Institute for the Study of Aging (ISOA),Oct-00,Alzheimer Disease;Atorvastatin;Calcium, Allergies to atorvastatin or HMG CoA reductase inhibitors.
NCT00024531,Phase 2,Alzheimer Disease,Institute for the Study of Aging (ISOA),Oct-00,Alzheimer Disease;Atorvastatin;Calcium, Pregnant women.
NCT00024531,Phase 2,Alzheimer Disease,Institute for the Study of Aging (ISOA),Oct-00,Alzheimer Disease;Atorvastatin;Calcium, History of head injury.
NCT00024531,Phase 2,Alzheimer Disease,Institute for the Study of Aging (ISOA),Oct-00,Alzheimer Disease;Atorvastatin;Calcium, On a cholesterol lowering drug at time of enrollment.
NCT00024531,Phase 2,Alzheimer Disease,Institute for the Study of Aging (ISOA),Oct-00,Alzheimer Disease;Atorvastatin;Calcium, History of significant liver disease and or elevated transaminases.
NCT00024531,Phase 2,Alzheimer Disease,Institute for the Study of Aging (ISOA),Oct-00,Alzheimer Disease;Atorvastatin;Calcium, Cholesterol level lower than 90 mg% at initial screening
NCT00031018,Phase 2,Alzheimer's Disease,National Center for Research Resources (NCRR),unknown,Alzheimer Disease;Memory Disorders;Cognitive Dysfunction;Interferon alpha-2;Donepezil," Males and females, age 50 or greater. Possible or probable dementia of the Alzheimer Type defined by NINDS-ARDA criteria with dementia of at least one year duration."
NCT00031018,Phase 2,Alzheimer's Disease,National Center for Research Resources (NCRR),unknown,Alzheimer Disease;Memory Disorders;Cognitive Dysfunction;Interferon alpha-2;Donepezil," Folstein MMSE Score 10-24 inclusive. Vision, hearing, speech, motor function and comprehension must be adequate for compliance with all testing procedures."
NCT00036114,Phase 3,Alzheimer Disease,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Mar-00,Alzheimer Disease;Aripiprazole, Institutionalized patients with Alzheimer's
NCT00041678,Phase 3,Alzheimer Disease,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Jan-00,Alzheimer Disease;Aripiprazole, Institutionalized patients with Alzheimer's Disease
NCT00051909,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Nov-02,Alzheimer Disease, Must have a clinical diagnosis of Alzheimer's Disease
NCT00051909,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Nov-02,Alzheimer Disease, Must be at least 50 years of age
NCT00051909,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Nov-02,Alzheimer Disease, Must fluently read and speak English
NCT00051909,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Nov-02,Alzheimer Disease, Must have a reliable caregiver
NCT00056225,Phase 3,Alzheimer's Disease,National Institute on Aging (NIA),Jan-03,Alzheimer Disease;Vitamins;Vitamin B 12;Vitamin B 6;Pyridoxal;Pyridoxine;Vitamin B Complex, National Institute of Neurological Disorders and Stroke (NINDS)/Alzheimer's Disease and Related Disorders Association (ADRDA) criteria for probable Alzheimer's disease.
NCT00056225,Phase 3,Alzheimer's Disease,National Institute on Aging (NIA),Jan-03,Alzheimer Disease;Vitamins;Vitamin B 12;Vitamin B 6;Pyridoxal;Pyridoxine;Vitamin B Complex," Mini-Mental Status Examination (MMSE) score between 14 and 26, inclusive"
NCT00056225,Phase 3,Alzheimer's Disease,National Institute on Aging (NIA),Jan-03,Alzheimer Disease;Vitamins;Vitamin B 12;Vitamin B 6;Pyridoxal;Pyridoxine;Vitamin B Complex, Stable medical condition for 3 months
NCT00056225,Phase 3,Alzheimer's Disease,National Institute on Aging (NIA),Jan-03,Alzheimer Disease;Vitamins;Vitamin B 12;Vitamin B 6;Pyridoxal;Pyridoxine;Vitamin B Complex, Stable medications for 4 weeks prior to the screening visit
NCT00056225,Phase 3,Alzheimer's Disease,National Institute on Aging (NIA),Jan-03,Alzheimer Disease;Vitamins;Vitamin B 12;Vitamin B 6;Pyridoxal;Pyridoxine;Vitamin B Complex," Physically acceptable for this study as confirmed by medical history, physical exam, neurologic exam and clinical laboratory tests"
NCT00056225,Phase 3,Alzheimer's Disease,National Institute on Aging (NIA),Jan-03,Alzheimer Disease;Vitamins;Vitamin B 12;Vitamin B 6;Pyridoxal;Pyridoxine;Vitamin B Complex, Supervision available for administration of study medications
NCT00056225,Phase 3,Alzheimer's Disease,National Institute on Aging (NIA),Jan-03,Alzheimer Disease;Vitamins;Vitamin B 12;Vitamin B 6;Pyridoxal;Pyridoxine;Vitamin B Complex, Study partner to accompany subject to all scheduled visits
NCT00056225,Phase 3,Alzheimer's Disease,National Institute on Aging (NIA),Jan-03,Alzheimer Disease;Vitamins;Vitamin B 12;Vitamin B 6;Pyridoxal;Pyridoxine;Vitamin B Complex, Fluent in English or Spanish
NCT00056225,Phase 3,Alzheimer's Disease,National Institute on Aging (NIA),Jan-03,Alzheimer Disease;Vitamins;Vitamin B 12;Vitamin B 6;Pyridoxal;Pyridoxine;Vitamin B Complex, Modified Hachinski equal to or less than 4 CT or magnetic resonance imaging (MRI) since onset of memory impairment demonstrating absence of clinically significant focal lesion
NCT00056225,Phase 3,Alzheimer's Disease,National Institute on Aging (NIA),Jan-03,Alzheimer Disease;Vitamins;Vitamin B 12;Vitamin B 6;Pyridoxal;Pyridoxine;Vitamin B Complex, Able to complete baseline assessments
NCT00056225,Phase 3,Alzheimer's Disease,National Institute on Aging (NIA),Jan-03,Alzheimer Disease;Vitamins;Vitamin B 12;Vitamin B 6;Pyridoxal;Pyridoxine;Vitamin B Complex, 6 years of education or work history sufficient to exclude mental retardation
NCT00056225,Phase 3,Alzheimer's Disease,National Institute on Aging (NIA),Jan-03,Alzheimer Disease;Vitamins;Vitamin B 12;Vitamin B 6;Pyridoxal;Pyridoxine;Vitamin B Complex, Able to ingest oral medication
NCT00056329,Phase 3,Alzheimer Disease,New York State Institute for Basic Research,Apr-02,Alzheimer Disease;Down Syndrome;Syndrome;Vitamin E;Tocopherols, Presence of clinically determined Down syndrome (karyotypes optional).
NCT00056329,Phase 3,Alzheimer Disease,New York State Institute for Basic Research,Apr-02,Alzheimer Disease;Down Syndrome;Syndrome;Vitamin E;Tocopherols, Medically stable.
NCT00056329,Phase 3,Alzheimer Disease,New York State Institute for Basic Research,Apr-02,Alzheimer Disease;Down Syndrome;Syndrome;Vitamin E;Tocopherols, Medications stable over 3 months.
NCT00056329,Phase 3,Alzheimer Disease,New York State Institute for Basic Research,Apr-02,Alzheimer Disease;Down Syndrome;Syndrome;Vitamin E;Tocopherols, Appropriately signed and witnessed consent form.
NCT00056329,Phase 3,Alzheimer Disease,New York State Institute for Basic Research,Apr-02,Alzheimer Disease;Down Syndrome;Syndrome;Vitamin E;Tocopherols, Involvement/cooperation of informant/caregiver.
NCT00063310,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Mar-03,Alzheimer Disease;Leuprolide, Patients who satisfy all of the inclusion criteria listed below will be eligible for entry into the trial. Patients will be considered eligible if:
NCT00063310,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Mar-03,Alzheimer Disease;Leuprolide," They give their consent by signing the IRB-approved Informed Consent Form and the responsible caregiver also signs the consent form; or, if the patient is judged by the Investigator to be unable to give consent, if the legally authorized representative gives consent by signing the consent form and the patient gives assent, in accord with local regulations;"
NCT00063310,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Mar-03,Alzheimer Disease;Leuprolide, They are female;
NCT00063310,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Mar-03,Alzheimer Disease;Leuprolide, They are 65 years of age or older;
NCT00063310,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Mar-03,Alzheimer Disease;Leuprolide, They have a diagnosis of probable AD according to the National Institute of Neurological Disorders-Alzheimer's Disease and Related Disorders Association (NINDS-ADRDA) criteria and the Investigator ascertains that the condition was present at least 6 months prior to screening;
NCT00063310,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Mar-03,Alzheimer Disease;Leuprolide," They are taking a cholinesterase inhibitor, they began taking it at least 90 days prior to baseline and, in the Investigator's opinion, the dosage will likely remain stable throughout the trial;"
NCT00063310,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Mar-03,Alzheimer Disease;Leuprolide," They are taking other drugs or substances that have purported cognition enhancing properties such as ginkgo biloba and Vitamin E, they began taking it at least 60 days prior to baseline and, in the Investigator's opinion, the dosage will likely remain stable throughout the trial;"
NCT00063310,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Mar-03,Alzheimer Disease;Leuprolide, They score no lower than 12 or higher than 24 on the (MMSE) administered at the screening visit;
NCT00063310,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Mar-03,Alzheimer Disease;Leuprolide," They have had a brain imaging study (CT scan, MRI or PET) performed at the time of their initial diagnosis of AD or after that time, and the findings were consistent with a diagnosis of probable AD, or, if a brain imaging study has not been performed, one will be performed during the screening process;"
NCT00063310,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Mar-03,Alzheimer Disease;Leuprolide," Their Rosen Modified Hachinski score was 4 or lower at the screening visit, supporting the Investigator's clinical judgment that the patient's dementia is probable AD and not of vascular origin;"
NCT00063310,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Mar-03,Alzheimer Disease;Leuprolide, They are fluent in English or Spanish and completed at least 6 years of education;
NCT00063310,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Mar-03,Alzheimer Disease;Leuprolide," They live at home or in a congregate living facility for requirements other than skilled nursing care, and have a caregiver who sees the patient at least three time a week for a total of at least 10 hours and can sign the consent form, provide information pertinent to the patient's cognitive status, accompany the patient on clinic visits and participate in the evaluations;"
NCT00063310,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Mar-03,Alzheimer Disease;Leuprolide," Their hormone replacement therapy (HRT), if any, has been stable for at least 60 days prior to baseline, and is not expected to change during the course of the trial;"
NCT00063310,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Mar-03,Alzheimer Disease;Leuprolide, They score less than 15 on the Hamilton Depression Scale (17-item version) (HamD) administered as part of the screening evaluation;
NCT00063310,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Mar-03,Alzheimer Disease;Leuprolide," Absorptiometry (dual-energy x-ray absorpometry (DEXA) scan), performed at screening, was within normal limits (i.e., a T- score of no less than -2.0); or, if their DEXA measure was abnormally low, they were receiving treatment for osteoporosis for at least 3 weeks and that treatment is not expected to change during the course of the trial; or, if their DEXA measure was abnormally low and they are not receiving treatment for osteoporosis, they may enter the trial after 3 weeks of treatment provided that assessments of the HamD, concomitant medications, ECG tracing and laboratory tests performed within 45 days of baseline show that they are eligible."
NCT00063310,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Mar-03,Alzheimer Disease;Leuprolide, values on their screening laboratory tests do not indicate significant medical conditions that would interfere with their participation in and completion of the study
NCT00065767,Phase 2/Phase 3,Alzheimer Disease,"University of Wisconsin, Madison",Sep-01,Alzheimer Disease;Raloxifene Hydrochloride, Postmenopausal women with Alzheimer's disease and without other dementias (diagnosed by study staff or from an outside clinic)
NCT00065767,Phase 2/Phase 3,Alzheimer Disease,"University of Wisconsin, Madison",Sep-01,Alzheimer Disease;Raloxifene Hydrochloride, Mini Mental Status Exam score greater than 15/30
NCT00066157,Phase 2/Phase 3,Alzheimer Disease,"University of Wisconsin, Madison",Sep-01,Alzheimer Disease;Medroxyprogesterone Acetate;Estradiol 17 beta-cypionate;Estradiol 3-benzoate;Medroxyprogesterone;Estradiol;Polyestradiol phosphate;Estrogens;Progesterone, Postmenopausal women with Alzheimer's disease and without other dementias (diagnosed by study staff or from an outside clinic)
NCT00066157,Phase 2/Phase 3,Alzheimer Disease,"University of Wisconsin, Madison",Sep-01,Alzheimer Disease;Medroxyprogesterone Acetate;Estradiol 17 beta-cypionate;Estradiol 3-benzoate;Medroxyprogesterone;Estradiol;Polyestradiol phosphate;Estrogens;Progesterone, Mini Mental State Examination score greater than 15/30
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid, Probable AD by National Institute of Neurological Disorders and Stroke (NINDS)-Alzheimer's Disease and Related Disorder Association (ADRDA) criteria.
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid, Males or females.
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid, greater than  55 and less than  90 years of age.
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid, Weight greater than  40 kg (88.2 lbs.).
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid," Residing in the community at Screen and Baseline. Participants may reside in assisted living facilities, but not in long-term care nursing facilities or assisted living facilities that provide intensive support for people with dementia nor may they reside in a secure unit necessary for behavioral management."
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid, Mini Mental State Examination (MMSE) at Screen and Baseline 12-20 inclusive.
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid, Computed tomography (CT) or magnetic resonance imaging (MRI) since onset of dementia consistent with the diagnosis of probable AD. Single lacunes in non-critical areas and non-specific white matter changes that are interpreted as age-related are not grounds for exclusion. Any ambiguous scan results must be reviewed with the Project Director.
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid, Fluent in English or Spanish.
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid, Supervision available for study medication.
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid, Study partner to accompany subject to all visits.
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid, Study partner must have in-person contact with the participant greater than  2 days/week.
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid, Able to ingest oral medication.
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid," Total Neuropsychiatric Inventory (NPI) score for previous 4 weeks less than  8 at Screening, and for the period between Screening and Baseline."
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid," NPI item score for the items assessing delusions, hallucinations, agitation/aggression all greater than or equal to 1 for 4 weeks prior to Screening (less than once/week and mild severity at most) and for the period between Screening and Baseline."
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid," Scores of greater than or equal to 1 for items rating delusions, hallucinations, and agitation/aggression taken from the NPI, modified to assess these features since onset of illness. This will be derived from a second interview with the modified NPI. (Agitation/psychosis during episodes of delirium are not considered exclusionary.)."
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide, Patients who satisfy all of the inclusion criteria listed below will be eligible for entry into the trial.
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide," Patient and responsible caregiver can give their consent by signing the IRB-approved Informed Consent Form; or, when the patient is judged by the Investigator to be unable to give consent, the legally authorized representative gives consent by signing the consent form and the patient gives assent, in accord with local regulations;"
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide, Male;
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide, 65 years of age or older;
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide," Diagnosis of probable AD according to the National Institute of Neurological Disorders-Alzheimer's Disease and Related Disorders Association (NINDS-ADRDA) criteria, and the Investigator ascertains that the condition was present at least 6 months prior to screening;"
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide," Taking a drug for the treatment of AD, such as a cholinesterase inhibitor and/or Memantine, which they began taking at least 90 days prior to baseline and, in the Investigator's opinion, the dosage will likely remain stable throughout the trial; or, they have never taken such a drug or stopped taking it at least 90 days prior to baseline and will likely refrain from taking such treatment throughout the trial;"
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide," Taking other drugs or substances that have purported cognition-enhancing properties such as ginkgo biloba or Vitamin E, which they began taking at least 60 days prior to baseline and, in the Investigator's opinion, the dosage will likely remain stable throughout the trial; or, they have never taken such a drug or stopped taking it at least 90 days prior to baseline and will likely refrain from taking such treatment throughout the trial;"
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide, Mini Mental State Examination (MMSE) score of 12 to 24 (inclusive) at the screening visit;
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide," Brain imaging study (CT scan, MRI or PET) performed at the time of their initial diagnosis of AD or after that time, and the findings were consistent with a diagnosis of probable AD, or, if a brain imaging study has not been performed, one will be performed during the screening process;"
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide," Rosen Modified Hachinski score of 4 or lower at the screening visit, supporting the Investigator's clinical judgment that the patient's dementia is probable AD and not of vascular origin;"
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide, Fluent in English or Spanish and completed at least 6 years of education;
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide," Live at home or in a congregate living facility for requirements other than skilled nursing care, and have a caregiver who sees the patient at least three times a week for a total of at least 10 hours and can sign the consent form, provide information pertinent to the patient's cognitive status, accompany the patient on clinic visits, and participate in the evaluations."
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide, Hamilton Depression Scale (17-item version) (HamD) score of 14 or less at the screening visit;
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide," DEXA scan, performed at screening, within normal limits (i.e., a T-score of greater than -2.0); or, if their DEXA measure was abnormally low (i.e., a T-score of -2.0 or lower), in either a lumbar vertebra or hip, to specifically include a T-score for the femoral neck), they were receiving treatment for osteoporosis/osteopenia for at least 3 weeks prior to baseline and that treatment is not expected to change during the course of the trial; or, if their DEXA measure was abnormally low and they are not receiving treatment for osteoporosis/osteopenia, they may proceed to baseline after 3 weeks of treatment for osteoporosis/osteopenia provided that all inclusion/exclusion criteria are met, including assessment of the HamD, concomitant medications, ECG and laboratory tests performed within 45 days of baseline show that they are eligible;"
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide, Screening laboratory test values do not indicate significant medical conditions that would interfere with their participation in and completion of the study.
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide, Exclusion criteria:
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide, Patients with any of the exclusion criteria listed below will be ineligible for entry into the study.
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide, Female;
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide, Younger than 65 years of age;
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide," Significant neurological disease affecting the brain or psychiatric disease other than AD, such as major depression, schizophrenia, epilepsy, Parkinson's disease, or stroke;"
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide, Current significant systemic illness or symptoms of organ failure;
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide, Screening ECG shows evidence of a serious and/or unstable condition or a recent (within 6 months) myocardial infarction as determined by the Investigator;
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide, PSA test result exceeds 4.0 ng/mL;
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide, Receiving testosterone;
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide," Taking a drug for the treatment of AD for less than 90 days prior to baseline; or, in the opinion of the Investigator, they are likely to either require a change in dose or discontinuation of the drug;"
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide," Never received cholinesterase inhibitor treatment, and the likelihood of their starting such treatment during the study is other than low, or they have taken and discontinued cholinesterase inhibitor treatment in the past and the likelihood of their resuming cholinesterase inhibitor treatment during the study is other than low;"
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide," Started or changed within 60 days prior to the screening visit the dosage of any drug (including OTC) that affects cognitive function, such as neuroleptics, antidepressants, anxiolytics, sedatives, hypnotics, anti-convulsants, centrally acting antihypertensive agents such as clonidine and Aldomet; or other medications that have been shown to have possible effects on cognition such as Vitamin E, nonsteroidal anti-inflammatory drugs, and statins, or if, in the Investigator's opinion, the dosage of such medication is likely to be changed during the course of this trial. Any changes in the dosage of any of these drugs during the course of the trial and the reason for the change must be fully recorded in the concomitant medication page of the patient's case report form (CRF). If a drug that affects cognition (e.g., a hypnotic or anxiolytic drug) is given on a PRN basis, such treatment should be interrupted for 12 hours before a visit, if possible;"
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide, Taking coumadin or anti-Parkinsonian medications;
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide," Have taken other investigational drugs within 30 days or 5 half-lives prior to randomization, whichever is longer;"
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide," Taking other medications known to affect serum gonadotropin (Gn) concentrations, such as goserelin or danazol;"
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide, A screening HamD score of 15 or higher;
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide, Abuse or dependence on alcohol or other substances satisfies criteria for DSM-IV categories 303.9 or 305;
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide, Donated blood within 30 days of baseline or are likely to do so during the course of the trial;
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide," History of cancer, particularly breast cancer or known or suspected prostate cancer, within the last 5 years, except for basal cell or squamous cell cancer of the skin;"
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide," Clinically significant bladder outlet obstruction, in the judgment of the Investigator or designated examining physician;"
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide," Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia, or are unable to stand or sit upright for at least 30 minutes;"
NCT00076440,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Dec-03,Alzheimer Disease;Leuprolide, Sleep apnea.
NCT00082602,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-04,Alzheimer Disease;Galantamine, Male or female outpatients diagnosed with Alzheimer's Disease
NCT00082602,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-04,Alzheimer Disease;Galantamine, Age greater than = 60 years
NCT00082602,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-04,Alzheimer Disease;Galantamine, Presence of mild to moderate dementia as evidenced by Mini Mental State Examination (MMSE) score of 10-24 inclusive at screening
NCT00082602,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-04,Alzheimer Disease;Galantamine, History of cognitive decline that had been gradual in onset and progressive over a period of at least six months
NCT00083421,Phase 2,Alzheimer's Disease,Ono Pharma USA Inc,Jun-04,Alzheimer Disease, Diagnosis of probable Alzheimer's Disease using NINCDS/ADRDA criteria
NCT00083421,Phase 2,Alzheimer's Disease,Ono Pharma USA Inc,Jun-04,Alzheimer Disease, Standardized MMSE Score of 13 to 24 points (inclusive)
NCT00083421,Phase 2,Alzheimer's Disease,Ono Pharma USA Inc,Jun-04,Alzheimer Disease, Modified Hachinski score equal or less than 4
NCT00083590,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Apr-04,Alzheimer Disease;Huperzine A, NINDS/ADRDA criteria for probable AD.
NCT00083590,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Apr-04,Alzheimer Disease;Huperzine A," Mini Mental State Examination between 10 and 24, inclusive."
NCT00083590,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Apr-04,Alzheimer Disease;Huperzine A, Stable medical condition for 3 months prior to screening.
NCT00083590,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Apr-04,Alzheimer Disease;Huperzine A, Supervision available for administration of study medications.
NCT00083590,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Apr-04,Alzheimer Disease;Huperzine A, Study partner to accompany participant to all scheduled visits.
NCT00083590,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Apr-04,Alzheimer Disease;Huperzine A, Fluent in English or Spanish.
NCT00083590,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Apr-04,Alzheimer Disease;Huperzine A, Age 55 years or older.
NCT00083590,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Apr-04,Alzheimer Disease;Huperzine A, Modified Hachinski score equal to or less than 4.
NCT00083590,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Apr-04,Alzheimer Disease;Huperzine A, CT or MRI since onset of memory impairment demonstrating absence of clinically significant focal lesion.
NCT00083590,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Apr-04,Alzheimer Disease;Huperzine A, Able to complete baseline assessments.
NCT00083590,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Apr-04,Alzheimer Disease;Huperzine A," 6 years of education, or work history sufficient to exclude mental retardation."
NCT00083590,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Apr-04,Alzheimer Disease;Huperzine A, Able to ingest oral medication.
NCT00083590,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Apr-04,Alzheimer Disease;Huperzine A, Stable doses of medications for 4 weeks prior to screening.
NCT00083590,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Apr-04,Alzheimer Disease;Huperzine A," Physically acceptable for this study as confirmed by medical history, physical exam, neurological exam and clinical tests."
NCT00087724,Phase 2,Alzheimer's Disease,Astellas Pharma Inc,Jul-04,Alzheimer Disease, Subject satisfies the criteria for the clinical diagnosis of probable AD
NCT00087724,Phase 2,Alzheimer's Disease,Astellas Pharma Inc,Jul-04,Alzheimer Disease, Subject has a score =less than  4 on the Modified Hachinski Ischemia Scale at the screening visit
NCT00088673,Phase 3,Alzheimer Disease,Bellus Health Inc,Jun-04,Alzheimer Disease, Patients may be included in this study if they meet all of the following criteria:
NCT00088673,Phase 3,Alzheimer Disease,Bellus Health Inc,Jun-04,Alzheimer Disease, Male or Female (age 50 years and older): Female must be of non-childbearing potential (i.e. surgically sterilized or at least 2 years post-menopausal).
NCT00088673,Phase 3,Alzheimer Disease,Bellus Health Inc,Jun-04,Alzheimer Disease, Diagnosis of probable Alzheimer's disease based on the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA criteria).
NCT00088673,Phase 3,Alzheimer Disease,Bellus Health Inc,Jun-04,Alzheimer Disease, Severity of dementia of mild to moderate degree as assessed by the Mini Mental State Examination (MMSE) performed at the screening visit.
NCT00088673,Phase 3,Alzheimer Disease,Bellus Health Inc,Jun-04,Alzheimer Disease, Patient must be living in the community with a reliable caregiver. Participant living in an assisted living facility may be included if study medication intake is supervised and participant has a reliable caregiver.
NCT00088673,Phase 3,Alzheimer Disease,Bellus Health Inc,Jun-04,Alzheimer Disease, Potential participant must be treated with conventional Alzheimer's disease therapies and must be on stable dose for at least 4 months prior to the screening visit and during the entire study period.
NCT00088673,Phase 3,Alzheimer Disease,Bellus Health Inc,Jun-04,Alzheimer Disease," Fluency in English, French or Spanish (oral and written)."
NCT00088673,Phase 3,Alzheimer Disease,Bellus Health Inc,Jun-04,Alzheimer Disease, Signed informed consent from potential participant or legal representative and caregiver.
NCT00090116,Phase 3,Alzheimer's Disease,Forest Laboratories,Mar-03,Alzheimer Disease, Clinical diagnosis of moderate to severe Alzheimer's disease;
NCT00090116,Phase 3,Alzheimer's Disease,Forest Laboratories,Mar-03,Alzheimer Disease, ambulatory patients
NCT00093951,Phase 2,Alzheimer's Disease,Saegis Pharmaceuticals,Apr-04,Alzheimer Disease;(3-aminopropyl)(n-butyl)phosphinic acid, 55 to 90 years of age
NCT00093951,Phase 2,Alzheimer's Disease,Saegis Pharmaceuticals,Apr-04,Alzheimer Disease;(3-aminopropyl)(n-butyl)phosphinic acid, Diagnosed with mild to moderate Alzheimer's disease
NCT00093951,Phase 2,Alzheimer's Disease,Saegis Pharmaceuticals,Apr-04,Alzheimer Disease;(3-aminopropyl)(n-butyl)phosphinic acid, Willing caregiver
NCT00093951,Phase 2,Alzheimer's Disease,Saegis Pharmaceuticals,Apr-04,Alzheimer Disease;(3-aminopropyl)(n-butyl)phosphinic acid, In general good health
NCT00095719,Phase 3,Alzheimer's Disease,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Dec-03,Alzheimer Disease;Dementia;Aripiprazole," Acute agitation in Patients with a DSM-IV diagnosis of Alzheimer's, vascular or mixed Dementia."
NCT00097916,Phase 3,Alzheimer's Disease,Forest Laboratories,Sep-04,Alzheimer Disease;Memantine, Moderate to Severe Alzheimer's Disease with a score greater than or equal to 4 on agitation/aggression domain of NPI
NCT00097916,Phase 3,Alzheimer's Disease,Forest Laboratories,Sep-04,Alzheimer Disease;Memantine, Stable dose of donepezil for 3 months
NCT00099242,Phase 3,"Dementia, Alzheimer Type",Novartis Pharmaceuticals,Nov-03,Alzheimer Disease;Dementia;Rivastigmine, Diagnosis of dementia of the Alzheimer's type
NCT00099242,Phase 3,"Dementia, Alzheimer Type",Novartis Pharmaceuticals,Nov-03,Alzheimer Disease;Dementia;Rivastigmine," Males, and females who are surgically sterile or one year postmenopausal"
NCT00099242,Phase 3,"Dementia, Alzheimer Type",Novartis Pharmaceuticals,Nov-03,Alzheimer Disease;Dementia;Rivastigmine, A primary caregiver willing to accept responsibility for supervising the treatment
NCT00100334,Phase 1/Phase 2,Alzheimer's Disease,PRAECIS Pharmaceuticals Inc.,Dec-04,Alzheimer Disease," Subject has the ability to understand the requirements of the study, provide written informed consent, and abide by the requirements of the study. In addition, a member of the subject's family or a legally authorized representative must consent to the subject's participation in the study."
NCT00100334,Phase 1/Phase 2,Alzheimer's Disease,PRAECIS Pharmaceuticals Inc.,Dec-04,Alzheimer Disease, Subject has a caregiver willing to assist the subject's involvement in the study.
NCT00100334,Phase 1/Phase 2,Alzheimer's Disease,PRAECIS Pharmaceuticals Inc.,Dec-04,Alzheimer Disease, Subject is a male or female between the ages of 50 and 80 with a body mass index (BMI) below 31. Females must be post-menopausal at least 1 year or surgically sterilized.
NCT00100334,Phase 1/Phase 2,Alzheimer's Disease,PRAECIS Pharmaceuticals Inc.,Dec-04,Alzheimer Disease, Subject must have a cognitive deficit present for at least 1 year and meet DSM -IV criteria for Alzheimer's disease and meet National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria for the presence of probable Alzheimer's disease.
NCT00100334,Phase 1/Phase 2,Alzheimer's Disease,PRAECIS Pharmaceuticals Inc.,Dec-04,Alzheimer Disease," Subject's severity of Alzheimer's disease must be mild-moderate, documented with a Mini Mental State Exam (MMSE) score of 12-26."
NCT00100334,Phase 1/Phase 2,Alzheimer's Disease,PRAECIS Pharmaceuticals Inc.,Dec-04,Alzheimer Disease, Subject has a computerized tomography (CT) scan or magnetic resonance imaging (MRI) within the prior 12 months which is compatible with a diagnosis of probable AD.
NCT00100334,Phase 1/Phase 2,Alzheimer's Disease,PRAECIS Pharmaceuticals Inc.,Dec-04,Alzheimer Disease," If a subject is being treated for Alzheimer's disease, it must be with a single cholinesterase inhibitor (donepezil, rivastigmine, or galantamine), with or without memantine, and with a dose which has been stable for at least 3 months prior to dosing."
NCT00100334,Phase 1/Phase 2,Alzheimer's Disease,PRAECIS Pharmaceuticals Inc.,Dec-04,Alzheimer Disease, Subject performance status is  3 on items 1 through 5 and  2 on item 6 from the Degree of Disability Section of the  Rapid Disability Scale-2 
NCT00100334,Phase 1/Phase 2,Alzheimer's Disease,PRAECIS Pharmaceuticals Inc.,Dec-04,Alzheimer Disease, Subject agrees not to donate blood or blood products while participating in this study and for at least 60 days after discontinuing from the study.
NCT00103649,Phase 3,Alzheimer Disease,Sanofi,Nov-03,Alzheimer Disease;Dementia;Xaliproden, Diagnosis of probable Alzheimer's disease using NINCDS-ADRDA criteria
NCT00103649,Phase 3,Alzheimer Disease,Sanofi,Nov-03,Alzheimer Disease;Dementia;Xaliproden, Mild to moderate degree of severity of dementia as assessed by the Mini-Mental State Examination score of 16 to 26 (inclusive)
NCT00103649,Phase 3,Alzheimer Disease,Sanofi,Nov-03,Alzheimer Disease;Dementia;Xaliproden, Potential participant may be treated with conventional Alzheimer's disease therapy and must be on stable dose for at least 6 months prior to the randomization and during the entire study period
NCT00103649,Phase 3,Alzheimer Disease,Sanofi,Nov-03,Alzheimer Disease;Dementia;Xaliproden, Potential participant must have a reliable caregiver and must be living in a community or in an assisted living facility
NCT00103649,Phase 3,Alzheimer Disease,Sanofi,Nov-03,Alzheimer Disease;Dementia;Xaliproden," Mother tongue is English, Spanish or French (oral and written fluency)"
NCT00103649,Phase 3,Alzheimer Disease,Sanofi,Nov-03,Alzheimer Disease;Dementia;Xaliproden, Signed informed consent from potential participant or legal representative and identified caregiver
NCT00104013,Phase 3,Alzheimer Disease,Sanofi,Nov-03,Alzheimer Disease;Dementia;Xaliproden, Diagnosis of probable Alzheimer's disease using NINCDS-ADRDA criteria
NCT00104013,Phase 3,Alzheimer Disease,Sanofi,Nov-03,Alzheimer Disease;Dementia;Xaliproden, Mild to moderate degree of severity of dementia as assessed by the Mini-Mental Status Examination score of 16 to 26 (inclusive)
NCT00104013,Phase 3,Alzheimer Disease,Sanofi,Nov-03,Alzheimer Disease;Dementia;Xaliproden, Potential participant may be treated with conventional Alzheimer's disease therapy and must be on a stable dose for at least 6 months prior to the randomization and during the entire study period
NCT00104013,Phase 3,Alzheimer Disease,Sanofi,Nov-03,Alzheimer Disease;Dementia;Xaliproden, Potential participant must have a reliable caregiver and must be living in a community or in an assisted living facility
NCT00104013,Phase 3,Alzheimer Disease,Sanofi,Nov-03,Alzheimer Disease;Dementia;Xaliproden," Mother tongue is English, Spanish or French (oral and written fluency)"
NCT00104013,Phase 3,Alzheimer Disease,Sanofi,Nov-03,Alzheimer Disease;Dementia;Xaliproden, Signed informed consent from potential participant or legal representative and identified caregiver
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline,"Age range: Adult patients, 45 to 90 years of age inclusive."
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline,Gender distribution: men and women. Women of child-bearing potential (less than  1 year post-menopausal) must be practicing effective contraception and have a negative serum b-hCG at Screening.
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline,Diagnosis: diagnostic evidence of probable Alzheimer's Disease consistent with DSM-IV 290.00 or 290.10 and NINCDS ADRDA criteria. This evidence may be compiled during Screening but must be fully documented in the patient's study file before the Baseline visit.
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline,Stable Aricept dose of 10 mg daily for greater than = 8 weeks.
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline,"Head image (CT or MRI): no evidence of focal disease to account for dementia on any head image (CT or MRI) obtained within 12 months prior to Baseline. If no such head image has been obtained prior to Screening, a head MRI will be obtained as part of the Screening evaluation; this MRI will also be used for Baseline volumetric analysis. The Baseline MRI obtained for volumetric analysis must also not show any evidence of focal disease to account for dementia."
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline,Degree of dementia: MMSE score of greater than = 15 and less than = 26 at Screening and Baseline.
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline,Race and ethnicity: any race and ethnic group.
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline,"Health: generally healthy and ambulatory or ambulatory-aided (i.e., walker or cane). Corrected vision and hearing sufficient for compliance with testing procedures."
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline,"Clinical laboratory values must be within normal limits or, if abnormal, must be judged clinically insignificant by the Investigator."
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline,Patients with vitamin B12 deficiency who are on a stable dose of medication for at least 12 weeks prior to Screening and who have normal serum vitamin B12 levels at Screening will be eligible. This stable dose of vitamin B12 must be maintained throughout the study. Subjects who might otherwise have been eligible can be re-screened for Vitamin B12 before Baseline.
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline,"Patients with hypothyroidism who are on a stable dose of medication for at least 12 weeks prior to Screening, have normal TSH and free T4 at screening, and are considered euthyroid will be eligible. This stable dose must be maintained throughout the study."
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline,"Patients must have a caregiver who has daily contact with the patient (e.g., an average of 10 or more hours per week), can observe for possible adverse events, and can accompany the patient to all visits."
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline,Patients must be sufficiently fluent in English to be capable of reliably completing all study assessments.
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, Diagnosis of Alzheimer's disease
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, Women must have had a partial or complete hysterectomy
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, Mini Mental Status Evaluation score of 18-27
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, HAM-D score less than or equal to 18
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, Able to provide written informed consent
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, On a stable dose of an acetylcholinesterase inhibitor for at least 12 weeks prior to screening visit
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone," Ambulatory, or ambulatory with walker or cane"
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, Sufficient hearing and vision to enable the patient to comply with the study procedures
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, Caregiver available to participate in the assessment of the patient and monitor dosing
NCT00112073,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Apr-05,Alzheimer Disease, Diagnosis of probable AD
NCT00112073,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Apr-05,Alzheimer Disease, Age from 50 to 85 years
NCT00112073,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Apr-05,Alzheimer Disease, Rosen Modified Hachinski Ischemic score less than or equal to 4
NCT00112073,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Apr-05,Alzheimer Disease, Magnetic resonance imaging (MRI) scan consistent with the diagnosis of AD
NCT00112073,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Apr-05,Alzheimer Disease, Fluency in English
NCT00112073,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Apr-05,Alzheimer Disease, Stable doses of medications
NCT00130429,Phase 2,Alzheimer's Disease,Phytopharm,Jan-04,Alzheimer Disease, At least 50 years of age
NCT00130429,Phase 2,Alzheimer's Disease,Phytopharm,Jan-04,Alzheimer Disease, Diagnosis of possible or probable Alzheimer's disease
NCT00130429,Phase 2,Alzheimer's Disease,Phytopharm,Jan-04,Alzheimer Disease, Mini mental state examination score at least 16
NCT00130429,Phase 2,Alzheimer's Disease,Phytopharm,Jan-04,Alzheimer Disease, Good understanding of both written and verbal English
NCT00130429,Phase 2,Alzheimer's Disease,Phytopharm,Jan-04,Alzheimer Disease, A recent head scan that is consistent with the diagnosis of Alzheimer's disease
NCT00141661,Phase 2,Alzheimer Disease,Pfizer,Oct-05,Alzheimer Disease, Diagnosis of probably Alzheimer's disease for at least 1 year.
NCT00141661,Phase 2,Alzheimer Disease,Pfizer,Oct-05,Alzheimer Disease, Mini Mental State Exam (MMSE) score between 12-26 at screening.
NCT00141661,Phase 2,Alzheimer Disease,Pfizer,Oct-05,Alzheimer Disease," Participants must be receiving a cholinesterase inhibitor and/or memantine for at least 4 months, and on a stable dose for at least 2 months."
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease, Informed Consent Form signed by patient and caregiver
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease, Diagnosis of probably Alzheimer's disease of mild to moderate severity
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease, Age 50 or older
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease," If female, 2 years postmenopausal or surgically sterile"
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease," Hearing, vision, and physical abilities adequate to perform assessments (corrective aids allowed)"
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease," Caregiver to attend all visits, perform assessments, and supervise administration of study medication"
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease, CT or MRI within 24 months prior to screening compatible with a diagnosis of probably Alzheimer's disease
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease, Modified Hachinski Ischemia Scale score of 4 or less
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease, ADAS-Cog score between 15 and 35 inclusive at screening
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease, MMSE score between 14 and 24 inclusive at screening
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease, Stable medical condition for 3 consecutive months immediately prior to baseline
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease," No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening"
NCT00151333,Phase 2,Alzheimer's Disease,Wyeth is now a wholly owned subsidiary of Pfizer,Feb-05,Alzheimer Disease, Diagnosis of probable AD according to the NINCDS-ADRDA criteria.
NCT00151333,Phase 2,Alzheimer's Disease,Wyeth is now a wholly owned subsidiary of Pfizer,Feb-05,Alzheimer Disease, Men and postmenopausal or surgically sterile women aged from 50 to 85 inclusive.
NCT00151333,Phase 2,Alzheimer's Disease,Wyeth is now a wholly owned subsidiary of Pfizer,Feb-05,Alzheimer Disease, Able to give informed consent. Patient's caregiver must consent to participate in the study.
NCT00151398,Phase 2,Alzheimer Disease,Wyeth is now a wholly owned subsidiary of Pfizer,unknown,Alzheimer Disease;Donepezil, Diagnosis of probable AD according to the NINCDS-ADRDA criteria.
NCT00151398,Phase 2,Alzheimer Disease,Wyeth is now a wholly owned subsidiary of Pfizer,unknown,Alzheimer Disease;Donepezil, Able to give informed consent. Patient' s caregiver must consent to participate in the study.
NCT00151502,Phase 3,Alzheimer's Disease,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Nov-02,Alzheimer Disease;Atorvastatin, Diagnostic evidence of probable Alzheimer's disease consistent with NINCDS/ADRDA and DSM IV criteria.
NCT00151502,Phase 3,Alzheimer's Disease,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Nov-02,Alzheimer Disease;Atorvastatin, Subject's Mini-Mental Status Examination Score (MMSE) must be in the range of 13 - 25 (inclusive) at Screening.
NCT00154635,Phase 2,"Dementia, Alzheimer Type",National Taiwan University Hospital,Sep-05,Alzheimer Disease,Male or post menopausal female patients aged 50 years old;
NCT00154635,Phase 2,"Dementia, Alzheimer Type",National Taiwan University Hospital,Sep-05,Alzheimer Disease,The informed consent must be signed by the patient and co-signed by their proxy or principal caregivers before undergoing any study procedures;
NCT00154635,Phase 2,"Dementia, Alzheimer Type",National Taiwan University Hospital,Sep-05,Alzheimer Disease,Probable Alzheimer's disease based on the National Institute of Neurological and Communicative Disorders and Alzheimer's dementia and related disorder (NINCDS-ADRDA)
NCT00154635,Phase 2,"Dementia, Alzheimer Type",National Taiwan University Hospital,Sep-05,Alzheimer Disease,Patients with Mini-Mental State Examination (MMSE) scores of 12~24
NCT00154635,Phase 2,"Dementia, Alzheimer Type",National Taiwan University Hospital,Sep-05,Alzheimer Disease,Patients with Clinical Dementia Rating (CDR)in mild (CDR = 1) and moderate (CDR = 2) AD
NCT00154635,Phase 2,"Dementia, Alzheimer Type",National Taiwan University Hospital,Sep-05,Alzheimer Disease,Cranial computed tomography (CT) or brain magnetic resonance imaging (MRI) must be within the past 12 months;
NCT00154635,Phase 2,"Dementia, Alzheimer Type",National Taiwan University Hospital,Sep-05,Alzheimer Disease,Patients must be able to complete baseline assessments;
NCT00154635,Phase 2,"Dementia, Alzheimer Type",National Taiwan University Hospital,Sep-05,Alzheimer Disease,An eligible principal caregiver must be able to accompany the patient to all scheduled visits;
NCT00154635,Phase 2,"Dementia, Alzheimer Type",National Taiwan University Hospital,Sep-05,Alzheimer Disease,"Patients currently taking ChEIs such as donepezil, rivastigmine, or galantamine are allowed if the dose has been unchanged for the last 3 months before the study entry."
NCT00160147,Phase 3,Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type,Solvay Pharmaceuticals,Dec-05,Dementia;Alzheimer Disease;Psychotic Disorders;Mental Disorders;Problem Behavior, Diagnosis of dementia of the Alzheimer's type
NCT00164749,Phase 1/Phase 2,Alzheimer's Disease,Chinese University of Hong Kong,Oct-04,Alzheimer Disease;Curcumin, Ethnic Chinese living in Hong Kong
NCT00164749,Phase 1/Phase 2,Alzheimer's Disease,Chinese University of Hong Kong,Oct-04,Alzheimer Disease;Curcumin, Progressive decline in memory and cognitive function for at least 6 months
NCT00164749,Phase 1/Phase 2,Alzheimer's Disease,Chinese University of Hong Kong,Oct-04,Alzheimer Disease;Curcumin, NINCDS-ADRDA diagnosis of possible or probable AD
NCT00164749,Phase 1/Phase 2,Alzheimer's Disease,Chinese University of Hong Kong,Oct-04,Alzheimer Disease;Curcumin, Mild to severe dementia with Cantonese version of MMSE scores between 0 and 28
NCT00164749,Phase 1/Phase 2,Alzheimer's Disease,Chinese University of Hong Kong,Oct-04,Alzheimer Disease;Curcumin, Informed consent from patient and/or caregiver
NCT00164749,Phase 1/Phase 2,Alzheimer's Disease,Chinese University of Hong Kong,Oct-04,Alzheimer Disease;Curcumin, Both elderly home residents and outpatients are eligible
NCT00164749,Phase 1/Phase 2,Alzheimer's Disease,Chinese University of Hong Kong,Oct-04,Alzheimer Disease;Curcumin, Patients may take any medication
NCT00165659,Phase 2,Alzheimer Disease,Eisai Limited,Nov-02,Alzheimer Disease;Donepezil, Patients with diagnostics of Alzheimer's disease (AD) according to DSM-IV.
NCT00165659,Phase 2,Alzheimer Disease,Eisai Limited,Nov-02,Alzheimer Disease;Donepezil, Patients with modified Hachinski Ischemic scale score of 6.
NCT00165659,Phase 2,Alzheimer Disease,Eisai Limited,Nov-02,Alzheimer Disease;Donepezil, FAST score of 6 at baseline (4 weeks before starting study treatment).
NCT00165659,Phase 2,Alzheimer Disease,Eisai Limited,Nov-02,Alzheimer Disease;Donepezil, MMSE score between 1 and 12 at baseline (4 weeks before starting study treatment).
NCT00165659,Phase 2,Alzheimer Disease,Eisai Limited,Nov-02,Alzheimer Disease;Donepezil," Imaging diagnostics (CT, MRI, etc., within 24 months consistent with the diagnosis of AD without any other comorbid pathologies found. If a significant change in clinical status suggesting other types of dementia (except AD) is suspected between the final image diagnosis and the time of starting observation, the scan test should be repeated."
NCT00165659,Phase 2,Alzheimer Disease,Eisai Limited,Nov-02,Alzheimer Disease;Donepezil, Patients who can comply with the requirements on concomitant drugs/therapies from the baseline phase or before.
NCT00165659,Phase 2,Alzheimer Disease,Eisai Limited,Nov-02,Alzheimer Disease;Donepezil, Patients aged 50 years or older.
NCT00165659,Phase 2,Alzheimer Disease,Eisai Limited,Nov-02,Alzheimer Disease;Donepezil," Outpatients. Even in the case of an outpatient or a patient attending on the outpatient-visit basis from a nursing home facility, the caregiver must be a constant and reliable informant with minimum of 3 days per week direct contact with the patient (for at least 4 hours per day on waking hours). This contact is necessary to ensure accurate reporting of the patient's behavior and his/her ability to perform ADLs."
NCT00165659,Phase 2,Alzheimer Disease,Eisai Limited,Nov-02,Alzheimer Disease;Donepezil," Patients who are expected to complete all procedures scheduled during the Screening and Baseline visit and who have a reliable caregiver or family member who agrees to accompany the patient to all clinic visits, provide information about the patient as required by the protocol, and ensure compliance with the treatment schedule."
NCT00165659,Phase 2,Alzheimer Disease,Eisai Limited,Nov-02,Alzheimer Disease;Donepezil, Patients who can swallow tablets without pulverization.
NCT00165659,Phase 2,Alzheimer Disease,Eisai Limited,Nov-02,Alzheimer Disease;Donepezil, Patients who are ambulatory at least aided (walker) and have vision and hearing necessary for compliance with testing procedures (eyeglasses and/or hearing aid permissible).
NCT00165659,Phase 2,Alzheimer Disease,Eisai Limited,Nov-02,Alzheimer Disease;Donepezil, Patients whose representatives can sign the written informed consent.
NCT00174525,Phase 2,Alzheimer's Disease,Pharmacology Research Institute,Apr-05,Alzheimer Disease, Diagnosis of probable AD
NCT00174525,Phase 2,Alzheimer's Disease,Pharmacology Research Institute,Apr-05,Alzheimer Disease," Age from 50 to 85 years, inclusive"
NCT00174525,Phase 2,Alzheimer's Disease,Pharmacology Research Institute,Apr-05,Alzheimer Disease, Rosen Modified Hachinski ischemic score less than or equal to 4
NCT00174525,Phase 2,Alzheimer's Disease,Pharmacology Research Institute,Apr-05,Alzheimer Disease, Magnetic Resonance Imaging (MRI) scan consistent with the diagnosis of AD
NCT00174525,Phase 2,Alzheimer's Disease,Pharmacology Research Institute,Apr-05,Alzheimer Disease, Fluency in English
NCT00174525,Phase 2,Alzheimer's Disease,Pharmacology Research Institute,Apr-05,Alzheimer Disease, Stable doses of medications
NCT00190021,Phase 3,Dementia of Alzheimer Type,Beersheva Mental Health Center,unknown,Dementia;Alzheimer Disease;Donepezil, age: 65-90
NCT00190021,Phase 3,Dementia of Alzheimer Type,Beersheva Mental Health Center,unknown,Dementia;Alzheimer Disease;Donepezil, DSM-IV diagnosis of Alzheimer's type dementia
NCT00190021,Phase 3,Dementia of Alzheimer Type,Beersheva Mental Health Center,unknown,Dementia;Alzheimer Disease;Donepezil," inclusion of psychotic symptoms such as: hallucinations and delusions, aggression/agitation, irritability and disinhibition calling for adminstration of antipsychotic drugs"
NCT00190021,Phase 3,Dementia of Alzheimer Type,Beersheva Mental Health Center,unknown,Dementia;Alzheimer Disease;Donepezil, duration of psychotic symptoms of at least 2 weeks before start of treatment
NCT00190021,Phase 3,Dementia of Alzheimer Type,Beersheva Mental Health Center,unknown,Dementia;Alzheimer Disease;Donepezil, lack of improvement of psychotic symptoms during perphenazine treatment for at least 3 weeks
NCT00191009,Phase 2/Phase 3,Alzheimer Disease,Eli Lilly and Company,Oct-03,Alzheimer Disease;Atomoxetine Hydrochloride, Patient presents with Alzheimer's Disease based on clinical history.
NCT00191009,Phase 2/Phase 3,Alzheimer Disease,Eli Lilly and Company,Oct-03,Alzheimer Disease;Atomoxetine Hydrochloride, Patient must have a Mini Mental Status Score between 10 and 26.
NCT00191009,Phase 2/Phase 3,Alzheimer Disease,Eli Lilly and Company,Oct-03,Alzheimer Disease;Atomoxetine Hydrochloride, Patient must have a reliable caregiver in frequent or daily contact with the patient.
NCT00191009,Phase 2/Phase 3,Alzheimer Disease,Eli Lilly and Company,Oct-03,Alzheimer Disease;Atomoxetine Hydrochloride, Patient must be currently treated with and on a stable dose of a standard Alzheimer's drug treatment for at least 3 months.
NCT00205179,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",Jan-05,Alzheimer Disease, Diagnosis of probable AD
NCT00205179,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",Jan-05,Alzheimer Disease, Has reliable and available caregiver to assist with medication and appointments
NCT00205179,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",Jan-05,Alzheimer Disease," On a stable dose of cholinesterase inhibitor, or if unable to tolerate medication, patient has no plans to re-initiate cholinergic therapies while in the study"
NCT00216593,Phase 3,Alzheimer Disease,"Janssen Pharmaceutica N.V., Belgium",Dec-03,Alzheimer Disease;Dementia;Galantamine," Diagnosis of Alzheimer's type dementia, rated as severe"
NCT00216593,Phase 3,Alzheimer Disease,"Janssen Pharmaceutica N.V., Belgium",Dec-03,Alzheimer Disease;Dementia;Galantamine, progressive worsening of memory and other cognitive functions
NCT00216593,Phase 3,Alzheimer Disease,"Janssen Pharmaceutica N.V., Belgium",Dec-03,Alzheimer Disease;Dementia;Galantamine, brain imaging (CTor MRI scan) within last 3 years
NCT00216593,Phase 3,Alzheimer Disease,"Janssen Pharmaceutica N.V., Belgium",Dec-03,Alzheimer Disease;Dementia;Galantamine, ability to be mobile (aided or unaided) with sufficient vision and hearing to comply with testing.
NCT00219232,Phase 3,Alzheimer's Disease,Novartis,Feb-03,Alzheimer Disease;Rivastigmine, Patients who fulfilled the inclusion and exclusion criteria as listed in the study CENA713D2320 and have completed the double-blind treatment phase on study medication without significant protocol violations.
NCT00231946,Phase 3,Alzheimer's Disease,Voyager Pharmaceutical Corporation,Sep-05,Alzheimer Disease, 60 years of age or older
NCT00231946,Phase 3,Alzheimer's Disease,Voyager Pharmaceutical Corporation,Sep-05,Alzheimer Disease, Diagnosis of probable mild-to-moderate Alzheimer's Disease
NCT00231946,Phase 3,Alzheimer's Disease,Voyager Pharmaceutical Corporation,Sep-05,Alzheimer Disease," On a stable dose of an acetylcholinesterase inhibitor (including, but not limited to: donepezil, galantamine, rivastigmine, and tacrine) for at least 120 days prior to baseline and will likely remain on the drug throughout the trial; all participants must be on acetylcholinesterase inhibitors"
NCT00231946,Phase 3,Alzheimer's Disease,Voyager Pharmaceutical Corporation,Sep-05,Alzheimer Disease, No other significant or interfering medical conditions
NCT00235716,Phase 3,Alzheimer's Disease,US Department of Veterans Affairs,Aug-07,Alzheimer Disease;Vitamins;Vitamin E;Tocopherols;Tocotrienols;alpha-Tocopherol;Memantine,Diagnoses of possible or probable Alzheimer's disease (NINCDS-ADRDA)
NCT00235716,Phase 3,Alzheimer's Disease,US Department of Veterans Affairs,Aug-07,Alzheimer Disease;Vitamins;Vitamin E;Tocopherols;Tocotrienols;alpha-Tocopherol;Memantine,"Presence of a caregiver (friend or relative) who can assume responsibility for medication compliance, can accompany the patient to all visits, and rate patient's condition"
NCT00235716,Phase 3,Alzheimer's Disease,US Department of Veterans Affairs,Aug-07,Alzheimer Disease;Vitamins;Vitamin E;Tocopherols;Tocotrienols;alpha-Tocopherol;Memantine,Written informed consent from both the patient (or surrogate) and caregiver
NCT00235716,Phase 3,Alzheimer's Disease,US Department of Veterans Affairs,Aug-07,Alzheimer Disease;Vitamins;Vitamin E;Tocopherols;Tocotrienols;alpha-Tocopherol;Memantine,An MMSE score between 12 and 26 inclusive
NCT00235716,Phase 3,Alzheimer's Disease,US Department of Veterans Affairs,Aug-07,Alzheimer Disease;Vitamins;Vitamin E;Tocopherols;Tocotrienols;alpha-Tocopherol;Memantine,"Administration of a maintenance dosage of donepezil (5-10mg/d), rivastigmine (6-12mg/d) or rivastigmine (Exelon) patch (4.6 mg or 9.5 mg), galantamine or galantamine ER (16-24mg/d) for a minimum of 4 weeks prior to randomization"
NCT00235716,Phase 3,Alzheimer's Disease,US Department of Veterans Affairs,Aug-07,Alzheimer Disease;Vitamins;Vitamin E;Tocopherols;Tocotrienols;alpha-Tocopherol;Memantine,Agreement not to take vitamin E supplements and/or memantine outside of the study (daily multivitamin is permitted containing up to 100 IU alpha-tocopherol)
NCT00236431,Phase 3,Alzheimer Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-01,Alzheimer Disease;Cognitive Dysfunction;Galantamine, Clinical decline of cognitive ability consistent with mild cognitive impairment
NCT00236431,Phase 3,Alzheimer Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-01,Alzheimer Disease;Cognitive Dysfunction;Galantamine, Delayed recall score less than = 10 on a New York University paragraph recall test
NCT00236431,Phase 3,Alzheimer Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-01,Alzheimer Disease;Cognitive Dysfunction;Galantamine," Sufficient visual, hearing and communication capabilities and be willing to complete serial standard tests of cognitive function"
NCT00236431,Phase 3,Alzheimer Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-01,Alzheimer Disease;Cognitive Dysfunction;Galantamine, Have a consistent informant to accompany them on scheduled visits
NCT00236431,Phase 3,Alzheimer Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-01,Alzheimer Disease;Cognitive Dysfunction;Galantamine," Be able to read, write and fully understand the language of the cognitive scales used in the study"
NCT00236574,Phase 3,Alzheimer Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-01,Alzheimer Disease;Dementia;Cognitive Dysfunction;Galantamine, Clinical decline of cognitive ability consistent with mild cognitive impairment
NCT00236574,Phase 3,Alzheimer Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-01,Alzheimer Disease;Dementia;Cognitive Dysfunction;Galantamine, Delayed recall score less than or equal to 10 on New York University paragraph recall test
NCT00236574,Phase 3,Alzheimer Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-01,Alzheimer Disease;Dementia;Cognitive Dysfunction;Galantamine," Sufficient visual, hearing and communication capabilities and willingness to complete serial standard tests of cognitive function"
NCT00236574,Phase 3,Alzheimer Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-01,Alzheimer Disease;Dementia;Cognitive Dysfunction;Galantamine, Have a consistent informant to accompany them on scheduled visits
NCT00236574,Phase 3,Alzheimer Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-01,Alzheimer Disease;Dementia;Cognitive Dysfunction;Galantamine," Be able to read, write and fully understand the language of the cognitive scales used in the study"
NCT00244322,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Oct-05,Alzheimer Disease, At least 50 years of age and diagnosed with mild to moderate probable Alzheimer's disease
NCT00244322,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Oct-05,Alzheimer Disease, Fluent in reading and speaking English and have a reliable study partner (caregiver) (someone who is in frequent contact and can make sure study medication is being taken correctly).
NCT00244322,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Oct-05,Alzheimer Disease," If currently treated with certain drugs for Alzheimer's disease, doses must be the same for at least the last 2 months prior to starting study drug."
NCT00255086,Phase 3,Alzheimer Disease,Stanford University,May-05,Alzheimer Disease;Memantine,50-95 years of age inclusive.
NCT00255086,Phase 3,Alzheimer Disease,Stanford University,May-05,Alzheimer Disease;Memantine,MMSE at screen and baseline 7-28 inclusive.
NCT00255086,Phase 3,Alzheimer Disease,Stanford University,May-05,Alzheimer Disease;Memantine,Conversant in English.
NCT00255086,Phase 3,Alzheimer Disease,Stanford University,May-05,Alzheimer Disease;Memantine,"Caregiver/study partner willing to participate, supervise the patient and be available for administration of study medication."
NCT00255086,Phase 3,Alzheimer Disease,Stanford University,May-05,Alzheimer Disease;Memantine,Able to ingest oral medication. Exclusion Criteria:1. History of clinically significant stroke without substantial recovery.
NCT00255086,Phase 3,Alzheimer Disease,Stanford University,May-05,Alzheimer Disease;Memantine,Neurological or medical conditions causing significant disability independent of dementia.
NCT00255086,Phase 3,Alzheimer Disease,Stanford University,May-05,Alzheimer Disease;Memantine,Parkinson's disease.
NCT00255086,Phase 3,Alzheimer Disease,Stanford University,May-05,Alzheimer Disease;Memantine,"History in past two years of focal brain lesion, head injury with loss of consciousness or DSM-IV criteria for any major psychiatric disorder including psychosis, major depression, bipolar disorder, alcohol or substance abuse."
NCT00255086,Phase 3,Alzheimer Disease,Stanford University,May-05,Alzheimer Disease;Memantine,"Dementia due to Korsakoff's syndrome or infectious diseases such as Creutzfeldt-Jakob disease, herpes, encephalitis, or human immunodeficiency virus."
NCT00255086,Phase 3,Alzheimer Disease,Stanford University,May-05,Alzheimer Disease;Memantine,Sensory impairment that would prevent subject from participating in or cooperating with the protocol.
NCT00255086,Phase 3,Alzheimer Disease,Stanford University,May-05,Alzheimer Disease;Memantine,"Significant clinical disorder or laboratory finding that renders the subject unsuitable for receiving an investigational drug including: clinically significant or unstable hematologic, hepatic, cardiovascular, pulmonary, gastrointestinal, endocrine, metabolic, renal, or other systemic disease or laboratory abnormality."
NCT00255086,Phase 3,Alzheimer Disease,Stanford University,May-05,Alzheimer Disease;Memantine,"Clinical contraindication to the use of memantine (e.g., hypersensitivity)."
NCT00255086,Phase 3,Alzheimer Disease,Stanford University,May-05,Alzheimer Disease;Memantine,History of seizure within past 5 years prior to screening.
NCT00255086,Phase 3,Alzheimer Disease,Stanford University,May-05,Alzheimer Disease;Memantine,"Platelet count less than  100,000/mm3."
NCT00255086,Phase 3,Alzheimer Disease,Stanford University,May-05,Alzheimer Disease;Memantine,History of claustrophobia
NCT00255086,Phase 3,Alzheimer Disease,Stanford University,May-05,Alzheimer Disease;Memantine,"Presence of metallic implants such as pacemakers, surgical aneurysm clips, or known metal fragments embedded in the body"
NCT00257673,Phase 2,Alzheimer's Disease,Memory Pharmaceuticals,Nov-05,Alzheimer Disease, standardized MMSE Score of 10 to 24 points
NCT00257673,Phase 2,Alzheimer's Disease,Memory Pharmaceuticals,Nov-05,Alzheimer Disease, diagnosis of probable Alzheimer's disease
NCT00257673,Phase 2,Alzheimer's Disease,Memory Pharmaceuticals,Nov-05,Alzheimer Disease, magnetic resonance imaging or computed tomography examination compatible with AD
NCT00257673,Phase 2,Alzheimer's Disease,Memory Pharmaceuticals,Nov-05,Alzheimer Disease, modified Hachinski Ischemia Score of less than or equal to 4
NCT00257673,Phase 2,Alzheimer's Disease,Memory Pharmaceuticals,Nov-05,Alzheimer Disease," currently receiving no AD therapy or currently receiving donepezil, rivastigmine, or galantamine"
NCT00257673,Phase 2,Alzheimer's Disease,Memory Pharmaceuticals,Nov-05,Alzheimer Disease, Exclusion criteria:
NCT00257673,Phase 2,Alzheimer's Disease,Memory Pharmaceuticals,Nov-05,Alzheimer Disease, head injury associated with cognitive impairment
NCT00257673,Phase 2,Alzheimer's Disease,Memory Pharmaceuticals,Nov-05,Alzheimer Disease," history of vascular dementia stroke, transient cerebral ischemic episodes, major depression, major psychotic disorder, or symptomatic postural hypotension"
NCT00257673,Phase 2,Alzheimer's Disease,Memory Pharmaceuticals,Nov-05,Alzheimer Disease," treatment for Alzheimer's disease other than donepezil, rivastigmine, or galantamine; tacrine is not permitted in the last 30 days or memantine in the last 90 days"
NCT00257673,Phase 2,Alzheimer's Disease,Memory Pharmaceuticals,Nov-05,Alzheimer Disease, treatment with calcium channel blockers or any investigational medications within the prior 30 days
NCT00277810,Phase 2/Phase 3,Alzheimer Disease,Pfizer,Mar-06,Alzheimer Disease, Diagnosis of probable Alzheimer's disease
NCT00277810,Phase 2/Phase 3,Alzheimer Disease,Pfizer,Mar-06,Alzheimer Disease, Current use of cholinesterase inhibitor
NCT00277810,Phase 2/Phase 3,Alzheimer Disease,Pfizer,Mar-06,Alzheimer Disease, Able to give signed and dated informed consent and lives with appropriate caregiver at home or in community dwelling with caregiver accompanying patient to all visits and visiting patient at least daily for duration of the study
NCT00285025,Phase 2,Alzheimer Disease,Sanofi,Mar-05,Alzheimer Disease, Male / female outpatients.
NCT00285025,Phase 2,Alzheimer Disease,Sanofi,Mar-05,Alzheimer Disease, Age greater than  50 years at screening.
NCT00285025,Phase 2,Alzheimer Disease,Sanofi,Mar-05,Alzheimer Disease," Dementia of Alzheimer's Type (DSM-IV 290.0) according to DSM-IV criteria, Probable AD according to NINCDS-ADRDA criteria, Mini-Mental State Examination score greater than  12 and less than  26."
NCT00285025,Phase 2,Alzheimer Disease,Sanofi,Mar-05,Alzheimer Disease, Untreated or treated for a minimum of 6 months before randomization with a stable dose of the cholinesterase inhibitors
NCT00285025,Phase 2,Alzheimer Disease,Sanofi,Mar-05,Alzheimer Disease," Generally healthy and ambulatory or ambulatory-aided (i.e., walker or cane)."
NCT00285025,Phase 2,Alzheimer Disease,Sanofi,Mar-05,Alzheimer Disease, Presence of a reliable caregiver.
NCT00285025,Phase 2,Alzheimer Disease,Sanofi,Mar-05,Alzheimer Disease," Patient, identified caregiver and, if applicable, patient surrogate (primary relative, legal guardian, medical proxy) have given their informed written consent and are capable of following study procedures"
NCT00285077,Phase 2,Alzheimer Disease,Sanofi,Mar-04,Alzheimer Disease, Patients who have participated in Study EFC5286 and completed the study.
NCT00285077,Phase 2,Alzheimer Disease,Sanofi,Mar-04,Alzheimer Disease," Patient, identified caregiver and, if applicable, patient surrogate (primary relative, legal guardian, medical proxy) have given their informed written consent and are capable of following study procedures specifically for this LTS5283 extension."
NCT00299988,Phase 2,Alzheimer's Disease,Weill Medical College of Cornell University,Feb-06,"Alzheimer Disease;Immunoglobulins;Immunoglobulins, Intravenous;Antibodies;gamma-Globulins;Rho(D) Immune Globulin",Diagnosis of probable Alzheimer's disease (AD) of mild to moderate severity (as determined by a Mini Mental State Examination (MMSE) score of 14 - 26 inclusive).
NCT00299988,Phase 2,Alzheimer's Disease,Weill Medical College of Cornell University,Feb-06,"Alzheimer Disease;Immunoglobulins;Immunoglobulins, Intravenous;Antibodies;gamma-Globulins;Rho(D) Immune Globulin","Ability to give informed consent, designate a decision-maker or have an already recognized decision-maker (such as a legal guardian or health care proxy)."
NCT00299988,Phase 2,Alzheimer's Disease,Weill Medical College of Cornell University,Feb-06,"Alzheimer Disease;Immunoglobulins;Immunoglobulins, Intravenous;Antibodies;gamma-Globulins;Rho(D) Immune Globulin",Ability to comply with testing and infusion regimen.
NCT00299988,Phase 2,Alzheimer's Disease,Weill Medical College of Cornell University,Feb-06,"Alzheimer Disease;Immunoglobulins;Immunoglobulins, Intravenous;Antibodies;gamma-Globulins;Rho(D) Immune Globulin","An able caregiver willing to participate (such as a spouse, child, other relative, close friend, aide or other professional caregiver closely involved in helping the patient take care of himself/herself)."
NCT00299988,Phase 2,Alzheimer's Disease,Weill Medical College of Cornell University,Feb-06,"Alzheimer Disease;Immunoglobulins;Immunoglobulins, Intravenous;Antibodies;gamma-Globulins;Rho(D) Immune Globulin",Venous access suitable for repeated infusion and phlebotomy.
NCT00299988,Phase 2,Alzheimer's Disease,Weill Medical College of Cornell University,Feb-06,"Alzheimer Disease;Immunoglobulins;Immunoglobulins, Intravenous;Antibodies;gamma-Globulins;Rho(D) Immune Globulin",On stable doses of approved AD medications for at least 3 months.
NCT00299988,Phase 2,Alzheimer's Disease,Weill Medical College of Cornell University,Feb-06,"Alzheimer Disease;Immunoglobulins;Immunoglobulins, Intravenous;Antibodies;gamma-Globulins;Rho(D) Immune Globulin","As applicable, on stable doses of psychoactive medications (e.g. antidepressants, antipsychotics) for at least 6 weeks."
NCT00299988,Phase 2,Alzheimer's Disease,Weill Medical College of Cornell University,Feb-06,"Alzheimer Disease;Immunoglobulins;Immunoglobulins, Intravenous;Antibodies;gamma-Globulins;Rho(D) Immune Globulin",Neuroimaging performed after symptom onset consistent with the patient's diagnosis.
NCT00299988,Phase 2,Alzheimer's Disease,Weill Medical College of Cornell University,Feb-06,"Alzheimer Disease;Immunoglobulins;Immunoglobulins, Intravenous;Antibodies;gamma-Globulins;Rho(D) Immune Globulin","Clinical laboratory values within normal limits or if abnormal, judged clinically insignificant by the Principal Investigator."
NCT00299988,Phase 2,Alzheimer's Disease,Weill Medical College of Cornell University,Feb-06,"Alzheimer Disease;Immunoglobulins;Immunoglobulins, Intravenous;Antibodies;gamma-Globulins;Rho(D) Immune Globulin","Women who want to take part in this study must either be post-menopausal, surgically sterilized or agree to avoid becoming pregnant during the entire period of their participation in this study."
NCT00301574,Phase 3,Alzheimer Disease,Janssen Pharmaceutical K.K.,Apr-01,Alzheimer Disease;Galantamine, Outpatients with a diagnosis of Alzheimer's disease according to the National Institute of Neurological and Communicative Disorders and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria
NCT00301574,Phase 3,Alzheimer Disease,Janssen Pharmaceutical K.K.,Apr-01,Alzheimer Disease;Galantamine, having a Mini-Mental Status Examination (MMSE) score of 10 - 22 inclusive
NCT00301574,Phase 3,Alzheimer Disease,Janssen Pharmaceutical K.K.,Apr-01,Alzheimer Disease;Galantamine, having an Alzheimer's Disease Assessment Scale - Japan cognitive subscale (ADAS-J cog) score of at least 18
NCT00301574,Phase 3,Alzheimer Disease,Janssen Pharmaceutical K.K.,Apr-01,Alzheimer Disease;Galantamine, exhibiting an onset and progression of cognitive dysfunction during at least 6 months prior to the screening period
NCT00304629,Phase 3,Alzheimer Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",Mar-00,Alzheimer Disease;Galantamine, Patients must have taken trial medication during the 24-month trial period of GAL-INT-8 and should be enrolled within 1 month after completion
NCT00304629,Phase 3,Alzheimer Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",Mar-00,Alzheimer Disease;Galantamine, Patients and their primary caregiver give informed consent for the participation in the trial
NCT00304629,Phase 3,Alzheimer Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",Mar-00,Alzheimer Disease;Galantamine," Patients must have remained in good health, as determined by medical history, complete physical examination and laboratory tests"
NCT00309725,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",unknown,Alzheimer Disease;Galantamine, Outpatients diagnosed with Alzheimer's disease in accordance with NINCDS-ADRDA (National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association) classification for probable Alzheimer's disease
NCT00309725,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",unknown,Alzheimer Disease;Galantamine," Mild/moderate dementia as evidenced by a Mini-Mental State Examination (MMSE) score ranging from 11 to 24, inclusive, at baseline"
NCT00309725,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",unknown,Alzheimer Disease;Galantamine, History of cognitive decline that has been gradual in onset and progressive over a period of at least 6 months
NCT00309725,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",unknown,Alzheimer Disease;Galantamine," Evidence of sustained memory deterioration in an otherwise alert patient, plus additional impairment in at least one of these five areas: orientation, judgment and problem-solving, functioning in community affairs, functioning in home and hobbies, and functioning in personal care"
NCT00309725,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",unknown,Alzheimer Disease;Galantamine," Patients who live with or have regular daily visits from one or more responsible caregiver who are capable of assisting with the patient's medication, able to accompany the patient for assessments, and willing to provide information about the patient.On days that the patient was sent home with a Holter monitor, the caregiver was required to stay with the patient in the same household for the 24 hour duration of the cardiac assessment to ensure that the monitor lead placement remained intact. The caregiver was to be available the following day for the return of the Holter monitoring device"
NCT00309725,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",unknown,Alzheimer Disease;Galantamine," Patient or patient's relative, guardian or legal representative have signed the informed consent."
NCT00314912,Phase 3,Alzheimer's Disease,Bellus Health Inc,May-06,Alzheimer Disease;Tramiprosate, The patient must have successfully completed the full 78-week duration of the double-blind CL-758007 study.
NCT00314912,Phase 3,Alzheimer's Disease,Bellus Health Inc,May-06,Alzheimer Disease;Tramiprosate, Male or female (age 50 years and older): Female must be of non-childbearing potential (i.e. surgically sterilized or at least 2 years post-menopausal).
NCT00314912,Phase 3,Alzheimer's Disease,Bellus Health Inc,May-06,Alzheimer Disease;Tramiprosate, Patient must be living in the community with a reliable caregiver. Participant living in an assisted living facility may be included if study medication intake is supervised and participant has a reliable caregiver.
NCT00314912,Phase 3,Alzheimer's Disease,Bellus Health Inc,May-06,Alzheimer Disease;Tramiprosate, The patient must be presenting a reasonably good nutritional status.
NCT00314912,Phase 3,Alzheimer's Disease,Bellus Health Inc,May-06,Alzheimer Disease;Tramiprosate, Signed inform consent from the patient or legal representative.
NCT00322153,Phase 3,Dementia of the Alzheimer's Type,Forest Laboratories,Jun-05,Alzheimer Disease;Dementia;Memantine, Ambulatory patients aged greater than /= 50 years
NCT00322153,Phase 3,Dementia of the Alzheimer's Type,Forest Laboratories,Jun-05,Alzheimer Disease;Dementia;Memantine," Diagnostic evidence of probable Alzheimer's disease consistent with criteria from the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) and the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)"
NCT00322153,Phase 3,Dementia of the Alzheimer's Type,Forest Laboratories,Jun-05,Alzheimer Disease;Dementia;Memantine, Confirmatory magnetic resonance imaging (MRI) or computed tomographic (CT) scan within the prior 12 months.
NCT00322153,Phase 3,Dementia of the Alzheimer's Type,Forest Laboratories,Jun-05,Alzheimer Disease;Dementia;Memantine, Mini-Mental State Examination (MMSE) scores greater than /= 3 and less than /= 14 at Screening (Visit 1) and Baseline (Visit 2)
NCT00322153,Phase 3,Dementia of the Alzheimer's Type,Forest Laboratories,Jun-05,Alzheimer Disease;Dementia;Memantine, Ongoing daily acetylcholinesterase inhibitor (AChEI) therapy at a stable dose for at least 3 months prior to Screening (Visit 1). It is preferred that patients continue to receive the same AChEI therapy for the duration of the study.
NCT00329082,Phase 2,Alzheimer's Disease,Eli Lilly and Company,May-06,Alzheimer Disease, At least 50 years of age and diagnosed with mild to moderate Alzheimer's disease or healthy volunteers
NCT00329082,Phase 2,Alzheimer's Disease,Eli Lilly and Company,May-06,Alzheimer Disease, fluent in reading and speaking English
NCT00329082,Phase 2,Alzheimer's Disease,Eli Lilly and Company,May-06,Alzheimer Disease, AD patients must have a reliable study partner who will be in frequent contact with the patient and comply with protocol requirements
NCT00329082,Phase 2,Alzheimer's Disease,Eli Lilly and Company,May-06,Alzheimer Disease, AD patients who have received AChEIs or memantine for at least 4 months and on stable therapy for at least 2 months prior to starting study drug
NCT00334568,Phase 2,Alzheimer's Disease,GlaxoSmithKline,Dec-04,Alzheimer Disease;Rosiglitazone," Meets the National Institute of Neurological and Communicative Diseases and Stroke/Alzheimers Disease and Related Disorders Association (NINCDS-ADRDA) criteria for Alzheimers disease, regardless of date of diagnosis relative to study entry date."
NCT00334568,Phase 2,Alzheimer's Disease,GlaxoSmithKline,Dec-04,Alzheimer Disease;Rosiglitazone," Has an Alzheimers disease status of mild to moderate, as classified by a Mini Mental State Examination (MMSE) score of 16 - 26 inclusive at screening."
NCT00334568,Phase 2,Alzheimer's Disease,GlaxoSmithKline,Dec-04,Alzheimer Disease;Rosiglitazone," Post-menopausal females defined as menopause is defined as greater than 6 months without menstrual period with an appropriate clinical profile, e.g. age appropriate, history of vasomotor symptoms. However if indicated this should be confirmed by oestradiol and FSH levels consistent with menopause (according to local laboratory ranges)."
NCT00334568,Phase 2,Alzheimer's Disease,GlaxoSmithKline,Dec-04,Alzheimer Disease;Rosiglitazone," Women who are on HRT (hormone replacement therapy) treatment, and have not been confirmed as post-menopausal should be advised to use contraception."
NCT00334568,Phase 2,Alzheimer's Disease,GlaxoSmithKline,Dec-04,Alzheimer Disease;Rosiglitazone," Has a permanent caregiver who is willing to attend all visits, oversee the subjects compliance with protocol-specified procedures and study medication, and report on subjects status. (Subjects living alone or in a nursing home are not eligible)."
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone, A subject will be eligible for inclusion in this study only if all of the following criteria apply:
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone, Male or female subject with a clinical diagnosis of probable Alzheimer's disease in accordance with NINCDS-ADRDA criteria (Appendix 2).
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone, (Note: National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and Alzheimer's Disease and Related Disorders Association (ADRDA).)
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone, Subject has mild to moderate Alzheimer's disease as defined by a MMSE score 10 to 26 inclusive at Screening.
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone, Hachinski Ischemia Score  4 at Screening (See Appendix 3).
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone, Age 50 and 90 years.
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone," At least 6 months of ongoing acetylcholinesterase inhibitor therapy for Alzheimer's disease, with stable dosing for at least the last 2 months (and with no intent to change for the duration of the study)."
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone," Current use of medication is in accordance with the criteria listed in Table 2 (Permitted Medications, Section 8.1)."
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone," Female subjects must be post-menopausal (i.e. greater than 1 year without menstrual period), surgically sterile, or agree to use adequate method of contraception (Appendix 4) for the duration of the study. Female subjects who are pre-menopausal or who have been post-menopausal for less than 1 year must undertake pregnancy testing (urine test) at Visit 1, which must be negative."
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone," Brain CT or MRI scan performed within the past 12 months or at Screening, showing no evidence of any other potential cause of dementia other than Alzheimer's disease."
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone," (Note: Questionable CT or MRI scans should be discussed with the medical monitor, using central imaging guidelines.)"
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone, Neurological exam without focal changes (excluding changes attributable to AD or peripheral trauma).
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone, Subject has the ability to comply with procedures for cognitive and other testing.
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone," Subject lives with (or has substantial periods of contact with) a regular caregiver who is willing to attend all visits, oversee the subject's compliance with protocol-specified procedures and study medication, and report on subject's status."
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone," (Note: A non-cohabiting caregiver must spend sufficient time with the subject so that, in the opinion of the Investigator, the caregiver can reliably assess cognitive function, activities and behavior, and report on the subject's compliance and health. As caregiver time spent with a potential subject is anticipated to be highly variable across countries and cultures, GSK will consider a variety of different measures by which this stipulation may be met, and GSK should be consulted if adequacy of a caregiver situation is in doubt. However, as guidance, the ability for a caregiver to meet his/her expected responsibilities for this study would normally be possible when the caregiver spends no less than 10 hours per week with the subject, divided over multiple days.)"
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone," Subject has provided full written informed consent prior to the performance of any protocol-specified procedure; or if unable to provide informed consent due to cognitive status, full written informed consent on behalf of the subject has been provided by a legally acceptable representative."
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone," (Note: Consent by legally acceptable representative is allowed where this is in accordance with local laws, regulations and ethics committee policy.)"
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone, Caregiver has provided full written informed consent on his/her own behalf prior to the performance of any protocol-specified procedure.
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone," Subjects considered for enrolment must have a QTc (either QTc B (Bazett's correction) or QTc F (Fridericia's correction)) less than 450msec at Visit 1, with the exception of subjects with bundle branch block (for whom either QTc B or QTc F must be less than 480msec)."
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone," (Note: For the purposes of these criteria, QTc B is defined as (QT interval [msec]) / (square root of RR interval [seconds]); and QTc F is defined as (QT interval [msec]) / (cube root of RR interval [seconds]).)"
NCT00359944,Phase 2,Alzheimer's Disease,Sunovion,Feb-06,Alzheimer Disease, Mild to moderate Alzheimer's Disease
NCT00359944,Phase 2,Alzheimer's Disease,Sunovion,Feb-06,Alzheimer Disease, Male or female 55 years or older
NCT00359944,Phase 2,Alzheimer's Disease,Sunovion,Feb-06,Alzheimer Disease, Living with caregiver
NCT00359944,Phase 2,Alzheimer's Disease,Sunovion,Feb-06,Alzheimer Disease," Read, understand and speak English"
NCT00362024,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,Nov-06,Alzheimer Disease, Male or females
NCT00362024,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,Nov-06,Alzheimer Disease," Age greater than /= 55 years, With mild-to-moderate AD, with MMSE between 18 and 26, inclusive, MHIS score less than /= 4, Global CDR score of 1 or 2"
NCT00362024,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,Nov-06,Alzheimer Disease, Who have a reliable informant/caregiver to accompany patient to all clinic visits
NCT00362024,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,Nov-06,Alzheimer Disease," If using a symptomatic AD treatments, patients must be on stable dose for greater than /= 6 months"
NCT00368459,Phase 2,Alzheimer Disease,Stanford University,Aug-06,Alzheimer Disease;Raloxifene Hydrochloride,Female
NCT00368459,Phase 2,Alzheimer Disease,Stanford University,Aug-06,Alzheimer Disease;Raloxifene Hydrochloride,Post menopausal
NCT00368459,Phase 2,Alzheimer Disease,Stanford University,Aug-06,Alzheimer Disease;Raloxifene Hydrochloride,Age at least 60 years
NCT00368459,Phase 2,Alzheimer Disease,Stanford University,Aug-06,Alzheimer Disease;Raloxifene Hydrochloride,Eight or more years of education with a history of premorbid literacy
NCT00368459,Phase 2,Alzheimer Disease,Stanford University,Aug-06,Alzheimer Disease;Raloxifene Hydrochloride,"By history, fluent speaker of English"
NCT00368459,Phase 2,Alzheimer Disease,Stanford University,Aug-06,Alzheimer Disease;Raloxifene Hydrochloride,Dementia (DSM-IV-derived criteria) present for at least six months beginning at age 60 or older
NCT00368459,Phase 2,Alzheimer Disease,Stanford University,Aug-06,Alzheimer Disease;Raloxifene Hydrochloride,"Mild or moderate dementia, defined by Mini-Mental State examination (MMSE) score between 12 and 26, inclusive"
NCT00368459,Phase 2,Alzheimer Disease,Stanford University,Aug-06,Alzheimer Disease;Raloxifene Hydrochloride,National Institute of Neurological and Communicative Disease and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for probable Alzheimer's disease (AD) based on results of a neurologist's evaluation and laboratory tests
NCT00368459,Phase 2,Alzheimer Disease,Stanford University,Aug-06,Alzheimer Disease;Raloxifene Hydrochloride,"Neurological history and examination within normal limits for age, except for changes consistent with AD or age"
NCT00368459,Phase 2,Alzheimer Disease,Stanford University,Aug-06,Alzheimer Disease;Raloxifene Hydrochloride,Modified Ischemia Scale score of 4 or less
NCT00368459,Phase 2,Alzheimer Disease,Stanford University,Aug-06,Alzheimer Disease;Raloxifene Hydrochloride,"Good physical health established by medical history, physical exam, and baseline laboratory tests"
NCT00368459,Phase 2,Alzheimer Disease,Stanford University,Aug-06,Alzheimer Disease;Raloxifene Hydrochloride,Blood pressure less than  180/100 at time of entry
NCT00368459,Phase 2,Alzheimer Disease,Stanford University,Aug-06,Alzheimer Disease;Raloxifene Hydrochloride,"No history of, or examination evidence for, current insulin-dependent diabetes, stroke thought to impair cognition (e.g., cortical or thalamic infarct), or other focal brain lesion or neurological disorder likely to affect cognition, or other serious medical illness likely to limit participant's ability to complete study protocol"
NCT00368459,Phase 2,Alzheimer Disease,Stanford University,Aug-06,Alzheimer Disease;Raloxifene Hydrochloride,"No history of pulmonary embolism, deep vein thrombosis, or retinal vein occlusion"
NCT00368459,Phase 2,Alzheimer Disease,Stanford University,Aug-06,Alzheimer Disease;Raloxifene Hydrochloride,"No Diagnostic and Statistical Manual (DSM) IV criteria for Major Depressive Episode or other Axis I psychiatric disorder, other than AD, within the past year"
NCT00368459,Phase 2,Alzheimer Disease,Stanford University,Aug-06,Alzheimer Disease;Raloxifene Hydrochloride,"Effective dose of an FDA-approved cholinesterase inhibitor for at least 6 months prior to randomization (usually donepezil 5 or 10 mg/d, rivastigmine 6 to 12 mg/d, or galantamine 16 to 24 mg/d); stable effective dose for at least 2 months prior to randomization"
NCT00368459,Phase 2,Alzheimer Disease,Stanford University,Aug-06,Alzheimer Disease;Raloxifene Hydrochloride,No psychotropic medication within 4 weeks of study entry or stable dose (for at least 4 weeks month) of psychotropic medications
NCT00368459,Phase 2,Alzheimer Disease,Stanford University,Aug-06,Alzheimer Disease;Raloxifene Hydrochloride,No experimental mediation for the treatment of cognitive impairment associated with dementia within 2 months of study entry
NCT00368459,Phase 2,Alzheimer Disease,Stanford University,Aug-06,Alzheimer Disease;Raloxifene Hydrochloride,No raloxifene within 6 months of study entry
NCT00368459,Phase 2,Alzheimer Disease,Stanford University,Aug-06,Alzheimer Disease;Raloxifene Hydrochloride,"No systemic estrogen, progestin, testosterone, related gonadal hormone therapy within 2 months of study entry"
NCT00368459,Phase 2,Alzheimer Disease,Stanford University,Aug-06,Alzheimer Disease;Raloxifene Hydrochloride,No other known contraindication to raloxifene or donepezil
NCT00368459,Phase 2,Alzheimer Disease,Stanford University,Aug-06,Alzheimer Disease;Raloxifene Hydrochloride,A primary caregiver who knows the participant well and who is able to accompany her for regular assessments during the course of the study
NCT00368459,Phase 2,Alzheimer Disease,Stanford University,Aug-06,Alzheimer Disease;Raloxifene Hydrochloride,Assent or consent of participant plus informed consent from participant's next of kin or legally authorized representative
NCT00377715,Phase 2,Alzheimer's Disease,"Medivation, Inc.",Sep-05,Alzheimer Disease,Males or females greater than or equal to 50 years of age.
NCT00377715,Phase 2,Alzheimer's Disease,"Medivation, Inc.",Sep-05,Alzheimer Disease,"Diagnosis of Alzheimer's Disease according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV TR) and Mini Mental State Exam between 10 and 24, inclusive and Modified Hachinski Ischemia Score less than or equal to 4."
NCT00377715,Phase 2,Alzheimer's Disease,"Medivation, Inc.",Sep-05,Alzheimer Disease,Brain imaging such as MRI and/or CT within one year of enrollment.
NCT00377715,Phase 2,Alzheimer's Disease,"Medivation, Inc.",Sep-05,Alzheimer Disease,Subjects must have a guardian or caregiver who assists the subject at least 5 days per week (at least 3 hours/day).
NCT00377715,Phase 2,Alzheimer's Disease,"Medivation, Inc.",Sep-05,Alzheimer Disease,Subjects must be able to cooperate with drug administration (including the ability to ingest oral medications) and study procedures and abide by study restrictions.
NCT00377715,Phase 2,Alzheimer's Disease,"Medivation, Inc.",Sep-05,Alzheimer Disease,"Subjects must have at least 6 years of prior education and should have previously (in pre-Alzheimer's condition) been capable of reading, writing and communicating effectively with others."
NCT00377715,Phase 2,Alzheimer's Disease,"Medivation, Inc.",Sep-05,Alzheimer Disease,Subjects must be willing and able to give informed consent or have a mentally competent legal representative authorized to provide informed consent on their behalf.
NCT00377715,Phase 2,Alzheimer's Disease,"Medivation, Inc.",Sep-05,Alzheimer Disease,Residence in an assisted care facility is allowed if subject is living independently.
NCT00380276,Phase 3,Alzheimer's Disease,Myrexis Inc.,Sep-06,Alzheimer Disease, Participation in a previous MPC-7869 randomized protocol
NCT00380276,Phase 3,Alzheimer's Disease,Myrexis Inc.,Sep-06,Alzheimer Disease, Have had a diagnosis of probable Alzheimer's disease.
NCT00380276,Phase 3,Alzheimer's Disease,Myrexis Inc.,Sep-06,Alzheimer Disease," Men or women ages 55 years or greater and living in the community at the time of enrollment (i.e., not living in a rest home or nursing care facility)."
NCT00380276,Phase 3,Alzheimer's Disease,Myrexis Inc.,Sep-06,Alzheimer Disease, Signed the subject Informed Consent Form and is willing and able to participate for the duration of the study.
NCT00380276,Phase 3,Alzheimer's Disease,Myrexis Inc.,Sep-06,Alzheimer Disease, Female subjects must be surgically sterile or postmenopausal for greater than  1 year.
NCT00380276,Phase 3,Alzheimer's Disease,Myrexis Inc.,Sep-06,Alzheimer Disease," Subjects must have a reliable caregiver who can read, understand and speak English or Spanish."
NCT00380302,Phase 1/Phase 2,Alzheimer Disease,Sanofi,Sep-06,Alzheimer Disease, The diagnosis of Alzheimer's disease
NCT00380302,Phase 1/Phase 2,Alzheimer Disease,Sanofi,Sep-06,Alzheimer Disease, Recent brain image(Computerized Axial Tomographic Scan -CAT scan or Magnetic Resonance Imaging - MRI)
NCT00380302,Phase 1/Phase 2,Alzheimer Disease,Sanofi,Sep-06,Alzheimer Disease, Mild to moderate range of disease; not too severe
NCT00384423,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",Oct-06,Alzheimer Disease, At least 60 years old.
NCT00384423,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",Oct-06,Alzheimer Disease, On a stable 10 mg dose of Aricept for at least 90 days and able to take it in the morning.
NCT00384423,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",Oct-06,Alzheimer Disease, Diagnosis of probable Alzheimer's Disease.
NCT00384423,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",Oct-06,Alzheimer Disease, Mild dementia.
NCT00384423,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",Oct-06,Alzheimer Disease, You or your authorized representative provide voluntary written informed consent.
NCT00384423,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",Oct-06,Alzheimer Disease," Not pregnant, planning a pregnancy, or capable of becoming pregnant."
NCT00414622,Phase 2,Alzheimer Disease,CoMentis,Nov-06,Alzheimer Disease, probable Alzheimer
NCT00420420,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,Nov-06,Alzheimer Disease, Male or females
NCT00420420,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,Nov-06,Alzheimer Disease, Age at least 55 years or older
NCT00420420,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,Nov-06,Alzheimer Disease," Mild-to-moderate Alzheimer's Disease, with Mini Mental State Examination (MMSE) between 18 and 26, inclusive, Modified Hachinski Ischemic Scale (MHIS) score =/less than 4, Global CDR score of 1 or 2, and who have a reliable informant/caregiver to accompany patient to all clinic visits"
NCT00420420,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,Nov-06,Alzheimer Disease," If using symptomatic Alzheimer's Disease treatments, patients must be on the medication for 3 months and on a STABLE DOSE for at least 2 months"
NCT00423085,Phase 3,Alzheimer's Disease,Novartis Pharmaceuticals,Jan-07,Alzheimer Disease;Rivastigmine, A diagnosis of dementia of the Alzheimer's type according to the DSM-IV criteria
NCT00423085,Phase 3,Alzheimer's Disease,Novartis Pharmaceuticals,Jan-07,Alzheimer Disease;Rivastigmine, A clinical diagnosis of probable AD according to NINCDS/ADRDA criteria
NCT00423085,Phase 3,Alzheimer's Disease,Novartis Pharmaceuticals,Jan-07,Alzheimer Disease;Rivastigmine, An MMSE score of greater than  or = 10 and less than  or = 20
NCT00423085,Phase 3,Alzheimer's Disease,Novartis Pharmaceuticals,Jan-07,Alzheimer Disease;Rivastigmine, Patients who have completed the Double-blind Treatment Phase on study medication
NCT00428389,Phase 3,Alzheimer's Disease,Novartis,Jan-07,Alzheimer Disease;Rivastigmine, Be at least 50 years of age;
NCT00428389,Phase 3,Alzheimer's Disease,Novartis,Jan-07,Alzheimer Disease;Rivastigmine, Have a diagnosis of probable Alzheimer's Disease;
NCT00428389,Phase 3,Alzheimer's Disease,Novartis,Jan-07,Alzheimer Disease;Rivastigmine, Have an MMSE score of greater than  or = 10 and less than  or = 24;
NCT00428389,Phase 3,Alzheimer's Disease,Novartis,Jan-07,Alzheimer Disease;Rivastigmine, Must have a caregiver who is able to attend all study visits;
NCT00428389,Phase 3,Alzheimer's Disease,Novartis,Jan-07,Alzheimer Disease;Rivastigmine," Have received continuous treatment with donepezil for at least 6 months prior to screening, and received a stable dose of 5 mg/day or 10 mg/day for at least the last 3 of these 6 months."
NCT00432081,Phase 3,Alzheimer Disease,Radboud University Medical Center,May-00,Alzheimer Disease;Indomethacin, The patient will satisfy the DSM-IV criteria for dementia of the Alzheimer's type.
NCT00432081,Phase 3,Alzheimer Disease,Radboud University Medical Center,May-00,Alzheimer Disease;Indomethacin, The patient will satisfy the NINCDS/ADRDA criteria for the clinical diagnosis of probable Alzheimer's disease (Appendix I).
NCT00432081,Phase 3,Alzheimer Disease,Radboud University Medical Center,May-00,Alzheimer Disease;Indomethacin, The severity of dementia for each patient will be quantified by a Mini-Mental State Examination (MMSE) score between 10 and 26 (both inclusive).
NCT00432081,Phase 3,Alzheimer Disease,Radboud University Medical Center,May-00,Alzheimer Disease;Indomethacin, The patient is living at home or in a home for the elderly.
NCT00432081,Phase 3,Alzheimer Disease,Radboud University Medical Center,May-00,Alzheimer Disease;Indomethacin, The patient has a responsible caregiver who is able to provide information about the patient's functional status.
NCT00432081,Phase 3,Alzheimer Disease,Radboud University Medical Center,May-00,Alzheimer Disease;Indomethacin, Written informed consent is obtained from the patient or the legally accepted representative.
NCT00438568,Phase 2,Alzheimer's Disease,University of Washington,Jun-06,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc", Age 55 or greater
NCT00438568,Phase 2,Alzheimer's Disease,University of Washington,Jun-06,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc", Good physical health
NCT00438568,Phase 2,Alzheimer's Disease,University of Washington,Jun-06,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc", Memory impairment with a diagnosis of mild cognitive impairment (MCI) or Alzheimer's disease (AD)
NCT00438568,Phase 2,Alzheimer's Disease,University of Washington,Jun-06,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc", Participants on stable doses of Memantine (Namenda) or cholinesterase inhibitors will be eligible
NCT00439166,Phase 3,Alzheimer's Disease,Hamilton Health Sciences Corporation,Feb-07,Alzheimer Disease;Doxycycline;Rifampin, Male or female
NCT00439166,Phase 3,Alzheimer's Disease,Hamilton Health Sciences Corporation,Feb-07,Alzheimer Disease;Doxycycline;Rifampin, Age greater than or equal to 50 years
NCT00439166,Phase 3,Alzheimer's Disease,Hamilton Health Sciences Corporation,Feb-07,Alzheimer Disease;Doxycycline;Rifampin, Diagnosis of probable Alzheimer's disease by NINCDS-ADRDA criteria
NCT00439166,Phase 3,Alzheimer's Disease,Hamilton Health Sciences Corporation,Feb-07,Alzheimer Disease;Doxycycline;Rifampin, Standardized Mini-Mental State Examination score 14-26 inclusive
NCT00439166,Phase 3,Alzheimer's Disease,Hamilton Health Sciences Corporation,Feb-07,Alzheimer Disease;Doxycycline;Rifampin," A caregiver who consents to monitor study medications, report on patient function, bring the patient to visits, etc."
NCT00439166,Phase 3,Alzheimer's Disease,Hamilton Health Sciences Corporation,Feb-07,Alzheimer Disease;Doxycycline;Rifampin," Vision, hearing, language ability sufficient to complete standardized testing in English."
NCT00439166,Phase 3,Alzheimer's Disease,Hamilton Health Sciences Corporation,Feb-07,Alzheimer Disease;Doxycycline;Rifampin, Patient consents (or legal representative consents for patient)
NCT00439166,Phase 3,Alzheimer's Disease,Hamilton Health Sciences Corporation,Feb-07,Alzheimer Disease;Doxycycline;Rifampin, Generally stable level of health where patient may be reasonably expected to complete a 1 year trial
NCT00440050,Phase 3,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),Feb-07,Alzheimer Disease, Male or female
NCT00440050,Phase 3,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),Feb-07,Alzheimer Disease, 50 years of age or older
NCT00440050,Phase 3,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),Feb-07,Alzheimer Disease," Residing in the community at baseline (includes assisted living facilities, but excludes long-term care nursing facilities)"
NCT00440050,Phase 3,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),Feb-07,Alzheimer Disease, MMSE (Mini-Mental State Examination) at screen of 14-26 (inclusive)
NCT00440050,Phase 3,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),Feb-07,Alzheimer Disease, No medical contraindications to study participation
NCT00440050,Phase 3,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),Feb-07,Alzheimer Disease, Fluent in English or Spanish
NCT00440050,Phase 3,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),Feb-07,Alzheimer Disease, Corrected vision and hearing sufficient for compliance with testing procedures
NCT00440050,Phase 3,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),Feb-07,Alzheimer Disease, Supervision available for study medication
NCT00440050,Phase 3,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),Feb-07,Alzheimer Disease, Caregiver/study partner to accompany participant to all visits
NCT00440050,Phase 3,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),Feb-07,Alzheimer Disease, Study partner must have direct contact with the participant more than 2 days/week
NCT00440050,Phase 3,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),Feb-07,Alzheimer Disease, Able to ingest oral medication
NCT00440050,Phase 3,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),Feb-07,Alzheimer Disease, Daily DHA consumption less than or equal to 200 mg/day in prior two months estimated by an abbreviated DHA food frequency questionnaire
NCT00440050,Phase 3,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),Feb-07,Alzheimer Disease, Neuroimaging consistent with the diagnosis of AD at some time after the onset of the memory decline
NCT00440050,Phase 3,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),Feb-07,Alzheimer Disease," Clinical laboratory values must be within normal limits or, if abnormal, must be judged to be clinically insignificant by the investigator"
NCT00440050,Phase 3,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),Feb-07,Alzheimer Disease, Stable use of cholinesterase inhibitors and memantine is permitted if doses are stable for 4 months prior to enrollment
NCT00443417,Phase 2,Alzheimer's Disease,"SK Chemicals Co., Ltd.",Apr-07,Alzheimer Disease, Age range : 50 ~ 85 years
NCT00443417,Phase 2,Alzheimer's Disease,"SK Chemicals Co., Ltd.",Apr-07,Alzheimer Disease, Clinical diagnosis of probable Alzheimer's disease (DSM-IV and NINCDS-ADRDA criteria)
NCT00443417,Phase 2,Alzheimer's Disease,"SK Chemicals Co., Ltd.",Apr-07,Alzheimer Disease, MRI within the last 12 months consistent with a diagnosis of AD
NCT00443417,Phase 2,Alzheimer's Disease,"SK Chemicals Co., Ltd.",Apr-07,Alzheimer Disease, MMSE score 10 to 26
NCT00443417,Phase 2,Alzheimer's Disease,"SK Chemicals Co., Ltd.",Apr-07,Alzheimer Disease, AChEI or memantine was discontinued at least 3 months prior to screening
NCT00454870,Phase 2,Alzheimer's Disease,Memory Pharmaceuticals,Feb-07,Alzheimer Disease, Diagnosis of probable or possible Alzheimer's disease
NCT00454870,Phase 2,Alzheimer's Disease,Memory Pharmaceuticals,Feb-07,Alzheimer Disease, MMSE score between 16 and 26 points
NCT00454870,Phase 2,Alzheimer's Disease,Memory Pharmaceuticals,Feb-07,Alzheimer Disease, Modified Hachinski Ischemia Score of less than or equal to 4
NCT00454870,Phase 2,Alzheimer's Disease,Memory Pharmaceuticals,Feb-07,Alzheimer Disease, Capable of performing cognitive tests and other procedures specified in protocol
NCT00471211,Phase 2,Alzheimer's Disease,Prana Biotechnology Limited,Dec-06,Alzheimer Disease, diagnosis of probable early Alzheimer's disease
NCT00471211,Phase 2,Alzheimer's Disease,Prana Biotechnology Limited,Dec-06,Alzheimer Disease, stable dose of acetylcholinesterase inhibitor
NCT00471211,Phase 2,Alzheimer's Disease,Prana Biotechnology Limited,Dec-06,Alzheimer Disease, community dwelling
NCT00471211,Phase 2,Alzheimer's Disease,Prana Biotechnology Limited,Dec-06,Alzheimer Disease, stable medical condition
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,Written informed consent.
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,"Patient Age range: Adult patients, 45 to 90 years of age, inclusive."
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,The caregiver must separately meet the specified inclusion/exclusion criteria for caregivers.
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,Women must be of non-child-bearing potential (greater than 1 year post-menopausal or surgically sterile).
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,There must be diagnostic evidence of probable Alzheimer's disease (AD).
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,"The patient must have been receiving Aricept at a dose of dose of 10 mg IR (or 10 mg dose of generic donepezil bioequivalent to Aricept), for at least 3 months prior to the Screening visit."
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,"A cranial image is required, with no evidence of focal brain disease that would account for dementia."
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,The patient must meet certain psychometric test criteria related to the degree of impairment of cognitive functioning.
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,"Health: physically healthy and ambulatory or ambulatory-aided (i.e., walker or cane); corrected vision and hearing sufficient for compliance with testing procedures, and able to read prior to disease onset."
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,"Clinical laboratory values must be within normal limits or, if abnormal, must be judged not clinically significant by the investigator."
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,Specified doses of selective serotonin reuptake inhibitors (SSRIs) are allowed in the study if dosage is within approved dose range and stable for 3 months prior to Screening.
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,"Other medical conditions, such as hypertension and cardiac disease must be well-controlled and the patient maintained on stable doses of medications for 3 months."
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,Patients with diabetes mellitus or risk factors for diabetes mellitus may be enrolled in the study provided that the patient's disease is stable and that there have been no recent hospitalizations for diabetes complications.
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,Patients whose serum B12 levels at Screening are below the normal range may nonetheless be admitted to the study if they subsequently show normal levels prior to Baseline.
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,"Patients with hypothyroidism who are on a stable dose of medication for at least 12 weeks prior to Screening, have normal TSH and free T4 at Screening, and are considered euthyroid will be eligible."
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,"Concomitant Medications: Under specified circumstances, the following medications may be allowed: chronic daily benzodiazepine use, bronchodilator medications for treatment of chronic obstructive pulmonary disease (COPD), and memantine. Certain other additional prescription treatments for AD, such as other cholinesterase inhibitors, must have been discontinued for at least 3 months prior to screening."
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,"The patient must have a relative/caregiver who supervises the regular taking of the drug at the correct dose and is alert for possible side effects, unless the patient's legal guardian takes on this task."
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil," The designated caregiver must be sufficiently familiar with the patient (as determined by the investigator) to provide accurate data. The caregiver must have regular contact with the patient (i.e., an average of 10 or more hours per week), must be able to observe for possible adverse events, and must be able to accompany the patient to all visits."
NCT00479557,Phase 2,Alzheimer Disease,Pfizer,May-07,Alzheimer Disease;Saponin QA-21V1, Diagnosis of probable Alzheimer's Disease with Mini-Mental State Examination (MMSE) score of 16-26 (except Germany: 21-26)
NCT00479557,Phase 2,Alzheimer Disease,Pfizer,May-07,Alzheimer Disease;Saponin QA-21V1, Brain MRI consistent with Alzheimer Disease
NCT00479557,Phase 2,Alzheimer Disease,Pfizer,May-07,Alzheimer Disease;Saponin QA-21V1, Concurent use of Chloniesterase inhibitor or memantine allowed if stable
NCT00479557,Phase 2,Alzheimer Disease,Pfizer,May-07,Alzheimer Disease;Saponin QA-21V1, Other inclusion criteria apply
NCT00481520,Phase 2,Alzheimer Disease,Wyeth is now a wholly owned subsidiary of Pfizer,Jun-07,Alzheimer Disease,"Signed and dated written informed consent obtained from the subject or the subject's legally authorized representative (LAR) or next of kin (if applicable), in accordance with the local regulations. The subject's caregiver must also consent to participate in the study."
NCT00481520,Phase 2,Alzheimer Disease,Wyeth is now a wholly owned subsidiary of Pfizer,Jun-07,Alzheimer Disease,Diagnosis of probable Alzheimer's Disease according to National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria.
NCT00481520,Phase 2,Alzheimer Disease,Wyeth is now a wholly owned subsidiary of Pfizer,Jun-07,Alzheimer Disease,"Men and postmenopausal or surgically sterile women aged from 50 to 90 inclusive. Postmenopausal women must have had 12 months of spontaneous amenorrhea. Surgically sterile women are defined as having a hysterectomy, bilateral ovariectomy [oophorectomy], or bilateral tubal ligation. Men who are sexually active will need to agree to use a form of contraception that is satisfactory as per the investigator."
NCT00481520,Phase 2,Alzheimer Disease,Wyeth is now a wholly owned subsidiary of Pfizer,Jun-07,Alzheimer Disease,Able to participate in all scheduled evaluations with a high probability of completing all required procedures and neuropsychological tests.
NCT00486044,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",Feb-05,Alzheimer Disease;Simvastatin, Age 35 to 69
NCT00486044,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",Feb-05,Alzheimer Disease;Simvastatin, Parent with Alzheimer's disease
NCT00500500,Phase 2,Alzheimer Disease,Ipsen,Jul-05,Alzheimer Disease, female or male of 50 to 85 years old with a care giver
NCT00500500,Phase 2,Alzheimer Disease,Ipsen,Jul-05,Alzheimer Disease, Mini Mental Status (MMS) test between 16 to 26 inclusive
NCT00500500,Phase 2,Alzheimer Disease,Ipsen,Jul-05,Alzheimer Disease, Clinical Dementia Rating (CDR) test inferior or equal to 1
NCT00500500,Phase 2,Alzheimer Disease,Ipsen,Jul-05,Alzheimer Disease, National Institute of Neurological and Communicative Disorders and Stroke / Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) test positive for an Alzheimer's disease
NCT00500500,Phase 2,Alzheimer Disease,Ipsen,Jul-05,Alzheimer Disease," Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM IV) test positive for dementia"
NCT00501111,Phase 2,Alzheimer Disease,AstraZeneca,Jul-07,Alzheimer Disease;Donepezil, Provision of informed consent from patient and caregiver
NCT00501111,Phase 2,Alzheimer Disease,AstraZeneca,Jul-07,Alzheimer Disease;Donepezil, Clinical prognosis of probable Alzheimer's disease
NCT00501111,Phase 2,Alzheimer Disease,AstraZeneca,Jul-07,Alzheimer Disease;Donepezil, Patient must have a caregiver visiting the patient at least three times weekly
NCT00506415,Phase 3,Alzheimer Disease,Novartis Pharmaceuticals,Jun-07,Alzheimer Disease;Cognitive Dysfunction;Rivastigmine," Male or female patients between 50 and 85 years of age with a diagnosis of probable Alzheimers Disease,"
NCT00506415,Phase 3,Alzheimer Disease,Novartis Pharmaceuticals,Jun-07,Alzheimer Disease;Cognitive Dysfunction;Rivastigmine," Baseline Mini-Mental State Examination (MMSE) score 10-24 inclusive,"
NCT00506415,Phase 3,Alzheimer Disease,Novartis Pharmaceuticals,Jun-07,Alzheimer Disease;Cognitive Dysfunction;Rivastigmine," A primary caregiver willing to accept responsibility for supervising treatment, assessing the patient's condition throughout the study, and for providing input into efficacy assessments."
NCT00506415,Phase 3,Alzheimer Disease,Novartis Pharmaceuticals,Jun-07,Alzheimer Disease;Cognitive Dysfunction;Rivastigmine," For double blind only: Meet the decline criteria of functional (as assessed by the investigator) and cognitive (assessed by a 1 point reduction in Mini-Mental State Examination) score between visits or a 3 point reduction from baseline) decline at weeks 23, 36 or 48."
NCT00515333,Phase 2,"Dementia, Alzheimer Type",TauRx Therapeutics Ltd,Aug-04,Dementia;Alzheimer Disease, Patient may be of either sex and must be supervised by a carer who is competent to ensure compliance with the medication and who is willing to participate in completing the various assessments.
NCT00515333,Phase 2,"Dementia, Alzheimer Type",TauRx Therapeutics Ltd,Aug-04,Dementia;Alzheimer Disease, Patients must be able to give written informed consent to participate in this study. Patients who lack capacity to consent may not be entered.
NCT00515333,Phase 2,"Dementia, Alzheimer Type",TauRx Therapeutics Ltd,Aug-04,Dementia;Alzheimer Disease, Competent carer must be available and must provide written consent to his or her own participation in the study.
NCT00515333,Phase 2,"Dementia, Alzheimer Type",TauRx Therapeutics Ltd,Aug-04,Dementia;Alzheimer Disease, Clinical diagnosis of dementia of the Alzheimer type determined by Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria and a diagnosis of Probable Alzheimer's Disease determined by the National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria. Information to support the diagnosis will include that derived from:
NCT00515333,Phase 2,"Dementia, Alzheimer Type",TauRx Therapeutics Ltd,Aug-04,Dementia;Alzheimer Disease," an abbreviated Cambridge Mental Disorders of the Elderly Examination (short CAMDEX) schedule, performed within six weeks prior to the baseline visit (Visit 0)."
NCT00515333,Phase 2,"Dementia, Alzheimer Type",TauRx Therapeutics Ltd,Aug-04,Dementia;Alzheimer Disease," Computerised tomography (CT) or magnetic resonance imaging (MRI), with no time limit on previous scans. In centres conducting SPECT/PET scans as part of their routine practice or as part of the study these may be used to inform the NINCDS-ADRDA diagnosis."
NCT00515333,Phase 2,"Dementia, Alzheimer Type",TauRx Therapeutics Ltd,Aug-04,Dementia;Alzheimer Disease, Patient must have mild or moderate dementia as determined by:
NCT00515333,Phase 2,"Dementia, Alzheimer Type",TauRx Therapeutics Ltd,Aug-04,Dementia;Alzheimer Disease, Mini-Mental State Examination (MMSE) value at screening of between 10 and 26 inclusive.
NCT00515333,Phase 2,"Dementia, Alzheimer Type",TauRx Therapeutics Ltd,Aug-04,Dementia;Alzheimer Disease, Clinical Dementia Rating (CDR) at screening of Stage 1 or Stage 2.
NCT00539305,Phase 3,Alzheimer's Disease,University of Washington,Jul-09,Alzheimer Disease;Cognitive Dysfunction;Methyltestosterone;Testosterone;Testosterone undecanoate;Testosterone enanthate;Testosterone 17 beta-cypionate, Male 60-90 years of age
NCT00539305,Phase 3,Alzheimer's Disease,University of Washington,Jul-09,Alzheimer Disease;Cognitive Dysfunction;Methyltestosterone;Testosterone;Testosterone undecanoate;Testosterone enanthate;Testosterone 17 beta-cypionate, Diagnosis of mild cognitive impairment (MCI)
NCT00539305,Phase 3,Alzheimer's Disease,University of Washington,Jul-09,Alzheimer Disease;Cognitive Dysfunction;Methyltestosterone;Testosterone;Testosterone undecanoate;Testosterone enanthate;Testosterone 17 beta-cypionate, Low testosterone level
NCT00539305,Phase 3,Alzheimer's Disease,University of Washington,Jul-09,Alzheimer Disease;Cognitive Dysfunction;Methyltestosterone;Testosterone;Testosterone undecanoate;Testosterone enanthate;Testosterone 17 beta-cypionate, Primary language is English
NCT00539305,Phase 3,Alzheimer's Disease,University of Washington,Jul-09,Alzheimer Disease;Cognitive Dysfunction;Methyltestosterone;Testosterone;Testosterone undecanoate;Testosterone enanthate;Testosterone 17 beta-cypionate, Availability of an informant who knows the participant well enough to answer questions
NCT00539305,Phase 3,Alzheimer's Disease,University of Washington,Jul-09,Alzheimer Disease;Cognitive Dysfunction;Methyltestosterone;Testosterone;Testosterone undecanoate;Testosterone enanthate;Testosterone 17 beta-cypionate, Stable medications for the previous 3 months
NCT00539305,Phase 3,Alzheimer's Disease,University of Washington,Jul-09,Alzheimer Disease;Cognitive Dysfunction;Methyltestosterone;Testosterone;Testosterone undecanoate;Testosterone enanthate;Testosterone 17 beta-cypionate," Normal complete blood count (CBC), and no clinically significant blood chemistry"
NCT00539305,Phase 3,Alzheimer's Disease,University of Washington,Jul-09,Alzheimer Disease;Cognitive Dysfunction;Methyltestosterone;Testosterone;Testosterone undecanoate;Testosterone enanthate;Testosterone 17 beta-cypionate, American Urological Association (AUA) symptom score less than or equal to 19
NCT00539305,Phase 3,Alzheimer's Disease,University of Washington,Jul-09,Alzheimer Disease;Cognitive Dysfunction;Methyltestosterone;Testosterone;Testosterone undecanoate;Testosterone enanthate;Testosterone 17 beta-cypionate, Body Mass Index (BMI) less than 33 and stable weight in the previous year
NCT00555204,Phase 2,Alzheimer's Disease,Abbott,Nov-07,Alzheimer Disease, Patient has mild to moderate Alzheimer's disease
NCT00555204,Phase 2,Alzheimer's Disease,Abbott,Nov-07,Alzheimer Disease, Patient has been receiving a stable dose of an acetylcholinesterase inhibitor
NCT00555204,Phase 2,Alzheimer's Disease,Abbott,Nov-07,Alzheimer Disease, Patient has a MMSE score between 12 and 26
NCT00555204,Phase 2,Alzheimer's Disease,Abbott,Nov-07,Alzheimer Disease, Patient has a MHIS score of less than or equal to 4
NCT00555204,Phase 2,Alzheimer's Disease,Abbott,Nov-07,Alzheimer Disease, Females must be postmenopausal for at least two years or surgically sterile
NCT00555204,Phase 2,Alzheimer's Disease,Abbott,Nov-07,Alzheimer Disease," Patient has an identified, reliable, caregiver who will support him/her to ensure compliance with treatment and will accompany them to each outpatient visit"
NCT00566397,Phase 2,Alzheimer's Disease,Pfizer,Dec-07,Alzheimer Disease, Mini Mental State Exam (MMSE) score between 14-26 (inclusive) at screening.
NCT00566397,Phase 2,Alzheimer's Disease,Pfizer,Dec-07,Alzheimer Disease, Participants must be receiving acetylcholinesterase inhibitors on a stable dose for at least 4 months prior to randomization
NCT00566501,Phase 3,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease;Donepezil,"Written informed consent from the participant (if possible) or from the participant's legal guardian or other representative at the time of the Baseline visit, prior to beginning any assessments or activities."
NCT00566501,Phase 3,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease;Donepezil,Completion of study E2020-G000-326 (NCT00478205) without ongoing SAEs or history of serious adverse drug reactions during study E2020-G000-326 (NCT00478205).
NCT00566501,Phase 3,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease;Donepezil,Participant must enroll in the present study within 3 days of completion of study E2020-G000-326 (NCT00478205).
NCT00566501,Phase 3,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease;Donepezil,"Health: physically healthy and ambulatory or ambulatory-aided (that is, walker or cane); corrected vision and hearing sufficient for compliance with testing procedures."
NCT00566501,Phase 3,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease;Donepezil,Co-morbid medical conditions must be well-controlled as determined by the investigator.
NCT00566501,Phase 3,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease;Donepezil,"Participants undergoing treatment with selective serotonin reuptake inhibitors (SSRIs) may be included, provided that doses are within the approved dose range as specified in the Physician's Desk Reference or local equivalent"
NCT00566501,Phase 3,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease;Donepezil,"Concomitant Medications: Participants undergoing treatment with the following medications may be enrolled in the study provided the following conditions are met: chronic daily benzodiazepine use if doses are stable within an approved dose range; bronchodilator medications for treatment of chronic obstructive pulmonary disease (COPD) as long as drug is administered via metered dose inhaler within approved dose range; memantine if taken at doses of 20 mg/day or less, provided that the dose is stable."
NCT00566501,Phase 3,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease;Donepezil,"The participants must have a relative/caregiver who supervises the regular taking of the drug at the correct dose and is alert for possible side effects, unless the participant's legal guardian takes on this task."
NCT00566501,Phase 3,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease;Donepezil," designated caregiver for participation in study assessments. The caregiver must be sufficiently familiar with the participant (as determined by the investigator) to provide accurate data. Specifically, the caregiver must have sufficient contact with the participant to provide accurate reports of the participant's functioning, must be able to observe for possible adverse events, and must be able to accompany the participant to all visits. It is preferable that the caregiver be the same as in study E2020-G000-326 (NCT00478205). If no replacement caregiver is available who meets the caregiver inclusion/exclusion criteria, the participant must be discontinued from the study."
NCT00568776,Phase 2,Alzheimer Disease,"OPKO Health, Inc.",Dec-07,Alzheimer Disease;Inositol, Diagnosis of probable AD
NCT00568776,Phase 2,Alzheimer Disease,"OPKO Health, Inc.",Dec-07,Alzheimer Disease;Inositol," Age 50 to 85 years, inclusive"
NCT00568776,Phase 2,Alzheimer Disease,"OPKO Health, Inc.",Dec-07,Alzheimer Disease;Inositol," Mini-Mental Status Exam (MMSE) score of 16-26, inclusive"
NCT00568776,Phase 2,Alzheimer Disease,"OPKO Health, Inc.",Dec-07,Alzheimer Disease;Inositol, Brain magnetic resonance imaging (MRI) scan consistent with the diagnosis of AD
NCT00568776,Phase 2,Alzheimer Disease,"OPKO Health, Inc.",Dec-07,Alzheimer Disease;Inositol," Fluency in English, French, or Spanish"
NCT00568776,Phase 2,Alzheimer Disease,"OPKO Health, Inc.",Dec-07,Alzheimer Disease;Inositol, Stable doses of medications (cholinesterase inhibitors and memantine allowed)
NCT00568776,Phase 2,Alzheimer Disease,"OPKO Health, Inc.",Dec-07,Alzheimer Disease;Inositol, Caregiver is able to attend all study visits
NCT00574132,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-07,Alzheimer Disease, Diagnosis of probable AD
NCT00574132,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-07,Alzheimer Disease, Age from 50 to less than 89
NCT00574132,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-07,Alzheimer Disease, Mini-Mental Status Exam score of 16-26 inclusive
NCT00574132,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-07,Alzheimer Disease, Brain magnetic resonance imaging (MRI) scan consistent with the diagnosis of AD
NCT00574132,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-07,Alzheimer Disease, Stable doses of medications (cholinesterase inhibitors and memantine allowed)
NCT00574132,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-07,Alzheimer Disease, Caregiver able to attend all clinic visits with patient
NCT00575055,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-07,Alzheimer Disease, Diagnosis of probable AD
NCT00575055,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-07,Alzheimer Disease, Age from 50 to less than 89
NCT00575055,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-07,Alzheimer Disease, Mini-Mental Status Exam score of 16-26 inclusive
NCT00575055,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-07,Alzheimer Disease, Brain magnetic resonance imaging (MRI) scan consistent with the diagnosis of AD
NCT00575055,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-07,Alzheimer Disease, Stable doses of medications (cholinesterase inhibitors and memantine allowed)
NCT00575055,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-07,Alzheimer Disease, Caregiver able to attend all clinic visits with patient
NCT00580931,Phase 1/Phase 2,Alzheimer's Disease,"University of California, Irvine",unknown,Alzheimer Disease;Niacinamide;Niacin;Nicotinic Acids, Diagnosis of probable AD according to DSM-IV criteria
NCT00580931,Phase 1/Phase 2,Alzheimer's Disease,"University of California, Irvine",unknown,Alzheimer Disease;Niacinamide;Niacin;Nicotinic Acids, Mild to moderate dementia based on Mini-Mental State Examination [MMSE] score between 13-25
NCT00580931,Phase 1/Phase 2,Alzheimer's Disease,"University of California, Irvine",unknown,Alzheimer Disease;Niacinamide;Niacin;Nicotinic Acids, Minimum age 50 years
NCT00580931,Phase 1/Phase 2,Alzheimer's Disease,"University of California, Irvine",unknown,Alzheimer Disease;Niacinamide;Niacin;Nicotinic Acids, Brain imaging (computed tomographic scan or magnetic resonance image) within 12 months consistent with a diagnosis of probable AD
NCT00580931,Phase 1/Phase 2,Alzheimer's Disease,"University of California, Irvine",unknown,Alzheimer Disease;Niacinamide;Niacin;Nicotinic Acids, Hachinski Ischemic Score of less than 4.
NCT00580931,Phase 1/Phase 2,Alzheimer's Disease,"University of California, Irvine",unknown,Alzheimer Disease;Niacinamide;Niacin;Nicotinic Acids," Stable doses of concomitant medications, including cholinesterase inhibitors (ChEIs) and/or memantine."
NCT00581867,Phase 1/Phase 2,Alzheimer's Disease,"Jeff Burns, MD",Oct-07,"Alzheimer Disease;Insulin;Insulin, Globin Zinc;Insulin Aspart", Patients with Early Alzheimer's disease
NCT00594568,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Mar-08,Alzheimer Disease, Meets criteria for mild to moderate Alzheimer's disease (AD) with Mini-Mental State Examination (MMSE) score of 16-26 at Visit 1
NCT00594568,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Mar-08,Alzheimer Disease, Modified Hachinski Ischemia Scale score of less than or equal to 4
NCT00594568,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Mar-08,Alzheimer Disease, Geriatric Depression Scale score of less than or equal to 6
NCT00594568,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Mar-08,Alzheimer Disease, A magnetic resonance imaging (MRI) or computerized tomography (CT) scan in the last 2 years with no findings inconsistent with a diagnosis of AD
NCT00594568,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Mar-08,Alzheimer Disease," If female, must be without menstruation for at least 12 consecutive months or have had both ovaries removed"
NCT00602680,Phase 2,Alzheimer's Disease,Sanofi,Jan-08,Alzheimer Disease;Donepezil, Outpatients with diagnosis of mild AD
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1," Male or female, age 50 yrs or older. Females must be of non-childbearing potential (surgically sterilized or at least 2 yrs post-menopausal)"
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1, Must have a cognitive deficit present for at least 1 yr  and  meet DSM-IV-TRTM criteria for AD  and  meet NINCDS/ADRDA criteria for the presence of probable AD
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1," Severity of AD must be mild to moderate, documented with a MMSE score of 12-26"
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1," Has a CT scan or MRI scan within the prior 12 months, which is compatible with a diagnosis of probable AD"
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1," Ability to walk, at least with an assistive device"
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1, Vision  and  hearing sufficient to comply with testing
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1, Normal cognitive  and  social functioning prior to onset of dementia
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1, Consistent caregiver to accompany patient to assessment visits
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1, Sufficient basic education to be able to complete the cognitive assessments
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1, Living outside an institution
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1, Informed consent signed  and  dated by patient or legal representative
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1, Has provided written authorization for the use  and  disclosure of protected health information
NCT00606476,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-06,Alzheimer Disease, A subject must meet ALL of the following criteria to be considered for enrollment into this study:
NCT00606476,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-06,Alzheimer Disease,Signed and dated written informed consent obtained from the subject and/or the subject's caregiver in accordance with the local regulations.
NCT00606476,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-06,Alzheimer Disease,"Subjects must have completed Study 201 Visit 22 (Week 78), or Study 102 Visit 11 (Week 16)."
NCT00606476,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-06,Alzheimer Disease,"Magnetic resonance imaging scan of sufficient quality for the Radiologist to evaluate subject safety from Study 201 Visit 21 (Week 71), or Study 251 Screening Visit for subjects from Study 102."
NCT00606476,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-06,Alzheimer Disease,"Lives at home with appropriate caregiver capable of accompanying the subject on all clinic visits, or community dwelling with caregiver capable of accompanying the subject on all clinic visits and visiting with the subject approximately five times per week for the duration of the study."
NCT00606476,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-06,Alzheimer Disease,"In the opinion of the investigator, the subject and the caregiver will be compliant."
NCT00624026,Phase 3,Alzheimer's Disease,Merz Pharmaceuticals GmbH,Nov-07,Alzheimer Disease;Memantine, Male or female outpatient at least 50 years of age and at least 8 years of education.
NCT00624026,Phase 3,Alzheimer's Disease,Merz Pharmaceuticals GmbH,Nov-07,Alzheimer Disease;Memantine, The patient should have German as a mother-tongue or at least speak the language fluently in order to achieve similar scores in verbal tasks.
NCT00624026,Phase 3,Alzheimer's Disease,Merz Pharmaceuticals GmbH,Nov-07,Alzheimer Disease;Memantine, Current diagnosis of probable Alzheimer's disease consistent with NINCDS- ADRDA criteria or with DSM IV TR criteria for Dementia of the Alzheimer's type.
NCT00624026,Phase 3,Alzheimer's Disease,Merz Pharmaceuticals GmbH,Nov-07,Alzheimer Disease;Memantine, Mini Mental State Examination (MMSE) total score is less than 20
NCT00624026,Phase 3,Alzheimer's Disease,Merz Pharmaceuticals GmbH,Nov-07,Alzheimer Disease;Memantine," Patients treated with any acetylcholinesterase inhibitor (AChEI) may be included, when treatment has started at least 6 months prior screening and was stable during the last 3 months."
NCT00630851,Phase 3,Alzheimer Disease,Pfizer,Oct-02,Alzheimer Disease;Donepezil, Probable or possible Alzheimer's disease
NCT00630851,Phase 3,Alzheimer Disease,Pfizer,Oct-02,Alzheimer Disease;Donepezil, Living in skilled nursing home
NCT00645190,Phase 3,Alzheimer Disease,Xian-Janssen Pharmaceutical Ltd.,Mar-04,Alzheimer Disease;Galantamine, Out-patients diagnosed with mild to moderate probable AD. The diagnosis should have been established in accordance with the classification for probable AD of NINCDS-ADRDA
NCT00645190,Phase 3,Alzheimer Disease,Xian-Janssen Pharmaceutical Ltd.,Mar-04,Alzheimer Disease;Galantamine, MMSE score of 10-24 (inclusive) at screening
NCT00645190,Phase 3,Alzheimer Disease,Xian-Janssen Pharmaceutical Ltd.,Mar-04,Alzheimer Disease;Galantamine, Patients who lived with or had regular daily visits from a responsible caregiver
NCT00645190,Phase 3,Alzheimer Disease,Xian-Janssen Pharmaceutical Ltd.,Mar-04,Alzheimer Disease;Galantamine, .Has signed the informed consent form by subject and assent form by care-giver
NCT00663026,Phase 2,Alzheimer Disease,Pfizer,Nov-08,Alzheimer Disease, Diagnosis of probable Alzheimer Disease according to National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria
NCT00663026,Phase 2,Alzheimer Disease,Pfizer,Nov-08,Alzheimer Disease, Mini-Mental State Examination (MMSE) score 16-26
NCT00663936,Phase 2,Alzheimer's Disease,"FUJIFILM Toyama Chemical Co., Ltd.",Apr-08,Alzheimer Disease,Male or female (post-menopausal or surgically sterile)
NCT00663936,Phase 2,Alzheimer's Disease,"FUJIFILM Toyama Chemical Co., Ltd.",Apr-08,Alzheimer Disease,Patients with Mild to moderate Alzheimer's disease who are receiving Donepezil.
NCT00663936,Phase 2,Alzheimer's Disease,"FUJIFILM Toyama Chemical Co., Ltd.",Apr-08,Alzheimer Disease,Age 50 to 90 inclusive
NCT00663936,Phase 2,Alzheimer's Disease,"FUJIFILM Toyama Chemical Co., Ltd.",Apr-08,Alzheimer Disease,Patients must be living in the community
NCT00663936,Phase 2,Alzheimer's Disease,"FUJIFILM Toyama Chemical Co., Ltd.",Apr-08,Alzheimer Disease,Patients must have an eligible informant or study partner (caregiver)
NCT00663936,Phase 2,Alzheimer's Disease,"FUJIFILM Toyama Chemical Co., Ltd.",Apr-08,Alzheimer Disease,Patients and eligible informant or study partner (caregiver) must be able to read and understand English.
NCT00663936,Phase 2,Alzheimer's Disease,"FUJIFILM Toyama Chemical Co., Ltd.",Apr-08,Alzheimer Disease,Informed consent obtained from both the patient and the caregiver etc (According to the protocol)
NCT00667810,Phase 3,Alzheimer Disease,Pfizer,Jun-08,Alzheimer Disease," Diagnosis of probable Alzheimer Disease (AD), with Mini Mental State Examination (MMSE) score of 16-26, and brain magnetic resonance imaging (MRI) consistent with the diagnosis of AD"
NCT00667810,Phase 3,Alzheimer Disease,Pfizer,Jun-08,Alzheimer Disease," Concurrent use of cholinesterase inhibitor or memantine allowed, if stable"
NCT00667810,Phase 3,Alzheimer Disease,Pfizer,Jun-08,Alzheimer Disease, Caregiver will participate and be able to attend clinic visits with patient
NCT00675623,Phase 3,Alzheimer's Disease,"Medivation, Inc.",May-08,Alzheimer Disease, Mild-to-Moderate Alzheimer's disease
NCT00675623,Phase 3,Alzheimer's Disease,"Medivation, Inc.",May-08,Alzheimer Disease, Probable AD (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) and Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV)
NCT00675623,Phase 3,Alzheimer's Disease,"Medivation, Inc.",May-08,Alzheimer Disease, MMSE score 10-24 inclusive
NCT00675623,Phase 3,Alzheimer's Disease,"Medivation, Inc.",May-08,Alzheimer Disease, Computerized tomography (CT) san or magnetic resonance imaging (MRI) consistent with AD
NCT00675623,Phase 3,Alzheimer's Disease,"Medivation, Inc.",May-08,Alzheimer Disease, Caregiver who cares for the patient at least 5 days per week
NCT00676143,Phase 3,Alzheimer Disease,Pfizer,Jan-08,Alzheimer Disease," Diagnosis of probable AD, with MMSE score of 16-26, and brain MRI consistent with the diagnosis of AD"
NCT00676143,Phase 3,Alzheimer Disease,Pfizer,Jan-08,Alzheimer Disease," Concurrent use of cholinesterase inhibitor or memantine allowed, if stable."
NCT00676143,Phase 3,Alzheimer Disease,Pfizer,Jan-08,Alzheimer Disease, Caregiver will participate and be able to attend clinic visits with patient.
NCT00679627,Phase 3,Alzheimer's Disease,"Janssen Research &amp; Development, LLC",Jun-08,Alzheimer Disease;Galantamine, Outpatients
NCT00679627,Phase 3,Alzheimer's Disease,"Janssen Research &amp; Development, LLC",Jun-08,Alzheimer Disease;Galantamine," diagnosed with mild to moderately-severe, probable or possible AD, established in accordance with the criteria defined by the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease Related Disorders Association or the Diagnostic and Statistical Manual, Fourth Edition"
NCT00679627,Phase 3,Alzheimer's Disease,"Janssen Research &amp; Development, LLC",Jun-08,Alzheimer Disease;Galantamine, living with or have regular and frequent visits from a responsible caregiver.
NCT00684944,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,unknown,Alzheimer Disease, The patient may be of either sex and must be supervised by a carer who is competent to ensure compliance with the medication and who is willing to participate in completing the various assessments. The carer must provide written consent to his or her own participation in the study.
NCT00684944,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,unknown,Alzheimer Disease, Patients with capacity must give written informed consent to participate in this study. Patients who lack capacity to consent must be in agreement with entering into the study and have a personal legal representative giving written informed consent to their participation.
NCT00684944,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,unknown,Alzheimer Disease, The patient must have been ongoing in TRx-014-001 at time of study termination.
NCT00693004,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",May-08,Alzheimer Disease;Donepezil, Men or Women with a clinical diagnosis of Probable AD
NCT00693004,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",May-08,Alzheimer Disease;Donepezil, MMSE score 16 to 24 inclusive
NCT00693004,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",May-08,Alzheimer Disease;Donepezil, Age greater than 50 and less than 90 years
NCT00693004,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",May-08,Alzheimer Disease;Donepezil, Brain CT or MRI scan Consistent with a primary diagnosis of AD within 12 months
NCT00693004,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",May-08,Alzheimer Disease;Donepezil," Neurological examination without focal deficits (excluding changes attributable to peripheral nervous system disease, trauma or congenital birth deficits)"
NCT00693004,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",May-08,Alzheimer Disease;Donepezil, No history or evidence of any other CNS disorder that could be interpreted as a cause of dementia
NCT00693004,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",May-08,Alzheimer Disease;Donepezil, No diagnosis of vascular dementia
NCT00693004,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",May-08,Alzheimer Disease;Donepezil, No history of significant psychiatric illness such as schizophrenia or bipolar affective disorder. Subjects with major depressive disorder on a stable dose of an antidepressant for greater than 6 months may be eligible
NCT00693004,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",May-08,Alzheimer Disease;Donepezil," No evidence of the following: current vitamin B12 deficiency, positive syphilis serology, positive HIV test, or abnormalities in thyroid function"
NCT00693004,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",May-08,Alzheimer Disease;Donepezil, No cognitive rehabilitation within 6 months of the study
NCT00693004,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",May-08,Alzheimer Disease;Donepezil, Subject has a regular caregiver willing to attend all study visits
NCT00693004,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",May-08,Alzheimer Disease;Donepezil," Signed informed consent by the subject (and legal guardian, if applicable)"
NCT00704782,Phase 2,Alzheimer's Disease,"Medivation, Inc.",Apr-08,Alzheimer Disease, Alzheimer's disease
NCT00704782,Phase 2,Alzheimer's Disease,"Medivation, Inc.",Apr-08,Alzheimer Disease, On donepezil (Aricept)
NCT00704782,Phase 2,Alzheimer's Disease,"Medivation, Inc.",Apr-08,Alzheimer Disease, Caregiver who cares for the patient at least 5 days per week
NCT00710684,Phase 2,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Donepezil, Subjects and their caregivers must provide informed consent prior to study entry.
NCT00710684,Phase 2,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Donepezil," Subjects must have a clinical diagnosis of probable mild-to-moderate Alzheimer's disease with no evidence of disorders that are thought to be the cause of, or contributing to the severity of the subject's dementia and a documented history of at least 6 months of ongoing donepezil therapy with stable dosing for at least the last 2 months."
NCT00710684,Phase 2,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Donepezil," Subjects must have a regular caregiver who is willing to attend visits, oversee the subject's compliance with the study and report on the subject's status."
NCT00710684,Phase 2,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Donepezil, Female subjects of child-bearing potential must agree to abstinence or an approved form of birth control.
NCT00710684,Phase 2,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Donepezil, Subjects must have adequate blood pressure and laboratory values.
NCT00715858,Phase 3,Alzheimer's Disease,McMaster University,May-08,Alzheimer Disease;Doxycycline;Rifampin, Giving informed consent to lumbar puncture
NCT00715858,Phase 3,Alzheimer's Disease,McMaster University,May-08,Alzheimer Disease;Doxycycline;Rifampin, Participation in the DARAD clinical trial which requires the following:
NCT00715858,Phase 3,Alzheimer's Disease,McMaster University,May-08,Alzheimer Disease;Doxycycline;Rifampin, diagnosis of probable Alzheimer's disease
NCT00715858,Phase 3,Alzheimer's Disease,McMaster University,May-08,Alzheimer Disease;Doxycycline;Rifampin, SMMSE 14-26 inclusive
NCT00715858,Phase 3,Alzheimer's Disease,McMaster University,May-08,Alzheimer Disease;Doxycycline;Rifampin, community-dwelling
NCT00715858,Phase 3,Alzheimer's Disease,McMaster University,May-08,Alzheimer Disease;Doxycycline;Rifampin, age 50 or greater
NCT00715858,Phase 3,Alzheimer's Disease,McMaster University,May-08,Alzheimer Disease;Doxycycline;Rifampin," caregiver to monitor study medication and report on ADLs, behaviour, etc."
NCT00715858,Phase 3,Alzheimer's Disease,McMaster University,May-08,Alzheimer Disease;Doxycycline;Rifampin, adequate English literacy to complete neuropsychological testing
NCT00715858,Phase 3,Alzheimer's Disease,McMaster University,May-08,Alzheimer Disease;Doxycycline;Rifampin, generally stable level of health
NCT00722046,Phase 2,Alzheimer's Disease,Pfizer,Dec-08,Alzheimer Disease," Males or females of non childbearing potential, age greater than  or = 50"
NCT00722046,Phase 2,Alzheimer's Disease,Pfizer,Dec-08,Alzheimer Disease," Diagnosis of probable Alzheimer's disease, consistent with criterial from both:"
NCT00722046,Phase 2,Alzheimer's Disease,Pfizer,Dec-08,Alzheimer Disease, National Institute of Neurological and Communicable Disease and Stroke and Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA)
NCT00722046,Phase 2,Alzheimer's Disease,Pfizer,Dec-08,Alzheimer Disease, Diagnostic and Statistical Manual of Mental Disorders (DSM IV)
NCT00722046,Phase 2,Alzheimer's Disease,Pfizer,Dec-08,Alzheimer Disease, Mini-mental status exam score of 16-26 inclusive
NCT00722046,Phase 2,Alzheimer's Disease,Pfizer,Dec-08,Alzheimer Disease, Rosen-Modified Hachinski Ischemia Score of less than  or = 4
NCT00744978,Phase 2,Alzheimer's Disease,Pfizer,Jul-09,Alzheimer Disease;Varenicline," Males or females, age 55-85"
NCT00744978,Phase 2,Alzheimer's Disease,Pfizer,Jul-09,Alzheimer Disease;Varenicline," Diagnosis of probable Alzheimer's disease, consistent with criteria from both: 1) National Institute of Neurological and Communicable Disease and Stroke and Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) and 2) Diagnostic and Statistical Manual of Mental Disorders (DSM IV)"
NCT00744978,Phase 2,Alzheimer's Disease,Pfizer,Jul-09,Alzheimer Disease;Varenicline, Mini-mental status exam score of 14-26 inclusive
NCT00744978,Phase 2,Alzheimer's Disease,Pfizer,Jul-09,Alzheimer Disease;Varenicline, Rosen-Modified Hachinski Ischemia Score of less than  or = 4
NCT00749216,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Sep-08,Alzheimer Disease," Men or non-fertile women, at least 50 years of age.(Women who are not surgically sterilized must be post-menopausal for at least 1 year.)"
NCT00749216,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Sep-08,Alzheimer Disease, Patients with mild to moderate AD by following disease diagnostic criteria
NCT00749216,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Sep-08,Alzheimer Disease, National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria
NCT00749216,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Sep-08,Alzheimer Disease, Modified Hachinski Ischemia Scale score of  4
NCT00749216,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Sep-08,Alzheimer Disease, Folstein Mini-Mental State Examination (MMSE) score of 15 through 26
NCT00749216,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Sep-08,Alzheimer Disease, Geriatric Depression Scale (GDS) score of  10 on the staff-administered short form
NCT00751907,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",Jun-06,Alzheimer Disease;Atorvastatin, Adult (ages 40-65) children of parent with documented Alzheimer's disease
NCT00762411,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Sep-08,Alzheimer Disease, Meets criteria for mild to moderate Alzheimer's disease (AD) with Mini-Mental State Examination score of 16 through 26 at visit 1
NCT00762411,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Sep-08,Alzheimer Disease, Modified Hachinski Ischemia Scale score of less than or equal to 4
NCT00762411,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Sep-08,Alzheimer Disease, Geriatric Depression Scale score of less than or equal to 6
NCT00762411,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Sep-08,Alzheimer Disease, A magnetic resonance imaging (MRI) or computerized tomography (CT) scan in the last 2 years with no findings inconsistent with a diagnosis of AD
NCT00762411,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Sep-08,Alzheimer Disease," If female, must be without menstruation for a least 12 consecutive months or have had both ovaries removed."
NCT00804271,Phase 3,Alzheimer's Disease,Merz Pharmaceuticals GmbH,Dec-08,Alzheimer Disease;Memantine, Diagnosis of probable Alzheimer's disease consistent with NINCDS-ADRDA criteria or with DSM IV TR criteria for Dementia of Alzheimer's type.
NCT00804271,Phase 3,Alzheimer's Disease,Merz Pharmaceuticals GmbH,Dec-08,Alzheimer Disease;Memantine, Signed informed consent prior to the initiation of any study specific procedures.
NCT00804271,Phase 3,Alzheimer's Disease,Merz Pharmaceuticals GmbH,Dec-08,Alzheimer Disease;Memantine, Sight and hearing (a hearing aid is permitted) are sufficiently good to allow the undertaking of study-related procedures and psychometric tests.
NCT00809510,Phase 2,Alzheimer's Disease,Abbott,Jan-09,Alzheimer Disease, The subject was randomized into Study M06-876 and completed the study.
NCT00809510,Phase 2,Alzheimer's Disease,Abbott,Jan-09,Alzheimer Disease, The subject must remain on the same dose of AChEI that was used during the M06-876 study.
NCT00809510,Phase 2,Alzheimer's Disease,Abbott,Jan-09,Alzheimer Disease," The subject is in general good health, as judged by the investigator"
NCT00810147,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,Feb-09,Alzheimer Disease, Clinical diagnosis of Mild to Moderate Alzheimer's disease (MMSE 16-26)
NCT00810147,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,Feb-09,Alzheimer Disease, 6 Month cognitive decline
NCT00810147,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,Feb-09,Alzheimer Disease, Stable marketed AD therapy x2 months or additional marketed AD therapy during study
NCT00810147,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,Feb-09,Alzheimer Disease, Score of less than =4 on the Modified Hachinski Ischemia Scale
NCT00810147,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,Feb-09,Alzheimer Disease, CT results consistent with Alzheimer's disease
NCT00810147,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,Feb-09,Alzheimer Disease, Medically stable
NCT00810147,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,Feb-09,Alzheimer Disease, 6 years education
NCT00810147,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,Feb-09,Alzheimer Disease, Reliable study partner (caregiver)
NCT00810147,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,Feb-09,Alzheimer Disease, Must be able to swallow capsules
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin", Probable Alzheimer's Disease (AD) according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria.
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin", Age of 50 to 85.
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin", Mini-mental State Examination (MMSE) score of 16 to 26.
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin", Sufficient language skills for testing.
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin", Sufficient vision and hearing for testing.
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin", Modified Hachinski-Rosen Score less than  5.
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin", Magnetic resonance imaging (MRI) of the head consistent with the diagnosis of AD.
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin", Caregiver available with contact at least 4 days per week for greater than 1 hour.
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin", Outpatient status or assisted living.
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin", Post-menopause (women) as evidenced by lack of menstruation for at least 12 consecutive months or by having bilateral oophorectomy.
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin"," Stable doses of approved AD medication(s) for at least 3 months prior to screening (eg, acetylcholine esterase (AChE) inhibitors, memantine)."
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin"," Normal vital signs or clinically insignificant, if outside normal limits."
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin"," Laboratory findings within normal limits or clinically insignificant, if outside normal limits."
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin"," Normal electrocardiogram (ECG) or clinically not significant, if outside normal limits."
NCT00814801,Phase 3,Alzheimer's Disease,Janssen Pharmaceutical K.K.,Feb-07,Alzheimer Disease;Galantamine, Outpatients with a diagnosis of Alzheimer's disease according to the National Institute of Neurological and Communicative Disorders and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria
NCT00814801,Phase 3,Alzheimer's Disease,Janssen Pharmaceutical K.K.,Feb-07,Alzheimer Disease;Galantamine, Having a Mini-Mental Status Examination (MMSE) score of 10 - 22 inclusive
NCT00814801,Phase 3,Alzheimer's Disease,Janssen Pharmaceutical K.K.,Feb-07,Alzheimer Disease;Galantamine, Having an Alzheimer's Disease Assessment Scale - Japan cognitive subscale (ADAS-J cog) score of at least 18
NCT00814801,Phase 3,Alzheimer's Disease,Janssen Pharmaceutical K.K.,Feb-07,Alzheimer Disease;Galantamine, Exhibiting an onset and progression of cognitive dysfunction during at least 6 months prior to the screening period
NCT00829374,Phase 3,Alzheimer's Disease,"Medivation, Inc.",Mar-09,Alzheimer Disease, Mild-to-moderate Alzheimer's disease (AD)
NCT00829374,Phase 3,Alzheimer's Disease,"Medivation, Inc.",Mar-09,Alzheimer Disease, Probable AD (Diagnostic Statistical Manual of Mental Disorders-IV-Text Revision (DSM-IV-TR))
NCT00829374,Phase 3,Alzheimer's Disease,"Medivation, Inc.",Mar-09,Alzheimer Disease," Mini-Mental State Examination (MMSE) score between 12 and 24, inclusive"
NCT00829374,Phase 3,Alzheimer's Disease,"Medivation, Inc.",Mar-09,Alzheimer Disease, Stable on donepezil for at least 6 months
NCT00838110,Phase 3,Alzheimer's Disease,Pfizer,Feb-09,Alzheimer Disease, Diagnosis of Alzheimer's Disease.
NCT00838110,Phase 3,Alzheimer's Disease,Pfizer,Feb-09,Alzheimer Disease, MMSE 12-26 inclusive.
NCT00838110,Phase 3,Alzheimer's Disease,Pfizer,Feb-09,Alzheimer Disease," If on existing anti-dementia therapy, have been on a stable dose of anti-dementia therapy (cholinesterase inhibitors and/or memantine) for at least 60 days prior to dosing in study."
NCT00838110,Phase 3,Alzheimer's Disease,Pfizer,Feb-09,Alzheimer Disease," If not taking existing anti-dementia therapy, have not received therapy with cholinesterase inhibitors and/or memantine within 60 days prior to dosing in this study."
NCT00842673,Phase 2,Alzheimer's Disease,"Sonexa Therapeutics, Inc.",Feb-09,Alzheimer Disease, Diagnostic evidence of mild to moderate Alzheimer's disease.
NCT00842673,Phase 2,Alzheimer's Disease,"Sonexa Therapeutics, Inc.",Feb-09,Alzheimer Disease, CT or MRI results within the past 12 months that rule out dementia due to non-Alzheimer's etiology.
NCT00842673,Phase 2,Alzheimer's Disease,"Sonexa Therapeutics, Inc.",Feb-09,Alzheimer Disease, A reliable and capable caregiver.
NCT00842816,Phase 2,Alzheimer's Disease,"Sonexa Therapeutics, Inc.",Feb-09,Alzheimer Disease, Subjects must be receiving concurrent treatment with 10 mg/day of Aricept (donepezil). The dose shall have been stable for three (3) months (90 days) prior to Screening.
NCT00842816,Phase 2,Alzheimer's Disease,"Sonexa Therapeutics, Inc.",Feb-09,Alzheimer Disease, Diagnostic evidence of Moderate to Moderately Severe Probable Alzheimer's disease
NCT00842816,Phase 2,Alzheimer's Disease,"Sonexa Therapeutics, Inc.",Feb-09,Alzheimer Disease, CT or MRI results within the past 18 months that rule out dementia due to non-Alzheimer's etiology.
NCT00842816,Phase 2,Alzheimer's Disease,"Sonexa Therapeutics, Inc.",Feb-09,Alzheimer Disease, A reliable and capable caregiver.
NCT00843518,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Feb-09,Alzheimer Disease;Psychomotor Agitation;Aggression, Community-dwelling participants with a diagnosis of probable Alzheimer's disease (AD) based on disease criteria from the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer's Association. Mini Mental State Examination (MMSE) score from 6 to 26 inclusive; Neuropsychiatric Inventory-10 (NPI-10) total score greater than or equal to 10.
NCT00843518,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Feb-09,Alzheimer Disease;Psychomotor Agitation;Aggression, Are men or women at least 60 years old.
NCT00843518,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Feb-09,Alzheimer Disease;Psychomotor Agitation;Aggression, Weight greater than or equal to 45 kilograms (kg).
NCT00843518,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Feb-09,Alzheimer Disease;Psychomotor Agitation;Aggression, Have clinically significant and persistent verbal or physical agitation and/or verbal or physical aggression behaviors that are disruptive to daily functioning or potentially harmful and occurred at least 3 days per week over the past 4 weeks prior to study entry.
NCT00843518,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Feb-09,Alzheimer Disease;Psychomotor Agitation;Aggression, Understand English.
NCT00843518,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Feb-09,Alzheimer Disease;Psychomotor Agitation;Aggression, Have a reliable and actively involved caregiver who must be able to communicate in English and be willing to comply with protocol requirements.
NCT00855868,Phase 2,Alzheimer's Disease,Avid Radiopharmaceuticals,Mar-09,Alzheimer Disease," Normal subjects: mini-mental state examination (MMSE) 27-30, clinical dementia rating (CDR) = 0, no symptoms of depression"
NCT00855868,Phase 2,Alzheimer's Disease,Avid Radiopharmaceuticals,Mar-09,Alzheimer Disease," Alzheimer's subjects: MMSE 18-26, CDR greater than =0.5, University of Pennsylvania Alzheimer's Disease Center consensus diagnosis of probable AD, absence of abnormalities on MRI"
NCT00857233,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Jun-04,Alzheimer Disease;Memantine, Ambulatory outpatients with moderate to severe dementia of the Alzheimer's type who have completed the 24-week Study 10158 and who have a knowledgeable and reliable caregiver who will accompany the patient to all clinic visits during the course of the study.
NCT00857415,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Dec-08,Alzheimer Disease;Amyloidosis, Have a projected life expectancy of  6 months as determined by the principal investigator (e.g. terminal medical condition) or are already enrolled in a longitudinal study of aging with an autopsy component;
NCT00857415,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Dec-08,Alzheimer Disease;Amyloidosis, Can tolerate a 10 minute PET scan; and
NCT00857415,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Dec-08,Alzheimer Disease;Amyloidosis, Give informed consent for study procedures and brain donation consistent with the legal requirements of the State in which they are enrolled and the State in which they die.
NCT00857415,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Dec-08,Alzheimer Disease;Amyloidosis, Cognitively and neurologically healthy males and females 18 to 40 years of age;
NCT00857415,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Dec-08,Alzheimer Disease;Amyloidosis," Who had no known risk factors for AD, including:"
NCT00857415,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Dec-08,Alzheimer Disease;Amyloidosis," Known genetic risk factors for AD, including an ApoE 4 allele (note: ApoE genotype was determined after enrollment and was not disclosed to healthy control subjects). Scans from subjects carrying an ApoE 4 allele were not included in the primary specificity analysis, but were included in an exploratory analysis;"
NCT00857415,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Dec-08,Alzheimer Disease;Amyloidosis, First degree relative with a known progressive dementing disorder;
NCT00857415,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Dec-08,Alzheimer Disease;Amyloidosis, History of cognitive decline;
NCT00857415,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Dec-08,Alzheimer Disease;Amyloidosis," History of neurologic, neurodegenerative, or psychiatric disease;"
NCT00857415,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Dec-08,Alzheimer Disease;Amyloidosis, History of head trauma; or
NCT00857415,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Dec-08,Alzheimer Disease;Amyloidosis, Evidence of brain abnormality on a MRI scan;
NCT00857415,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Dec-08,Alzheimer Disease;Amyloidosis," Who performed in an age-appropriate normal range on the Wechsler Logical Memory I  and  II, story A;"
NCT00857415,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Dec-08,Alzheimer Disease;Amyloidosis, Who could tolerate a 10-minute PET scan; and
NCT00857415,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Dec-08,Alzheimer Disease;Amyloidosis, Who provided informed consent before any study procedures were performed.
NCT00857649,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Dec-03,Alzheimer Disease;Memantine, Outpatients who:
NCT00857649,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Dec-03,Alzheimer Disease;Memantine," had a primary diagnosis of probable Alzheimer's Disease (AD) according to National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINDS-ADRDA) criteria, and with Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revised (DSM IV TR) criteria for dementia of the Alzheimer's type"
NCT00857649,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Dec-03,Alzheimer Disease;Memantine," had moderate to severe dementia, defined as a Mini Mental State Examination (MMSE) total score greater than =5 and less than =15 at screening. Before substantial protocol amendment SA04 (dated 7 October 2004) was implemented, the MMSE total score range at screening was greater than =8 and less than =18. Substantial protocol amendment SA07 (dated 4 September 2009) allowed patients who had previously had an MMSE score of 16 or 17 to be re-screened greater than 6 months after their initial screening and, if there was documented evidence of cognitive decline, to be enrolled in the study"
NCT00857649,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Dec-03,Alzheimer Disease;Memantine, had a Neuropsychiatric Inventory (NPI) total score greater than =13 and an NPI agitation/aggression subitem score greater than =1 at screening and baseline
NCT00857649,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Dec-03,Alzheimer Disease;Memantine, did not have vascular dementia or a modified Hachinski Ischaemia Scale score greater than 4 at screening
NCT00876863,Phase 2,Alzheimer's Disease,Sangamo Therapeutics,unknown,Alzheimer Disease, Diagnosis of mild to moderate Alzheimer's disease
NCT00876863,Phase 2,Alzheimer's Disease,Sangamo Therapeutics,unknown,Alzheimer Disease, Approved medications for Alzheimer's disease may be taken if the dose has been stable for 3 months
NCT00876863,Phase 2,Alzheimer's Disease,Sangamo Therapeutics,unknown,Alzheimer Disease, A study partner who can attend all study visits
NCT00876863,Phase 2,Alzheimer's Disease,Sangamo Therapeutics,unknown,Alzheimer Disease, Good general health
NCT00876863,Phase 2,Alzheimer's Disease,Sangamo Therapeutics,unknown,Alzheimer Disease, Medically able to undergo neurosurgery
NCT00880412,Phase 2,Alzheimer's Disease,Exonhit,Apr-08,Alzheimer Disease;Etazolate," Ambulatory male or female patient, aged 60-90 years old included at screening, and living at home."
NCT00880412,Phase 2,Alzheimer's Disease,Exonhit,Apr-08,Alzheimer Disease;Etazolate, Patient having a clinical diagnosis of probable AD according to National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria.
NCT00880412,Phase 2,Alzheimer's Disease,Exonhit,Apr-08,Alzheimer Disease;Etazolate, Mild to moderate AD with a MMSE total score  12 and  24 at screening.
NCT00880412,Phase 2,Alzheimer's Disease,Exonhit,Apr-08,Alzheimer Disease;Etazolate," Written informed consent obtained from the patient or, if appropriate, from legal representative according to local laws and regulations. The caregiver will also have to sign a specific informed consent form regarding his/her participation in the study."
NCT00880412,Phase 2,Alzheimer's Disease,Exonhit,Apr-08,Alzheimer Disease;Etazolate," Patient treated for AD treatment with one AChEI (donepezil, galantamine, or rivastigmine), according to the recommended posology mentioned in the summary of product characteristics, for at least 3 months and with a stable dose for at least 2 months prior to screening. The dose should be kept unchanged throughout the study duration."
NCT00880412,Phase 2,Alzheimer's Disease,Exonhit,Apr-08,Alzheimer Disease;Etazolate," Patient with a cerebral CT-scan or cerebral MRI compatible with AD diagnosis, with no brain lesions that may be related to another diagnosis and that could be responsible for the current patient's condition (ex, but not limited to, non-AD dementia, brain injury, brain tumour, stroke, normal pressure hydrocephalus,). A cerebral CT-scan or cerebral MRI has to be performed and results have to be available prior patient's randomization if the results of the brain imagery performed to settle the AD diagnosis are not available in the patient's file. Brain imaging has also to be performed if considered necessary by the investigator, such as in case of emerging neurological symptoms or in case of worsening of existing neurological symptoms."
NCT00880412,Phase 2,Alzheimer's Disease,Exonhit,Apr-08,Alzheimer Disease;Etazolate, Neurological exam without any particularities or without any specific focal signs likely to be related to other conditions than AD.
NCT00880412,Phase 2,Alzheimer's Disease,Exonhit,Apr-08,Alzheimer Disease;Etazolate, No contra-indication to AChEI treatment and absence of significant adverse events considered to be related to AChEI treatment at screening and randomisation.
NCT00880412,Phase 2,Alzheimer's Disease,Exonhit,Apr-08,Alzheimer Disease;Etazolate," Patient and patient's caregiver able to comply with study procedures, notably regarding the drug intake at the end of the meal which has to be supervised by the caregiver or another competent person."
NCT00884507,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,May-09,Alzheimer Disease," adult patients, greater than /=50 years of age;"
NCT00884507,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,May-09,Alzheimer Disease, probable Alzheimer's disease;
NCT00884507,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,May-09,Alzheimer Disease, MMSE score at screening of 13-22;
NCT00884507,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,May-09,Alzheimer Disease, under stable donepezil treatment given at a fixed dose of 5 or 10mg daily for greater than =4 months prior to baseline;
NCT00884507,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,May-09,Alzheimer Disease," not requiring nursing home care, but looked after by a caregiver/carer."
NCT00890890,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,May-09,Alzheimer Disease, Patient meets clinical criteria for prodromal Alzheimer's disease (MMSE 24-30)
NCT00890890,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,May-09,Alzheimer Disease, Memory complaint by subject or study partner
NCT00890890,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,May-09,Alzheimer Disease, CSF a42 levels less than  200pg/mL or Total Tau/a42 ratio of  0.39
NCT00890890,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,May-09,Alzheimer Disease, Score of 4 on the Modified Hachinski Ischemia Scale
NCT00890890,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,May-09,Alzheimer Disease, CT results consistent with Alzheimer's disease
NCT00890890,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,May-09,Alzheimer Disease, Medically stable
NCT00890890,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,May-09,Alzheimer Disease, 6 years education
NCT00890890,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,May-09,Alzheimer Disease, Reliable study partner
NCT00890890,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,May-09,Alzheimer Disease, Must be able to swallow capsules
NCT00895895,Phase 2,Alzheimer Disease,Pfizer,May-09,Alzheimer Disease;Donepezil, Diagnosis of probable Alzheimer Disease according to the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Diseases and Related Disorders Association (NINCDS-ADRDA) criteria.
NCT00895895,Phase 2,Alzheimer Disease,Pfizer,May-09,Alzheimer Disease;Donepezil, Mini-Mental State Examination (MMSE) score of 12 to 24 at screening
NCT00895895,Phase 2,Alzheimer Disease,Pfizer,May-09,Alzheimer Disease;Donepezil, Rosen Modified Hachinski Ischemic score less than  or equal to 4 at screening.
NCT00904683,Phase 3,Alzheimer's Disease,Eli Lilly and Company,May-09,Alzheimer Disease, Meets criteria for mild to moderate Alzheimer's Disease (AD) with Mini-Mental State Examination score of 16 through 26 at screening
NCT00904683,Phase 3,Alzheimer's Disease,Eli Lilly and Company,May-09,Alzheimer Disease, Modified Hachinski Ischemia Scale score of less than or equal to 4
NCT00904683,Phase 3,Alzheimer's Disease,Eli Lilly and Company,May-09,Alzheimer Disease, Geriatric Depression Scale score of less than or equal to 6
NCT00904683,Phase 3,Alzheimer's Disease,Eli Lilly and Company,May-09,Alzheimer Disease, A magnetic resonance imaging (MRI) or computerized tomography (CT) scan in the last 2 years with no findings inconsistent with a diagnosis of AD
NCT00904683,Phase 3,Alzheimer's Disease,Eli Lilly and Company,May-09,Alzheimer Disease," If receiving concurrent AD treatment, must be on the medication for at least 4 months at a stable dose for at least 2 months prior to randomization"
NCT00905372,Phase 3,Alzheimer's Disease,Eli Lilly and Company,May-09,Alzheimer Disease, Meets criteria for mild to moderate Alzheimer's Disease (AD) with Mini-Mental State Examination score of 16 through 26 at screening
NCT00905372,Phase 3,Alzheimer's Disease,Eli Lilly and Company,May-09,Alzheimer Disease, Modified Hachinski Ischemia Scale score of less than or equal to 4
NCT00905372,Phase 3,Alzheimer's Disease,Eli Lilly and Company,May-09,Alzheimer Disease, Geriatric Depression Scale score of less than or equal to 6
NCT00905372,Phase 3,Alzheimer's Disease,Eli Lilly and Company,May-09,Alzheimer Disease, A magnetic resonance imaging (MRI) or computerized tomography (CT) scan in the last 2 years with no findings inconsistent with a diagnosis of AD
NCT00905372,Phase 3,Alzheimer's Disease,Eli Lilly and Company,May-09,Alzheimer Disease," If receiving concurrent AD treatment, must be on the medication for at least 4 months at a stable dose for at least 2 months prior to randomization"
NCT00912288,Phase 3,Alzheimer Disease,Pfizer,Sep-09,Alzheimer Disease, Are men and women  50 years of age with a diagnosis of Alzheimers disease.
NCT00912288,Phase 3,Alzheimer Disease,Pfizer,Sep-09,Alzheimer Disease, Have a Mini-Mental State Exam between 5 and 14 inclusive.
NCT00912288,Phase 3,Alzheimer Disease,Pfizer,Sep-09,Alzheimer Disease," Have been taking the medication memantine (ie., Namenda) for at least six months prior to this study."
NCT00912288,Phase 3,Alzheimer Disease,Pfizer,Sep-09,Alzheimer Disease," Must have a caregiver who assists the patient at least five days per week for at least three hours per day, who can accompany patient to study visits, and who has an intimate knowledge of the patient's health states and personal care."
NCT00916617,Phase 2,Alzheimer Disease,Pfizer,Jun-09,Alzheimer Disease, Diagnosis of probable Alzheimer disease
NCT00916617,Phase 2,Alzheimer Disease,Pfizer,Jun-09,Alzheimer Disease, Completed preceding double-blind study (3133L1-2203 US)
NCT00916617,Phase 2,Alzheimer Disease,Pfizer,Jun-09,Alzheimer Disease, MMSE score greater than  9.
NCT00930059,Phase 2,Alzheimer's Disease,Pfizer,unknown,Alzheimer Disease, Mild to moderate Alzheimer's disease (MMSE 14-26)
NCT00930059,Phase 2,Alzheimer's Disease,Pfizer,unknown,Alzheimer Disease, Good general health (such controlled conditions as Type 2 diabetes and hypertension allowed)
NCT00934050,Phase 2,Alzheimer's Disease,"OPKO Health, Inc.",Jun-09,Alzheimer Disease;Inositol, This study is open only to subjects who have completed the week 78 visit in Study ELND005-AD201 while taking their assigned dose of study drug medication.
NCT00937352,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Jul-09,Alzheimer Disease, Diagnosis of probable AD
NCT00937352,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Jul-09,Alzheimer Disease, Must have completed study 301 or study 302; and have completed Visit 15 (Week 78)
NCT00937352,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Jul-09,Alzheimer Disease, Brain MRI scan to evaluate safety from Study 301 or 302 at Visit 14/Week 71
NCT00937352,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Jul-09,Alzheimer Disease, Caregiver able to attend all clinic visits with patient
NCT00939783,Phase 3,Alzheimer's Disease,Pfizer,Sep-09,Alzheimer Disease, Completion of previous Phase 3 Dimebon study (B1451027).
NCT00939822,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease;Simvastatin, Parent diagnosed with Alzheimer's disease
NCT00939822,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease;Simvastatin, Age 40-72
NCT00945672,Phase 2,Alzheimer's Disease,Pfizer,Aug-09,Alzheimer Disease," Males or females of non childbearing potential, age greater than  or = 50."
NCT00945672,Phase 2,Alzheimer's Disease,Pfizer,Aug-09,Alzheimer Disease," Diagnosis of probable Alzheimer's disease, consistent with criteria from both:"
NCT00945672,Phase 2,Alzheimer's Disease,Pfizer,Aug-09,Alzheimer Disease, National Institute of Neurological and Communicable Disease and Stroke and Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA).
NCT00945672,Phase 2,Alzheimer's Disease,Pfizer,Aug-09,Alzheimer Disease, Diagnostic and Statistical Manual of Mental Disorders (DSM IV).
NCT00945672,Phase 2,Alzheimer's Disease,Pfizer,Aug-09,Alzheimer Disease, Mini-mental status exam score of 16-26 inclusive.
NCT00945672,Phase 2,Alzheimer's Disease,Pfizer,Aug-09,Alzheimer Disease, Rosen-Modified Hachinski Ischemia Score of less than  or = 4.
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease,Men and women (non-childbearing potential) with a diagnosis of probable Alzheimer's disease according to the NINCDS-ADRDA clinical criteria.
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease,Age 60 - 85 years (patients over 85 years could be included after a previous assessment by the investigator and in agreement with the sponsor)
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease,"MRI or CT-scan assessment within 12 months before baseline corroborating the clinical diagnosis (diffuse brain atrophy predominating in medial temporal regions) and excluding other potential causes of dementia, especially cerebrovascular lesions (see exclusion criteria, number 3)."
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease,Mild to moderate stage of Alzheimer's disease according to MMSE 16-26.
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease,Modified Hachinski ischemic score equal to or below 4.
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease,Geriatric Depression Scale below or equal 7.
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease,"Female patients must be either surgically sterilized or at least 1 year postmenopausal (confirmed by FSH greater than 20, for women not surgically sterilized)."
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease,"A caregiver/nurse is available and is living in the same household, or interacts with the patient to assure the correct preparation and administration of the study drug to the patient."
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease,Patients living at home or old people's home.
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease,General health status acceptable for a participation in a 6 months clinical trial.
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease,Ability to swallow 100 -150 ml of water suspension.
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease,"No daily-regular/chronic intake of medications acting on central nervous system, immunosuppressants, steroids or non-steroid anti-inflammatory agents except the following allowed treatments:"
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease, SSRIs as antidepressants if they are administered at a stable and well tolerated dose for two months prior to baseline evaluation
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease," the following drugs at a stable and well tolerated dose to symptomatic treatment of mild behavioral disorder, sleep onset-insomnia or mild depressive mood:"
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease, Risperidon max 1mg/day
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease, Quetiapin max 25mg/day
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease, Zolpidem max 10mg in the evening
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease, Lorazepam max 1mg/day
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease," Triazolam max 0,25mg/day"
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease, Alprazolam max 1mg/day
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease, Mirtazapin max 30mg/day
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease, Hydromorphon max 4mg/day
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease, Levodopa max 50mg t.i.d as treatment of an age-associated extrapyramidal syndrome or restless-legs-syndrome
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease, Acetylsalicylic acid max 100mg/day as antiplatelet agent.
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease, Non-steroid anti-rheumatics as concomitant medication taken per request
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease,"No history of treatment with Warfarin, Digitoxin or Coumarin (including its derivatives) within 1 month prior to baseline. Chronic treatment with heparin s.c. as anticoagulant or digoxin for the treatment of heart disease are allowed."
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease,Other drugs metabolized by the CYP3A4 with wide therapeutic window are permitted if their dose and regimen are stable and well tolerated for at least 1 month prior to baseline.
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease,Stable pharmacological treatment of any other chronic condition for at least one month prior to screening.
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease,"Treatment with a stable and well tolerated dose of one of the approved Acetylcholinesterase-Inhibitors (Donepezil, Galantamine or Rivastigmine) for at least 2 months prior to baseline evaluations. Dosage of Acetylcholine-esterase inhibitors should not be increased during the ongoing study."
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease,No history of treatment with Memantine within 3 months prior to baseline evaluation. Patients with a stable and well tolerated dose of Memantine are not allowed to be included in the study.
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease,Signed informed consent by patient prior to the initiation of any study specific procedure
NCT00948909,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Oct-09,Alzheimer Disease;Donepezil," The subject is a male or female between the ages of 55 and 90 years, inclusive, at Screening Visit 1."
NCT00948909,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Oct-09,Alzheimer Disease;Donepezil, The subject meets the NINCDS/ADRDA criteria for probable AD.
NCT00948909,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Oct-09,Alzheimer Disease;Donepezil," The subject has a Mini-Mental Status Examination (MMSE) total score of 10 to 24, inclusive, at Screening Visit 1."
NCT00948909,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Oct-09,Alzheimer Disease;Donepezil, The subject has a Modified Hachinski Ischemic Scale (MHIS) score of less than or equal to 4 at Screening Visit 1.
NCT00948909,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Oct-09,Alzheimer Disease;Donepezil," If female, subject must be postmenopausal for at least two years or surgically sterile"
NCT00948909,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Oct-09,Alzheimer Disease;Donepezil," The subject has an identified, reliable, caregiver."
NCT00951834,Phase 2/Phase 3,Alzheimer's Disease,"Charite University, Berlin, Germany",Oct-09,Alzheimer Disease;Epigallocatechin gallate," early stage of AD (Diagnosis DSM-IV and NINCDS/ADRDA, Dubois-criteria 2007)"
NCT00951834,Phase 2/Phase 3,Alzheimer's Disease,"Charite University, Berlin, Germany",Oct-09,Alzheimer Disease;Epigallocatechin gallate, age 60-100
NCT00951834,Phase 2/Phase 3,Alzheimer's Disease,"Charite University, Berlin, Germany",Oct-09,Alzheimer Disease;Epigallocatechin gallate, MMSE 20-26
NCT00951834,Phase 2/Phase 3,Alzheimer's Disease,"Charite University, Berlin, Germany",Oct-09,Alzheimer Disease;Epigallocatechin gallate, patient lives at home with at least one relative who perform external ratings/assessment
NCT00951834,Phase 2/Phase 3,Alzheimer's Disease,"Charite University, Berlin, Germany",Oct-09,Alzheimer Disease;Epigallocatechin gallate," co-medication with Donepezil (Aricept, Pfizer Pharma GmbH) with at least 3 months to maximum 6 months of existing stable medication"
NCT00951834,Phase 2/Phase 3,Alzheimer's Disease,"Charite University, Berlin, Germany",Oct-09,Alzheimer Disease;Epigallocatechin gallate," maximum of 2 cups of black tea/die, no green tea, not more than greater than  500 ml/die of grapefruit juice"
NCT00954590,Phase 3,Moderate to Severe Alzheimer,"Medivation, Inc.",Oct-09,Alzheimer Disease, Moderate-to-Severe Alzheimer's disease
NCT00954590,Phase 3,Moderate to Severe Alzheimer,"Medivation, Inc.",Oct-09,Alzheimer Disease," Mini-Mental State Examination (MMSE) Score between 5 to 14, inclusive"
NCT00954590,Phase 3,Moderate to Severe Alzheimer,"Medivation, Inc.",Oct-09,Alzheimer Disease, Stable on donepezil for at least 6 months
NCT00976118,Phase 2,Alzheimer's Disease,AB Science,Feb-06,Alzheimer Disease,Outpatients from both sex
NCT00976118,Phase 2,Alzheimer's Disease,AB Science,Feb-06,Alzheimer Disease,Age  50 years at screening
NCT00976118,Phase 2,Alzheimer's Disease,AB Science,Feb-06,Alzheimer Disease,Menopause  2 years for women
NCT00976118,Phase 2,Alzheimer's Disease,AB Science,Feb-06,Alzheimer Disease,"Dementia of Alzheimer's type, according to DSM IV criteria"
NCT00976118,Phase 2,Alzheimer's Disease,AB Science,Feb-06,Alzheimer Disease,Probable Alzheimer' disease according to NINCDS-ADRDA criteria
NCT00976118,Phase 2,Alzheimer's Disease,AB Science,Feb-06,Alzheimer Disease,MMSE  12 and  26 at baseline
NCT00976118,Phase 2,Alzheimer's Disease,AB Science,Feb-06,Alzheimer Disease,CDR of 1 or 2 at baseline
NCT00976118,Phase 2,Alzheimer's Disease,AB Science,Feb-06,Alzheimer Disease,"Treated for a minimum of 6 months with a stable dose of cholinesterase inhibitors (donepezil, rivastigmine or galantamine) at baseline, and/or a stable dose of memantine for a minimum of 3 months at baseline, with no changes foreseen in therapy throughout the study"
NCT00976118,Phase 2,Alzheimer's Disease,AB Science,Feb-06,Alzheimer Disease,Presence of a reliable caregiver
NCT00976118,Phase 2,Alzheimer's Disease,AB Science,Feb-06,Alzheimer Disease,"Patient, identified caregiver and, if applicable, patient surrogate are able and willing to comply with study visits and procedures per protocol, understand, sign, and date the written voluntary informed consent form at the screening visit prior to any protocol-specific procedures performed"
NCT00976118,Phase 2,Alzheimer's Disease,AB Science,Feb-06,Alzheimer Disease,Affiliated to the French Social Security regimen
NCT00982202,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Jan-02,Alzheimer Disease;Pioglitazone, CT or MRI since disease onset excluding structural lesions sufficient to account for the participant's dementia
NCT00982202,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Jan-02,Alzheimer Disease;Pioglitazone," Mini-Mental State Exam (MMSE) score between 12 and 26, inclusively"
NCT00982202,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Jan-02,Alzheimer Disease;Pioglitazone, Clinical Dementia Rating (CDR) score of 1 or 2 (mild to moderate AD severity) at both screening and baseline
NCT00982202,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Jan-02,Alzheimer Disease;Pioglitazone, Women must be 2-years post-menopausal or surgically sterile.
NCT00982202,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Jan-02,Alzheimer Disease;Pioglitazone," Generally healthy and ambulatory or ambulatory-aided (i.e., walker or cane); vision and hearing (hearing aid permissible) sufficient for compliance with testing procedures"
NCT00982202,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Jan-02,Alzheimer Disease;Pioglitazone, Concomitant medications: Participants may be on stable doses of cholinesterase inhibitors for 90 days prior to screening (may not be started during the trial); antidepressant or antipsychotic medications are acceptable if symptoms are controlled and therapy is at stable dosage for at least 30 days prior to screening; vitamin E at 200 IU daily will be provided to all participants beginning at baseline/randomization (higher doses must be discontinued at the screening visit)
NCT00991419,Phase 2,Alzheimer's Disease,AstraZeneca,Feb-10,Alzheimer Disease," Male or female, of any race or/ethnicity"
NCT00991419,Phase 2,Alzheimer's Disease,AstraZeneca,Feb-10,Alzheimer Disease," ECG, vital signs, and clinical laboratory values are within normal limits at enrollment or deemed not clinically significant by the physician"
NCT00996918,Phase 3,Alzheimer Disease,Pfizer,Dec-09,Alzheimer Disease, Subject has completed study 3133K1-3000 and brain magnetic resonance imaging (MRI) scan consistent with the diagnosis of Alzheimer Disease
NCT00996918,Phase 3,Alzheimer Disease,Pfizer,Dec-09,Alzheimer Disease, Mini-Mental Status Examination (MMSE) greater than =10 at screening
NCT00996918,Phase 3,Alzheimer Disease,Pfizer,Dec-09,Alzheimer Disease, Caregiver able to attend all clinic visits with subject
NCT00998764,Phase 3,Alzheimer Disease,Pfizer,Dec-09,Alzheimer Disease, Subject has completed study 3133K1-3001 (Week 78) and brain magnetic resonance imaging (MRI) scan consistent with the diagnosis of Alzheimer Disease
NCT00998764,Phase 3,Alzheimer Disease,Pfizer,Dec-09,Alzheimer Disease, Mini-Mental Status Examination (MMSE) greater than =10 at screening
NCT00998764,Phase 3,Alzheimer Disease,Pfizer,Dec-09,Alzheimer Disease, Caregiver able to attend all clinic visits with subject
NCT01018875,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Dec-09,Alzheimer Disease;Donepezil," diagnostic criteria criteria for probable AD (Alzheimer's Disease). 3. Female subjects must be postmenopausal for at least 2 years or surgically sterile. 4. Male subjects must be surgically sterile, sexually inactive or using a barrier method of birth control. 5. Subject has an identified, reliable caregiver. 6. Subject has a CT or MRI scan within 36 months prior to randomization. 7. With the exception of a diagnosis of mild-to-moderate AD and the presence of stable medical conditions, the subject is generally in good health based on medical history, physical examination, vital signs, clinical lab tests and ECG"
NCT01019421,Phase 2,Alzheimer's Disease,H. Lundbeck A/S,Dec-09,Alzheimer Disease, The patient (or if applicable the legally acceptable representative (LAR) and if different from the responsible caregiver) and the responsible caregiver are able to read and understand the Informed Consent Form.
NCT01019421,Phase 2,Alzheimer's Disease,H. Lundbeck A/S,Dec-09,Alzheimer Disease, The patient has a knowledgeable and reliable caregiver who will accompany the patient to all clinic visits during the study.
NCT01019421,Phase 2,Alzheimer's Disease,H. Lundbeck A/S,Dec-09,Alzheimer Disease, The patient (or if applicable the LAR and if different from the responsible caregiver) and the responsible caregiver have signed the Informed Consent Form.
NCT01019421,Phase 2,Alzheimer's Disease,H. Lundbeck A/S,Dec-09,Alzheimer Disease, The patient has probable AD consistent with NINCDS-ADRDA criteria.
NCT01019421,Phase 2,Alzheimer's Disease,H. Lundbeck A/S,Dec-09,Alzheimer Disease," The patient is a man or woman, aged at least 50 years."
NCT01019421,Phase 2,Alzheimer's Disease,H. Lundbeck A/S,Dec-09,Alzheimer Disease, The patient has been treated with donepezil on a stable dose for at least 3 months prior to screening.
NCT01020838,Phase 3,Alzheimer Disease,Life Molecular Imaging SA,Nov-09,Alzheimer Disease," Females, no child-bearing potential or negative urine pregnancy test on day of BAY94-9172 injection"
NCT01020838,Phase 3,Alzheimer Disease,Life Molecular Imaging SA,Nov-09,Alzheimer Disease," Exhibits visual, auditory, and communicative capabilities adequate to provide informed consent or assent and comply with study procedures"
NCT01020838,Phase 3,Alzheimer Disease,Life Molecular Imaging SA,Nov-09,Alzheimer Disease, Is willing and able to lie down in magnetic resonance imaging (MRI) and positron emission tomography (PET) scanners
NCT01020838,Phase 3,Alzheimer Disease,Life Molecular Imaging SA,Nov-09,Alzheimer Disease, Is willing to donate their brain for postmortem examination in case of death
NCT01020838,Phase 3,Alzheimer Disease,Life Molecular Imaging SA,Nov-09,Alzheimer Disease," The subject, or the subject and/or legally acceptable representative will be compliant and have a high probability of completing the study in the opinion of the investigator"
NCT01020838,Phase 3,Alzheimer Disease,Life Molecular Imaging SA,Nov-09,Alzheimer Disease," Has been fully informed about the study, including provisions of the Health Insurance Portability and Accountability Act (HIPAA), as applicable, and informed consent or assent has been signed and dated (with time) by the subject and/or the subject's legally acceptable representative"
NCT01020838,Phase 3,Alzheimer Disease,Life Molecular Imaging SA,Nov-09,Alzheimer Disease, The subjects who have participated in a previous florbetaben study e.g. study 311741 may be included in the present study. The MRI- and florbetaben PET scan do not need to be repeated if both scans were performed within twelve months prior to inclusion.
NCT01028053,Phase 3,Alzheimer's Disease,GE Healthcare,Dec-09,Alzheimer Disease;Cognitive Dysfunction;Flutemetamol, The subject is 60 years old or older.
NCT01028053,Phase 3,Alzheimer's Disease,GE Healthcare,Dec-09,Alzheimer Disease;Cognitive Dysfunction;Flutemetamol, The subject meets the Petersen criteria for amnestic MCI.
NCT01028053,Phase 3,Alzheimer's Disease,GE Healthcare,Dec-09,Alzheimer Disease;Cognitive Dysfunction;Flutemetamol, The subject has a score of less than or equal to 4 on the Modified Hachinski Ischemic Scale.
NCT01028053,Phase 3,Alzheimer's Disease,GE Healthcare,Dec-09,Alzheimer Disease;Cognitive Dysfunction;Flutemetamol, The subject has a MMSE score of 24-30.
NCT01028053,Phase 3,Alzheimer's Disease,GE Healthcare,Dec-09,Alzheimer Disease;Cognitive Dysfunction;Flutemetamol, The subject has a non-contrast MRI examination as part of the screening visit that excludes aMCI arising from structural causes.
NCT01028053,Phase 3,Alzheimer's Disease,GE Healthcare,Dec-09,Alzheimer Disease;Cognitive Dysfunction;Flutemetamol," The subject and/or the subject's legally acceptable representative, if applicable, in accordance with local regulations, has signed and dated an informed consent."
NCT01035138,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Dec-09,Alzheimer Disease, Meets National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria for probable Alzheimer's Disease
NCT01035138,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Dec-09,Alzheimer Disease, Completed semagacestat study LFAN or study LFBC through 88 weeks
NCT01035138,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Dec-09,Alzheimer Disease, Must continue to have a reliable caregiver
NCT01035138,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Dec-09,Alzheimer Disease, Capable of swallowing whole oral medication
NCT01035138,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Dec-09,Alzheimer Disease, Agrees not to participate in other investigational compounds for the duration of study
NCT01039701,Phase 2,Mild to Moderate Alzheimer's Disease,AstraZeneca,Dec-09,Alzheimer Disease, history of progressive worsening of memory and other cognitive functions for at least 12 months
NCT01039701,Phase 2,Mild to Moderate Alzheimer's Disease,AstraZeneca,Dec-09,Alzheimer Disease, treatment with stable dose of donepezil (10 mg) for at least 3 months
NCT01039701,Phase 2,Mild to Moderate Alzheimer's Disease,AstraZeneca,Dec-09,Alzheimer Disease," the patient should have an appropriate caregiver, who is required for all study visits"
NCT01055392,Phase 2,Alzheimer Disease,University of Sao Paulo,Mar-07,Alzheimer Disease;Cognitive Dysfunction;Lithium Carbonate, patients with amnestic mild cognitive impairment;
NCT01055392,Phase 2,Alzheimer Disease,University of Sao Paulo,Mar-07,Alzheimer Disease;Cognitive Dysfunction;Lithium Carbonate, age: 60 to 80 years-old;
NCT01058941,Phase 1/Phase 2,Alzheimer's Disease,Oregon Health and Science University,Sep-10,Alzheimer Disease;Thioctic Acid,55 years or older
NCT01058941,Phase 1/Phase 2,Alzheimer's Disease,Oregon Health and Science University,Sep-10,Alzheimer Disease;Thioctic Acid,Probable AD by National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association - NINCDS/ADRDA criteria
NCT01058941,Phase 1/Phase 2,Alzheimer's Disease,Oregon Health and Science University,Sep-10,Alzheimer Disease;Thioctic Acid,MMSE between 15-26
NCT01058941,Phase 1/Phase 2,Alzheimer's Disease,Oregon Health and Science University,Sep-10,Alzheimer Disease;Thioctic Acid,Caregiver/study partner that can accompany participant to all study visits
NCT01058941,Phase 1/Phase 2,Alzheimer's Disease,Oregon Health and Science University,Sep-10,Alzheimer Disease;Thioctic Acid,Stable use of cholinesterase inhibitors and memantine permitted - doses must be stable for 4 months prior to study enrollment
NCT01058941,Phase 1/Phase 2,Alzheimer's Disease,Oregon Health and Science University,Sep-10,Alzheimer Disease;Thioctic Acid,"Stable doses of over-the-counter antioxidants (e.g. vitamin E, ginkgo biloba) are permitted - dose must be stable for 4 months prior to study enrollment"
NCT01058941,Phase 1/Phase 2,Alzheimer's Disease,Oregon Health and Science University,Sep-10,Alzheimer Disease;Thioctic Acid,Stable dose of lipid lowering medication - dose must be stable for 4 months prior to study enrollment
NCT01058941,Phase 1/Phase 2,Alzheimer's Disease,Oregon Health and Science University,Sep-10,Alzheimer Disease;Thioctic Acid,Geriatric Depression Scale (GDS) - Score of less than  5
NCT01058941,Phase 1/Phase 2,Alzheimer's Disease,Oregon Health and Science University,Sep-10,Alzheimer Disease;Thioctic Acid,General health status that will not interfere with the participant's ability to complete the study.
NCT01058941,Phase 1/Phase 2,Alzheimer's Disease,Oregon Health and Science University,Sep-10,Alzheimer Disease;Thioctic Acid,"Screening laboratory values within normal limits or, if abnormal, deemed clinically insignificant by the investigator"
NCT01058941,Phase 1/Phase 2,Alzheimer's Disease,Oregon Health and Science University,Sep-10,Alzheimer Disease;Thioctic Acid,Sufficient English language skills to complete all testing
NCT01066546,Phase 3,Alzheimer's Disease,Pfizer,Apr-10,Alzheimer Disease, Successful completion of 6 months treatment in the previous B1451006 Phase 3 dimebon study
NCT01075763,Phase 2,Alzheimer's Disease,"Merck KGaA, Darmstadt, Germany",Nov-04,Alzheimer Disease;Interferons;Interferon-beta;Interferon beta-1a, Subjects aged between 50 and 75 years
NCT01075763,Phase 2,Alzheimer's Disease,"Merck KGaA, Darmstadt, Germany",Nov-04,Alzheimer Disease;Interferons;Interferon-beta;Interferon beta-1a," Subjects diagnosed with AD, according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV)"
NCT01075763,Phase 2,Alzheimer's Disease,"Merck KGaA, Darmstadt, Germany",Nov-04,Alzheimer Disease;Interferons;Interferon-beta;Interferon beta-1a, Subjects with MMSE score of 20 to 26 (inclusive)
NCT01075763,Phase 2,Alzheimer's Disease,"Merck KGaA, Darmstadt, Germany",Nov-04,Alzheimer Disease;Interferons;Interferon-beta;Interferon beta-1a, Subjects supervised by a caregiver
NCT01075763,Phase 2,Alzheimer's Disease,"Merck KGaA, Darmstadt, Germany",Nov-04,Alzheimer Disease;Interferons;Interferon-beta;Interferon beta-1a, Subjects who have been given informed written consent and approval of the Local Ethical Committee
NCT01078168,Phase 2,Alzheimer Disease,K. Lieb,Mar-10,Alzheimer Disease;Acitretin, mild to moderate AD (NINCDS-ADRDA criteria)
NCT01078168,Phase 2,Alzheimer Disease,K. Lieb,Mar-10,Alzheimer Disease;Acitretin, Mini-Mental State Examination (MMSE): 27-14 points
NCT01078168,Phase 2,Alzheimer Disease,K. Lieb,Mar-10,Alzheimer Disease;Acitretin, Geriatric Depression Scale  14
NCT01094340,Phase 2/Phase 3,Alzheimer's Disease,Banner Health,Mar-10,Alzheimer Disease;Thalidomide, Subjects must have a screening diagnosis of Probable Alzheimer's disease according to National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria.
NCT01094340,Phase 2/Phase 3,Alzheimer's Disease,Banner Health,Mar-10,Alzheimer Disease;Thalidomide, Subjects must have a Mini-Mental State Examination (MMSE) score of 12-26
NCT01094340,Phase 2/Phase 3,Alzheimer's Disease,Banner Health,Mar-10,Alzheimer Disease;Thalidomide, Subject must live at home.
NCT01094340,Phase 2/Phase 3,Alzheimer's Disease,Banner Health,Mar-10,Alzheimer Disease;Thalidomide, Must have a caregiver to participate in this study
NCT01117948,Phase 2,Alzheimers Disease,JSW Lifesciences,Sep-09,Alzheimer Disease;Lornoxicam,Men and women (non-childbearing potential) with a diagnosis of Alzheimer's Disease according to the NINCDS-ADRDA clinical criteria.
NCT01117948,Phase 2,Alzheimers Disease,JSW Lifesciences,Sep-09,Alzheimer Disease;Lornoxicam,Mild to moderate stage of Alzheimer's disease according to MMSE 18-26 inclusive.
NCT01117948,Phase 2,Alzheimers Disease,JSW Lifesciences,Sep-09,Alzheimer Disease;Lornoxicam,Modified Hachinski Ischemic Scale equal to or below 4.
NCT01117948,Phase 2,Alzheimers Disease,JSW Lifesciences,Sep-09,Alzheimer Disease;Lornoxicam,Geriatric Depression Scale below or equal 7.
NCT01117948,Phase 2,Alzheimers Disease,JSW Lifesciences,Sep-09,Alzheimer Disease;Lornoxicam,"If anticholinesterasic treatment had been prescribed, the patient must undergo a 4 week wash out period before the baseline visit (visit 1)."
NCT01117948,Phase 2,Alzheimers Disease,JSW Lifesciences,Sep-09,Alzheimer Disease;Lornoxicam,"If Memantine treatment had been prescribed, the patient must undergo a 4 week wash out period before the baseline visit (visit 1)."
NCT01117948,Phase 2,Alzheimers Disease,JSW Lifesciences,Sep-09,Alzheimer Disease;Lornoxicam, Exclusion criteria:
NCT01117948,Phase 2,Alzheimers Disease,JSW Lifesciences,Sep-09,Alzheimer Disease;Lornoxicam,"Clinical, laboratory or neuroimaging findings consistent with:"
NCT01117948,Phase 2,Alzheimers Disease,JSW Lifesciences,Sep-09,Alzheimer Disease;Lornoxicam," other primary degenerative dementia, (dementia with Lewy bodies, frontotemporal dementia, Huntington's disease, Jacob-Creutzfeld Disease, Down's syndrome, etc.)"
NCT01117948,Phase 2,Alzheimers Disease,JSW Lifesciences,Sep-09,Alzheimer Disease;Lornoxicam," other neurodegenerative condition (Parkinson's Disease, amyotrophic lateral sclerosis, etc.)"
NCT01117948,Phase 2,Alzheimers Disease,JSW Lifesciences,Sep-09,Alzheimer Disease;Lornoxicam," cerebrovascular Disease (major infarct, one strategic or multiple lacunar infarcts, extensive white matter lesions greater than  one quarter of the total white matter)"
NCT01117948,Phase 2,Alzheimers Disease,JSW Lifesciences,Sep-09,Alzheimer Disease;Lornoxicam," other central nervous system diseases (severe head trauma, tumors, subdural haematoma or other space occupying processes, etc.)"
NCT01117948,Phase 2,Alzheimers Disease,JSW Lifesciences,Sep-09,Alzheimer Disease;Lornoxicam, seizure disorder
NCT01117948,Phase 2,Alzheimers Disease,JSW Lifesciences,Sep-09,Alzheimer Disease;Lornoxicam," other infectious, metabolic or systemic diseases affecting central nervous system (syphilis, present hypothyroidism, present vitamin B12 or folate deficiency confirmed by current analyses not older than 1 month, serum electrolytes out of normal range, juvenile onset diabetes mellitus, etc.) 2. A current DSM-IV diagnosis of active major depression, schizophrenia or bipolar disorder."
NCT01117948,Phase 2,Alzheimers Disease,JSW Lifesciences,Sep-09,Alzheimer Disease;Lornoxicam,Chronic daily drug intake for a time period of  14 days or expected for  14 days:  
NCT01117948,Phase 2,Alzheimers Disease,JSW Lifesciences,Sep-09,Alzheimer Disease;Lornoxicam," antidepressants, benzodiazepines, neuroleptics, major sedatives or other anti-inflammatory drugs including acetylic salicylic acid defined"
NCT01117948,Phase 2,Alzheimers Disease,JSW Lifesciences,Sep-09,Alzheimer Disease;Lornoxicam, antiepileptics
NCT01117948,Phase 2,Alzheimers Disease,JSW Lifesciences,Sep-09,Alzheimer Disease;Lornoxicam, anticholinergics
NCT01117948,Phase 2,Alzheimers Disease,JSW Lifesciences,Sep-09,Alzheimer Disease;Lornoxicam, nootropics (including Ginkgo)
NCT01117948,Phase 2,Alzheimers Disease,JSW Lifesciences,Sep-09,Alzheimer Disease;Lornoxicam," centrally active anti-hypertensive drugs (clonidine, alpha-methyl dopa, guanidine, guanfacine,)"
NCT01117948,Phase 2,Alzheimers Disease,JSW Lifesciences,Sep-09,Alzheimer Disease;Lornoxicam, opioid containing analgesics
NCT01117948,Phase 2,Alzheimers Disease,JSW Lifesciences,Sep-09,Alzheimer Disease;Lornoxicam," anti-inflammatory agents, cortico-steroids or immunosuppressants"
NCT01117948,Phase 2,Alzheimers Disease,JSW Lifesciences,Sep-09,Alzheimer Disease;Lornoxicam, Cimetidin as gastroprotective drug 4. Severe thrombocytopenia defined as platelet counts less than 100.000 per mm3. 5. Coagulation disorders
NCT01120002,Phase 2,Alzheimer's Disease,Osaka City University,May-10,Alzheimer Disease, Japanese patients who are diagnosed as probable Alzheimer' Disease according to NINCDS-ADRDA criteria
NCT01120002,Phase 2,Alzheimer's Disease,Osaka City University,May-10,Alzheimer Disease," Diagnosed by brain diagnostic imaging (CT, MRI) within six months before the consent and no occurrence of the event after that to suggest cerebral vascular disease"
NCT01120002,Phase 2,Alzheimer's Disease,Osaka City University,May-10,Alzheimer Disease, Mild to Moderate Alzheimer's Disease of MMSE from 10 to 26
NCT01120002,Phase 2,Alzheimer's Disease,Osaka City University,May-10,Alzheimer Disease, Age from 55 to 80
NCT01120002,Phase 2,Alzheimer's Disease,Osaka City University,May-10,Alzheimer Disease, Treated for a minimum of 12 weeks with a stable dose of donepezil and willing to continue the same during the trial period
NCT01120002,Phase 2,Alzheimer's Disease,Osaka City University,May-10,Alzheimer Disease, For women Menopause  2 years
NCT01120002,Phase 2,Alzheimer's Disease,Osaka City University,May-10,Alzheimer Disease, For men contraceptive measures are required during the study and after 6 months
NCT01120002,Phase 2,Alzheimer's Disease,Osaka City University,May-10,Alzheimer Disease," In principle patients should be living at their home in the presence of a caregiver who is defined as a healthy person in contact with the patient for more than 10 hours a week, could provide required information of the behavior and activities of daily living, accompany all the clinical examination, and supervise the handling and administration of the drug throughout the study period."
NCT01120002,Phase 2,Alzheimer's Disease,Osaka City University,May-10,Alzheimer Disease, Patients who could take pills as a whole
NCT01120002,Phase 2,Alzheimer's Disease,Osaka City University,May-10,Alzheimer Disease," Patient, caregiver and patient surrogate are able and willing to comply with study visits and procedures per protocol, understand, sign, and date the written voluntary informed consent form"
NCT01125683,Phase 2,Alzheimers Disease,AstraZeneca,Jun-10,Alzheimer Disease;Donepezil, Clinical diagnosis of probable Alzheimers Disease
NCT01125683,Phase 2,Alzheimers Disease,AstraZeneca,Jun-10,Alzheimer Disease;Donepezil, Hachinski Ischaemic score less than  4
NCT01125683,Phase 2,Alzheimers Disease,AstraZeneca,Jun-10,Alzheimer Disease;Donepezil, MSE score 18 to 24
NCT01127633,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Dec-10,Alzheimer Disease, Meets National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria for probable Alzheimer's Disease
NCT01127633,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Dec-10,Alzheimer Disease, Has completed participation in solanezumab Study LZAM or Study LZAN through 80 weeks
NCT01127633,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Dec-10,Alzheimer Disease, Must continue to have a reliable caregiver who is in frequent contact with the patient for the entire study
NCT01127633,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Dec-10,Alzheimer Disease, Must have good vein access to administer infusions
NCT01127633,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Dec-10,Alzheimer Disease, Agrees not to participate in studies of any other investigational compounds for the duration of their participation in Study LZAO
NCT01137526,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",May-10,Alzheimer Disease;Donepezil,"The subject and caregiver must voluntarily sign and date and informed consent. If the subject is not fully competent, full informed consent must be obtained from a legal representative and assent must be obtained from the subject."
NCT01137526,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",May-10,Alzheimer Disease;Donepezil,"Subject is male or female between the ages of 55 and 90 years of age, inclusive, at Day-1."
NCT01137526,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",May-10,Alzheimer Disease;Donepezil,Subject meets the NINCDS/ADRDA criteria for probable AD.
NCT01137526,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",May-10,Alzheimer Disease;Donepezil,"Subject has a Mini-Mental Status Examination (MMSE) score of 10 to 24, inclusive, at Screening Visit 1."
NCT01137526,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",May-10,Alzheimer Disease;Donepezil,Subject has a Cornell Scale for Depression in Dementia (CSDD) score  10 at Screening Visit 1.
NCT01137526,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",May-10,Alzheimer Disease;Donepezil,"With the exception of a diagnosis of mild-to-moderate AD and the presence of stable medical conditions, the subject is generally in good health based on medical history, physical examination, vital signs, clinical lab tests and 12-lead ECG."
NCT01137526,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",May-10,Alzheimer Disease;Donepezil,"If female, subject must be postmenopausal for at least 2 years or surgically sterile."
NCT01137526,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",May-10,Alzheimer Disease;Donepezil,"If male, the subject is surgically sterile (vasectomy), is sexually inactive, or is using a barrier method of birth control."
NCT01137526,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",May-10,Alzheimer Disease;Donepezil,"Subject has an identified reliable, caregiver (e.g., family member, social worker, nurse), who will provide support and ensure compliance with the study medication and procedures."
NCT01137526,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",May-10,Alzheimer Disease;Donepezil,"Subject and caregiver are fluent in the language used for administration of the rating scales or cognitive tests and have sufficient visual, hearing and graphomotor skills to complete procedures."
NCT01142258,Phase 3,Alzheimer's Disease,Brasilia University Hospital,Mar-10,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Trazodone, Fifty-five years of age or older;
NCT01142258,Phase 3,Alzheimer's Disease,Brasilia University Hospital,Mar-10,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Trazodone, Diagnosis of probable Alzheimer's disease by National Institute of Neurological and Communicative Disorders and Stroke/the Alzheimer's Disease and Related Disorders Association criteria;
NCT01142258,Phase 3,Alzheimer's Disease,Brasilia University Hospital,Mar-10,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Trazodone, Hachinski Ischemia Scale score less than 5
NCT01142258,Phase 3,Alzheimer's Disease,Brasilia University Hospital,Mar-10,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Trazodone, Mini-Mental State Examination score of O to 26
NCT01142258,Phase 3,Alzheimer's Disease,Brasilia University Hospital,Mar-10,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Trazodone, Actigraph evidence of a mean time immobile of less than 7 hours per night based on at least 7 nights of complete actigraph data collected over a single week;
NCT01142258,Phase 3,Alzheimer's Disease,Brasilia University Hospital,Mar-10,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Trazodone," For-week history of sleep disorder behaviors, occurring at least once weekly, as reported by the caregiver using the Neuropsychiatric Inventory (NPI) Nighttime Behavior scale;"
NCT01142258,Phase 3,Alzheimer's Disease,Brasilia University Hospital,Mar-10,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Trazodone, Sleep disturbance observed was not present before the diagnosis of AD;
NCT01142258,Phase 3,Alzheimer's Disease,Brasilia University Hospital,Mar-10,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Trazodone," Other co-morbidities, especially delirium, depression, chronic pain and medication use may be present, but do not cooperate in the primary symptoms;"
NCT01142258,Phase 3,Alzheimer's Disease,Brasilia University Hospital,Mar-10,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Trazodone, Computed tomography or magnetic resonance imaging since the onset of memory problems showing no more than 1 lacunar infarct in a nonstrategic area and no clinical events suggestive of stroke or other intracranial disease or normal;
NCT01142258,Phase 3,Alzheimer's Disease,Brasilia University Hospital,Mar-10,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Trazodone, Stable medications for 4 weeks prior to the screening visit;
NCT01142258,Phase 3,Alzheimer's Disease,Brasilia University Hospital,Mar-10,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Trazodone, Having a mobile upper extremity to which to attach an actigraph;
NCT01142258,Phase 3,Alzheimer's Disease,Brasilia University Hospital,Mar-10,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Trazodone," Residing with a responsible spouse, family member, or professional caregiver who is present during the night and would agree to assume the role of the principal caregiver for the 3-week protocol;"
NCT01142258,Phase 3,Alzheimer's Disease,Brasilia University Hospital,Mar-10,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Trazodone, Ability to ingest oral medication and participate in all scheduled evaluations
NCT01148498,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Aug-10,Alzheimer Disease," Individuals in Groups 1, 2, and 3, described below, will be participants in the longitudinal studies of memory and aging at the Washington University Alzheimer's Disease Research Center (WU-ADRC). These participants must have results from apolipoprotein E (ApoE) genotyping from the WU-ADRC. At the beginning of the study they must be between 45 and 90 years of age and if a female of childbearing potential, not be breastfeeding, test negative for pregnancy, and be using a medically accepted form of birth control at the time of the infusion and for 6 months afterward. Subjects must also meet the criteria below for each study group"
NCT01148498,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Aug-10,Alzheimer Disease," Group 1, Mild dementia of Alzheimer's type (DAT):"
NCT01148498,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Aug-10,Alzheimer Disease," Have mild DAT, as determined by Clinical Dementia Rating (CDR) of 0.5 or 1"
NCT01148498,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Aug-10,Alzheimer Disease, Have florbetapir PET imaging findings consistent with underlying AD pathology.
NCT01148498,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Aug-10,Alzheimer Disease," Group 2, Older Adult Controls with Possible AD Pathology:"
NCT01148498,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Aug-10,Alzheimer Disease," Have no cognitive impairment as indicated by a CDR rating of 0. Have possible AD pathology, as determined by florbetapir PET imaging."
NCT01148498,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Aug-10,Alzheimer Disease," Group 3, Older Adult Controls with No Evidence of AD Pathology:"
NCT01148498,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Aug-10,Alzheimer Disease, Have no cognitive impairment as indicated by a CDR rating of 0. Have no evidence of AD pathology as determined by florbetapir PET imaging.
NCT01148498,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Aug-10,Alzheimer Disease," Individuals recruited into Group 4 will not be participants in the longitudinal studies of memory and aging at WU-ADRC. To be included in Group 4, individuals must meet these criteria:"
NCT01148498,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Aug-10,Alzheimer Disease," Are at least 18 years and less than 35 years of age at the beginning of the study and if a female of childbearing potential, is not breastfeeding, tests negative for pregnancy and is using highly effective contraception at the time of the solanezumab infusion and for 6 months following infusion"
NCT01148498,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Aug-10,Alzheimer Disease, Have a Folstein Mini-Mental State Examination (MMSE) score of 29 to 30 at the beginning of the study
NCT01152216,Phase 3,Alzheimer's Disease,"Medivation, Inc.",Apr-10,Alzheimer Disease, Successful completion of the 12 month DIM18 CONCERT study
NCT01152216,Phase 3,Alzheimer's Disease,"Medivation, Inc.",Apr-10,Alzheimer Disease, Mild-to-moderate Alzheimer's disease
NCT01152216,Phase 3,Alzheimer's Disease,"Medivation, Inc.",Apr-10,Alzheimer Disease," Probable AD, Diagnostic and Statistical Manual of Mental Disorders-IV-Text Revised (DSM-IV-TR)"
NCT01152216,Phase 3,Alzheimer's Disease,"Medivation, Inc.",Apr-10,Alzheimer Disease," Mini-Mental State Exam (MMSE) score between 12 and 24, inclusive"
NCT01152216,Phase 3,Alzheimer's Disease,"Medivation, Inc.",Apr-10,Alzheimer Disease, Stable on donepezil for at least 6 months
NCT01172145,Phase 3,Alzheimer's Disease,Brown University,Jul-05,Alzheimer Disease;Modafinil, diagnosis of mild to moderate stage Probable Alzheimer's disease
NCT01172145,Phase 3,Alzheimer's Disease,Brown University,Jul-05,Alzheimer Disease;Modafinil, on a stable dose of a cholinesterase inhibitor medication for at least 30 days
NCT01172145,Phase 3,Alzheimer's Disease,Brown University,Jul-05,Alzheimer Disease;Modafinil, clinically elevated levels of apathy as measured by the Frontal Systems Behavior Scale
NCT01183806,Phase 3,Alzheimer Disease,Federal University of Bahia,Jul-10,Alzheimer Disease;Rivastigmine, Previous diagnosis of probable Alzheimer's disease
NCT01183806,Phase 3,Alzheimer Disease,Federal University of Bahia,Jul-10,Alzheimer Disease;Rivastigmine, At least 55 years of age
NCT01183806,Phase 3,Alzheimer Disease,Federal University of Bahia,Jul-10,Alzheimer Disease;Rivastigmine," Same caregiver (familiar or paid one) for at least 3 months before, who is able to follow the patient in a two-day/week exercise program"
NCT01183806,Phase 3,Alzheimer Disease,Federal University of Bahia,Jul-10,Alzheimer Disease;Rivastigmine, Do not be taking other prescribed medication for Alzheimer disease
NCT01183806,Phase 3,Alzheimer Disease,Federal University of Bahia,Jul-10,Alzheimer Disease;Rivastigmine, Treated stable hypertension
NCT01202994,Phase 2,Alzheimer's Disease,University of Utah,May-11,Alzheimer Disease;Flutemetamol," Subjects must be currently enrolled in an NIA-sponsored, community-based study of practice effects in non-demented adults age 65 and older living independently (NIA #5K23AG028417-05)"
NCT01211782,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease, Males/females between age of 55 -85 years
NCT01211782,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease, MMSE scores between 16-26
NCT01211782,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease, Probable mild to moderate AD
NCT01224106,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Adult participants, 50-85 years of age"
NCT01224106,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Participants with prodromal Alzheimer's disease who are not receiving memantine or cholinesterase inhibitors
NCT01224106,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Has a study partner who in the investigator's judgement has frequent and sufficient contact with the participant as to be able to provide accurate information as to the participant's cognitive and functional abilities, who agrees to provide information at clinic visits which require partner input for scale completion"
NCT01224106,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Has had sufficient education or work experience to exclude mental retardation
NCT01224106,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Study partner has noticed a recent gradual decrease in participant's memory (over the last 12 months), which the participant may or may not be aware of"
NCT01224106,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Screening Mini Mental State Exam (MMSE) score of 24 or above
NCT01224106,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Additional inclusion criteria for sub study:
NCT01224106,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Able and willing to travel to PET imaging center and complete the planned scanning sessions
NCT01224106,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Past and planned exposure to ionizing radiation not exceeding safe and permissible levels
NCT01238458,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,Nov-09,Alzheimer Disease;Cognitive Dysfunction, Both genders  50 years old.
NCT01238458,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,Nov-09,Alzheimer Disease;Cognitive Dysfunction," Written and dated informed consent by self or by legal representative, to be obtained before any of the study procedures."
NCT01238458,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,Nov-09,Alzheimer Disease;Cognitive Dysfunction, 30 cognitively normal volunteers with no evidence of significant cognitive impairment by history and psychometrictesting (MMSE greater than  24).
NCT01238458,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,Nov-09,Alzheimer Disease;Cognitive Dysfunction, 60 subjects with a diagnosis of AD according to the NINCDS-ADRDA criteria.
NCT01238458,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,Nov-09,Alzheimer Disease;Cognitive Dysfunction, 60 subjects with a diagnosis of MCI
NCT01245530,Phase 3,Alzheimer Type Dementia,Whanin Pharmaceutical Company,Jun-08,Dementia;Alzheimer Disease;Donepezil,"Male or female, age range : 50 ~ 80 years old"
NCT01245530,Phase 3,Alzheimer Type Dementia,Whanin Pharmaceutical Company,Jun-08,Dementia;Alzheimer Disease;Donepezil,Informed consent signed and dated by patient or legal representative
NCT01245530,Phase 3,Alzheimer Type Dementia,Whanin Pharmaceutical Company,Jun-08,Dementia;Alzheimer Disease;Donepezil,Subjects diagnosed with Alzheimer's disease according to DSM-IV criteria
NCT01245530,Phase 3,Alzheimer Type Dementia,Whanin Pharmaceutical Company,Jun-08,Dementia;Alzheimer Disease;Donepezil,Subjects diagnosed with probable Alzheimer's disease according to the National Institute of Neurological and Communicative Disorders and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria
NCT01245530,Phase 3,Alzheimer Type Dementia,Whanin Pharmaceutical Company,Jun-08,Dementia;Alzheimer Disease;Donepezil,MMSE score 10 to 26
NCT01245530,Phase 3,Alzheimer Type Dementia,Whanin Pharmaceutical Company,Jun-08,Dementia;Alzheimer Disease;Donepezil,CDR(Clinical Dementia Rating) score 1~2 or GDS(Global Deterioration Scale) 3~5 stage
NCT01245530,Phase 3,Alzheimer Type Dementia,Whanin Pharmaceutical Company,Jun-08,Dementia;Alzheimer Disease;Donepezil,"Subjects who didn't take any medication for AchEI (donepezil, memantine, galantamin, etc) before treating or can stop medication at least 4 weeks more prior to screening visit"
NCT01245530,Phase 3,Alzheimer Type Dementia,Whanin Pharmaceutical Company,Jun-08,Dementia;Alzheimer Disease;Donepezil,Subjects menopause women or her/his spouse consent with contraception during the study period and 90 days after end of study
NCT01249196,Phase 3,Alzheimer's Disease,"SK Chemicals Co., Ltd.",May-10,Alzheimer Disease, Clinical diagnosis of probable Alzheimer's disease(DSM-IV and NINCDS-ADRDA criteria)
NCT01249196,Phase 3,Alzheimer's Disease,"SK Chemicals Co., Ltd.",May-10,Alzheimer Disease, MRI within the last 12 months consistent with a diagnosis of AD
NCT01249196,Phase 3,Alzheimer's Disease,"SK Chemicals Co., Ltd.",May-10,Alzheimer Disease, MMSE score of 10 to 26 and CDR of 1 or 2
NCT01249196,Phase 3,Alzheimer's Disease,"SK Chemicals Co., Ltd.",May-10,Alzheimer Disease, AChEI or memantine was not taken at least 3 months prior to screening
NCT01254773,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-10,Alzheimer Disease, Diagnosis of probable AD
NCT01254773,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-10,Alzheimer Disease, Age from 50 to less than 89
NCT01254773,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-10,Alzheimer Disease, Mini-Mental Status Exam score of 18-26 inclusive
NCT01254773,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-10,Alzheimer Disease, Brain magnetic resonance imaging (MRI) scan consistent with the diagnosis of AD
NCT01254773,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-10,Alzheimer Disease, Stable doses of medications (cholinesterase inhibitors and memantine allowed)
NCT01254773,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-10,Alzheimer Disease, Caregiver able to attend all clinic visits with patient
NCT01254773,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-10,Alzheimer Disease, Amyloid burden on screening PET scan consistent with diagnosis of AD
NCT01255046,Phase 2,Alzheimer Disease,"Sinphar Pharmaceutical Co., Ltd",Dec-15,Alzheimer Disease;Donepezil, Male or female patient aged  50 years;
NCT01255046,Phase 2,Alzheimer Disease,"Sinphar Pharmaceutical Co., Ltd",Dec-15,Alzheimer Disease;Donepezil, Probable Alzheimer's disease diagnosed by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria;
NCT01255046,Phase 2,Alzheimer Disease,"Sinphar Pharmaceutical Co., Ltd",Dec-15,Alzheimer Disease;Donepezil," MMSE score between 10-26, inclusive;"
NCT01255046,Phase 2,Alzheimer Disease,"Sinphar Pharmaceutical Co., Ltd",Dec-15,Alzheimer Disease;Donepezil, Patient has been treated with donepezil 10 mg per day for at least 3 months prior to screening;
NCT01255046,Phase 2,Alzheimer Disease,"Sinphar Pharmaceutical Co., Ltd",Dec-15,Alzheimer Disease;Donepezil, Patient able to participate in all study evaluations and ingest oral medication as indicated;
NCT01255046,Phase 2,Alzheimer Disease,"Sinphar Pharmaceutical Co., Ltd",Dec-15,Alzheimer Disease;Donepezil, Patient has a responsible caregiver who will accompany the patient to all clinic visits during the study;
NCT01255046,Phase 2,Alzheimer Disease,"Sinphar Pharmaceutical Co., Ltd",Dec-15,Alzheimer Disease;Donepezil, Patient and the responsible caregiver have provided written informed consent before undergoing any study procedures.
NCT01276353,Phase 2,Alzheimer's Type Dementia,Eisai Inc.,Jan-11,Dementia;Alzheimer Disease;Donepezil, Diagnostic evidence of probable Alzheimer's disease (AD) consistent with the Diagnostic and Statistical Manual for Mental Disorders-version IV (DSM-IV)
NCT01276353,Phase 2,Alzheimer's Type Dementia,Eisai Inc.,Jan-11,Dementia;Alzheimer Disease;Donepezil, Hachinski Ischemic Score
NCT01276353,Phase 2,Alzheimer's Type Dementia,Eisai Inc.,Jan-11,Dementia;Alzheimer Disease;Donepezil, Functional Assessment Staging (FAST) scale greater than or equal to 6 at Screening.
NCT01276353,Phase 2,Alzheimer's Type Dementia,Eisai Inc.,Jan-11,Dementia;Alzheimer Disease;Donepezil, Mini-Mental State Examination (MMSE) score of 1 to 12 at Screening
NCT01276353,Phase 2,Alzheimer's Type Dementia,Eisai Inc.,Jan-11,Dementia;Alzheimer Disease;Donepezil," Subjects who are on a stable Aricept- dose of 10 mg immediate release (IR), taken as a single, daily dose for 3 months prior to the Screening Visit"
NCT01276353,Phase 2,Alzheimer's Type Dementia,Eisai Inc.,Jan-11,Dementia;Alzheimer Disease;Donepezil, Evidence consistent with Alzheimer's disease (AD) on any cranial image on magnetic resonance imaging (MRI) or computed tomography (CT) scan or etc. obtained within 24 months prior to the Screening Visit. Subjects who have any observations of dementia other than Alzheimer's type after the last image diagnosis should be reconfirmed.
NCT01276353,Phase 2,Alzheimer's Type Dementia,Eisai Inc.,Jan-11,Dementia;Alzheimer Disease;Donepezil, Age 50 years
NCT01276353,Phase 2,Alzheimer's Type Dementia,Eisai Inc.,Jan-11,Dementia;Alzheimer Disease;Donepezil, Written informed consent is to have been obtained from the subject (if possible) or from the subject's legal guardian or other representative
NCT01282619,Phase 2/Phase 3,Alzheimer's Disease,"Shandong Luye Pharmaceutical Co., Ltd.",May-10,Alzheimer Disease;Huperzine A,Male/female patient aged between 50 and 85
NCT01282619,Phase 2/Phase 3,Alzheimer's Disease,"Shandong Luye Pharmaceutical Co., Ltd.",May-10,Alzheimer Disease;Huperzine A,Clinical diagnosis of mild to moderate probable AD based on DSM-IV and the NINCDS-ADRDA criteria
NCT01282619,Phase 2/Phase 3,Alzheimer's Disease,"Shandong Luye Pharmaceutical Co., Ltd.",May-10,Alzheimer Disease;Huperzine A,"Middle school or above: 11 MMSE  24, elementary school: 8  MMSE  20, illiteracy: 5  MMSE  16;"
NCT01282619,Phase 2/Phase 3,Alzheimer's Disease,"Shandong Luye Pharmaceutical Co., Ltd.",May-10,Alzheimer Disease;Huperzine A,CT or MRI scan excluding another structural brain disease;
NCT01282619,Phase 2/Phase 3,Alzheimer's Disease,"Shandong Luye Pharmaceutical Co., Ltd.",May-10,Alzheimer Disease;Huperzine A,Hachinski Ischemic Score less than  4
NCT01282619,Phase 2/Phase 3,Alzheimer's Disease,"Shandong Luye Pharmaceutical Co., Ltd.",May-10,Alzheimer Disease;Huperzine A,Hamilton Depression Scale 10
NCT01282619,Phase 2/Phase 3,Alzheimer's Disease,"Shandong Luye Pharmaceutical Co., Ltd.",May-10,Alzheimer Disease;Huperzine A,Informed consent of the patient (or legal representative) and of the caregiver agreeing to take part in the study.
NCT01303744,Phase 2,Alzheimer's Disease,CERESPIR,Mar-11,Alzheimer Disease;Flurbiprofen, Diagnosis of amnestic or non-amnestic Mild Cognitive Impairment.
NCT01303744,Phase 2,Alzheimer's Disease,CERESPIR,Mar-11,Alzheimer Disease;Flurbiprofen, Mini-Mental State Examination score higher than 24 at screening.
NCT01303744,Phase 2,Alzheimer's Disease,CERESPIR,Mar-11,Alzheimer Disease;Flurbiprofen, MRI scan of the brain at screening with fluid-attenuation inversion recovery (FLAIR) and T2*-weighted gradient-recalled-echo (GRE) sequences.
NCT01324518,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease," Informed consent obtained from the patient and legally acceptable representative, if required"
NCT01324518,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease, Informed consent obtained from the caregiver
NCT01324518,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease, Males and and females between 55-90 years
NCT01324518,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease," Diagnosis of probable Alzheimer's disease, history of progressive cognitive deterioration"
NCT01324518,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease, Brain imaging consistent with Alzheimer's disease
NCT01324518,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease, Mini-mental state examination score 12-21
NCT01324518,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease," Treated with donepezil, rivastigmine or galantamine"
NCT01324518,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease, At least mild level of behavioral symptoms
NCT01343966,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,"Alzheimer Disease;Antibodies, Monoclonal", Diagnosis of probable AD according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorder Association (NINCDS-ADRDA) criteria
NCT01343966,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,"Alzheimer Disease;Antibodies, Monoclonal", Mini-Mental State Examination (MMSE) score of 18-26 points at screening
NCT01343966,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,"Alzheimer Disease;Antibodies, Monoclonal", Geriatric Depression Scale (GDS-15) score of less than  6
NCT01343966,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,"Alzheimer Disease;Antibodies, Monoclonal", Completion of 6 years of education (or good work history consistent with exclusion of mental retardation or other pervasive developmental disorders)
NCT01343966,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,"Alzheimer Disease;Antibodies, Monoclonal"," If receiving concurrent AD treatment, patient must be on the medication for at least 3 months at a stable dose for at least 2 months prior to randomization."
NCT01374438,Phase 2,Alzheimer's Disease,Metabolic Solutions Development Company,Jul-11,Alzheimer Disease,Male or females 55-85 years of age.
NCT01374438,Phase 2,Alzheimer's Disease,Metabolic Solutions Development Company,Jul-11,Alzheimer Disease,Females should be either postmenopausal or surgically sterilized. Males with female partners of child-bearing potential must use contraception if engaging in sexual intercourse.
NCT01374438,Phase 2,Alzheimer's Disease,Metabolic Solutions Development Company,Jul-11,Alzheimer Disease,Diagnosis of probable Alzheimer's disease based on NIA-AA criteria with MMSE scores of 20 or greater.
NCT01374438,Phase 2,Alzheimer's Disease,Metabolic Solutions Development Company,Jul-11,Alzheimer Disease,"Willing and able to take part in up to six study visits over a 5-month period, with the support of a caregiver as needed."
NCT01374438,Phase 2,Alzheimer's Disease,Metabolic Solutions Development Company,Jul-11,Alzheimer Disease,"Willing and able to sign an informed consent document indicating understanding the purpose of and procedures required for the study and willingness to participate in the study, with the support of a caregiver as needed."
NCT01388478,Phase 2,Alzheimer's Disease,Virginia Commonwealth University,Jul-11,Alzheimer Disease;Pramipexole, Informed consent provided by the participant or the participant's legally acceptable representative
NCT01388478,Phase 2,Alzheimer's Disease,Virginia Commonwealth University,Jul-11,Alzheimer Disease;Pramipexole, Age 55 years or older
NCT01388478,Phase 2,Alzheimer's Disease,Virginia Commonwealth University,Jul-11,Alzheimer Disease;Pramipexole, Possible/probable Alzheimer's Disease (AD)
NCT01388478,Phase 2,Alzheimer's Disease,Virginia Commonwealth University,Jul-11,Alzheimer Disease;Pramipexole," Community dwelling with a caregiver able and willing to accompany the participant on all visits, if necessary. Caregiver must visit with the subject greater than 5 times per week."
NCT01388478,Phase 2,Alzheimer's Disease,Virginia Commonwealth University,Jul-11,Alzheimer Disease;Pramipexole, Rosen Modified Hachinski score of 4 or less
NCT01388478,Phase 2,Alzheimer's Disease,Virginia Commonwealth University,Jul-11,Alzheimer Disease;Pramipexole," Imaging Study (CT or MRI) compatible with AD or age-related changes (absence of significant abnormalities that may explain cognitive decline, such as multiple lacunar infarcts or a single prior infarct greater than 1 cubic cm, microhemorrhages or evidence of a prior hemorrhage greater than  1 cubic cm, evidence of cerebral contusion encephalomalacia, aneurysm, vascular malformation, or space occupying lesion such as an arachnoid cyst or brain tumor)."
NCT01388478,Phase 2,Alzheimer's Disease,Virginia Commonwealth University,Jul-11,Alzheimer Disease;Pramipexole, Adequate visual and auditory abilities to perform all aspects of the cognitive and functional assessments
NCT01397578,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,"Alzheimer Disease;Antibodies, Monoclonal", Diagnosis of probable AD according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorder Association (NINCDS-ADRDA) criteria
NCT01397578,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,"Alzheimer Disease;Antibodies, Monoclonal", Mini-Mental State Examination (MMSE) score of 18-26 points at screening
NCT01397578,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,"Alzheimer Disease;Antibodies, Monoclonal", Geriatric Depression Scale (GDS-15) score of less than  6
NCT01397578,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,"Alzheimer Disease;Antibodies, Monoclonal", Completion of 6 years of education (or good work history consistent with exclusion of mental retardation or other pervasive developmental disorders)
NCT01397578,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,"Alzheimer Disease;Antibodies, Monoclonal"," For patients currently receiving treatment with approved AD treatments (AChE inhibitors or memantine): Treatment initiated and continued for at least the last 3 months prior to randomization, at a stable dose for at least the last 2 months prior to randomization"
NCT01404169,Phase 3,Alzheimer's Type Dementia,Eisai Limited,unknown,Alzheimer Disease;Dementia;Donepezil, Written informed consent (IC) will be obtained from the subject (if possible) or from the subject's legal guardian or legal representative prior to beginning screening activities.
NCT01404169,Phase 3,Alzheimer's Type Dementia,Eisai Limited,unknown,Alzheimer Disease;Dementia;Donepezil," Subject age range: male and female subjects 50 to 90 years of age, inclusive"
NCT01404169,Phase 3,Alzheimer's Type Dementia,Eisai Limited,unknown,Alzheimer Disease;Dementia;Donepezil," Diagnosis: diagnostic evidence of probable Alzheimer's Disease (AD) consistent with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) and National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria"
NCT01404169,Phase 3,Alzheimer's Type Dementia,Eisai Limited,unknown,Alzheimer Disease;Dementia;Donepezil," MMSE 1 to 12 inclusive, at both Screening and Baseline"
NCT01404169,Phase 3,Alzheimer's Type Dementia,Eisai Limited,unknown,Alzheimer Disease;Dementia;Donepezil, SIB less than or equal to 90 and greater than or equal to 10 at both Screening and Baseline
NCT01404169,Phase 3,Alzheimer's Type Dementia,Eisai Limited,unknown,Alzheimer Disease;Dementia;Donepezil," Comorbid medical conditions must be clinically stable prior to Baseline, unless otherwise specified."
NCT01409694,Phase 3,Alzheimer Disease,"University Hospital, Angers",Sep-11,Alzheimer Disease;Vitamin D;Ergocalciferols;Cholecalciferol;Vitamins;Memantine, Age  60 years
NCT01409694,Phase 3,Alzheimer Disease,"University Hospital, Angers",Sep-11,Alzheimer Disease;Vitamin D;Ergocalciferols;Cholecalciferol;Vitamins;Memantine, Diagnosis of moderate Alzheimer's disease or related disorders (DSM-IV/NINCDSADRDA) with a score of Mini-Mental State Examination (MMSE) between 10 and 20 inclusively
NCT01409694,Phase 3,Alzheimer Disease,"University Hospital, Angers",Sep-11,Alzheimer Disease;Vitamin D;Ergocalciferols;Cholecalciferol;Vitamins;Memantine," To have hypovitaminosis D (i.e., serum 25-hydroxyvitamin D [25OHD]concentration less than  30 ng/mL)"
NCT01409694,Phase 3,Alzheimer Disease,"University Hospital, Angers",Sep-11,Alzheimer Disease;Vitamin D;Ergocalciferols;Cholecalciferol;Vitamins;Memantine," To have no hypercalcemia (defined as serum calcium concentration  2,65 mmol/L)"
NCT01409694,Phase 3,Alzheimer Disease,"University Hospital, Angers",Sep-11,Alzheimer Disease;Vitamin D;Ergocalciferols;Cholecalciferol;Vitamins;Memantine," To have given and signed an informed consent form to participate in the trial (or informed consent form obtained from the trusted person or legal representative, as appropriate)"
NCT01409694,Phase 3,Alzheimer Disease,"University Hospital, Angers",Sep-11,Alzheimer Disease;Vitamin D;Ergocalciferols;Cholecalciferol;Vitamins;Memantine, To be affiliated to French Social Security
NCT01409915,Phase 2,Alzheimer's Disease,"University of Colorado, Denver",Mar-11,Alzheimer Disease;Molgramostim;Sargramostim,age 55 to 85 years;
NCT01409915,Phase 2,Alzheimer's Disease,"University of Colorado, Denver",Mar-11,Alzheimer Disease;Molgramostim;Sargramostim,should have a mild-to-moderate AD diagnosis (MMSE 10-26 inclusive);
NCT01409915,Phase 2,Alzheimer's Disease,"University of Colorado, Denver",Mar-11,Alzheimer Disease;Molgramostim;Sargramostim,"should have evidence of elevated cortical amyloid by PET using florbetapir F18 (Amyvid) [i.e. a positive scan], assessed qualitatively according to the Amyvid product label."
NCT01409915,Phase 2,Alzheimer's Disease,"University of Colorado, Denver",Mar-11,Alzheimer Disease;Molgramostim;Sargramostim,if on anti-dementia treatment should be on stable treatment for at least 2 months (i.e. cholinesterase inhibitor and/or Memantine or Axona);
NCT01409915,Phase 2,Alzheimer's Disease,"University of Colorado, Denver",Mar-11,Alzheimer Disease;Molgramostim;Sargramostim,stable on all other medications for at least 30 days prior to screen;
NCT01409915,Phase 2,Alzheimer's Disease,"University of Colorado, Denver",Mar-11,Alzheimer Disease;Molgramostim;Sargramostim,should be fluent in English;
NCT01409915,Phase 2,Alzheimer's Disease,"University of Colorado, Denver",Mar-11,Alzheimer Disease;Molgramostim;Sargramostim,"should be physically able to participate by medical history, clinical exam and tests;"
NCT01409915,Phase 2,Alzheimer's Disease,"University of Colorado, Denver",Mar-11,Alzheimer Disease;Molgramostim;Sargramostim,should have a study partner to accompany them to scheduled visits.
NCT01421056,Phase 2,Alzheimer's Disease,Chiesi Farmaceutici S.p.A.,Jul-11,Alzheimer Disease;Cognitive Dysfunction;Flurbiprofen, Diagnosis of amnestic or non-amnestic Mild Cognitive Impairment.
NCT01421056,Phase 2,Alzheimer's Disease,Chiesi Farmaceutici S.p.A.,Jul-11,Alzheimer Disease;Cognitive Dysfunction;Flurbiprofen, Mini-Mental State Examination score higher than 24 at screening.
NCT01421056,Phase 2,Alzheimer's Disease,Chiesi Farmaceutici S.p.A.,Jul-11,Alzheimer Disease;Cognitive Dysfunction;Flurbiprofen, MRI scan of the brain at screening with fluid-attenuation inversion recovery (FLAIR) and T2*-weighted gradient-recalled-echo (GRE) sequences.
NCT01428362,Phase 2,Alzheimer's Disease,VIVUS LLC,Aug-11,Alzheimer Disease, clinical diagnosis of Alzheimer's disease
NCT01428362,Phase 2,Alzheimer's Disease,VIVUS LLC,Aug-11,Alzheimer Disease, CT or MRI within 2 years prior to study
NCT01428362,Phase 2,Alzheimer's Disease,VIVUS LLC,Aug-11,Alzheimer Disease, stable dose of current Alzheimer's treatment for at least 3 months
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,"A clinical diagnosis of possible Alzheimer's disease in accordance with the National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria, with radiological (Magnetic Resonance Imaging [MRI] or Computed Tomography [CT]) evidence of significant cerebrovascular disease (CVD), assessed within the last 12 months"
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,"Male or female between 50 and 80 years of age inclusive, at the time of signing the informed consent."
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,Subject has a documented history of at least 6 months of ongoing Alzheimer's disease therapy (AChEIs and/or memantine) with stable dosing for at least the last 2 months (and with no intent to change for the duration of the study).
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,Mini-Mental Status Examination (MMSE) score between 20 and 26 at Screening.
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,Clinical Dementia Rating Scale (CDR) score of 0.5 or 1.0 at Screening.
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,A female subject is eligible to participate if she is of non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea; or of child-bearing potential and agrees to use acceptable contraception methods
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,"Subject has provided full written informed consent prior to the performance of any protocol-specified procedure; or if the subject is unable to provide informed consent due to cognitive status, the subject will provide assent and full written informed consent will be provided by a legally acceptable representative"
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,The subject has a dedicated caregiver who is willing to supervise participation in the study
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,"In the opinion of the investigator, the subject has the ability to comply with study procedures (cognitive and other testing) and is fluent in the language used for the administration of the cognitive tests."
NCT01436045,Phase 2,Alzheimer's Disease,HealthPartners Institute,Sep-11,Alzheimer Disease;Insulin glulisine, Male or female subject with a clinical diagnosis of probable AD in accordance with National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria and Dementia Rating Scale (McKhann 1984).
NCT01436045,Phase 2,Alzheimer's Disease,HealthPartners Institute,Sep-11,Alzheimer Disease;Insulin glulisine, Mini-Mental State Examination (MMSE) score of 18-26.
NCT01436045,Phase 2,Alzheimer's Disease,HealthPartners Institute,Sep-11,Alzheimer Disease;Insulin glulisine, Hachinski Ischemia Score less than  4.
NCT01436045,Phase 2,Alzheimer's Disease,HealthPartners Institute,Sep-11,Alzheimer Disease;Insulin glulisine, Age is greater than  65 and less than 85 years
NCT01436045,Phase 2,Alzheimer's Disease,HealthPartners Institute,Sep-11,Alzheimer Disease;Insulin glulisine, Females must be greater than  2 years post-menopausal or surgically sterile.
NCT01436045,Phase 2,Alzheimer's Disease,HealthPartners Institute,Sep-11,Alzheimer Disease;Insulin glulisine," Must be able to speak, read and understand English in order to comply with testing of cognitive function, memory and physiology."
NCT01436045,Phase 2,Alzheimer's Disease,HealthPartners Institute,Sep-11,Alzheimer Disease;Insulin glulisine," Must have a dedicated family member /caregiver, able to attend all visits and report on subject's status."
NCT01436045,Phase 2,Alzheimer's Disease,HealthPartners Institute,Sep-11,Alzheimer Disease;Insulin glulisine," Subject and family member/caregiver have both provided fully informed written consent prior to participation. In the event that subject is legally unable to provide informed written consent due to deterioration in cognitive abilities, fully informed written consent must be provided by a legally authorized representative."
NCT01436045,Phase 2,Alzheimer's Disease,HealthPartners Institute,Sep-11,Alzheimer Disease;Insulin glulisine," On a stable dose ( 1 months) of a prescribed acetylcholinesterase inhibitor (e.g. donepezil, rivastigmine, galantamine) and/or memantine."
NCT01436045,Phase 2,Alzheimer's Disease,HealthPartners Institute,Sep-11,Alzheimer Disease;Insulin glulisine, A brain CT or MRI in the last 2 years compatible with the diagnosis of probable Alzheimer's Disease.
NCT01436045,Phase 2,Alzheimer's Disease,HealthPartners Institute,Sep-11,Alzheimer Disease;Insulin glulisine, A Clinical Dementia Rating (CDR) ranging from 1 to 2.
NCT01438060,Phase 3,"Dementia, Alzheimer Type","Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Aug-00,Dementia;Alzheimer Disease;Aripiprazole," Non-institutionalized patients with a diagnosis of Alzheimer's disease as defined by Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV) criteria with symptoms of delusions or hallucinations, which have been present, at least intermittently for one month or longer"
NCT01438060,Phase 3,"Dementia, Alzheimer Type","Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Aug-00,Dementia;Alzheimer Disease;Aripiprazole, Mini Mental State Examination (MMSE) score of 6 to 24 points
NCT01438060,Phase 3,"Dementia, Alzheimer Type","Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Aug-00,Dementia;Alzheimer Disease;Aripiprazole, Patients capable of self locomotion or locomotion with the aid of an assistive device
NCT01438060,Phase 3,"Dementia, Alzheimer Type","Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Aug-00,Dementia;Alzheimer Disease;Aripiprazole, Patients with an identified caregiver or proxy
NCT01438060,Phase 3,"Dementia, Alzheimer Type","Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Aug-00,Dementia;Alzheimer Disease;Aripiprazole, For Extension Phase:
NCT01438060,Phase 3,"Dementia, Alzheimer Type","Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Aug-00,Dementia;Alzheimer Disease;Aripiprazole," Eligible patients were males and females who had completed the 10-week Acute Phase in either treatment group; had a Week 10 Total Score of  6 on the NPI; and were, in the judgment of the investigator, deemed suitable for participation in the long-term trial."
NCT01438060,Phase 3,"Dementia, Alzheimer Type","Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Aug-00,Dementia;Alzheimer Disease;Aripiprazole, Treatment beyond 140 weeks:
NCT01438060,Phase 3,"Dementia, Alzheimer Type","Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Aug-00,Dementia;Alzheimer Disease;Aripiprazole," All subjects who completed the extension phase of CN138-006 in any French Investigational Site may be considered eligible for entry until they are no longer receiving clinical benefit, per the investigator's judgment"
NCT01439555,Phase 2,Alzheimer's Disease,"University of Massachusetts, Worcester",Nov-11,Alzheimer Disease;Simvastatin, Subjects must have mild Alzheimer's Disease or Mild Cognitive Impairment (MCI);
NCT01439555,Phase 2,Alzheimer's Disease,"University of Massachusetts, Worcester",Nov-11,Alzheimer Disease;Simvastatin, age between 55-85;
NCT01439555,Phase 2,Alzheimer's Disease,"University of Massachusetts, Worcester",Nov-11,Alzheimer Disease;Simvastatin, Mini Mental Status Exam (MMSE) between 15-26;
NCT01439555,Phase 2,Alzheimer's Disease,"University of Massachusetts, Worcester",Nov-11,Alzheimer Disease;Simvastatin," a caregiver who can provide information, and bring patient to the sessions;"
NCT01439555,Phase 2,Alzheimer's Disease,"University of Massachusetts, Worcester",Nov-11,Alzheimer Disease;Simvastatin, no known allergies to any of the medications to be used;
NCT01439555,Phase 2,Alzheimer's Disease,"University of Massachusetts, Worcester",Nov-11,Alzheimer Disease;Simvastatin, normal renal function; willingness of patient and spouse/responsible caregiver to participate.
NCT01447719,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Mar-10,Alzheimer Disease, Subjects are enrolled in this study if they:
NCT01447719,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Mar-10,Alzheimer Disease, Met entrance criteria and were enrolled and imaged in trial 18F-AV-45-A07 (NCT00857415)
NCT01447719,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Mar-10,Alzheimer Disease, Gave informed consent for the 18F-AV-45-A07 (NCT00857415) study procedures and brain donation consistent with the legal requirements of the State in which they are enrolled and the State in which they die
NCT01447719,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Mar-10,Alzheimer Disease," Consent to participate in the 18F-AV-45-A16 (NCT01447719) extension protocol, if required by the IRB"
NCT01447719,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Mar-10,Alzheimer Disease," Reconfirm their consent to a research brain autopsy, if required by the IRB."
NCT01463384,Phase 2,Alzheimer's Disease,Huntington Medical Research Institutes,Sep-11,Alzheimer Disease;Cognitive Dysfunction;Minocycline;Tetracycline, Cognitively normal elderly subjects between the ages of 55-90 and patients aged 55 - 90 years who have mild cognitive impairment (MCI) or clinically defined Alzheimer's disease.
NCT01466088,Phase 2,Alzheimer's Disease,Targacept Inc.,Oct-11,Alzheimer Disease;Dementia;Donepezil,A clinical diagnosis of AD per NINCDS-ADRDA criteria; mild to moderate severity as defined by Mini-Mental State Examination (MMSE) scores of 12 to 22.
NCT01466088,Phase 2,Alzheimer's Disease,Targacept Inc.,Oct-11,Alzheimer Disease;Dementia;Donepezil,"AD diagnosed at least 12 months prior to Screening, and supported by brain imaging studies within 6 months prior to Screening."
NCT01466088,Phase 2,Alzheimer's Disease,Targacept Inc.,Oct-11,Alzheimer Disease;Dementia;Donepezil,Absence of vascular dementia both per AIRENS criteria and as defined by modified Hachinski ischemia score (HIS) of less than /= 4.
NCT01466088,Phase 2,Alzheimer's Disease,Targacept Inc.,Oct-11,Alzheimer Disease;Dementia;Donepezil,Presence of a caregiver with significant proportion of time in contact with subject and who will oversee administration of study drug during the trial
NCT01466088,Phase 2,Alzheimer's Disease,Targacept Inc.,Oct-11,Alzheimer Disease;Dementia;Donepezil,Able to complete test assessments and to sign informed consent with the help of a caregiver if needed
NCT01504854,Phase 2,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),May-12,Alzheimer Disease;Resveratrol, Diagnosis of probable AD (NINDS-ADRDA criteria).
NCT01504854,Phase 2,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),May-12,Alzheimer Disease;Resveratrol, Age must be 50 years or older.
NCT01504854,Phase 2,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),May-12,Alzheimer Disease;Resveratrol, Able to ingest oral medications.
NCT01504854,Phase 2,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),May-12,Alzheimer Disease;Resveratrol, Caregiver/Study Partner who has direct contact with the participant more than 2 days per week to accompany participant to all visits.
NCT01504854,Phase 2,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),May-12,Alzheimer Disease;Resveratrol, MMSE score between 14 and 26 (inclusive).
NCT01504854,Phase 2,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),May-12,Alzheimer Disease;Resveratrol, Modified Hachinski score of less than or equal to 4.
NCT01504854,Phase 2,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),May-12,Alzheimer Disease;Resveratrol, Able to abstain from ingesting large quantities of resveratrol-containing foods (including red wine). 1-2 glasses of red wine or red grape juice daily acceptable; 1 serving of red grapes daily acceptable.
NCT01504854,Phase 2,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),May-12,Alzheimer Disease;Resveratrol, Able to abstain from ingesting herbal/natural preparations or dietary supplements containing resveratrol.
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease," healthy male or female subjects 18 to 65 years of age, inclusive"
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease," body mass index (BMI) within the range of 18.0 to 33.0 kg/m2, inclusive, and a minimum weight of at least 50.0 kg at Screening"
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease," female subjects of childbearing potential must be practicing abstinence or using and willing to continue using two medically acceptable form of birth control for at least 1 month prior to Screening (at least 3 months for oral and transdermal contraceptives) and for at least 1 month after the last study drug administration. Medically acceptable forms of contraception include oral or patch hormonal contraceptives, intrauterine device, progestin implant or injection, bilateral tubal ligation, or double-barrier (i.e., male condom in addition to a diaphragm or a contraceptive sponge)."
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease, female subjects of non-childbearing potential must be amenorrheic for at least 2 years or had a hysterectomy and/or bilateral oophorectomy/salpingo-oophorectomy (as determined by subject medical history)
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease," male subjects of reproductive potential with a partner(s) of childbearing potential, must be using and willing to continue to using two medically acceptable contraceptive precautions from Screening and for at least 1 month after the last study drug administration. Medically acceptable forms of contraception include abstinence, vasectomy, or male condom for subjects"
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease, female subjects must have a negative pregnancy test
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease," able to speak, read, and understand English sufficiently to understand the nature of the study, to provide written informed consent, and to allow completion of all study assessments"
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease, must understand and provide written informed consent prior to the initiation of any protocol-specific procedures
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease, must be willing and able to abide by all study requirements and restrictions
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease, males and females ages  55 years of age at Screening visit
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease," diagnosis of AD, consistent with criteria from both the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) Criteria for Probable AD and Diagnostic and Statistical Manual of Mental Disorders - IV TR (DSM-IV TR) Criteria for Dementia of the Alzheimer's Type"
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease," Mini-Mental Status Evaluation (MMSE) score of 5-15, inclusive, at Screening visit"
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease, Rosen-Modified Hachninski Ischemia score of  4 at Screening visit
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease," subjects and caregivers must be able to read, write, and speak the language in which psychometric tests are provided with acceptable visual and auditory acuity"
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease, subject must have a reliable informant (caregiver) to provide collateral history and who will facilitate the subject's full participation in the study
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease," subject and caregivers must provide written informed consent and be willing to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures"
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease, subjects may continue on background cholinesterase inhibitor and/or memantine
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease," subjects must be in satisfactory good health, in the opinion of the investigator, based on medical history, physical examination, vital signs, 12-lead ECG, and laboratory tests"
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease, magnetic resonance imaging (MRI) or computed tomography (CT) within 12 months of Screening visit consistent with a diagnosis of Probable AD without any other clinically significant findings
NCT01527916,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Feb-12,Alzheimer Disease;Donepezil," The subject and caregiver must voluntarily sign and date an informed consent. If the subject does not have the capacity to provide informed consent, full informed consent must be obtained from the subject's representative and assent must be obtained from the subject."
NCT01527916,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Feb-12,Alzheimer Disease;Donepezil," The subject is a male or female between the ages of 55 and 90 years, inclusive, at Screening Visit 1."
NCT01527916,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Feb-12,Alzheimer Disease;Donepezil, The subject meets the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria for probable Alzheimer's disease.
NCT01527916,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Feb-12,Alzheimer Disease;Donepezil," The subject has a Mini-Mental Status Examination (MMSE) total score of 10 to 24, inclusive, at Screening Visit 1."
NCT01527916,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Feb-12,Alzheimer Disease;Donepezil, The subject has a Cornell Scale for Depression in Dementia (CSDD) score  10 at Screening Visit 1.
NCT01527916,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Feb-12,Alzheimer Disease;Donepezil, The subject has a Modified Hachinski Ischemic Scale (MHIS) score of  4 at Screening Visit 1.
NCT01527916,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Feb-12,Alzheimer Disease;Donepezil," With the exception of a diagnosis of mild to moderate AD and the presence of stable medical conditions, the subject is in general good health, based upon the results of medical history, physical examination, vital signs, laboratory profile, and a 12-lead electrocardiogram (ECG)."
NCT01527916,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Feb-12,Alzheimer Disease;Donepezil," The subject has an identified, reliable caregiver who will provide support and ensure compliance with the study medication and procedures, and provide accurate information about the subject's status during the study."
NCT01539031,Phase 3,Alzheimer's Type Dementia,"Eisai Co., Ltd.",Mar-12,Alzheimer Disease;Dementia;Donepezil," Diagnosis: diagnostic evidence of probable Alzheimer's disease (AD) consistent with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV-TR) 290.00 or 290.10"
NCT01539031,Phase 3,Alzheimer's Type Dementia,"Eisai Co., Ltd.",Mar-12,Alzheimer Disease;Dementia;Donepezil," Mini Mental State Examination (MMSE) less than or equal to 12 and greater than or equal to1 inclusive, at Screening"
NCT01539031,Phase 3,Alzheimer's Type Dementia,"Eisai Co., Ltd.",Mar-12,Alzheimer Disease;Dementia;Donepezil, SIB less than or equal to 90 and greater than or equal to10 at both Screening and Baseline
NCT01539031,Phase 3,Alzheimer's Type Dementia,"Eisai Co., Ltd.",Mar-12,Alzheimer Disease;Dementia;Donepezil, No evidence of focal disease to account for dementia on any cranial image (magnetic resonance imaging [MRI] or computed tomography [CT]).
NCT01539031,Phase 3,Alzheimer's Type Dementia,"Eisai Co., Ltd.",Mar-12,Alzheimer Disease;Dementia;Donepezil, Subject age range: male and female subjects greater than or equal to 50 years of age inclusive
NCT01539031,Phase 3,Alzheimer's Type Dementia,"Eisai Co., Ltd.",Mar-12,Alzheimer Disease;Dementia;Donepezil, Outpatients (patients in nursing homes are eligible)
NCT01539031,Phase 3,Alzheimer's Type Dementia,"Eisai Co., Ltd.",Mar-12,Alzheimer Disease;Dementia;Donepezil," The subject must have a caregiver who will provide informed consent separately for his/her own participation in the study, who will have regular contact with the subject."
NCT01539031,Phase 3,Alzheimer's Type Dementia,"Eisai Co., Ltd.",Mar-12,Alzheimer Disease;Dementia;Donepezil," Stable donepezil dose of 10 mg, taken as a single, daily dose for greater than or equal to 3 months prior to the Screening visit"
NCT01539031,Phase 3,Alzheimer's Type Dementia,"Eisai Co., Ltd.",Mar-12,Alzheimer Disease;Dementia;Donepezil," Subjects who can swallow hole tablets, as tablets should not be broken or crushed"
NCT01539031,Phase 3,Alzheimer's Type Dementia,"Eisai Co., Ltd.",Mar-12,Alzheimer Disease;Dementia;Donepezil, Comorbid medical conditions must be clinically stable prior to Screening unless otherwise specified.
NCT01539031,Phase 3,Alzheimer's Type Dementia,"Eisai Co., Ltd.",Mar-12,Alzheimer Disease;Dementia;Donepezil, Written informed consent will be obtained from the subject (if possible) or from the subject's legal guardian or other representative (according to Japanese regulations as appropriate) prior to beginning screening activities.
NCT01548287,Phase 2,Mild Alzheimer's Disease,AstraZeneca,Apr-12,Alzheimer Disease;Cognitive Dysfunction, Patient and study partner to sign informed consent before initiation of any study-related procedures.
NCT01548287,Phase 2,Mild Alzheimer's Disease,AstraZeneca,Apr-12,Alzheimer Disease;Cognitive Dysfunction, Clinical diagnosis of Alzheimers (AD) or mild cognitive impairment (MCI) disease.
NCT01548287,Phase 2,Mild Alzheimer's Disease,AstraZeneca,Apr-12,Alzheimer Disease;Cognitive Dysfunction," Single caregiver for at least 6 months prior to Screening, capable of accompanying the patient on clinic visits as needed. The caregiver must either be living with or visiting the patient at least 10 hours per week, split over multiple (at least 2) days, for the duration of the study."
NCT01548287,Phase 2,Mild Alzheimer's Disease,AstraZeneca,Apr-12,Alzheimer Disease;Cognitive Dysfunction," Single study partner, for at least several months prior to Screening, capable of accompanying the patient on clinic visits as needed. The study partner must either be living with or visiting the patient at least 3 days per week for the duration of the study."
NCT01548287,Phase 2,Mild Alzheimer's Disease,AstraZeneca,Apr-12,Alzheimer Disease;Cognitive Dysfunction, A body mass index (BMI=weight/height2) of 18 kg/m2 to 32 kg/m2.
NCT01549834,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Mar-12,Alzheimer Disease," The subject and caregiver must voluntarily sign and date an informed consent. If the subject does not have the capacity to provide informed consent, full informed consent must be obtained from the subject's representative and assent must be obtained from the subject."
NCT01549834,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Mar-12,Alzheimer Disease," The subject is a male or female between the ages of 55 and 90 years, inclusive, at Screening Visit 1. Main Inclusion (Continued):"
NCT01549834,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Mar-12,Alzheimer Disease, The subject meets the Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria for probable AD.
NCT01549834,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Mar-12,Alzheimer Disease, The subject must be receiving a stable dose of an AChEI (donepezil or rivastigmine) for at least 90 days prior to Screening Visit 1.
NCT01549834,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Mar-12,Alzheimer Disease," The subject has a Mini-Mental Status Examination (MMSE) total score of 12 to 24, inclusive, at Screening Visit 1."
NCT01549834,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Mar-12,Alzheimer Disease, The subject has a Cornell Scale for Depression in Dementia (CSDD) score  10 at Screening Visit 1.
NCT01549834,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Mar-12,Alzheimer Disease, The subject has a Modified Hachinski Ischemic Scale (MHIS) score of  4 at Screening Visit 1.
NCT01549834,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Mar-12,Alzheimer Disease," With the exception of a diagnosis of mild-to-moderate Alzheimer's disease and the presence of stable medical conditions, the subject is in general good health, based upon the results of medical history, physical examination, vital signs, laboratory profile, and a 12-lead electrocardiogram (ECG)."
NCT01549834,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Mar-12,Alzheimer Disease," The subject has an identified, reliable caregiver who will provide support and ensure compliance with the study medication and procedures, and provide accurate information about the subject's status during the study."
NCT01560585,Phase 1/Phase 2,Alzheimer's Disease,University Hospitals Cleveland Medical Center,unknown,Alzheimer Disease;Isotretinoin, Probable AD by DSM IV and NINCDS-ADRDA criteria
NCT01560585,Phase 1/Phase 2,Alzheimer's Disease,University Hospitals Cleveland Medical Center,unknown,Alzheimer Disease;Isotretinoin," Females must be surgically sterile (bilateral tubal ligation, both ovaries removed or hysterectomy) or post-menopausal for at least 2 years."
NCT01560585,Phase 1/Phase 2,Alzheimer's Disease,University Hospitals Cleveland Medical Center,unknown,Alzheimer Disease;Isotretinoin, greater than  50 years of age
NCT01560585,Phase 1/Phase 2,Alzheimer's Disease,University Hospitals Cleveland Medical Center,unknown,Alzheimer Disease;Isotretinoin," Residing in the community at baseline (includes assisted living facilities, long-term care nursing facilities)"
NCT01560585,Phase 1/Phase 2,Alzheimer's Disease,University Hospitals Cleveland Medical Center,unknown,Alzheimer Disease;Isotretinoin, Mini Mental State Examination at screen of 12-26 (inclusive)
NCT01560585,Phase 1/Phase 2,Alzheimer's Disease,University Hospitals Cleveland Medical Center,unknown,Alzheimer Disease;Isotretinoin, No medical contraindications to study participation
NCT01560585,Phase 1/Phase 2,Alzheimer's Disease,University Hospitals Cleveland Medical Center,unknown,Alzheimer Disease;Isotretinoin, Fluent in English at least 8 years of education.
NCT01560585,Phase 1/Phase 2,Alzheimer's Disease,University Hospitals Cleveland Medical Center,unknown,Alzheimer Disease;Isotretinoin, Supervision available for study medication. Caregiver/study partner to accompany participant to all visits. Study partner must have direct contact with the participant greater than  2 days/week
NCT01560585,Phase 1/Phase 2,Alzheimer's Disease,University Hospitals Cleveland Medical Center,unknown,Alzheimer Disease;Isotretinoin, Able to ingest oral medication.
NCT01560585,Phase 1/Phase 2,Alzheimer's Disease,University Hospitals Cleveland Medical Center,unknown,Alzheimer Disease;Isotretinoin, Neuroimaging (CT or MRI or PET) consistent with the diagnosis of AD at some time after the onset of the memory decline.
NCT01560585,Phase 1/Phase 2,Alzheimer's Disease,University Hospitals Cleveland Medical Center,unknown,Alzheimer Disease;Isotretinoin," Clinical laboratory values must be within normal limits or, if abnormal, must be judged to be clinically insignificant by the investigator"
NCT01560585,Phase 1/Phase 2,Alzheimer's Disease,University Hospitals Cleveland Medical Center,unknown,Alzheimer Disease;Isotretinoin, Stable use of cholinesterase inhibitors and memantine is permitted if doses are stable for 3 months prior to enrollment. Dose should be stable throughout the study unless it is clinically necessary to adjust the medication.
NCT01560585,Phase 1/Phase 2,Alzheimer's Disease,University Hospitals Cleveland Medical Center,unknown,Alzheimer Disease;Isotretinoin, Stable use of anti-depressants is permitted if doses are stable for 3 months prior to enrollment. Dose should be stable throughout the study unless it is clinically necessary to adjust the medication.
NCT01561430,Phase 1/Phase 2,Alzheimer's Disease,Eli Lilly and Company,Mar-12,Alzheimer Disease;Cognitive Dysfunction, Meets criteria for MCI due to AD or Mild AD
NCT01561430,Phase 1/Phase 2,Alzheimer's Disease,Eli Lilly and Company,Mar-12,Alzheimer Disease;Cognitive Dysfunction, All participants will be required to undergo assessment via the Mini Mental State Examination (MMSE) scale at screening
NCT01561430,Phase 1/Phase 2,Alzheimer's Disease,Eli Lilly and Company,Mar-12,Alzheimer Disease;Cognitive Dysfunction," Participants with MMSE scores of 20 to 26, inclusive, may be enrolled provided they meet the criteria for mild AD, as follows:"
NCT01561430,Phase 1/Phase 2,Alzheimer's Disease,Eli Lilly and Company,Mar-12,Alzheimer Disease;Cognitive Dysfunction, Participant meets the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria for probable AD
NCT01561430,Phase 1/Phase 2,Alzheimer's Disease,Eli Lilly and Company,Mar-12,Alzheimer Disease;Cognitive Dysfunction, Clinical Dementia Rating Scale (CDR) score of 0.5 or 1
NCT01561430,Phase 1/Phase 2,Alzheimer's Disease,Eli Lilly and Company,Mar-12,Alzheimer Disease;Cognitive Dysfunction, Positive scan for the presence of amyloid beta
NCT01561430,Phase 1/Phase 2,Alzheimer's Disease,Eli Lilly and Company,Mar-12,Alzheimer Disease;Cognitive Dysfunction," Participants with MMSE of 27 to 30, inclusive, may be enrolled as participants with MCI due to AD provided they meet the following criteria:"
NCT01561430,Phase 1/Phase 2,Alzheimer's Disease,Eli Lilly and Company,Mar-12,Alzheimer Disease;Cognitive Dysfunction, Gradual and progressive change in memory function as reported by the participant or a caregiver during a period of more than 6 months
NCT01561430,Phase 1/Phase 2,Alzheimer's Disease,Eli Lilly and Company,Mar-12,Alzheimer Disease;Cognitive Dysfunction, Free and Cued Selective Reminding Test with Immediate Recall (FCSRT-IR): free recall 22 and total recall 46
NCT01561430,Phase 1/Phase 2,Alzheimer's Disease,Eli Lilly and Company,Mar-12,Alzheimer Disease;Cognitive Dysfunction, Absence of dementia
NCT01561430,Phase 1/Phase 2,Alzheimer's Disease,Eli Lilly and Company,Mar-12,Alzheimer Disease;Cognitive Dysfunction, Preservation of functional independence
NCT01561430,Phase 1/Phase 2,Alzheimer's Disease,Eli Lilly and Company,Mar-12,Alzheimer Disease;Cognitive Dysfunction," Exclusion of other potential (vascular, traumatic, or medical) causes of cognitive decline, where possible"
NCT01561430,Phase 1/Phase 2,Alzheimer's Disease,Eli Lilly and Company,Mar-12,Alzheimer Disease;Cognitive Dysfunction, Positive scan for the presence of amyloid beta
NCT01561430,Phase 1/Phase 2,Alzheimer's Disease,Eli Lilly and Company,Mar-12,Alzheimer Disease;Cognitive Dysfunction, Women must be postmenopausal
NCT01561430,Phase 1/Phase 2,Alzheimer's Disease,Eli Lilly and Company,Mar-12,Alzheimer Disease;Cognitive Dysfunction," Men are required to use an approved barrier method of contraception if their partners are pregnant, or of childbearing potential and not using approved contraceptive methods"
NCT01569516,Phase 2,Alzheimer's Disease,"Changchun Huayang High-tech Co., Ltd",Jun-11,Alzheimer Disease,Clinical diagnosis of probable AD based on DSM-IV and the NINCDS-ADRDA criteria.
NCT01569516,Phase 2,Alzheimer's Disease,"Changchun Huayang High-tech Co., Ltd",Jun-11,Alzheimer Disease,Male/female patient aged between 50 and 85.
NCT01569516,Phase 2,Alzheimer's Disease,"Changchun Huayang High-tech Co., Ltd",Jun-11,Alzheimer Disease,"mild to moderate probable AD Middle school or above: 11 MMSE  25, elementary school: 8  MMSE  20, illiteracy: 5  MMSE  16."
NCT01569516,Phase 2,Alzheimer's Disease,"Changchun Huayang High-tech Co., Ltd",Jun-11,Alzheimer Disease,CT or MRI scan excluding another structural brain disease in one year.
NCT01569516,Phase 2,Alzheimer's Disease,"Changchun Huayang High-tech Co., Ltd",Jun-11,Alzheimer Disease,Neurologic examination no significant abnormalities.
NCT01569516,Phase 2,Alzheimer's Disease,"Changchun Huayang High-tech Co., Ltd",Jun-11,Alzheimer Disease,"Hachinski Ischemic Score less than  4Hamilton Depression Scale 10. Able to complete the test procedure, audio-visual and physical ability to act to complete the neuropsychological measure."
NCT01569516,Phase 2,Alzheimer's Disease,"Changchun Huayang High-tech Co., Ltd",Jun-11,Alzheimer Disease,"Stable chaperone, more than 2 hours a day together with the patient or accumulated fewer than 14 hours per week."
NCT01569516,Phase 2,Alzheimer's Disease,"Changchun Huayang High-tech Co., Ltd",Jun-11,Alzheimer Disease,Informed consent of the patient (or legal representative) and of the caregiver agreeing to take part in the study.
NCT01602393,Phase 2,Alzheimer's Disease,Chiesi Farmaceutici S.p.A.,May-12,Alzheimer Disease;Cognitive Dysfunction;Flurbiprofen, Diagnosis of amnestic or non-amnestic Mild Cognitive Impairment.
NCT01602393,Phase 2,Alzheimer's Disease,Chiesi Farmaceutici S.p.A.,May-12,Alzheimer Disease;Cognitive Dysfunction;Flurbiprofen, Mini-Mental State Examination score higher than 24 at screening.
NCT01602393,Phase 2,Alzheimer's Disease,Chiesi Farmaceutici S.p.A.,May-12,Alzheimer Disease;Cognitive Dysfunction;Flurbiprofen, MRI scan of the brain at screening with fluid-attenuation inversion recovery (FLAIR) and T2*-weighted gradient-recalled-echo (GRE) sequences.
NCT01607476,Phase 2,Alzheimer's Disease,Mayo Clinic,Jul-12,Alzheimer Disease;Corticosterone;Flutemetamol,Males or females 30 years of age or older.
NCT01607476,Phase 2,Alzheimer's Disease,Mayo Clinic,Jul-12,Alzheimer Disease;Corticosterone;Flutemetamol,"Subjects who have the clinical diagnosis of probable AD (30) ages 50 and older who have a study partner who is the participant's power of attorney (POA) or legally authorized representative (LAR), cognitive normal elderly (30) age greater than 60 and cognitive normal young subjects (30) ages 30-60."
NCT01607476,Phase 2,Alzheimer's Disease,Mayo Clinic,Jul-12,Alzheimer Disease;Corticosterone;Flutemetamol,Normal subjects with Clinical Dementia Rating (CDR) 0-0.5 and AD subjects with CDR of 0.5 or greater.
NCT01614886,Phase 3,Alzheimer's Disease,Novartis Pharmaceuticals,Jul-12,Alzheimer Disease;Rivastigmine, A diagnosis of dementia of the Alzheimer's type according to the DSM-IV criteria
NCT01614886,Phase 3,Alzheimer's Disease,Novartis Pharmaceuticals,Jul-12,Alzheimer Disease;Rivastigmine, A clinical diagnosis of probable AD according to NINCDS/ADRDA criteria
NCT01614886,Phase 3,Alzheimer's Disease,Novartis Pharmaceuticals,Jul-12,Alzheimer Disease;Rivastigmine, An MMSE score of  10 and  20 at baseline
NCT01617577,Phase 1/Phase 2,Alzheimer's Disease,University of South Florida,Jun-09,Alzheimer Disease;Lenograstim," People with probable AD (by NINDS/ADRDA criteria) who are likely to be testable at the conclusion of the study period, and who do not have concurrent medical conditions or medications that might influence cognitive testing or that would increase the risk of treatment"
NCT01617577,Phase 1/Phase 2,Alzheimer's Disease,University of South Florida,Jun-09,Alzheimer Disease;Lenograstim, The participants will have a Min Mental State Examination score of between 10 and 24
NCT01617577,Phase 1/Phase 2,Alzheimer's Disease,University of South Florida,Jun-09,Alzheimer Disease;Lenograstim, stable medical condition and stable medications for 3 months prior to screening
NCT01617577,Phase 1/Phase 2,Alzheimer's Disease,University of South Florida,Jun-09,Alzheimer Disease;Lenograstim, study partner (spouse or caregiver) to accompany patient to all scheduled visits; able to complete baseline assessments
NCT01617577,Phase 1/Phase 2,Alzheimer's Disease,University of South Florida,Jun-09,Alzheimer Disease;Lenograstim," physically acceptable for this study as confirmed by medical history, physical exam, neurological exam and clinical tests"
NCT01626391,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,Sep-12,Alzheimer Disease, Clinical diagnosis of all cause dementia and probable Alzheimer's disease (AD)
NCT01626391,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,Sep-12,Alzheimer Disease, Mini-Mental State Examination (MMSE) score of 14-26 (inclusive)
NCT01626391,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,Sep-12,Alzheimer Disease, Cognitive impairment present for at least 6 months
NCT01626391,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,Sep-12,Alzheimer Disease, Age 90 years
NCT01626391,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,Sep-12,Alzheimer Disease, Modified Hachinski ischaemic score of 4
NCT01626391,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,Sep-12,Alzheimer Disease," Females, if of childbearing potential, must use adequate contraception and maintain this use throughout participation in the study"
NCT01626391,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,Sep-12,Alzheimer Disease," Patient is able to read, understand, and provide written informed consent"
NCT01626391,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,Sep-12,Alzheimer Disease, Has one or more identified caregivers who are able to verify daily compliance with study drug and provide information on safety and tolerability; the caregiver(s) must also give consent to participate
NCT01626391,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,Sep-12,Alzheimer Disease, Currently taking an taking an acetylcholinesterase inhibitor and/or memantine; the subject must have been taking such medication(s) for 3 months. The dosage regimen must have remained stable for 6 weeks and it must be planned to remain stable throughout participation in the study.
NCT01626391,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,Sep-12,Alzheimer Disease, Able to comply with the study procedures
NCT01661673,Phase 2,Alzheimer's Disease,FORUM Pharmaceuticals Inc,Nov-12,Alzheimer Disease;Cognitive Dysfunction, Part 1: Male and female subjects between the ages of 45 to 65 (inclusive) in good health with a BMI of 18-32 kg/m2 and negative urine drug screen of abuse test.
NCT01661673,Phase 2,Alzheimer's Disease,FORUM Pharmaceuticals Inc,Nov-12,Alzheimer Disease;Cognitive Dysfunction," Part 2: Male and female subjects between the ages of 45 to 85 (inclusive), MRI/CT scans compatible with diagnosis of MCI or early AD, meets the classification of MCI due to AD as defined by the National Institute on Aging-Alzheimer's Association, and a BMI of 18-32 kg/m2(inclusive). Subjects must meet the following Cognitive criteria: Subject Memory Complaint, cognitive impairment in one or more areas, CDR-SB score less than or equal 1.0, MMSE greater than 24, and no impairment in social or occupational functioning."
NCT01676935,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Aug-12,Alzheimer Disease," The subject and caregiver must voluntarily sign and date an informed consent. If the subject does not have the capacity to provide informed consent, full informed consent must be obtained from the subject's representative and assent must be obtained from the subject. The subject was randomized into Study M10-985 and completed dosing through Week 24 in that study. - With the exception of a diagnosis of mild to moderate AD and the presence of stable medical conditions, the subject is in general good health, based upon the results of medical history, physical examination, vital signs, laboratory profile, and a 12-lead ECG. If male, the subject is surgically sterile (vasectomy, is sexually inactive, or is using a barrier method of birth control (condom) with spermicidal foam/gel/film/cream/suppository for the duration of the study and for 30 days following the last dose of study drug. However, if the male subject's partner has been postmenopausal for at least 2 years or is surgically sterile, then use of a barrier method of birth control is not required. - The subject has an identified, reliable caregiver who will provide support and ensure compliance with the study medication and procedures, and provide accurate information about the subject's status during the study. - The subject and caregiver must have sufficient visual, hearing and graphomotor skills to complete the study procedures."
NCT01677754,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease;Memantine;Rivastigmine;Donepezil;Galantamine," Probable Alzheimer disease, based on the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS)/Alzheimer's Disease and Related Disorders Association (ADRDA) and Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV-TR) criteria"
NCT01677754,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease;Memantine;Rivastigmine;Donepezil;Galantamine," Mini-Mental State Exam (MMSE) score at screening between 13 and 20, inclusive"
NCT01677754,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease;Memantine;Rivastigmine;Donepezil;Galantamine, Body mass index (BMI) between 18 and 36 kilograms per square meter (kg/m^2) (inclusive) at screening
NCT01677754,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease;Memantine;Rivastigmine;Donepezil;Galantamine, Modified Hachinski Ischemia Score of less than or equal to (less than /=) 4
NCT01677754,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease;Memantine;Rivastigmine;Donepezil;Galantamine, Participants with Cornell Scale for Depression in Dementia (CSDD) scores less than /= 13 at screening
NCT01677754,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease;Memantine;Rivastigmine;Donepezil;Galantamine," Receiving treatment with donepezil, rivastigmine, galantamine or any AChEIs in combination with memantine for at least 4 months before screening, with their dose and formulation stabilized at least 3 months before screening. All formulation and dosages are allowed except donezepil 23 mg (alone or in combination)"
NCT01677754,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease;Memantine;Rivastigmine;Donepezil;Galantamine, Females of childbearing potential must have a negative pregnancy test and must agree to use effective contraception
NCT01677754,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease;Memantine;Rivastigmine;Donepezil;Galantamine," Generally healthy and ambulatory or ambulatory-aided (i.e., walker or cane)"
NCT01677754,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease;Memantine;Rivastigmine;Donepezil;Galantamine, Have a reliable caregiver or some other identified responsible person who has frequent contact with the participant
NCT01680588,Phase 2,Alzheimer Disease,Navidea Biopharmaceuticals,Aug-12,Alzheimer Disease, All participants:
NCT01680588,Phase 2,Alzheimer Disease,Navidea Biopharmaceuticals,Aug-12,Alzheimer Disease," is able to provide informed consent or assent, and exhibits adequate visual, auditory, and communication capabilities to enable compliance with study procedures"
NCT01680588,Phase 2,Alzheimer Disease,Navidea Biopharmaceuticals,Aug-12,Alzheimer Disease, should be able to perform the psychometric testing
NCT01680588,Phase 2,Alzheimer Disease,Navidea Biopharmaceuticals,Aug-12,Alzheimer Disease," has a modified Hachinski score ((Hachinski, et al., 2012; Rosen, et al., 1980)  4 at screening"
NCT01680588,Phase 2,Alzheimer Disease,Navidea Biopharmaceuticals,Aug-12,Alzheimer Disease," possesses a general health that permits adequate compliance with all study procedures as ascertained by a detailed review of the medical history, surgical history, laboratory and physical examination findings, which must be performed within 56 days prior to administration of [18F]NAV4694"
NCT01680588,Phase 2,Alzheimer Disease,Navidea Biopharmaceuticals,Aug-12,Alzheimer Disease, informed consent has been signed and dated by the subject and/or the subject's legally authorized representative (LAR; for probable AD subjects)
NCT01680588,Phase 2,Alzheimer Disease,Navidea Biopharmaceuticals,Aug-12,Alzheimer Disease, Healthy Volunteers Only
NCT01680588,Phase 2,Alzheimer Disease,Navidea Biopharmaceuticals,Aug-12,Alzheimer Disease, is male or female and is between the age of 18 and 40 years (for younger HVs) or 55 to 85 years of age (for older HVs)
NCT01680588,Phase 2,Alzheimer Disease,Navidea Biopharmaceuticals,Aug-12,Alzheimer Disease, if female does not have childbearing potential: must be confirmed by either: post-menopausal status; or history of surgical sterilization or of hysterectomy
NCT01680588,Phase 2,Alzheimer Disease,Navidea Biopharmaceuticals,Aug-12,Alzheimer Disease, if female has childbearing potential: must demonstrate a negative serum beta-HCG level at screening and a negative urine pregnancy test on the day of injection (prior to injection) consistent with a non-gravid state and agree to use two acceptable forms of birth control
NCT01680588,Phase 2,Alzheimer Disease,Navidea Biopharmaceuticals,Aug-12,Alzheimer Disease," has no evidence of cognitive impairment as indicated by a clinical dementia rating (CDR) (Morris, 1993) score of 0 (zero) and a score of  28 in the Mini-Mental State Examination (MMSE) (Folstein, et al., 1975)"
NCT01680588,Phase 2,Alzheimer Disease,Navidea Biopharmaceuticals,Aug-12,Alzheimer Disease," has MRI brain scan that has been judged as  normal (age-appropriate)  supporting the lack of cerebrovascular disease (e.g., a white matter lesion score of 0, 1, or 2 and a basal ganglia score of 0 to 1 on the ARWMC scale)"
NCT01680588,Phase 2,Alzheimer Disease,Navidea Biopharmaceuticals,Aug-12,Alzheimer Disease, Probable Alzheimer's Disease Subjects Only
NCT01680588,Phase 2,Alzheimer Disease,Navidea Biopharmaceuticals,Aug-12,Alzheimer Disease," is male or female and is  55 of age, whereby females must be without childbearing potential (confirmed by either:post-menopausal status; or history of surgical sterilization or of hysterectomy)"
NCT01680588,Phase 2,Alzheimer Disease,Navidea Biopharmaceuticals,Aug-12,Alzheimer Disease, presents with positive assessment for dementia of Alzheimer's type in accordance with the DSM-IV-TR and probable AD according to the NINCDS-ADRDA criteria and fulfills none of the exclusion criteria of either
NCT01680588,Phase 2,Alzheimer Disease,Navidea Biopharmaceuticals,Aug-12,Alzheimer Disease," does not fulfill the International Consensus Criteria (ICC) for probable diffuse Lewy body disease (DLBD), the NINDS-AIREN for probable vascular dementia, or the Neary criteria for frontotemporal dementia (FTD) [Neary et al. 1998]"
NCT01680588,Phase 2,Alzheimer Disease,Navidea Biopharmaceuticals,Aug-12,Alzheimer Disease, has a MMSE score between 16 and 23
NCT01680588,Phase 2,Alzheimer Disease,Navidea Biopharmaceuticals,Aug-12,Alzheimer Disease," has a CDR (Morris, 1993) score of 1 to 2"
NCT01680588,Phase 2,Alzheimer Disease,Navidea Biopharmaceuticals,Aug-12,Alzheimer Disease," has a Cornell Scale for Depression in Dementia (CSDD; (Alexopoulos, et al., 1988)) score less than or equal to 18 (definite major depression)"
NCT01680588,Phase 2,Alzheimer Disease,Navidea Biopharmaceuticals,Aug-12,Alzheimer Disease," MRI brain scan findings that do not reveal changes indicative of stroke and/or generalized cerebrovascular disease changes (limited to: a white matter lesion score of 0, 1, or 2 and a basal ganglia score of 0 or 1 on the ARWMC scale)"
NCT01680588,Phase 2,Alzheimer Disease,Navidea Biopharmaceuticals,Aug-12,Alzheimer Disease, has a caregiver who is willing and able to attend study visits and perform the psychometric tests requiring the presence of a caregiver
NCT01689233,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Oct-12,Alzheimer Disease, Diagnosis of all cause dementia and probable Alzheimer's disease
NCT01689233,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Oct-12,Alzheimer Disease, Clinical Dementia Rating (CDR) total score of 0.5 or 1 (mild) and MMSE score of 20-26 (inclusive)
NCT01689233,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Oct-12,Alzheimer Disease, Age less than 90 years
NCT01689233,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Oct-12,Alzheimer Disease, Modified Hachinski ischemic score of 4
NCT01689233,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Oct-12,Alzheimer Disease," Females, if of child-bearing potential, must practice true abstinence or be competent to use adequate contraception and agree to maintain this throughout the study"
NCT01689233,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Oct-12,Alzheimer Disease," Subject, and/or, in the case of reduced decision-making capacity, legally acceptable representative(s) consistent with national law is/are able to read, understand, and provide written informed consent"
NCT01689233,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Oct-12,Alzheimer Disease," Has one (or more) identified adult caregiver who is willing to provide written informed consent for his/her own participation; is able to read, understand, and speak the designated language at the study site; either lives with the subject or sees the subject for 2 hours/day 3 days/week; agrees to accompany the subject to each study visit; and is able to verify daily compliance with study drug"
NCT01689233,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Oct-12,Alzheimer Disease," If currently taking an acetylcholinesterase inhibitor and/or memantine at the time of Screening, the subject must have been taking such medication(s) for 3 months. The dosage regimen must have remained stable for 6 weeks and it must be planned to remain stable throughout participation in the study."
NCT01689233,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Oct-12,Alzheimer Disease, Able to comply with the study procedures
NCT01689246,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Jan-13,Alzheimer Disease;Methylene Blue, Diagnosis of all cause dementia and probable Alzheimer's disease
NCT01689246,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Jan-13,Alzheimer Disease;Methylene Blue, Clinical Dementia Rating (CDR) total score of 1 (mild) to 2 (moderate) and MMSE score of 14-26 (inclusive)
NCT01689246,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Jan-13,Alzheimer Disease;Methylene Blue, Age less than  90 years
NCT01689246,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Jan-13,Alzheimer Disease;Methylene Blue, Modified Hachinski ischemic score of  4
NCT01689246,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Jan-13,Alzheimer Disease;Methylene Blue," Females, if of child-bearing potential, must practice true abstinence or be competent to use adequate contraception and agree to maintain this throughout the study"
NCT01689246,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Jan-13,Alzheimer Disease;Methylene Blue," Subject, and/or, in the case of reduced decision-making capacity, legally acceptable representative(s) consistent with national law is/are able to read, understand, and provide written informed consent"
NCT01689246,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Jan-13,Alzheimer Disease;Methylene Blue," Has one (or more) identified adult caregiver who is willing to provide written informed consent for his/her own participation; is able to read, understand, and speak the designated language at the study site; either lives with the subject or sees the subject for 2 hours/day 3 days/week; agrees to accompany the subject to each study visit; and is able to verify daily compliance with study drug"
NCT01689246,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Jan-13,Alzheimer Disease;Methylene Blue," If currently taking an acetylcholinesterase inhibitor and/or memantine at the time of Screening, the subject must have been taking such medication(s) for 3 months. The dosage regimen must have remained stable for 6 weeks and it must be planned to remain stable throughout participation in the study."
NCT01689246,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Jan-13,Alzheimer Disease;Methylene Blue, Able to comply with the study procedures
NCT01690195,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Sep-12,Alzheimer Disease," The subject and caregiver must voluntarily sign and date an informed consent. If the subject does not have the capacity to provide informed consent, full informed consent must be obtained from the subject's representative and assent must be obtained from the subject."
NCT01690195,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Sep-12,Alzheimer Disease, The subject was randomized into Study M11-793 and completed dosing through Week 24 in that study.
NCT01690195,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Sep-12,Alzheimer Disease," With the exception of a diagnosis of mild to moderate AD and the presence of stable medical conditions, the subject is in general good health, based upon the results of medical history, physical examination, vital signs, laboratory profile, and a 12-lead ECG."
NCT01690195,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Sep-12,Alzheimer Disease," If male, the subject is surgically sterile (vasectomy, is sexually inactive, or is using a barrier method of birth control (condom) with spermicidal foam/gel/film/cream/suppository for the duration of the study and for 30 days following the last dose of study drug. However, if the male subject's partner has been postmenopausal for at least two years or is surgically sterile, then use of a barrier method of birth control is not required."
NCT01690195,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Sep-12,Alzheimer Disease," The subject has an identified, reliable caregiver who will provide support and ensure compliance with the study medication and procedures, and provide accurate information about the subject's status during the study."
NCT01690195,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Sep-12,Alzheimer Disease," The subject and caregiver must have sufficient visual, hearing and graphomotor skills to complete the study procedures."
NCT01696123,Phase 2,Alzheimer Disease,Shahid Beheshti University of Medical Sciences,Jan-11,Alzheimer Disease, at least 50 years old
NCT01696123,Phase 2,Alzheimer Disease,Shahid Beheshti University of Medical Sciences,Jan-11,Alzheimer Disease, met the criteria for AD according to the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
NCT01696123,Phase 2,Alzheimer Disease,Shahid Beheshti University of Medical Sciences,Jan-11,Alzheimer Disease, failed treatment with the cholinesterase inhibitor Rivastigmine for any reason
NCT01703117,Phase 2,Alzheimer's Disease,Icahn School of Medicine at Mount Sinai,unknown,Alzheimer Disease;Riluzole," Male or female; 50 - 95 years old with mild Alzheimer's disease determined after neurological and neuropsychological evaluation following the National Institute on Aging - Alzheimer's disease Association criteria that recently revisited the NINCDS-ADRDA criteria. For mild Alzheimer's disease, Clinical Dementia Ratings Scale (CDR) should be 0.5 or 1 and Mini Mental State Examination (MMSS) between 19 and 27."
NCT01703117,Phase 2,Alzheimer's Disease,Icahn School of Medicine at Mount Sinai,unknown,Alzheimer Disease;Riluzole," Must be on donepezil (Aricept) or rivastigmine (Exelon) or galantamine (Razadyne) at a consistent dose for at least 2 months. Patients will be considered for inclusion if they were previously unable to tolerate acetylcholinesterase inhibitors and as a result, are no longer on the medication for at least 2 months."
NCT01703117,Phase 2,Alzheimer's Disease,Icahn School of Medicine at Mount Sinai,unknown,Alzheimer Disease;Riluzole, Must be fluent in English
NCT01703117,Phase 2,Alzheimer's Disease,Icahn School of Medicine at Mount Sinai,unknown,Alzheimer Disease;Riluzole, The subject will appoint or have previously appointed a health care proxy specifically designated for research consent and that this be documented.
NCT01712074,Phase 2,Alzheimer's Disease,Pfizer,Nov-12,Alzheimer Disease, Clinical diagnosis of probable AD with supportive brain imaging documentation
NCT01712074,Phase 2,Alzheimer's Disease,Pfizer,Nov-12,Alzheimer Disease," Have existing neuropsychiatric symptoms as defined by a score equal or greater than 10 on the NPI at screening, arising from item scores equal or greater than 2 (frequency X severity) on at least 2 domains."
NCT01712074,Phase 2,Alzheimer's Disease,Pfizer,Nov-12,Alzheimer Disease," Has been on donepezil (stable dose of 5 mg or 10 mg) for at least four months, with no intent to change such for the duration of the study."
NCT01715350,Phase 2,Alzheimer's Disease,VTBIO Co. LTD,May-12,Alzheimer Disease, 1)Male and female patients aged  50 and  85 years
NCT01715350,Phase 2,Alzheimer's Disease,VTBIO Co. LTD,May-12,Alzheimer Disease, 2)Clinically diagnosed with probable Alzheimer's disease based on DSM-IV and NINCDS-ADRDA criteria
NCT01715350,Phase 2,Alzheimer's Disease,VTBIO Co. LTD,May-12,Alzheimer Disease, 3)K-MMSE score of 12~26 at screening visit
NCT01715350,Phase 2,Alzheimer's Disease,VTBIO Co. LTD,May-12,Alzheimer Disease, 4)For females: 2 years of confirmed menopause or surgical sterilization.
NCT01715350,Phase 2,Alzheimer's Disease,VTBIO Co. LTD,May-12,Alzheimer Disease, 5)Able to walk (including the use of aids)
NCT01715350,Phase 2,Alzheimer's Disease,VTBIO Co. LTD,May-12,Alzheimer Disease, 6)Able to perform procedures for cognitive and other tests
NCT01715350,Phase 2,Alzheimer's Disease,VTBIO Co. LTD,May-12,Alzheimer Disease," 7)Residing with a life-long guardian willing to accompany the subject's on all visits, oversee his/her compliance with the procedures specified in the protocol and the study drug, and report his/her condition."
NCT01715350,Phase 2,Alzheimer's Disease,VTBIO Co. LTD,May-12,Alzheimer Disease, 8)Having signed him/herself or his/her legally acceptable representative having signed the written informed consent form
NCT01723670,Phase 2,Alzheimer's Disease,CERESPIR,Dec-12,Alzheimer Disease;Nerve Degeneration;Cognitive Dysfunction;Flurbiprofen, One or two 4 alleles of the apolipoprotein E (APOE) gene.
NCT01723670,Phase 2,Alzheimer's Disease,CERESPIR,Dec-12,Alzheimer Disease;Nerve Degeneration;Cognitive Dysfunction;Flurbiprofen, Diagnosis of amnestic Mild Cognitive Impairment.
NCT01723670,Phase 2,Alzheimer's Disease,CERESPIR,Dec-12,Alzheimer Disease;Nerve Degeneration;Cognitive Dysfunction;Flurbiprofen, Mini-Mental State Examination score higher than 24 at screening.
NCT01723826,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Previous participation in Study ABE4869g or ABE4955g and completion of the Week 73 visit
NCT01723826,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," Adequate visual and auditory acuity, in the investigator's judgment, to allow for neuropsychological testing"
NCT01723826,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Availability of a person ( caregiver ) who can provide information on activities of daily living and behavior in order to complete the study-specific assessments
NCT01723826,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Diagnosis of probable Alzheimer's disease according to the National Institute on Neurological and Communication Disease and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria (McKhann et al. 1984)
NCT01723826,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Mini-Mental State Examination (MMSE) score of 10 or more at screening (Folstein et al. 1975)
NCT01723826,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," For male participants with partners with reproductive potential, agreement to use a reliable means of contraception (e.g., condoms) during the study and for at least 8 weeks following the last dose of study drug"
NCT01723826,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," For female participants, a negative pregnancy test at screening"
NCT01735630,Phase 2,Alzheimer's Disease,"OPKO Health, Inc.",Nov-12,Alzheimer Disease;Psychomotor Agitation;Aggression;Inositol, Diagnosis of Probable AD according to the National Institute on Aging- Alzheimer's Association (NIA-AA) guidelines (McKhann et al 2011).
NCT01735630,Phase 2,Alzheimer's Disease,"OPKO Health, Inc.",Nov-12,Alzheimer Disease;Psychomotor Agitation;Aggression;Inositol, MMSE score of 5 to 24 (inclusive) at the Screening Visit.
NCT01735630,Phase 2,Alzheimer's Disease,"OPKO Health, Inc.",Nov-12,Alzheimer Disease;Psychomotor Agitation;Aggression;Inositol, Has clinically significant agitation/aggression defined as Neuropsychiatric Inventory (NPI)-agitation/aggression subscore of 4.
NCT01735630,Phase 2,Alzheimer's Disease,"OPKO Health, Inc.",Nov-12,Alzheimer Disease;Psychomotor Agitation;Aggression;Inositol, No response or suboptimal response to standard nonpharmacological interventions.
NCT01739348,Phase 2/Phase 3,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease," Diagnosis of probable AD based on both a) the National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria and b) the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) criteria for AD"
NCT01739348,Phase 2/Phase 3,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease, AD is of mild to moderate severity
NCT01739348,Phase 2/Phase 3,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease, Clear history of cognitive and functional decline over at least one year that is either a) documented in medical records or b) documented by history from an informant who knows the subject well
NCT01739348,Phase 2/Phase 3,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease," Able to read at a 6th grade level or equivalent, and must have a history of academic achievement and/or employment sufficient to exclude mental retardation"
NCT01739348,Phase 2/Phase 3,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease," If a participant is receiving an acetylcholinesterase inhibitor, memantine, medical food/supplement (e.g., vitamin E) and/or herbal medications for AD, the dose must have been stable for at least three months before Screening, and the participant must be willing to remain on the same dose for the duration of the trial. Participants may need to be on AD treatments in accordance with local requirements"
NCT01739348,Phase 2/Phase 3,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease, Participant must have a reliable and competent trial partner/caregiver who must have a close relationship with the subject
NCT01739348,Phase 2/Phase 3,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease, Tolerated study drug and completed the initial 78-week period of the trial (Part I)
NCT01739348,Phase 2/Phase 3,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease, Participant must have a reliable and competent trial partner who must have a close relationship with the subject
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease, Dementia status of mild to moderate
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease, CT or MRI scan within 18 months prior to screening compatible with a diagnosis of probable Alzheimer's disease
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease," Score on the Wechsler Memory Scale - Logical Memory II recall below a pre-determined cut-off, adjusted for education level"
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease, Confirmed apolipoprotein E genotype prior to randomization
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease, Prior and current use of medication that corresponds with protocol requirements
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease," Stable medical condition, with the exception of dementia, for at least 3 consecutive months prior to screening"
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease," No active suicidal thoughts within 6 months of screening, no active history of suicide attempt in the previous 2 years, no more than 1 lifetime suicide attempt, no serious suicidal risk"
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease, Able to comply with protocol testing and procedures for the duration of the study
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease," Has a permanent caregiver (caregiver is not expected to change during the course of the study) who is willing to attend all visits, oversee the participant's compliance with protocol procedures and study medication administration, and report on the participant's status"
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease," Resides in the community (includes assisted living facilities, but excludes long-term care nursing facilities)"
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease," Both participant and caregiver have the ability to read and write in English or Spanish and have hearing, vision and physical abilities adequate to perform the assessments (corrective aids allowed)"
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease," Participant and caregiver have provided full written informed consent prior to the performance of any protocol-specified procedure. If participant is unable to provide informed consent due to cognitive status, provision of informed consent by cognitively intact legally acceptable representative (where this is in accordance with local laws, regulations and ethics committee policy)"
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease, Participant is able to ingest oral medication
NCT01760005,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal", Between 18-80 years of age
NCT01760005,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal", Individuals who know they have an Alzheimer's disease-causing mutation or are unaware of their genetic status and have dominantly inherited Alzheimer's disease (DIAD) mutation in their family.
NCT01760005,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal"," Are within -15 to + 10 years of the predicted or actual age of cognitive symptom onset. For Cognitive Run-In (CRI): includes participants who are younger than 15 years prior to the expected age of cognitive symptom onset, in addition to those 15 years younger and no more than 10 years older than expected or actual age of cognitive symptom onset."
NCT01760005,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal"," Cognitively normal or with mild cognitive impairment or mild dementia, Clinical Dementia Rating (CDR) of 0-1 (inclusive)"
NCT01760005,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal", Fluency in DIAN-TU trial approved language and evidence of adequate premorbid intellectual functioning
NCT01760005,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal"," Able to undergo Magnetic Resonance Imaging (MRI), Lumbar Puncture (LP), Positron Emission Tomography (PET), and complete all study related testing and evaluations."
NCT01760005,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal"," For women of childbearing potential, if partner is not sterilized, subject must agree to use effective contraceptive measures (hormonal contraception, intra-uterine device, sexual abstinence, barrier method with spermicide)."
NCT01760005,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal", Adequate visual and auditory abilities to perform all aspects of the cognitive and functional assessments.
NCT01760005,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal"," Has a Study Partner who in the investigator's judgment is able to provide accurate information as to the subject's cognitive and functional abilities, who agrees to provide information at the study visits which require informant input for scale completion."
NCT01764243,Phase 2,Alzheimer's Disease,Mitsubishi Tanabe Pharma Corporation,Nov-12,Alzheimer Disease, Probable Alzheimer's disease consistent with National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and Alzheimer's Disease and Related Disorders Association (ADRDA) criteria
NCT01764243,Phase 2,Alzheimer's Disease,Mitsubishi Tanabe Pharma Corporation,Nov-12,Alzheimer Disease," MMSE score of 10 to 24 inclusive at screening and at Day 1, and CDR-SB score of  2 at screening"
NCT01764243,Phase 2,Alzheimer's Disease,Mitsubishi Tanabe Pharma Corporation,Nov-12,Alzheimer Disease, Modified Hachinski Ischemic Score (mHIS)  4 at screening
NCT01764243,Phase 2,Alzheimer's Disease,Mitsubishi Tanabe Pharma Corporation,Nov-12,Alzheimer Disease, Caregiver available; caregiver sees subject at least four days (at least 12 hours) each week
NCT01764243,Phase 2,Alzheimer's Disease,Mitsubishi Tanabe Pharma Corporation,Nov-12,Alzheimer Disease," Subject living at home; if living at senior residential setting, or an institutional setting, subject with caregiver indicated above is available"
NCT01766336,Phase 2,Alzheimer's Disease,"OPKO Health, Inc.",Jan-13,Alzheimer Disease;Psychomotor Agitation;Aggression;Inositol, Complete Week 12 visit of AG201
NCT01766336,Phase 2,Alzheimer's Disease,"OPKO Health, Inc.",Jan-13,Alzheimer Disease;Psychomotor Agitation;Aggression;Inositol, Both patient and study partner/caregiver are willing and able to participate in all scheduled evaluations and complete all required tests
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,Subjects with objective impairment in episodic memory as indicated by at least 1 standard deviation below age-adjusted mean in the Wechsler Memory Scale - IV Logical Memory II (WMS-IV LMII):
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,Less than or equal to 15 for age 50 to 64 years
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,Less than or equal to 12 for age 65 to 69 years
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,Less than or equal to 11 for age 70 to 74 years
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,Less than or equal to 9 for age 75 to 79 years
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,Less than or equal to 7 for age 80 to 90 years
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,Positive amyloid load as indicated by PET or CSF assessment
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,PET assessment of imaging agent uptake into brain
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,CSF assessment of A(1-42)
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,"Age between 50 and 90 years, inclusive"
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,"Mini Mental State Examination (MMSE) score equal to or greater than 22, and equal to or less than 30, at Screening and Baseline"
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,Body Mass Index (BMI) greater than 17 and less than 35 at Screening or Baseline
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,Females must not be lactating or pregnant at Screening or Baseline (as documented by a negative beta-human chorionic gonadotropin assay [-hCG]). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,"Subjects on acetylcholinesterase inhibitor or memantine therapy or both for AD must be on a stable dose for at least 12 weeks prior to Baseline. Treatment naive subjects can be entered into the study. Unless otherwise stated, subjects must have been on stable doses of all other permitted concomitant medications (ie, non-AD related) for at least 4 weeks prior to Baseline."
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,Subjects must have identified caregivers/informants
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,Subjects must provide written informed consent
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,Subjects who have completed Visit 42 (Week 79) of the Core Study or who discontinued study drug during the Core Study due to any of the following reasons:
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,Alzheimer's Related Imaging Abnormality-Edema (ARIA-E)
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,"Amyloid related imaging abnormality hemorrhage (ARIA-H) (superficial siderosis, macrohemorrhage, or symptomatic microhemorrhage)"
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,Prohibited or restricted medications that were prohibited during Core Study conduct but are no longer prohibited in the Extension Phase
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,Subjects who were APOE4 positive and receiving treatment with lecanemab 10 mg/kg biweekly
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,"Any reason for discontinuation not related to prohibited medications, including any AE that was considered not related to study drug, and that was not severe or life-threatening"
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,Must continue to have an identified caregiver or informant who is willing and able to provide follow-up information on the subject throughout the course of the Extension Phase
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,"Provide written informed consent. If a subject lacks capacity to consent in the investigator's opinion, the subject's assent should be obtained, if required in accordance with local laws, regulations and customs, plus the written informed consent of a legal representative should be obtained (capacity to consent and definition of legal representative should be determined in accordance with applicable local laws and regulations)."
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,Must be able to physically attend clinic visits and be willing and able to comply with all aspects of the protocol
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease, Key Exclusion Criteria (Core study):
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,Any neurological condition that may be contributing to cognitive impairment above and beyond that caused by the subject's AD
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,"History of transient ischemic attacks (TIA), stroke, or seizures within 12 months of Screening"
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,"Any psychiatric diagnosis or symptoms, (e.g., hallucinations, major depression, or delusions) that could interfere with study procedures in the subject"
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,Geriatric Depression Scale (GDS) score 8 at Screening
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,"Contraindications to MRI scanning, including cardiac pacemaker/ defibrillator, ferromagnetic metal implants, e,g., in skull and cardiac devices other than those approved as safe for use in MR scanners"
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,"Evidence of other clinically significant lesions that could indicate a dementia diagnosis other than AD on brain MRI at Screening, or other significant pathological findings on brain MRI at Screening"
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,A prolonged QT/QTc interval (QTc greater than 450 ms) as demonstrated by a repeated electrocardiogram (ECG)
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,Certain other specified medical conditions
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,Severe visual or hearing impairment that would prevent the subject from performing psychometric tests accurately
NCT01767909,Phase 2/Phase 3,Alzheimer's Disease,University of Southern California,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc", Fluent in English or Spanish
NCT01767909,Phase 2/Phase 3,Alzheimer's Disease,University of Southern California,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc", Diagnosis of aMCI by Petersen criteria or probable AD by National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria
NCT01767909,Phase 2/Phase 3,Alzheimer's Disease,University of Southern California,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc", Mini Mental State Examination (MMSE) score at screening is greater than or equal to 20
NCT01767909,Phase 2/Phase 3,Alzheimer's Disease,University of Southern California,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc", Clinical Dementia Rating is 0.5-1 at screening
NCT01767909,Phase 2/Phase 3,Alzheimer's Disease,University of Southern California,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc"," Logical Memory is less than or equal to 8 for 16 or more years of education, less than or equal to 4 for 8-15 years of education, less than or equal to 2 for 0-7 years of education. Scores measured at screening on Delayed Paragraph Recall (Paragraph A only) from the Wechsler Memory Scale-Revised"
NCT01767909,Phase 2/Phase 3,Alzheimer's Disease,University of Southern California,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc", Able to complete baseline assessments
NCT01767909,Phase 2/Phase 3,Alzheimer's Disease,University of Southern California,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc", Modified Hachinski score of less than or equal to 4
NCT01767909,Phase 2/Phase 3,Alzheimer's Disease,University of Southern California,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc", A study partner able to accompany the participant to most visits and answer questions about the participant
NCT01767909,Phase 2/Phase 3,Alzheimer's Disease,University of Southern California,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc", The study partner must have direct contact with the participant more than 2 days per week (minimum of 10 hours per week) and provide supervision of drug administration as needed
NCT01767909,Phase 2/Phase 3,Alzheimer's Disease,University of Southern California,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc", Stable medical condition for 3 months prior to screening visit
NCT01767909,Phase 2/Phase 3,Alzheimer's Disease,University of Southern California,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc", Stable medications for 4 weeks prior to the screening and baseline visits
NCT01767909,Phase 2/Phase 3,Alzheimer's Disease,University of Southern California,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc", Stable use of permitted medications
NCT01767909,Phase 2/Phase 3,Alzheimer's Disease,University of Southern California,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc", At least six years of education or work history
NCT01767909,Phase 2/Phase 3,Alzheimer's Disease,University of Southern California,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc"," Clinical laboratory values must be within normal limits or, if abnormal, must be judged to be clinically insignificant by the investigator"
NCT01767909,Phase 2/Phase 3,Alzheimer's Disease,University of Southern California,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc", Visual and auditory acuity adequate for neuropsychological testing
NCT01782742,Phase 2,Alzheimer's Disease,The Cleveland Clinic,Feb-13,Alzheimer Disease;Bexarotene, Males or females 50 to 90 of age inclusive.
NCT01782742,Phase 2,Alzheimer's Disease,The Cleveland Clinic,Feb-13,Alzheimer Disease;Bexarotene, Diagnosis of probable AD according to National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria.
NCT01782742,Phase 2,Alzheimer's Disease,The Cleveland Clinic,Feb-13,Alzheimer Disease;Bexarotene, Willing and able to provide informed consent by either the subject or subject's legal representative.
NCT01782742,Phase 2,Alzheimer's Disease,The Cleveland Clinic,Feb-13,Alzheimer Disease;Bexarotene," Willing and able to comply with study visits, treatment plan, laboratory tests, brain imaging and other procedures."
NCT01782742,Phase 2,Alzheimer's Disease,The Cleveland Clinic,Feb-13,Alzheimer Disease;Bexarotene, Subjects must have a positive 18f-AV-45 PET scan as determined by a qualified rater.
NCT01782742,Phase 2,Alzheimer's Disease,The Cleveland Clinic,Feb-13,Alzheimer Disease;Bexarotene, Mini-Mental State Examinations (MMSE) score between 10-20 inclusive.
NCT01782742,Phase 2,Alzheimer's Disease,The Cleveland Clinic,Feb-13,Alzheimer Disease;Bexarotene, Must have a study partner who is able and willing to comply with all required study procedures.
NCT01782742,Phase 2,Alzheimer's Disease,The Cleveland Clinic,Feb-13,Alzheimer Disease;Bexarotene, Females must be postmenopausal.
NCT01782742,Phase 2,Alzheimer's Disease,The Cleveland Clinic,Feb-13,Alzheimer Disease;Bexarotene," Have at least eight years of education and should have previously (in pre-AD condition) been capable of reading, writing, and communicating effectively with others in English."
NCT01782742,Phase 2,Alzheimer's Disease,The Cleveland Clinic,Feb-13,Alzheimer Disease;Bexarotene," If receiving therapy with a cholinesterase inhibitor and/or memantine, the dose of these agents has been stable for at least 4 weeks prior to randomization"
NCT01782742,Phase 2,Alzheimer's Disease,The Cleveland Clinic,Feb-13,Alzheimer Disease;Bexarotene," Normal laboratory findings at baseline including CBC, chemistry panel, serum lipids, liver functions, TSH, and vitamin B12."
NCT01782742,Phase 2,Alzheimer's Disease,The Cleveland Clinic,Feb-13,Alzheimer Disease;Bexarotene, Must consent to ApoE genotyping
NCT01843075,Phase 2,Alzheimer's Disease,Imperial College London,unknown,Alzheimer Disease;Liraglutide,Capable of giving and capacity to give informed consent
NCT01843075,Phase 2,Alzheimer's Disease,Imperial College London,unknown,Alzheimer Disease;Liraglutide,"An individual who can act as a reliable study partner with regular contact (combination of face to face visits / telephone contact acceptable) who has sufficient subject interaction to provide meaningful input into rating scales and, if necessary, supervise or perform the injections, as judged by the investigator"
NCT01843075,Phase 2,Alzheimer's Disease,Imperial College London,unknown,Alzheimer Disease;Liraglutide,"Diagnosis of Probable Alzheimer's disease according to Dubois criteria (Dubois, Feldman et al. 2007) or National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria"
NCT01843075,Phase 2,Alzheimer's Disease,Imperial College London,unknown,Alzheimer Disease;Liraglutide,Age from 50 years
NCT01843075,Phase 2,Alzheimer's Disease,Imperial College London,unknown,Alzheimer Disease;Liraglutide,Mini-Mental State Examination (MMSE) score of 20 and CDR-Global score of 0.5 or 1
NCT01843075,Phase 2,Alzheimer's Disease,Imperial College London,unknown,Alzheimer Disease;Liraglutide,Rosen Modified Hachinski Ischemic score 4
NCT01843075,Phase 2,Alzheimer's Disease,Imperial College London,unknown,Alzheimer Disease;Liraglutide,On stable medication for 2 months before the screening visit; on or off cholinesterase inhibitors
NCT01843075,Phase 2,Alzheimer's Disease,Imperial College London,unknown,Alzheimer Disease;Liraglutide,Fluency in English and evidence of adequate premorbid intellectual functioning
NCT01843075,Phase 2,Alzheimer's Disease,Imperial College London,unknown,Alzheimer Disease;Liraglutide,Likely to be able to participate in all scheduled evaluations and complete all required tests
NCT01852110,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease," Diagnosis of probable AD based on both a) the National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria and b) the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) criteria for AD"
NCT01852110,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease, AD is of mild to moderate severity
NCT01852110,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease, Clear history of cognitive and functional decline over at least one year that is either a) documented in medical records or b) documented by history from an informant who knows the participant well
NCT01852110,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease," On a stable and effective daily dose of AChEI (either donepezil, rivastigmine, or galantamine), for at least two months before Screening, and willing to remain on the same dose for the duration of the trial. Effective doses are considered to be: donepezil, 10 mg total daily dose administered orally; rivastigmine, 9.5 or 13.3 mg/24 hours administered by transdermal patch or 6-12 mg total daily dose administered orally; galantamine, 16-24 mg total daily dose administered orally"
NCT01852110,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease," Able to read at a 6th grade level or equivalent, and must have a history of academic achievement and/or employment sufficient to exclude mental retardation"
NCT01852110,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease, Have a reliable and competent trial partner who must have a close relationship with the subject
NCT01876823,Phase 2/Phase 3,Alzheimer's Disease,New York State Psychiatric Institute,Apr-06,"Alzheimer Disease;Depressive Disorder;Cognitive Dysfunction;Depressive Disorder, Major;Memantine;Citalopram","Of either sex, age greater than 49 years old"
NCT01876823,Phase 2/Phase 3,Alzheimer's Disease,New York State Psychiatric Institute,Apr-06,"Alzheimer Disease;Depressive Disorder;Cognitive Dysfunction;Depressive Disorder, Major;Memantine;Citalopram",Meets criteria for both  depression  and  cognitive impairment .
NCT01876823,Phase 2/Phase 3,Alzheimer's Disease,New York State Psychiatric Institute,Apr-06,"Alzheimer Disease;Depressive Disorder;Cognitive Dysfunction;Depressive Disorder, Major;Memantine;Citalopram",Study Criteria for  depression :
NCT01876823,Phase 2/Phase 3,Alzheimer's Disease,New York State Psychiatric Institute,Apr-06,"Alzheimer Disease;Depressive Disorder;Cognitive Dysfunction;Depressive Disorder, Major;Memantine;Citalopram"," i. Patients who meet DSM-IV criteria for Major Depression, Dysthymic Disorder, or Dysthymia symptoms criteria of minimum 6 month duration (not the 2 year DSM-IV criteria). ii. 24-item HAM-D greater than 13; and iii. Clinical Global Impression (CGI) for severity of Depression greater than 2 (absolute score at least mild to moderate depression on a 7-point scale)"
NCT01876823,Phase 2/Phase 3,Alzheimer's Disease,New York State Psychiatric Institute,Apr-06,"Alzheimer Disease;Depressive Disorder;Cognitive Dysfunction;Depressive Disorder, Major;Memantine;Citalopram",Study Criteria for  cognitive deficit :
NCT01876823,Phase 2/Phase 3,Alzheimer's Disease,New York State Psychiatric Institute,Apr-06,"Alzheimer Disease;Depressive Disorder;Cognitive Dysfunction;Depressive Disorder, Major;Memantine;Citalopram"," i. Subjective memory complaint ii.Mini Mental Status Exam (MMSE) greater than 24; and at least one of a, b, or c:"
NCT01876823,Phase 2/Phase 3,Alzheimer's Disease,New York State Psychiatric Institute,Apr-06,"Alzheimer Disease;Depressive Disorder;Cognitive Dysfunction;Depressive Disorder, Major;Memantine;Citalopram",less than 3 on MMSE 5 min delay on recall
NCT01876823,Phase 2/Phase 3,Alzheimer's Disease,New York State Psychiatric Institute,Apr-06,"Alzheimer Disease;Depressive Disorder;Cognitive Dysfunction;Depressive Disorder, Major;Memantine;Citalopram","scores on 2 neuropsychological tests greater than 1 Standard Deviation (SD) below standardized norms, or"
NCT01876823,Phase 2/Phase 3,Alzheimer's Disease,New York State Psychiatric Institute,Apr-06,"Alzheimer Disease;Depressive Disorder;Cognitive Dysfunction;Depressive Disorder, Major;Memantine;Citalopram",score on 1 neuropsychological tests greater than 2 SD below standardized norms.
NCT01876823,Phase 2/Phase 3,Alzheimer's Disease,New York State Psychiatric Institute,Apr-06,"Alzheimer Disease;Depressive Disorder;Cognitive Dysfunction;Depressive Disorder, Major;Memantine;Citalopram", Neuropsychological tests for inclusion criteria (subset of larger battery):
NCT01876823,Phase 2/Phase 3,Alzheimer's Disease,New York State Psychiatric Institute,Apr-06,"Alzheimer Disease;Depressive Disorder;Cognitive Dysfunction;Depressive Disorder, Major;Memantine;Citalopram"," Selective Reminding Test with delay Wechsler Memory Scale (WMS): Visual Reproduction - with delay, % savings from immed to delay Controlled Oral Word Association Test Trails B Digit symbol subtest of Wechsler Adult Intelligence Scale (WAIS)-III Continuous Performance Test iii. CGI for severity of Cognitive deficit greater than 2 (absolute score on a 7-point scale:1=no deficit to 7=severe deficit). iv. Clinical Dementia Rating (CDR) = 0 or 0.5"
NCT01876823,Phase 2/Phase 3,Alzheimer's Disease,New York State Psychiatric Institute,Apr-06,"Alzheimer Disease;Depressive Disorder;Cognitive Dysfunction;Depressive Disorder, Major;Memantine;Citalopram",Willing and capable of giving informed consent
NCT01883648,Phase 2/Phase 3,Alzheimer's Disease,University of South Florida,Jun-13,Alzheimer Disease, Men and women aged 55 to 90 years with a diagnosis of mild to moderate Alzheimer's disease
NCT01883648,Phase 2/Phase 3,Alzheimer's Disease,University of South Florida,Jun-13,Alzheimer Disease, Informed consent signed and dated by subject (or legally authorized representative).
NCT01883648,Phase 2/Phase 3,Alzheimer's Disease,University of South Florida,Jun-13,Alzheimer Disease," Subjects must have a study partner must also consent to participate in the study, who they spend at least 10 hours/week with during the study. The study partner must attend applicable clinic visits and provide information about the subject."
NCT01883648,Phase 2/Phase 3,Alzheimer's Disease,University of South Florida,Jun-13,Alzheimer Disease, Subject must have a screening Mini-Mental State Examination score of 16-26.
NCT01883648,Phase 2/Phase 3,Alzheimer's Disease,University of South Florida,Jun-13,Alzheimer Disease, Subjects must have a Rosen Modified Hachinski Ischemic score of 4.
NCT01883648,Phase 2/Phase 3,Alzheimer's Disease,University of South Florida,Jun-13,Alzheimer Disease, Subject must undergo ApoE genetic laboratory testing at the baseline visit.
NCT01883648,Phase 2/Phase 3,Alzheimer's Disease,University of South Florida,Jun-13,Alzheimer Disease, Subject must be willing and able to take study medication (or placebo) for the duration of the study.
NCT01883648,Phase 2/Phase 3,Alzheimer's Disease,University of South Florida,Jun-13,Alzheimer Disease," Subject must be stable on all memory enhancing medications including cholinesterase inhibitors (including donepezil, rivastigmine, and galantamine) and NMDA antagonist (memantine) for at least 3 months prior to screening and agree not to change these medications during the course of their participation, unless medically necessary."
NCT01883648,Phase 2/Phase 3,Alzheimer's Disease,University of South Florida,Jun-13,Alzheimer Disease," Subject must be stable on all memory enhancing nonprescription supplements (including gingko biloba, huperzine, resveratrol, or docosahexaenoic acid) for at least 3 months prior to screening and agree not to change these medications during the course of their participation."
NCT01883648,Phase 2/Phase 3,Alzheimer's Disease,University of South Florida,Jun-13,Alzheimer Disease," As judged by Investigator, the subject and study partner will be compliant and have a high probability of completing the study, including all scheduled evaluations and required tests."
NCT01883648,Phase 2/Phase 3,Alzheimer's Disease,University of South Florida,Jun-13,Alzheimer Disease, Be fluent in English.
NCT01886820,Phase 3,Alzheimer's Disease,Navidea Biopharmaceuticals,unknown,Alzheimer Disease;Dementia, Male or female subjects will be at least 21 years of age.
NCT01886820,Phase 3,Alzheimer's Disease,Navidea Biopharmaceuticals,unknown,Alzheimer Disease;Dementia, Subjects will have a life expectancy of approximately 6 months
NCT01886820,Phase 3,Alzheimer's Disease,Navidea Biopharmaceuticals,unknown,Alzheimer Disease;Dementia, Subject health is adequate as determined by the investigator to receive [18F]NAV4694
NCT01886820,Phase 3,Alzheimer's Disease,Navidea Biopharmaceuticals,unknown,Alzheimer Disease;Dementia, Female subjects will not be of child-bearing potential or will have a negative urine pregnancy test on day of [18F]NAV4694 injection.
NCT01886820,Phase 3,Alzheimer's Disease,Navidea Biopharmaceuticals,unknown,Alzheimer Disease;Dementia," Must exhibit adequate visual, auditory, and communication capabilities to enable compliance with study procedures. This includes being able to lie down flat in the MRI or CT and PET scanner for a period of approximately 1 hour."
NCT01886820,Phase 3,Alzheimer's Disease,Navidea Biopharmaceuticals,unknown,Alzheimer Disease;Dementia, Subjects must be willing to donate their brains for post mortem examination upon death (this consent can be obtained in the manner specific to the country/region involved).
NCT01886820,Phase 3,Alzheimer's Disease,Navidea Biopharmaceuticals,unknown,Alzheimer Disease;Dementia," Subjects have been fully informed about the study, including provisions of the Health Insurance Portability and Accountability Act (HIPAA), as applicable, and informed consent or assent has been signed and dated (with time) by the subject and/or the subject's legally acceptable representative (LAR) (for individuals with dementia)."
NCT01900665,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Jul-13,Alzheimer Disease, Meets National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria for probable AD
NCT01900665,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Jul-13,Alzheimer Disease, Has a Modified Hachinski Ischemia Scale score of less than or equal to 4
NCT01900665,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Jul-13,Alzheimer Disease, Has a Mini-Mental State Examination (MMSE) score of 20 through 26 at Screening visit
NCT01900665,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Jul-13,Alzheimer Disease, Has a Geriatric Depression Scale score of less than or equal to 6 (on the staff-administered short form)
NCT01900665,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Jul-13,Alzheimer Disease, Has had a magnetic resonance imaging (MRI) or computerized tomography (CT) scan performed within the past 2 years that has confirmed no findings inconsistent with a diagnosis of AD
NCT01900665,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Jul-13,Alzheimer Disease, Has a florbetapir positron emission tomography (PET) scan or cerebrospinal fluid (CSF) result consistent with the presence of amyloid pathology at screening
NCT01931566,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,"In the opinion of the investigator, participant is capable of understanding and complying with protocol requirements."
NCT01931566,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,"Signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures."
NCT01931566,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,Is able to physically perform the cognitive tests in the opinion of the investigator and is fluent in the language that tests will be administered.
NCT01931566,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,"Is cognitively normal at baseline, scoring as indicated for the following tests:"
NCT01931566,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone, Clinical Dementia Rating (CDR)=0.
NCT01931566,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone, At least one memory test above -1.5 standard deviation (SD) of the demographically corrected normative mean.
NCT01931566,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,Must score 25 on the Mini-Mental State Examination (MMSE) at the screening visit after the education and age adjustment.
NCT01931566,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,"Is male or postmenopausal female between the ages of 65 and 83 years, inclusive, at time of the Screening visit."
NCT01931566,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,"Has the ability and intention to participate in regular study visits, in the opinion of the Investigator."
NCT01931566,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,"Has a project partner who can separately complete an Acknowledgement Form on his/her own behalf and take part in the study (with the intent to do so as long as the participant is enrolled) to provide information on the cognitive, functional, and behavioral status of the participant and to assist with monitoring of study medication, if needed."
NCT01940952,Phase 3,Alzheimer's Disease,Samsung Medical Center,Sep-13,Alzheimer Disease;Donepezil;Udenafil, Signed written informed consent;
NCT01940952,Phase 3,Alzheimer's Disease,Samsung Medical Center,Sep-13,Alzheimer Disease;Donepezil;Udenafil, Male or female subjects 50 to 90 years of age;
NCT01940952,Phase 3,Alzheimer's Disease,Samsung Medical Center,Sep-13,Alzheimer Disease;Donepezil;Udenafil, Diagnosis of probable Alzheimer's disease according to National Institute of Neurological Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria;
NCT01940952,Phase 3,Alzheimer's Disease,Samsung Medical Center,Sep-13,Alzheimer Disease;Donepezil;Udenafil, A Mini-Mental State Examination (MMSE) score of 10 and 26;
NCT01940952,Phase 3,Alzheimer's Disease,Samsung Medical Center,Sep-13,Alzheimer Disease;Donepezil;Udenafil, Global Clinical Dementia Rating  0.5;
NCT01940952,Phase 3,Alzheimer's Disease,Samsung Medical Center,Sep-13,Alzheimer Disease;Donepezil;Udenafil, Mild to moderate (not severe) white matter hyperintensities on brain MRI performed within three years from screening;
NCT01940952,Phase 3,Alzheimer's Disease,Samsung Medical Center,Sep-13,Alzheimer Disease;Donepezil;Udenafil, Good enough hearing and visual function to complete neuropsychological tests
NCT01940952,Phase 3,Alzheimer's Disease,Samsung Medical Center,Sep-13,Alzheimer Disease;Donepezil;Udenafil, Caregivers living with patients or spending 10 or more hours a week with patients;
NCT01940952,Phase 3,Alzheimer's Disease,Samsung Medical Center,Sep-13,Alzheimer Disease;Donepezil;Udenafil, Stable dose of donepezil (5mg to 10mg) for at least 60 days;
NCT01940952,Phase 3,Alzheimer's Disease,Samsung Medical Center,Sep-13,Alzheimer Disease;Donepezil;Udenafil," If patients have been on memantine, it should be washed out for at least 60 days;"
NCT01940952,Phase 3,Alzheimer's Disease,Samsung Medical Center,Sep-13,Alzheimer Disease;Donepezil;Udenafil," Medications including anxiolytics, antipsychotics, and hypnotics may be taken if the dose has been stable for at least two weeks"
NCT01953601,Phase 3,Prodromal Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Cognitive Dysfunction,"Diagnosis of prodromal AD, including the following:"
NCT01953601,Phase 3,Prodromal Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Cognitive Dysfunction,"History of subjective memory decline with gradual onset and slow progression for at least one year corroborated by an informant,"
NCT01953601,Phase 3,Prodromal Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Cognitive Dysfunction,"Objective impairment in episodic memory by memory test performed at Screening,"
NCT01953601,Phase 3,Prodromal Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Cognitive Dysfunction,"Does not meet criteria for dementia, AND"
NCT01953601,Phase 3,Prodromal Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Cognitive Dysfunction,Positive Screening amyloid imaging PET scan using [18F]flutametamol tracer or positive Screening CSF tau:amyloid-42 (A42) ratio (Participants with a prior positive amyloid imaging PET scan or a Screening PET scan with florbetaben or florbetapir may be enrolled without a Screening flutemetamol scan with Sponsor approval)
NCT01953601,Phase 3,Prodromal Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Cognitive Dysfunction,Able to read at a 6th grade level or equivalent
NCT01953601,Phase 3,Prodromal Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Cognitive Dysfunction,"If participant is receiving an acetylcholinesterase inhibitor or memantine, the dose must have been stable for at least three months before Screening"
NCT01953601,Phase 3,Prodromal Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Cognitive Dysfunction,"Must have a reliable and competent trial partner/informant who has a close relationship with the participant and is willing to accompany the participant to all required trial visits, and to monitor compliance of the administration of the trial medication"
NCT01953601,Phase 3,Prodromal Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Cognitive Dysfunction,Tolerated study drug and completed the initial 104-week period of the trial (Part 1)
NCT01953601,Phase 3,Prodromal Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Cognitive Dysfunction,Participant must have a reliable and competent trial partner who must have a close relationship with the subject
NCT01955161,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Oct-13,Alzheimer Disease, The patient has a knowledgeable and reliable caregiver.
NCT01955161,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Oct-13,Alzheimer Disease, The patient is an outpatient.
NCT01955161,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Oct-13,Alzheimer Disease, The patient has probable AD.
NCT01955161,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Oct-13,Alzheimer Disease, The patient has mild to moderate AD.
NCT01955161,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Oct-13,Alzheimer Disease, Stable treatment with donepezil.
NCT01955161,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Oct-13,Alzheimer Disease," The patient, if a woman, must have had her last natural menstruation 24 months prior to baseline, OR be surgically sterile."
NCT01955161,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Oct-13,Alzheimer Disease," The patient, if a man, agrees to protocol-defined use of effective contraception if his female partner is of childbearing potential, OR must have been surgically sterilised prior to the screening visit."
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Membership in PSEN1 E280A mutation carrier kindred
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," Agrees to conditions of, and is willing to undergo, genetic testing (for example [e.g.], apolipoprotein E [APOE], PSEN1 E280A, and other genetic testing)"
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, PSEN1 E280A mutation carrier or non-carrier status has been confirmed prior to or during the screening period
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Mini-Mental Stage Examination (MMSE) greater than or equal to (greater than =) 24 for participants with less than (less than ) 9 years of education or MMSE greater than =26 for participants with 9 or more years of education
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Does not meet criteria for dementia due to AD per the National Institute on Aging and the Alzheimer's Association Workgroup (McKhann et al. 2011) criteria
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Does not meet criteria for mild cognitive impairment (MCI) due to AD per the National Institute on Aging and the Alzheimer's Association Workgroup (Albert et al. 2011) criteria
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Adequate vision and hearing in the investigator's judgment to be able to complete testing
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," If female, and not documented (by medical records or physician's note) to be surgically sterile (absence of ovaries and/or uterus) or postmenopausal, willing to undergo pregnancy tests at protocol-specific timepoints"
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," For women who are not documented (by medical records or physician's note) to be surgically sterile (absence of ovaries and/or uterus) or postmenopausal, agreement to remain abstinent or use two adequate methods of contraception, including at least one method with a failure rate of less than 1 percent (%) per year (e.g., hormonal implants, combined oral contraceptives, vasectomized partner, tubal ligation) during the treatment period and for at least 16 weeks after the last dose of study drug"
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," For men with partners of childbearing potential (that is [i.e.], women who are not surgically sterile and are not postmenopausal), agreement to remain abstinent or use a condom as a method of contraception during the treatment period and for at least 8 weeks after the last dose of study drug"
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," Study partner who agrees to participate in the study and is capable of and willing to: accompany the participant to all required visits; provide information for required telephone assessments; spend sufficient time with the participant to be familiar with his/her overall function and behavior and be able to provide adequate information about the participant including knowledge about domestic activities, hobbies, routines, social skills and basic activities of daily life; work and educational history; cognitive performance including memory abilities, language abilities, temporal and spatial orientation, judgment and problem solving; emotional and psychological state; and general health status"
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," Participant and study partner have evidence of adequate premorbid functioning (e.g., intellectual, visual, and auditory) and are fluent in, and able to read, the language in which study assessments are administered"
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Willing and able to undergo neuroimaging (PET and MRI)
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," Serum thyroid stimulating hormone (TSH) and B12 levels within normal or expected ranges for the testing laboratory or if TSH and B12 values are out of range they are judged by the investigator not to be clinically significant. If participant is undergoing thyroid replacement therapy, TSH levels must be within normal or expected ranges for the testing laboratory or, if TSH values are out of range, they do not require any therapeutic actions (treatment or surveillance). If participant is receiving vitamin B12 injections or oral vitamin B12 therapy, B12 levels must be at or above the lower limit of normal for the testing laboratory or, if B12 values are out of range, they do not require any therapeutic actions (treatment or surveillance)"
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, In good general health with no known co-morbidities expected to interfere with participation in the study
NCT02006641,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Feb-14,Alzheimer Disease, The patient has a knowledgeable and reliable caregiver.
NCT02006641,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Feb-14,Alzheimer Disease, The patient is an outpatient.
NCT02006641,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Feb-14,Alzheimer Disease, The patient has probable AD.
NCT02006641,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Feb-14,Alzheimer Disease, The patient has mild to moderate AD.
NCT02006641,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Feb-14,Alzheimer Disease, Stable treatment with donepezil.
NCT02006641,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Feb-14,Alzheimer Disease," The patient, if a woman, must have had her last natural menstruation 24 months prior to baseline, OR be surgically sterile."
NCT02006641,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Feb-14,Alzheimer Disease," The patient, if a man, agrees to protocol-defined use of effective contraception if his female partner is of childbearing potential, OR must have been surgically sterilised prior to the screening visit."
NCT02006654,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Mar-14,Alzheimer Disease, The patient has a knowledgeable and reliable caregiver.
NCT02006654,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Mar-14,Alzheimer Disease, The patient is an outpatient.
NCT02006654,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Mar-14,Alzheimer Disease, The patient has probable AD.
NCT02006654,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Mar-14,Alzheimer Disease, The patient has mild to moderate AD.
NCT02006654,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Mar-14,Alzheimer Disease, Stable treatment with an AChEI.
NCT02006654,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Mar-14,Alzheimer Disease," The patient, if a woman, must have had her last natural menstruation 24 months prior to baseline, OR be surgically sterile."
NCT02006654,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Mar-14,Alzheimer Disease," The patient, if a man, agrees to protocol-defined use of effective contraception if his female partner is of childbearing potential, OR must have been surgically sterilised prior to the screening visit."
NCT02016560,Phase 2/Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Exploratory Cognitively Healthy Subjects
NCT02016560,Phase 2/Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,  20 to  40 years of age OR  50 years of age
NCT02016560,Phase 2/Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Mini-mental state examination (MMSE)  29
NCT02016560,Phase 2/Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, No significant history of cognitive impairment
NCT02016560,Phase 2/Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Exploratory MCI Subjects
NCT02016560,Phase 2/Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,  50 years of age
NCT02016560,Phase 2/Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, MMSE  24
NCT02016560,Phase 2/Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Have MCI consistent with National Institute on Aging-Alzheimer's Association (NIA-AA) working group's diagnostic guidelines for AD
NCT02016560,Phase 2/Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Have a study partner that can report on subject's activities of daily living
NCT02016560,Phase 2/Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Exploratory AD Subjects
NCT02016560,Phase 2/Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,  50 years of age
NCT02016560,Phase 2/Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, MMSE greater than  10
NCT02016560,Phase 2/Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Have possible or probable AD based on the NIA-AA working group's diagnostic guidelines for AD
NCT02016560,Phase 2/Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Have a study partner that can report on subject's activities of daily living
NCT02016560,Phase 2/Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Confirmatory Subjects
NCT02016560,Phase 2/Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,  50 years of age
NCT02016560,Phase 2/Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, MMSE  20 and  27
NCT02016560,Phase 2/Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Cognitively impaired subjects with either MCI or dementia with a suspected neurodegenerative cause
NCT02016560,Phase 2/Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Have a study partner that can report on subject's activities of daily living
NCT02017340,Phase 3,Alzheimer's Disease,Prof Brian Lawlor,unknown,Alzheimer Disease;Nilvadipine,"Age range: Adult subjects, males and females over age 50 years."
NCT02017340,Phase 3,Alzheimer's Disease,Prof Brian Lawlor,unknown,Alzheimer Disease;Nilvadipine,Prior diagnosis of mild to moderate probable AD based on NINCDS-ADRDA criteria (see Appendix B) and
NCT02017340,Phase 3,Alzheimer's Disease,Prof Brian Lawlor,unknown,Alzheimer Disease;Nilvadipine,Standardised Mini-Mental State Examination (SMMSE) score greater than  12 on stable dose (greater than 3 months of cholinesterase inhibitor and or memantine). Subjects who are not on cholinesterase inhibitors or memantine due to poor tolerability and/or who will not require treatment with these medications during the course of the study can be included.
NCT02017340,Phase 3,Alzheimer's Disease,Prof Brian Lawlor,unknown,Alzheimer Disease;Nilvadipine,"Collateral informants such as a spouse, family member, close friend. The informant must have close contact with the subject and agree to monitor/manage study drug adherence, observe for possible adverse events, assist with psychometric measures requiring informant information, and accompany the subject to all evaluation visits."
NCT02017340,Phase 3,Alzheimer's Disease,Prof Brian Lawlor,unknown,Alzheimer Disease;Nilvadipine,Fluency in relevant language sufficient to reliably complete all study assessments.
NCT02017340,Phase 3,Alzheimer's Disease,Prof Brian Lawlor,unknown,Alzheimer Disease;Nilvadipine,"Systolic BP greater than  100 mmHg but  159 mmHg, and diastolic BP greater than  65 mmHg but  99 mmHg on resting office based BP measurements, or a Systolic BP greater than  105 mmHg but  140 mmHg, and diastolic BP greater than  70 mmHg but  90 mmHg on ABPM measurement"
NCT02033941,Phase 2,Alzheimer's Disease,Hillel Grossman,Nov-14,Alzheimer Disease;Phenol, NINCDS/ADRDA criteria for probable AD
NCT02033941,Phase 2,Alzheimer's Disease,Hillel Grossman,Nov-14,Alzheimer Disease;Phenol, MMSE between 12-26
NCT02033941,Phase 2,Alzheimer's Disease,Hillel Grossman,Nov-14,Alzheimer Disease;Phenol, Treatment with a cholinesterase inhibitor or an NMDA (N-methyl-D-asparate) antagonist with stable dose for at least 12 weeks
NCT02033941,Phase 2,Alzheimer's Disease,Hillel Grossman,Nov-14,Alzheimer Disease;Phenol, Home monitoring available for supervision of medications
NCT02033941,Phase 2,Alzheimer's Disease,Hillel Grossman,Nov-14,Alzheimer Disease;Phenol, Caregiver available to accompany patient to all visits and willing to participate in study as informant
NCT02033941,Phase 2,Alzheimer's Disease,Hillel Grossman,Nov-14,Alzheimer Disease;Phenol, Fluent in English or Spanish
NCT02033941,Phase 2,Alzheimer's Disease,Hillel Grossman,Nov-14,Alzheimer Disease;Phenol," Medical stability for this study as confirmed by review of records, internist's physical exam, neurological exam, and laboratory tests"
NCT02033941,Phase 2,Alzheimer's Disease,Hillel Grossman,Nov-14,Alzheimer Disease;Phenol, Stable doses of non-excluded medication
NCT02033941,Phase 2,Alzheimer's Disease,Hillel Grossman,Nov-14,Alzheimer Disease;Phenol, No evidence of hepatic insufficiency
NCT02033941,Phase 2,Alzheimer's Disease,Hillel Grossman,Nov-14,Alzheimer Disease;Phenol, Able to swallow oral medications
NCT02033941,Phase 2,Alzheimer's Disease,Hillel Grossman,Nov-14,Alzheimer Disease;Phenol, Ability to participate in the informed consent process
NCT02035553,Phase 2,Alzheimer's Disease Psychosis,ACADIA Pharmaceuticals Inc.,Nov-13,Alzheimer Disease;Psychotic Disorders;Mental Disorders;Pimavanserin, Patient must be 50 years of age or older with NINCDS-ADRDA defined possible or probable AD
NCT02035553,Phase 2,Alzheimer's Disease Psychosis,ACADIA Pharmaceuticals Inc.,Nov-13,Alzheimer Disease;Psychotic Disorders;Mental Disorders;Pimavanserin," Patient must have psychotic symptoms that developed after the diagnosis of AD was established. These symptoms must include visual and/or auditory hallucinations, and/or delusions"
NCT02035553,Phase 2,Alzheimer's Disease Psychosis,ACADIA Pharmaceuticals Inc.,Nov-13,Alzheimer Disease;Psychotic Disorders;Mental Disorders;Pimavanserin," Patient must have been a nursing home resident for  4 weeks prior to randomization, not bedridden and expected to remain in the facility throughout the study"
NCT02035553,Phase 2,Alzheimer's Disease Psychosis,ACADIA Pharmaceuticals Inc.,Nov-13,Alzheimer Disease;Psychotic Disorders;Mental Disorders;Pimavanserin, Patient must have actively experienced and verbally communicated psychotic symptoms during the month prior to the Screening visit and weekly during the previous 2 weeks prior to Baseline
NCT02035553,Phase 2,Alzheimer's Disease Psychosis,ACADIA Pharmaceuticals Inc.,Nov-13,Alzheimer Disease;Psychotic Disorders;Mental Disorders;Pimavanserin," If patient is on acetylcholinesterase inhibitor (AChEI) therapy and/or memantine, must be on stable doses for 3 months prior to the Baseline visit and during the study"
NCT02035553,Phase 2,Alzheimer's Disease Psychosis,ACADIA Pharmaceuticals Inc.,Nov-13,Alzheimer Disease;Psychotic Disorders;Mental Disorders;Pimavanserin," Patient is willing and able to provide informed consent. If the subject is unable to provide written consent due to the severity of dementia, consent must be given by a legally authorized representative"
NCT02051608,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Clinical diagnosis of probable mild Alzheimer disease (AD) based on National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria or major NCD based whether or not receiving AD approved medication
NCT02051608,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Cerebral spinal fluid (CSF) result consistent with the presence of amyloid pathology
NCT02051608,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Availability of a person ('caregiver') who in the investigator's judgment has frequent and sufficient contact with the participant, and is able to provide accurate information regarding the participant's cognitive and functional abilities"
NCT02051608,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Fluency in the language of the tests used at the study site
NCT02051608,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Willingness and ability to complete all aspects of the study
NCT02051608,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Adequate visual and auditory acuity, in the investigator's judgment, sufficient to perform the neuropsychological testing (eye glasses and hearing aids are permitted)"
NCT02051608,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," If currently receiving approved medications for AD, the dosing regimen must have been stable for 3 months prior to screening"
NCT02051608,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Agreement not to participate in other research studies for the duration of this trial and its associated substudies
NCT02051608,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, PART 2 - All participants who have been randomized and are actively participating in the study are eligible for Part 2
NCT02051764,Phase 2,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Have a previous 18F-AV-1451 brain scan
NCT02051764,Phase 2,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Can tolerate up to two Positron Emission Tomography (PET) imaging sessions and a Magnetic Resonance Imaging (MRI) scan
NCT02051764,Phase 2,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Ability to provide informed consent
NCT02064920,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Donepezil, Meets listed criteria for a diagnosis of probable AD
NCT02064920,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Donepezil, Has a clearly documented history either in medical records or from an informant of cognitive decline over at least 6 months
NCT02064920,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Donepezil, Has a reliable partner/caregiver who is willing to provide input by participating in assessments
NCT02064920,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Donepezil, Has results of a physical examination and clinical laboratory tests within normal or clinically acceptable limits
NCT02064920,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Donepezil," Can communicate with trial staff acceptably, possesses the ability to respond verbally to questions, follow instructions, complete questionnaires, and adhere to visit schedules"
NCT02064920,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Donepezil," Can read at a 9th grade level or equivalent, and has an acceptable history of academic achievement and/or employment"
NCT02064920,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Donepezil, Has a magnetic resonance imaging (MRI) scan that rules out non-AD conditions contributing to cognitive dysfunction
NCT02064920,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Donepezil, Capably performs the CogState screening battery
NCT02064920,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Donepezil, Has adequate visual acuity and function
NCT02064920,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Donepezil, Females are not of childbearing potential
NCT02078310,Phase 1/Phase 2,Alzheimer's Disease,"Intra-Cellular Therapies, Inc.",Feb-14,Alzheimer Disease;Dementia, Part 1
NCT02078310,Phase 1/Phase 2,Alzheimer's Disease,"Intra-Cellular Therapies, Inc.",Feb-14,Alzheimer Disease;Dementia, Healthy geriatric volunteers
NCT02078310,Phase 1/Phase 2,Alzheimer's Disease,"Intra-Cellular Therapies, Inc.",Feb-14,Alzheimer Disease;Dementia, MMSE score of greater than = 26 at screening
NCT02078310,Phase 1/Phase 2,Alzheimer's Disease,"Intra-Cellular Therapies, Inc.",Feb-14,Alzheimer Disease;Dementia, BMI between 19.0 and 40.0 kg/m2 and a minimum body weight of 50 kg at screening
NCT02078310,Phase 1/Phase 2,Alzheimer's Disease,"Intra-Cellular Therapies, Inc.",Feb-14,Alzheimer Disease;Dementia, Part 2
NCT02078310,Phase 1/Phase 2,Alzheimer's Disease,"Intra-Cellular Therapies, Inc.",Feb-14,Alzheimer Disease;Dementia, Geriatric patients with a clinical diagnosis of dementia
NCT02078310,Phase 1/Phase 2,Alzheimer's Disease,"Intra-Cellular Therapies, Inc.",Feb-14,Alzheimer Disease;Dementia, MMSE score of less than  26 at screening
NCT02078310,Phase 1/Phase 2,Alzheimer's Disease,"Intra-Cellular Therapies, Inc.",Feb-14,Alzheimer Disease;Dementia, BMI between 19.0 and 40.0 kg/m2 and a minimum body weight of 50 kg at screening
NCT02079246,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,unknown,Alzheimer Disease," the patient has completed Visit 7 (Completion Visit) in the lead-in double-blind, placebo controlled clinical studies 14861A/NCT01955161 or 14862A/NCT02006641"
NCT02079246,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,unknown,Alzheimer Disease, For patients in the OLEX-MEM:
NCT02079246,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,unknown,Alzheimer Disease, The patient has completed Visit 6 (Week 28) of the OLEX.
NCT02079246,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,unknown,Alzheimer Disease," The patient, according to the judgement of the investigator, requires initiation of treatment with memantine as per local label/SmPC/treatment guidelines."
NCT02079909,Phase 2,Alzheimer's Disease,"FUJIFILM Toyama Chemical Co., Ltd.",Mar-14,Alzheimer Disease, Male or female (post-menopausal or surgically sterile)
NCT02079909,Phase 2,Alzheimer's Disease,"FUJIFILM Toyama Chemical Co., Ltd.",Mar-14,Alzheimer Disease," Patients with Mild to moderate Alzheimer's disease who are receiving donepezil (Aricept) or rivastigmine transdermal system (Exelon Patch), . Memantine (Namenda) is allowed only when prescribed in combination with donepezil or rivastigmine transdermal system."
NCT02079909,Phase 2,Alzheimer's Disease,"FUJIFILM Toyama Chemical Co., Ltd.",Mar-14,Alzheimer Disease, Age 55 to 85 inclusive
NCT02079909,Phase 2,Alzheimer's Disease,"FUJIFILM Toyama Chemical Co., Ltd.",Mar-14,Alzheimer Disease, Patients must be living in the community
NCT02079909,Phase 2,Alzheimer's Disease,"FUJIFILM Toyama Chemical Co., Ltd.",Mar-14,Alzheimer Disease, Patients must have an eligible informant or study partner (caregiver)
NCT02079909,Phase 2,Alzheimer's Disease,"FUJIFILM Toyama Chemical Co., Ltd.",Mar-14,Alzheimer Disease, Patients and eligible informant or study partner (caregiver) must be able to read and understand English.
NCT02079909,Phase 2,Alzheimer's Disease,"FUJIFILM Toyama Chemical Co., Ltd.",Mar-14,Alzheimer Disease, Informed consent obtained from both the patient and the caregiver
NCT02080364,Phase 3,Alzheimer's Disease,vTv Therapeutics,unknown,Alzheimer Disease, Diagnosis of probable Alzheimer Disease (AD) with documented evidence of progression of disease
NCT02080364,Phase 3,Alzheimer's Disease,vTv Therapeutics,unknown,Alzheimer Disease," Mini Mental State Examination (MMSE) score of 21-26, inclusive"
NCT02080364,Phase 3,Alzheimer's Disease,vTv Therapeutics,unknown,Alzheimer Disease, Clinical Dementia Rating global score of 0.5 or 1
NCT02080364,Phase 3,Alzheimer's Disease,vTv Therapeutics,unknown,Alzheimer Disease, Rosen-Modified Hachinski Ischemia Score less than or equal to 4
NCT02080364,Phase 3,Alzheimer's Disease,vTv Therapeutics,unknown,Alzheimer Disease, Brain magnetic resonance imaging (MRI) consistent with the diagnosis of probable AD
NCT02080364,Phase 3,Alzheimer's Disease,vTv Therapeutics,unknown,Alzheimer Disease, Concurrent use of cholinesterase inhibitor or memantine with stable dose for at least 3 months prior to randomization
NCT02080364,Phase 3,Alzheimer's Disease,vTv Therapeutics,unknown,Alzheimer Disease, Caregiver willing to participate and be able to attend clinic visits with patient
NCT02080364,Phase 3,Alzheimer's Disease,vTv Therapeutics,unknown,Alzheimer Disease, Ability to ingest oral medications
NCT02164643,Phase 3,Alzheimer's Disease (AD) and Related Disorders,"University Hospital, Bordeaux",unknown,Alzheimer Disease;Flutemetamol, To be included in MEMENTO
NCT02164643,Phase 3,Alzheimer's Disease (AD) and Related Disorders,"University Hospital, Bordeaux",unknown,Alzheimer Disease;Flutemetamol," To have signed a specific MEMENTO-AmyGing informed consent form, prior to any amyloid PET procedures"
NCT02164643,Phase 3,Alzheimer's Disease (AD) and Related Disorders,"University Hospital, Bordeaux",unknown,Alzheimer Disease;Flutemetamol, To have had or agreed to have 18F-FDG PET scan in MEMENTO
NCT02164643,Phase 3,Alzheimer's Disease (AD) and Related Disorders,"University Hospital, Bordeaux",unknown,Alzheimer Disease;Flutemetamol," To tolerate the (18F) PET scan procedures, in the opinion of the clinical site investigator"
NCT02164643,Phase 3,Alzheimer's Disease (AD) and Related Disorders,"University Hospital, Bordeaux",unknown,Alzheimer Disease;Flutemetamol, Clinical Dementia Rating scale less than 0.5 and not demented
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib,NIA-Alzheimer's Association core clinical criteria for probable AD
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib,18F-Florbetapir scan with evidence of elevated A (based on central review)
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib,Age between 55-85 (inclusive)
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib,MMSE score between 18 and 26 (inclusive)
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib,Stability of permitted medications for 4 weeks. In particular:
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib, Stable doses of antidepressants lacking significant anticholinergic side effects (if they are not currently depressed and do not have a history of major depression within the past 1 year)
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib, Cholinesterase inhibitors and memantine are allowable if stable for 12 weeks prior to screen
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib,"Geriatric Depression Scale less than 6 [Note: a score 6 on this screening scale may be permissible, if the subject is examined by a site clinician and judged not to be depressed.]"
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib,"Study partner is available who has frequent contact with the subject (e.g., average of 10 hours per week or more), and can accompany the subject to most visits to answer questions about the subject"
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib,Visual and auditory acuity adequate for neuropsychological testing
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib,Good general health with no disease expected to interfere with the study
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib,"Subject is not pregnant, lactating, or of childbearing potential (i.e., women must be two years post-menopausal or surgically sterile)"
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib,Modified Hachinski less than or equal to 4
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib,Completed six grades of education or has a good work history
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib,Must speak English or Spanish fluently
NCT02168920,Phase 3,Agitation Associated With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Co., Ltd.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation, Patients whose legal representatives can provide informed consent (Informed consent from the patients where possible).
NCT02168920,Phase 3,Agitation Associated With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Co., Ltd.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation, Patients who satisfy both of the following diagnostic criteria:
NCT02168920,Phase 3,Agitation Associated With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Co., Ltd.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation, Diagnosis of major neurocognitive disorder due to Alzheimer's disease according to Diagnostic and Statistical Manual of mental disorders (DSM-5)
NCT02168920,Phase 3,Agitation Associated With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Co., Ltd.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation, Diagnosis of probable Alzheimer's disease according to National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA)
NCT02168920,Phase 3,Agitation Associated With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Co., Ltd.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation, Hospitalized patients or care facility patients
NCT02168920,Phase 3,Agitation Associated With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Co., Ltd.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation, Patients with an Mini-Mental State Examination (MMSE) score of 1 to 22
NCT02185053,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia, Aged 50 - 79 years inclusive.
NCT02185053,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia, Meeting the diagnosis of probable Alzheimer's Disease
NCT02185053,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia, Of moderate severity (Mini-Mental Status Exam [MMSE] score 10 - 20 inclusive).
NCT02185053,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia," Patients must be in generally good health as indicated by their medical history and physical examination, vital signs, electrocardiogram (ECG), and standard laboratory tests."
NCT02221947,Phase 1/Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Jun-14,Alzheimer Disease;Bryostatin 1," Male or female, age 50 - 85 yrs. Females are non-childbearing potential"
NCT02221947,Phase 1/Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Jun-14,Alzheimer Disease;Bryostatin 1, Patient must have a cognitive deficit present for at least 1 year and meet diagnostic criteria for probable Alzheimer's Disease Dementia by NIA-AA criteria or prodromal Alzheimer's Disease
NCT02221947,Phase 1/Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Jun-14,Alzheimer Disease;Bryostatin 1, Mini Mental State Exam score of 16-26
NCT02221947,Phase 1/Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Jun-14,Alzheimer Disease;Bryostatin 1," Ability to walk, at least with an assistive device"
NCT02221947,Phase 1/Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Jun-14,Alzheimer Disease;Bryostatin 1, Vision and hearing sufficient to comply with testing
NCT02221947,Phase 1/Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Jun-14,Alzheimer Disease;Bryostatin 1," Normal cognitive and social functioning prior to onset of dementia, with evidence of progressive symptoms from patient or informant"
NCT02221947,Phase 1/Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Jun-14,Alzheimer Disease;Bryostatin 1, Consistent caregiver to accompany patient to visits
NCT02221947,Phase 1/Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Jun-14,Alzheimer Disease;Bryostatin 1, Sufficient basic education to be able to complete the cognitive assessments
NCT02221947,Phase 1/Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Jun-14,Alzheimer Disease;Bryostatin 1, Living outside an institution
NCT02245737,Phase 2/Phase 3,Alzheimers Disease,AstraZeneca,unknown,Alzheimer Disease," Gradual and progressive change in the participant's memory function over more than 6 months, reported by participant and study partner"
NCT02245737,Phase 2/Phase 3,Alzheimers Disease,AstraZeneca,unknown,Alzheimer Disease, Mini-Mental State Examination score of 20-30 inclusive at screening
NCT02245737,Phase 2/Phase 3,Alzheimers Disease,AstraZeneca,unknown,Alzheimer Disease, Objective impairment in memory as evaluated by memory test performed at screening
NCT02245737,Phase 2/Phase 3,Alzheimers Disease,AstraZeneca,unknown,Alzheimer Disease," For a diagnosis of mild Alzheimer's Disease (AD), participant meets the National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria for probable AD"
NCT02245737,Phase 2/Phase 3,Alzheimers Disease,AstraZeneca,unknown,Alzheimer Disease," For a diagnosis of MCI due to AD, participant meets NIA-AA criteria for MCI due to AD"
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia, Patient met the inclusion criteria for the preceding talsaclidine trial
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia, Patient completed the preceding talsaclidine trial within the last four weeks with adequate compliance
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia," Patient is able to understand the patient information and give written informed consent in accordance with GCP (good clinical practice) and local legislation. In case of doubt, a study independent physician should assess the patient. If in the opinion of study independent physician the patient is unable to provide written inform consent, a legal guardian may provide consent on behalf of the patient"
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia, Patient has a relative or caregiver who has given written informed consent to provide trial related information for self and patient and is willing and capable of supporting the clinical trial
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia," Patient and caregiver are able to complete the trial examinations, to hear, speak, read and write in a basic way and primary sensorial function are intact"
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia," Male or female patient, age: over 40 years (lower age if genetic Dementia of Alzheimer Type (DAT) is documented). Patients over 85 years need to be in a clinically stable state (investigator's judgement)"
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, Patient's educational level is greater than  4 years
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, Patient is able to understand the patient information and give informed consent
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, Patient has given written informed consent in accordance with Good Clinical Practice and local legislation
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, Patient has a relative or caregiver who is willing and capable to support the clinical trial; his/her written informed consent is optional
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, Body weight:  50 kg and within +/- 30% of normal weight (Broca index)
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, Diagnosis of DAT by the National Institute of Neurological and communicative Disorders-Alzheimer's Disease and Related Disorder Association (NINCDS-ADRDA) criteria
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, MMS-score 10 - 24 inclusive
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, Rosen ischemia score is lower or equal to two
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia," Patient is able to complete the trial examinations, to hear, speak, read and write in a basic way and primary sensorial functions are intact"
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia," Male or female patient, age: over 40 years (lower age if genetic Dementia of Alzheimer Type (DAT) is documented. Patients over 85 years need to be in a clinically stable state (investigator's judgement)"
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia, Patient's educational level is greater than  4 years
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia, Patient is able to understand the patient information and give informed consent
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia, Patient has given written informed consent in accordance with Good Clinical Practice and local legislation
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia, Patient has a non-demented relative or care giver who is willing to support the clinical trial; his/her written informed consent is optional
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia, Body weight: within +/- 30% of normal weight (Broca index)
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia, Diagnosis of DAT by the National Institute of Neurological and communicative Disorders-Alzheimer's Disease and Related Disorder Association (NINCDS-ADRDA) criteria
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia, MMS-score 10 - 24 inclusive
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia, Rosen ischemia score is lower or equal to two
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia," Patient is able to complete the trial examinations, to hear, speak, read and write in a basic way and primary sensorial functions are intact"
NCT02260674,Phase 2,Alzheimer's Disease,"Janssen Research &amp; Development, LLC",Nov-14,Alzheimer Disease, Participants in the early alzheimer's disease (AD) spectrum must have a global Clinical Dementia Rating Scale( CDR) score of 0 (asymptomatic at risk for AD) to 0.5 prodromal AD (pAD) inclusive
NCT02260674,Phase 2,Alzheimer's Disease,"Janssen Research &amp; Development, LLC",Nov-14,Alzheimer Disease, Participants must have evidence of amyloid pathology by means of either: a) low Cerebrospinal Fluid (CSF) ABeta 1-42 levels at screening; b) a positive amyloid positron emission tomography (PET) scan at screening (depending on the site's PET capability) by visual read
NCT02260674,Phase 2,Alzheimer's Disease,"Janssen Research &amp; Development, LLC",Nov-14,Alzheimer Disease," Participants must have a body mass index between 18 and 35 kilogram per square meter (kg/m^2), inclusive, at screening"
NCT02260674,Phase 2,Alzheimer's Disease,"Janssen Research &amp; Development, LLC",Nov-14,Alzheimer Disease," Participants must be otherwise healthy for their age group or medically stable with or without medication on the basis of physical examination, medical history, vital signs, and 12-lead ECG performed at screening or at baseline. If there are abnormalities, they must be consistent with the underlying illness in the study population and not a potential cause of cognitive impairment, with written concurrence with the sponsor's medical monitor"
NCT02260674,Phase 2,Alzheimer's Disease,"Janssen Research &amp; Development, LLC",Nov-14,Alzheimer Disease," Before randomization, a woman must be not of childbearing potential: postmenopausal (greater than or equal to [greater than =] 50 years of age with amenorrhea for at least 12 months; permanently sterilized [e.g., tubal occlusion, hysterectomy, bilateral salpingectomy]); or otherwise be incapable of pregnancy. In case of questionable status qualified personal of the sponsor should be consulted to decide on the potential for inclusion of the participant"
NCT02279511,Phase 2,Alzheimer's Disease,Sara Varea,unknown,Alzheimer Disease;Adenosine,Men and women aged 55-85 years
NCT02279511,Phase 2,Alzheimer's Disease,Sara Varea,unknown,Alzheimer Disease;Adenosine,Diagnosis of possible or probable Alzheimer disease according to NIA-AA 2011 criteria.
NCT02279511,Phase 2,Alzheimer's Disease,Sara Varea,unknown,Alzheimer Disease;Adenosine,Global Deterioration Scale Stadium 5-6 / 15-5 Mini-mental State examination
NCT02279511,Phase 2,Alzheimer's Disease,Sara Varea,unknown,Alzheimer Disease;Adenosine,The patient is living with a family as a primary caregiver or a caregiver trained to accompany adequate and all intervention and follow-up visits. Patient and caregiver knowledge of local languages sufficient.
NCT02279511,Phase 2,Alzheimer's Disease,Sara Varea,unknown,Alzheimer Disease;Adenosine,The patient and caregiver willing to participate in the study. There is a high probability that patient and caregiver to complete the study.
NCT02279511,Phase 2,Alzheimer's Disease,Sara Varea,unknown,Alzheimer Disease;Adenosine,The patient has no sensory deficits preventing evaluation.
NCT02279511,Phase 2,Alzheimer's Disease,Sara Varea,unknown,Alzheimer Disease;Adenosine,The patient receives a stable Alzheimer Disease conventional medication. No change in treatment at least 90 days prior to selection.
NCT02279511,Phase 2,Alzheimer's Disease,Sara Varea,unknown,Alzheimer Disease;Adenosine,The patient receives a conventional stable medication for possible comorbidities. No change in treatment at least 90 days prior to selection.
NCT02279511,Phase 2,Alzheimer's Disease,Sara Varea,unknown,Alzheimer Disease;Adenosine,The subject or his legal representative give prior informed consent that includes genetic studies of Apolipoprotein E and rs11870474.
NCT02284906,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,Completed the pivotal AD-4833/TOMM40_301 study with an adjudicated diagnosis of mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) without ongoing serious adverse events (SAEs) from AD-4833/TOMM40_301.
NCT02284906,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,Is male or female and is at least 65 years of age at the time of the Baseline Visit.
NCT02284906,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,"In the opinion of the investigator, is capable of understanding and complying with the protocol requirements."
NCT02284906,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,"The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures."
NCT02284906,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,Must be living independently or in nonmedical residential care.
NCT02284906,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,"Has a project partner able to separately consent on his/her own behalf and take part in the study (with the intent to do so as long as the participant is enrolled), providing information on the cognitive, functional, and behavioral status of the participant and assisting with observation of adverse events (AEs) and monitoring of study medication, if needed. Project partners participating in the pivotal AD-4833/TOMM40_301 study are encouraged to participate in this extension study in this capacity."
NCT02292238,Phase 2,Alzheimer's Disease,Burke Medical Research Institute,unknown,Alzheimer Disease;Benphothiamine, 60 years of age or older
NCT02292238,Phase 2,Alzheimer's Disease,Burke Medical Research Institute,unknown,Alzheimer Disease;Benphothiamine, Clinical diagnosis of AMCI by the Peterson criteria or probable AD dementia according to the National Institute of Neurological Disorders and stroke and the Alzheimer's Disease related Disorders Association (NINCDS/ADRDA)
NCT02292238,Phase 2,Alzheimer's Disease,Burke Medical Research Institute,unknown,Alzheimer Disease;Benphothiamine, MMSE score greater than  or equal to 21
NCT02292238,Phase 2,Alzheimer's Disease,Burke Medical Research Institute,unknown,Alzheimer Disease;Benphothiamine, CDR score greater than  or equal to 0.5 and less than  or equal to1
NCT02292238,Phase 2,Alzheimer's Disease,Burke Medical Research Institute,unknown,Alzheimer Disease;Benphothiamine, Cornell Scale for Depression in Dementia(CSDD) score less than 10.
NCT02292238,Phase 2,Alzheimer's Disease,Burke Medical Research Institute,unknown,Alzheimer Disease;Benphothiamine, Ambulatory or ambulatory with aide
NCT02292238,Phase 2,Alzheimer's Disease,Burke Medical Research Institute,unknown,Alzheimer Disease;Benphothiamine," Have a caregiver willing to accompany the patient to each visit, accept responsibility for supervising treatment and provided input to clinical outcome assessments"
NCT02292238,Phase 2,Alzheimer's Disease,Burke Medical Research Institute,unknown,Alzheimer Disease;Benphothiamine, Reside at home
NCT02292238,Phase 2,Alzheimer's Disease,Burke Medical Research Institute,unknown,Alzheimer Disease;Benphothiamine, Speak English
NCT02292238,Phase 2,Alzheimer's Disease,Burke Medical Research Institute,unknown,Alzheimer Disease;Benphothiamine, Amyloid positive PET-scan
NCT02292238,Phase 2,Alzheimer's Disease,Burke Medical Research Institute,unknown,Alzheimer Disease;Benphothiamine, If they are on AD medications they must be stable on AD medications for at least three months prior to baseline
NCT02292238,Phase 2,Alzheimer's Disease,Burke Medical Research Institute,unknown,Alzheimer Disease;Benphothiamine, Subjects ore willing/able to provide informed consent.
NCT02327182,Phase 3,Alzheimer's Disease,Mitsubishi Tanabe Pharma Corporation,Dec-14,Alzheimer Disease, Probable Alzheimer's disease consistent with the National Institute on Aging and the Alzheimer's Association Criteria for Diagnosis of Alzheimer's Disease (McKhann et al. 2011).
NCT02327182,Phase 3,Alzheimer's Disease,Mitsubishi Tanabe Pharma Corporation,Dec-14,Alzheimer Disease, MMSE score of  14 and  24 at the screening and  12 and  26 at the baseline.
NCT02327182,Phase 3,Alzheimer's Disease,Mitsubishi Tanabe Pharma Corporation,Dec-14,Alzheimer Disease, Modified Hachinski Ischemic Score (mHIS)  4 at the screening
NCT02327182,Phase 3,Alzheimer's Disease,Mitsubishi Tanabe Pharma Corporation,Dec-14,Alzheimer Disease, Appropriate caregiver available
NCT02327182,Phase 3,Alzheimer's Disease,Mitsubishi Tanabe Pharma Corporation,Dec-14,Alzheimer Disease, Subject living at home or in facilities who do not require continuous (24-hour) nursing care.
NCT02359552,Phase 2,Alzheimer's Disease,The Cleveland Clinic,unknown,Alzheimer Disease;Rasagiline, Males or females 50 to 90 of age inclusive.
NCT02359552,Phase 2,Alzheimer's Disease,The Cleveland Clinic,unknown,Alzheimer Disease;Rasagiline, Diagnosis of probable AD (NINCDS-ADRDA criteria)
NCT02359552,Phase 2,Alzheimer's Disease,The Cleveland Clinic,unknown,Alzheimer Disease;Rasagiline, Positive fluoro-deoxyglucose PET ([18F]-FDG PET) scan compatible with AD as determined by the ADM Diagnostics LLC (ADMdx) Criteria at screening
NCT02359552,Phase 2,Alzheimer's Disease,The Cleveland Clinic,unknown,Alzheimer Disease;Rasagiline, Mini Mental Status Exam = 12 - 22 (inclusive)
NCT02359552,Phase 2,Alzheimer's Disease,The Cleveland Clinic,unknown,Alzheimer Disease;Rasagiline, Must have a study partner who is able and willing to comply with all required study procedures.
NCT02359552,Phase 2,Alzheimer's Disease,The Cleveland Clinic,unknown,Alzheimer Disease;Rasagiline," Have at least eight years of education and should have previously (in pre-AD condition) been capable of reading, writing, and communicating effectively with others in English."
NCT02359552,Phase 2,Alzheimer's Disease,The Cleveland Clinic,unknown,Alzheimer Disease;Rasagiline," If receiving therapy with a cholinesterase inhibitor and/or memantine, the dose of these agents has been stable for at least 3 months prior to screening"
NCT02361424,Phase 2,Alzheimer Disease,Pharnext SA,Feb-13,Alzheimer Disease, Male or female patients aged  60 years.
NCT02361424,Phase 2,Alzheimer Disease,Pharnext SA,Feb-13,Alzheimer Disease, Patient with a diagnosis of probable AD
NCT02361424,Phase 2,Alzheimer Disease,Pharnext SA,Feb-13,Alzheimer Disease, Progressive decline in cognition for more than six months which story is documented in patient medical records
NCT02361424,Phase 2,Alzheimer Disease,Pharnext SA,Feb-13,Alzheimer Disease, A Mini-Mental State Examination (MMSE) score of 20-26
NCT02361424,Phase 2,Alzheimer Disease,Pharnext SA,Feb-13,Alzheimer Disease, With a minimum of educational background
NCT02361424,Phase 2,Alzheimer Disease,Pharnext SA,Feb-13,Alzheimer Disease, Nave to anti-dementia treatment
NCT02361424,Phase 2,Alzheimer Disease,Pharnext SA,Feb-13,Alzheimer Disease, MRI assessment which corroborates the clinical diagnosis (hippocampal atrophy) and excludes other potential causes of dementia especially cerebrovascular lesions
NCT02361424,Phase 2,Alzheimer Disease,Pharnext SA,Feb-13,Alzheimer Disease," If available, Cerebral Spinal Fluid (CSF) classical biomarkers should be at levels which corroborate the clinical diagnosis"
NCT02361424,Phase 2,Alzheimer Disease,Pharnext SA,Feb-13,Alzheimer Disease, Ambulatory patient living at home with a caregiver available and living in the same household or interacting with the patient daily and available if necessary to ensure administration of the investigational product
NCT02361424,Phase 2,Alzheimer Disease,Pharnext SA,Feb-13,Alzheimer Disease, Absence of major or severe depressive disease
NCT02361424,Phase 2,Alzheimer Disease,Pharnext SA,Feb-13,Alzheimer Disease, Patient with a willingness to participate in this study and who have signed an informed consent form
NCT02406027,Phase 2,Alzheimer Disease,"Janssen Research &amp; Development, LLC",unknown,Alzheimer Disease," Participants in the early Alzheimer's disease (AD) spectrum at time of enrollment under the parent protocol and according to its inclusion and exclusion criteria, must have very recently completed their treatment in a Phase 1b or Phase 2 JNJ-54861911 clinical study (example [e.g.], 54861911ALZ2002) under the parent protocol. Enrollment in this study should be completed (Day 1 of double-blind [DB] treatment phase) as soon as possible, but within 6 weeks, following completion of their treatment period under the parent protocol. If not defined under the parent protocol, completion of the treatment period is defined as having completed all study related procedures of the last visit of the treatment period under the parent protocol. A screening phase of up to 12 weeks may be allowed following written approval of the Sponsor"
NCT02406027,Phase 2,Alzheimer Disease,"Janssen Research &amp; Development, LLC",unknown,Alzheimer Disease, Participant must be willing and able to adhere to the prohibitions and restrictions specified in this protocol
NCT02406027,Phase 2,Alzheimer Disease,"Janssen Research &amp; Development, LLC",unknown,Alzheimer Disease, Each Participants (or their legally acceptable representative and caregiver depending on disease state and local requirements) must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study and are willing to participate in the study
NCT02406027,Phase 2,Alzheimer Disease,"Janssen Research &amp; Development, LLC",unknown,Alzheimer Disease," Participants must have a reliable informant (relative, partner, or friend). The informant must be willing to participate as a source of information and has at least weekly contact with the participant (contact can be in-person, via telephone or other audio/visual communication). The informant must have sufficient contact such that the Investigator feels he/she can provide meaningful information about the participant's daily function. If possible, an alternate informant meeting these criteria who can replace the primary informant should be identified prior to randomization"
NCT02423200,Phase 2,Alzheimer's Disease,EIP Pharma Inc,Apr-15,Alzheimer Disease;Cognitive Dysfunction, Age 60 - 85 (inclusive)
NCT02423200,Phase 2,Alzheimer's Disease,EIP Pharma Inc,Apr-15,Alzheimer Disease;Cognitive Dysfunction, Willing and able to provide informed consent
NCT02423200,Phase 2,Alzheimer's Disease,EIP Pharma Inc,Apr-15,Alzheimer Disease;Cognitive Dysfunction, Clinical presentation consistent with MCI due to AD or of mild AD
NCT02423200,Phase 2,Alzheimer's Disease,EIP Pharma Inc,Apr-15,Alzheimer Disease;Cognitive Dysfunction, Gradual progressive decline in memory function over greater than 6 months
NCT02423200,Phase 2,Alzheimer's Disease,EIP Pharma Inc,Apr-15,Alzheimer Disease;Cognitive Dysfunction, Amnestic presentation on neuropsychological testing with rapid forgetting (% reduction 1.5 standard deviations below the mean)
NCT02423200,Phase 2,Alzheimer's Disease,EIP Pharma Inc,Apr-15,Alzheimer Disease;Cognitive Dysfunction, Clinical Dementia Rating (CDR) Sum of Box (SOB) score 0.5
NCT02423200,Phase 2,Alzheimer's Disease,EIP Pharma Inc,Apr-15,Alzheimer Disease;Cognitive Dysfunction, Mini-Mental State Examination (MMSE) range: 20 to 30
NCT02423200,Phase 2,Alzheimer's Disease,EIP Pharma Inc,Apr-15,Alzheimer Disease;Cognitive Dysfunction, Brain hypometabolism by 18F-2-fluoro-2-deoxyglucose (FDG)-PET
NCT02423200,Phase 2,Alzheimer's Disease,EIP Pharma Inc,Apr-15,Alzheimer Disease;Cognitive Dysfunction," Participants may be taking medications for AD, provided that the dose of these medications has been stable for greater than 3 months."
NCT02431468,Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Nov-15,Alzheimer Disease;Bryostatin 1, Written informed consent from caregiver and subject (if possible) or legally acceptable representative if different from caregiver
NCT02431468,Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Nov-15,Alzheimer Disease;Bryostatin 1, Male and female subjects 55-85 years of age inclusive
NCT02431468,Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Nov-15,Alzheimer Disease;Bryostatin 1, Cognitive deficit present for at least 2 years that meet the diagnostic criteria for probable Alzheimer's
NCT02431468,Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Nov-15,Alzheimer Disease;Bryostatin 1, Mini Mental State Exam (MMSE-2) score of 4-15
NCT02431468,Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Nov-15,Alzheimer Disease;Bryostatin 1, Patients must be able to perform at least one item on the Severe Impairment Battery Scale
NCT02431468,Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Nov-15,Alzheimer Disease;Bryostatin 1, Neuroimaging (computerized tomography (CT) or Magnetic Resonance Imaging (MRI)) within the last 24 months consistent with a diagnosis of probable Alzheimer's disease (AD)
NCT02431468,Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Nov-15,Alzheimer Disease;Bryostatin 1, Reliable caregiver(s) or informant(s) who attends the subject at least an average of 3 hours or more per day for 3 or more days per week
NCT02431468,Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Nov-15,Alzheimer Disease;Bryostatin 1, Adequate vision and motor function to comply with testing
NCT02431468,Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Nov-15,Alzheimer Disease;Bryostatin 1," If taking drugs approved for treatment of Alzheimer's disease (e.g. cholinesterase inhibitors, memantine), must be on a stable dose for at least 3 months prior to entry into study and the dose must not change during the study unless a change is required due to an adverse event or a clinically significant change in the patient's status."
NCT02434666,Phase 2,Dementia of the Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease,Have signed an Institutional Review Board (IRB) approved informed consent document indicating that they understand the purpose of and procedures required by the study and are willing to participate in the study and comply with all study procedures and restrictions. Informed consent must be obtained from the patient and/or a designated representative prior to initiating any procedures of the study.
NCT02434666,Phase 2,Dementia of the Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease,Have safely completed 12 week maintenance phase of CPC-001-07 study.
NCT02442765,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,Avanir Pharmaceuticals,Sep-15,Dementia;Alzheimer Disease;Psychomotor Agitation, Diagnosis of probable Alzheimer's Disease (AD) according to the 2011 National Institute on Aging-Alzheimer's Association (NIA-AA) working groups criteria
NCT02442765,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,Avanir Pharmaceuticals,Sep-15,Dementia;Alzheimer Disease;Psychomotor Agitation," The participant has clinically significant, moderate/severe agitation at the time of screening and for at least 2 weeks prior to randomization"
NCT02442765,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,Avanir Pharmaceuticals,Sep-15,Dementia;Alzheimer Disease;Psychomotor Agitation, The diagnosis of agitation must meet the International Psychogeriatric Association (IPA) provisional definition of agitation
NCT02442765,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,Avanir Pharmaceuticals,Sep-15,Dementia;Alzheimer Disease;Psychomotor Agitation, Either out patients or residents of an assisted-living facility or a skilled nursing home
NCT02442765,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,Avanir Pharmaceuticals,Sep-15,Dementia;Alzheimer Disease;Psychomotor Agitation, Clinical Global Impression of Severity of Illness (CGIS) score assessing Agitation is greater than = 4 (moderately ill) at screening and baseline
NCT02442765,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,Avanir Pharmaceuticals,Sep-15,Dementia;Alzheimer Disease;Psychomotor Agitation, Mini-Mental State Examination (MMSE) score is between 6 and 26 (inclusive) at screening and baseline
NCT02442765,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,Avanir Pharmaceuticals,Sep-15,Dementia;Alzheimer Disease;Psychomotor Agitation," Caregiver who is able and willing to comply with all required study procedures. In order to qualify as a reliable informant (i.e., caregiver) capable of assessing changes in participant's condition during the study, the individual must spend a minimum of 2 hours per day for 4 days per week with the participant."
NCT02442778,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,Avanir Pharmaceuticals,Sep-15,Dementia;Alzheimer Disease;Psychomotor Agitation, Diagnosis of probable Alzheimer's Disease (AD) according to the 2011 National Institute on Aging-Alzheimer's Association (NIA-AA) working groups criteria
NCT02442778,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,Avanir Pharmaceuticals,Sep-15,Dementia;Alzheimer Disease;Psychomotor Agitation," The participant has clinically significant, moderate/severe agitation at the time of screening and for at least 2 weeks prior to randomization"
NCT02442778,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,Avanir Pharmaceuticals,Sep-15,Dementia;Alzheimer Disease;Psychomotor Agitation, The diagnosis of agitation must meet the International Psychogeriatric Association (IPA) provisional definition of agitation
NCT02442778,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,Avanir Pharmaceuticals,Sep-15,Dementia;Alzheimer Disease;Psychomotor Agitation, Either out patients or residents of an assisted-living facility or a skilled nursing home
NCT02442778,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,Avanir Pharmaceuticals,Sep-15,Dementia;Alzheimer Disease;Psychomotor Agitation, Clinical Global Impression of Severity of Illness (CGIS) score assessing Agitation is greater than =4 (moderately ill) at screening and baseline
NCT02442778,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,Avanir Pharmaceuticals,Sep-15,Dementia;Alzheimer Disease;Psychomotor Agitation, Mini-Mental State Examination (MMSE) score is between 6 and 26 (inclusive) at screening and baseline
NCT02442778,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,Avanir Pharmaceuticals,Sep-15,Dementia;Alzheimer Disease;Psychomotor Agitation," Caregiver who is able and willing to comply with all required study procedures. In order to qualify as a reliable informant (i.e., caregiver) capable of assessing changes in participant's condition during the study, the individual must spend a minimum of 2 hours per day for 4 days per week with the participant."
NCT02446132,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Dec-15,Dementia;Alzheimer Disease;Psychomotor Agitation," Participant has successfully completed Studies 15-AVP-786-301, 15-AVP-786-302, 12-AVR-131, or 17-AVP-786-305. (Note: A delay in enrollment may include delays associated with COVID-19 restrictions.)"
NCT02446132,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Dec-15,Dementia;Alzheimer Disease;Psychomotor Agitation, Participants with a diagnosis of probable Alzheimer's Disease (AD) according to the 2011 National Institute on Aging-Alzheimer's Association (NIA-AA) working group criteria
NCT02446132,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Dec-15,Dementia;Alzheimer Disease;Psychomotor Agitation, Either out-patients or residents of an assisted-living facility or a skilled nursing home
NCT02446132,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Dec-15,Dementia;Alzheimer Disease;Psychomotor Agitation," Participants who delay enrollment must have clinically significant, moderate/severe agitation at least 2 weeks prior to baseline"
NCT02446132,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Dec-15,Dementia;Alzheimer Disease;Psychomotor Agitation, Participants who delay enrollment must have a diagnosis of agitation that must meet the International Psychogeriatric Association (IPA) provisional definition of agitation
NCT02446132,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Dec-15,Dementia;Alzheimer Disease;Psychomotor Agitation, Participants who delay enrollment must have a Clinical Global Impression of Severity of Illness (CGIS) score assessing Agitation of  4 (moderately ill) at screening and baseline
NCT02446132,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Dec-15,Dementia;Alzheimer Disease;Psychomotor Agitation, Participants who delay enrollment must have a Mini-Mental State Examination (MMSE) score between 6 and 26 (inclusive) at screening and baseline
NCT02471196,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease;Aggression," Written informed consent (IC) for participation in the study (co-signed by the subject's next of kin or caregiver, or other legally acceptable representative."
NCT02471196,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease;Aggression, Written IC obtained from a consistently available caregiver informant who is knowledgeable of the subject's condition and its progression and is willing to accompany the subject to all visits and supervise the administration of the study medication.
NCT02471196,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease;Aggression, Age of 55-90 years (inclusive).
NCT02471196,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease;Aggression, Male or female subjects with diagnosis of probable Alzheimer's Disease.
NCT02471196,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease;Aggression, Brain imaging (computed tomography [CT] or magnetic resonance imaging [MRI]) consistent with a diagnosis of Alzheimer's Disease (within 18 months or at screening).
NCT02471196,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease;Aggression, Mini-mental state examination (MMSE) score between 10-24 (inclusive).
NCT02471196,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease;Aggression, Clinically significant agitation meeting the International Psychogeriatric Association Provisional Criteria for Agitation in Cognitive Impairment. The agitation symptoms need to have been present for at least 4 weeks before the screening visit.
NCT02471196,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease;Aggression, Neuropsychiatric Inventory agitation/aggression item score at least 4 at screening visit.
NCT02503501,Phase 2,Alzheimer's Disease (AD),HealthPartners Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Insulin glulisine, Subject is/has
NCT02503501,Phase 2,Alzheimer's Disease (AD),HealthPartners Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Insulin glulisine, clinical and research diagnosis of amnestic-MCI OR probable mild AD in accordance with National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria
NCT02503501,Phase 2,Alzheimer's Disease (AD),HealthPartners Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Insulin glulisine, Montreal Cognitive Assessment (MoCA) score 18-27
NCT02503501,Phase 2,Alzheimer's Disease (AD),HealthPartners Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Insulin glulisine, Hachinski Ischemia Score less than 4
NCT02503501,Phase 2,Alzheimer's Disease (AD),HealthPartners Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Insulin glulisine, 50-90 years of age
NCT02503501,Phase 2,Alzheimer's Disease (AD),HealthPartners Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Insulin glulisine, Females at least 2 years post-menopausal or surgically sterile
NCT02503501,Phase 2,Alzheimer's Disease (AD),HealthPartners Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Insulin glulisine," Proficiency in speaking, reading and understanding English"
NCT02503501,Phase 2,Alzheimer's Disease (AD),HealthPartners Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Insulin glulisine," Dedicated family member /caregiver, who will be able to attend all visits and report on subject's status"
NCT02503501,Phase 2,Alzheimer's Disease (AD),HealthPartners Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Insulin glulisine," (and family member/caregiver) provided fully informed written consent prior to participation. In the event that subject is legally unable to provide informed written consent due to deterioration in cognitive abilities, fully informed written consent must be provided by a legally authorized representative"
NCT02503501,Phase 2,Alzheimer's Disease (AD),HealthPartners Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Insulin glulisine," If AD, a brain computed tomography (CT) or magnetic resonance imaging (MRI) in the initial diagnostic workup or subsequent care that is compatible with the diagnosis of probable AD"
NCT02516046,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Sep-15,Alzheimer Disease, Have a projected life expectancy of  6 months
NCT02516046,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Sep-15,Alzheimer Disease, Can tolerate a 20 minute PET scan
NCT02516046,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Sep-15,Alzheimer Disease, Give informed consent or have a legally authorized representative to consent for study procedures and brain donation consistent with the legal requirements of the State in which they die
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen, 55-79 years old;
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen,  8 years of education;
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen," Study partner is available who has frequent contact with the participant (e.g. an average of 10 hours per week or more), and can accompany the participant to all clinic visits for the duration of the protocol;"
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen," Evidence of early AD, as defined by all of the following:"
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen,Memory complaint by subject or study partner that is verified by a study partner;
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen,"Objective memory impairment for age, documented by scoring below the education adjusted cutoff of the Logical Memory II subscale (Delayed Paragraph Recall) from the Wechsler Memory Scale Third Edition (the maximum score is 25):"
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen,"  8 for 16 or more years of education, or"
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen,  4 for 8-15 years of education;
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen, Essentially preserved general cognitive function;
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen, Largely intact functional activities;
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen, Not demented;
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen," Cerebrospinal fluid (CSF) biomarker results consistent with early AD, including CSF A-42 levels  180 pg/mL and  690 pg/mL;"
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen, Clinical Dementia Rating (Global) = 0.5; Memory Box score must be at least 0.5;
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen, Must be fluent in the language of the cognitive testing material being administered;
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen, Stability of permitted medications for 4 weeks prior to study start; subjects receiving acetylcholinesterase inhibitors and/or memantine should be on stable dose of those medications for at least 12 weeks prior to study start with every effort to maintain stable dose for the duration of the study;
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen, Visual and auditory acuity adequate for neuropsychological testing;
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen, Good general health with no diseases expected to interfere with the study;
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen, Must provide written informed consent for APOe4 genotype testing;
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen, Must provide written informed consent for CSF sampling.
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate,Signed an Institutional Review Board (IRB) approved informed consent document
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate,Aged 50 - 89 years inclusive.
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate,Meeting the diagnosis of probable AD consistent with:
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate, Revised National Institute on Aging-Alzheimer's Disease Association (NIA-ADA) criteria and
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate, Diagnostic and Statistical Manual of Mental Disorders (DSM IV) criteria.
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate,Mild to severe severity (Mini-Mental Status Exam [MMSE] scores 7 - 24 inclusive).
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate,Rosen-Modified Hachinski Ischemia Score of 4.
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate,Have a suitable caregiver to supervise the at-home administration of study drugs and observe for AEs.
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate,Patients treated with donepezil 5 or 10 mg/day (given once daily) for at least 4 weeks just prior to Day1 for Population (group) 1 or;
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate,Patients never been treated with donepezil before (donepezil nave) or who have not received any other AChEI for the past 6 months for Population (group) 2.
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate,"Patients in generally good health as indicated by their medical history and physical examination, vital signs, electrocardiogram (ECG), and standard laboratory tests."
NCT02550665,Phase 3,Alzheimer's Disease,Asan Medical Center,unknown,Alzheimer Disease;Donepezil, dementia according to Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria
NCT02550665,Phase 3,Alzheimer's Disease,Asan Medical Center,unknown,Alzheimer Disease;Donepezil, probable Alzheimer's disease dementia according to National Institute on Aging-Alzheimer's Association (NIAAA) criteria
NCT02550665,Phase 3,Alzheimer's Disease,Asan Medical Center,unknown,Alzheimer Disease;Donepezil, Mini-Mental State Examination (MMSE) score of 20 or less
NCT02550665,Phase 3,Alzheimer's Disease,Asan Medical Center,unknown,Alzheimer Disease;Donepezil, General Deterioration Scale (GDS) score of 4 or more / Clinical Dementia Rating (CDR) score of 2 or more
NCT02550665,Phase 3,Alzheimer's Disease,Asan Medical Center,unknown,Alzheimer Disease;Donepezil, stable dose of 10mg donepezil at least 3 months before screening
NCT02550665,Phase 3,Alzheimer's Disease,Asan Medical Center,unknown,Alzheimer Disease;Donepezil, caregiver who can come together at every visit and give informations about side effects profiles should exist
NCT02550665,Phase 3,Alzheimer's Disease,Asan Medical Center,unknown,Alzheimer Disease;Donepezil, patients and caregivers accepted the study
NCT02551809,Phase 2,Alzheimer's Disease,United Neuroscience Ltd.,unknown,Alzheimer Disease, Diagnosis of mild Alzheimer's Disease
NCT02551809,Phase 2,Alzheimer's Disease,United Neuroscience Ltd.,unknown,Alzheimer Disease, Mini-Mental State Examination (MMSE) scores between 20 and 26 (inclusive)
NCT02551809,Phase 2,Alzheimer's Disease,United Neuroscience Ltd.,unknown,Alzheimer Disease, Clinical dementia rating (CDR) scores of 0.5 or 1
NCT02551809,Phase 2,Alzheimer's Disease,United Neuroscience Ltd.,unknown,Alzheimer Disease, Other inclusion criteria apply
NCT02560753,Phase 1/Phase 2,Alzheimer's Disease,"T3D Therapeutics, Inc.",Jul-15,Alzheimer Disease, Meets criteria for mild-to-moderate AD with Mini-Mental State Examination (MMSE) score of 14 through 26
NCT02560753,Phase 1/Phase 2,Alzheimer's Disease,"T3D Therapeutics, Inc.",Jul-15,Alzheimer Disease, Clinical Dementia Rating = 0.5 to 2.0
NCT02560753,Phase 1/Phase 2,Alzheimer's Disease,"T3D Therapeutics, Inc.",Jul-15,Alzheimer Disease, Modified Hachinski less than or equal to 4
NCT02560753,Phase 1/Phase 2,Alzheimer's Disease,"T3D Therapeutics, Inc.",Jul-15,Alzheimer Disease, A clinical diagnosis of AD per NINCDS-ADRDA criteria
NCT02560753,Phase 1/Phase 2,Alzheimer's Disease,"T3D Therapeutics, Inc.",Jul-15,Alzheimer Disease, Washout of psychoactive medication (other than anti-depressants): at least 4 weeks prior to baseline
NCT02560753,Phase 1/Phase 2,Alzheimer's Disease,"T3D Therapeutics, Inc.",Jul-15,Alzheimer Disease, Stability of all permitted medications for 4-12 weeks prior to baseline
NCT02560753,Phase 1/Phase 2,Alzheimer's Disease,"T3D Therapeutics, Inc.",Jul-15,Alzheimer Disease, Visual and auditory acuity adequate for neuropsychological testing
NCT02560753,Phase 1/Phase 2,Alzheimer's Disease,"T3D Therapeutics, Inc.",Jul-15,Alzheimer Disease, Home monitoring available for supervision of medications
NCT02580305,Phase 2,Alzheimer's Disease,Suven Life Sciences Limited,Sep-15,Alzheimer Disease;Memantine;Donepezil;1-((2-bromophenyl)sulfonyl)-5-methoxy-3-((4-methyl-1-piperazinyl)methyl)-1H-indole dimesylate monohydrate, Has a diagnosis of probable Alzheimer's disease based on the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria at least 1 year prior to the screening visit.
NCT02580305,Phase 2,Alzheimer's Disease,Suven Life Sciences Limited,Sep-15,Alzheimer Disease;Memantine;Donepezil;1-((2-bromophenyl)sulfonyl)-5-methoxy-3-((4-methyl-1-piperazinyl)methyl)-1H-indole dimesylate monohydrate, Has a score between 12 and 20 inclusive on the MMSE at the screening and baseline visits.
NCT02580305,Phase 2,Alzheimer's Disease,Suven Life Sciences Limited,Sep-15,Alzheimer Disease;Memantine;Donepezil;1-((2-bromophenyl)sulfonyl)-5-methoxy-3-((4-methyl-1-piperazinyl)methyl)-1H-indole dimesylate monohydrate, Has a MRI or CT scan performed within 12 months prior to screening with findings consistent with the diagnosis of dementia due to Alzheimer's disease without any other clinically significant comorbid pathologies.
NCT02580305,Phase 2,Alzheimer's Disease,Suven Life Sciences Limited,Sep-15,Alzheimer Disease;Memantine;Donepezil;1-((2-bromophenyl)sulfonyl)-5-methoxy-3-((4-methyl-1-piperazinyl)methyl)-1H-indole dimesylate monohydrate, Must be receiving treatment with stable doses of donepezil HCl and memantine HCl for at least 3 months prior to the screening visit
NCT02580305,Phase 2,Alzheimer's Disease,Suven Life Sciences Limited,Sep-15,Alzheimer Disease;Memantine;Donepezil;1-((2-bromophenyl)sulfonyl)-5-methoxy-3-((4-methyl-1-piperazinyl)methyl)-1H-indole dimesylate monohydrate, Availability of an eligible and reliable caregiver
NCT02580305,Phase 2,Alzheimer's Disease,Suven Life Sciences Limited,Sep-15,Alzheimer Disease;Memantine;Donepezil;1-((2-bromophenyl)sulfonyl)-5-methoxy-3-((4-methyl-1-piperazinyl)methyl)-1H-indole dimesylate monohydrate, Must be living in the community or an assisted living facility.
NCT02580305,Phase 2,Alzheimer's Disease,Suven Life Sciences Limited,Sep-15,Alzheimer Disease;Memantine;Donepezil;1-((2-bromophenyl)sulfonyl)-5-methoxy-3-((4-methyl-1-piperazinyl)methyl)-1H-indole dimesylate monohydrate, Must be ambulatory or ambulatory aided (use of cane or walker).
NCT02580305,Phase 2,Alzheimer's Disease,Suven Life Sciences Limited,Sep-15,Alzheimer Disease;Memantine;Donepezil;1-((2-bromophenyl)sulfonyl)-5-methoxy-3-((4-methyl-1-piperazinyl)methyl)-1H-indole dimesylate monohydrate, Is not pregnant or planning to become pregnant during the study.
NCT02580305,Phase 2,Alzheimer's Disease,Suven Life Sciences Limited,Sep-15,Alzheimer Disease;Memantine;Donepezil;1-((2-bromophenyl)sulfonyl)-5-methoxy-3-((4-methyl-1-piperazinyl)methyl)-1H-indole dimesylate monohydrate, Subject (or subject's legally acceptable representative) and caregiver must sign an Informed Consent to participate in the study.
NCT02585934,Phase 3,Alzheimer's Disease,Axovant Sciences Ltd.,unknown,Alzheimer Disease, Male or female subject with AD
NCT02585934,Phase 3,Alzheimer's Disease,Axovant Sciences Ltd.,unknown,Alzheimer Disease, Ongoing donepezil therapy for AD
NCT02585934,Phase 3,Alzheimer's Disease,Axovant Sciences Ltd.,unknown,Alzheimer Disease, An MMSE score 12 to 24 inclusive at Screening; MMSE score 10-26 inclusive at Baseline
NCT02585934,Phase 3,Alzheimer's Disease,Axovant Sciences Ltd.,unknown,Alzheimer Disease, Hachinski Ischaemia score less than or equal to 4 at Screening.
NCT02585934,Phase 3,Alzheimer's Disease,Axovant Sciences Ltd.,unknown,Alzheimer Disease," If female, subject must be: a. of non-childbearing potential or surgically sterile; or, b. willing to use an adequate methods of birth control. Male subjects who are sexually active will also be required to use an adequate form of birth control."
NCT02585934,Phase 3,Alzheimer's Disease,Axovant Sciences Ltd.,unknown,Alzheimer Disease, Subject has the ability to comply with procedures for cognitive and other testing in the opinion of the investigator.
NCT02585934,Phase 3,Alzheimer's Disease,Axovant Sciences Ltd.,unknown,Alzheimer Disease, Subject has a reliable caregiver who is willing to report on subject's status throughout the study.
NCT02586909,Phase 3,Alzheimer's Disease,Axovant Sciences Ltd.,unknown,Alzheimer Disease, Completed last on-treatment visit of the lead-in study RVT-101-3001
NCT02615002,Phase 2,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,Nov-15,Alzheimer Disease, Patient and caregiver are willing to take part in the entire study
NCT02615002,Phase 2,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,Nov-15,Alzheimer Disease, Signed informed consent from the patient and the caregiver
NCT02615002,Phase 2,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,Nov-15,Alzheimer Disease, Patient has a clearly documented history either in medical records or from an informant of cognitive decline over at least 6 months
NCT02615002,Phase 2,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,Nov-15,Alzheimer Disease, Patient has mild probable AD as consistent with criteria established by the NIA-AA
NCT02615002,Phase 2,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,Nov-15,Alzheimer Disease, CT/MRI scan with finding consisted with probable AD obtained during the last 12 months before Screening
NCT02615002,Phase 2,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,Nov-15,Alzheimer Disease, Patient has an MMSE score of 21-26 (inclusive) at Screening
NCT02615002,Phase 2,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,Nov-15,Alzheimer Disease, Patient has a Clinical Dementia Rating Global Score (CDR-GS) of 0.5-1 (mild dementia) at Screening
NCT02615002,Phase 2,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,Nov-15,Alzheimer Disease," Patients receiving prescribed drugs for treatment of AD including acetyl cholinesterase inhibitors [eg, donepezil, galantamine, rivastigmine] should be on a stable dose for at least 3 months before Screening"
NCT02615002,Phase 2,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,Nov-15,Alzheimer Disease, Patient has a negative drug screen (benzodiazepines or opiates) at Screening
NCT02615002,Phase 2,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,Nov-15,Alzheimer Disease," Female patients must have had last natural menstruation  24 months before Screening, OR be surgically sterile"
NCT02615002,Phase 2,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,Nov-15,Alzheimer Disease," Male patients must agree to use of effective contraception if female partner is of childbearing potential, OR be surgically sterile"
NCT02626572,Phase 2,Alzheimer's Disease,Institut de Recherches Internationales Servier,Feb-15,Alzheimer Disease;Depression, Out-patients
NCT02626572,Phase 2,Alzheimer's Disease,Institut de Recherches Internationales Servier,Feb-15,Alzheimer Disease;Depression, Able to perform neuropsychological tests
NCT02626572,Phase 2,Alzheimer's Disease,Institut de Recherches Internationales Servier,Feb-15,Alzheimer Disease;Depression, Have a responsible informant
NCT02626572,Phase 2,Alzheimer's Disease,Institut de Recherches Internationales Servier,Feb-15,Alzheimer Disease;Depression, DSM-IV-TR criteria for Dementia of the Alzheimer's Disease Type
NCT02626572,Phase 2,Alzheimer's Disease,Institut de Recherches Internationales Servier,Feb-15,Alzheimer Disease;Depression, Mini mental State Examination (MMSE) = 15-24 both inclusive
NCT02626572,Phase 2,Alzheimer's Disease,Institut de Recherches Internationales Servier,Feb-15,Alzheimer Disease;Depression, National Institute of Mental Health (NIMH) provisional criteria for depression in AD (NIMH-dAD)
NCT02626572,Phase 2,Alzheimer's Disease,Institut de Recherches Internationales Servier,Feb-15,Alzheimer Disease;Depression, Cornell Scale for Depression in Dementia total score greater than  or = 8
NCT02626572,Phase 2,Alzheimer's Disease,Institut de Recherches Internationales Servier,Feb-15,Alzheimer Disease;Depression, Patients who have never been treated with AD treatments or patients who have stopped AD treatment whatever the reason
NCT02626572,Phase 2,Alzheimer's Disease,Institut de Recherches Internationales Servier,Feb-15,Alzheimer Disease;Depression," Patients either not currently treated with an antidepressant or patients being treated with an antidepressant at the recommended dose for at least 8 weeks without clinical efficacy, who can stop this treatment according to the investigator's opinion."
NCT02649985,Phase 1/Phase 2,Alzheimer's Disease,Brigham and Women's Hospital,unknown,Multiple Sclerosis;Alzheimer Disease;Sclerosis,"Male and female subjects age 18 to 70 years. For Alzheimer's Disease patients and healthy controls, the age range is going to be 18 to 85 years."
NCT02649985,Phase 1/Phase 2,Alzheimer's Disease,Brigham and Women's Hospital,unknown,Multiple Sclerosis;Alzheimer Disease;Sclerosis,"For RRMS, it needs to be active, which is defined as at least one relapse in the past 12 months, at least one gadolinium enhancing lesion on MRI within 12 months of enrollment or at least one new FLAIR bright lesion on MRI within 6 months of enrollment."
NCT02649985,Phase 1/Phase 2,Alzheimer's Disease,Brigham and Women's Hospital,unknown,Multiple Sclerosis;Alzheimer Disease;Sclerosis,"For SPMS, deterioration in EDSS score in the last year is required."
NCT02649985,Phase 1/Phase 2,Alzheimer's Disease,Brigham and Women's Hospital,unknown,Multiple Sclerosis;Alzheimer Disease;Sclerosis,"For the subjects in the Ocrelizumab arm, only the subjects who have already been prescribed Ocrelizumab by their treating MS neurologist but have not yet started the first infusion, will be included."
NCT02649985,Phase 1/Phase 2,Alzheimer's Disease,Brigham and Women's Hospital,unknown,Multiple Sclerosis;Alzheimer Disease;Sclerosis,AD subjects with MMSE score of 20-26.
NCT02649985,Phase 1/Phase 2,Alzheimer's Disease,Brigham and Women's Hospital,unknown,Multiple Sclerosis;Alzheimer Disease;Sclerosis,Subjects willing to undergo PET and MRI imaging
NCT02649985,Phase 1/Phase 2,Alzheimer's Disease,Brigham and Women's Hospital,unknown,Multiple Sclerosis;Alzheimer Disease;Sclerosis,Subjects willing and able to give informed consent
NCT02670083,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Weight between 40 and 120 kilograms (Kg) inclusive
NCT02670083,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Availability of a person (referred to as the  caregiver ) who in the investigator's judgment:
NCT02670083,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Has frequent and sufficient contact with the participant to be able to provide accurate information regarding the participant's cognitive and functional abilities, agrees to provide information at clinic visits (which require partner input for scale completion), signs the necessary consent form, and has sufficient cognitive capacity to accurately report upon the participant's behavior and cognitive and functional abilities"
NCT02670083,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Fluency in the language of the tests used at the study site
NCT02670083,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Adequate visual and auditory acuity, in the investigator's judgment, sufficient to perform the neuropsychological testing (eye glasses and hearing aids are permitted)"
NCT02670083,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Evidence of the AD pathological process, by a positive amyloid assessment either on cerebrospinal fluid (CSF) amyloid beta 1-42 levels as measured on the Elecsys beta-amyloid(1-42) test system or amyloid PET scan by qualitative read by the core/central PET laboratory"
NCT02670083,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Demonstrated abnormal memory function at screening (up to 4 weeks before screening begins) or screening (FCSRT cueing index =less than 0.67 AND free recall =less than 27)
NCT02670083,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Screening mini mental state examination (MMSE) score of greater than or equal to (greater than =) 22 points and Clinical Dementia Rating-Global Score (CDR-GS) of 0.5 or 1.0
NCT02670083,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Meets National Institute on Aging/Alzheimer's Association (NIAAA) core clinical criteria for probable AD dementia or prodromal AD (consistent with the NIAAA diagnostic criteria and guidelines for mild cognitive impairment (MCI)
NCT02670083,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," If receiving symptomatic AD medications, the dosing regimen must have been stable for 3 months prior to screening"
NCT02670083,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Participant must have completed at least 6 years of formal education after the age of 5 years
NCT02702817,Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Naproxen, good physical health including normal hemoglobin and hematocrit
NCT02702817,Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Naproxen," history or documentation of AD dementia in at least one parent, or in two siblings"
NCT02702817,Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Naproxen," cognitive performance without diagnosable deficit such as dementia,  mild cognitive impairment "
NCT02702817,Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Naproxen, must have spouse or companion able to accompany participant for clinic visits
NCT02702817,Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Naproxen, six or more years of formal education
NCT02702817,Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Naproxen, fluent in either English or French
NCT02702817,Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Naproxen, provision of informed consent
NCT02707458,Phase 1/Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,Apr-16,Alzheimer Disease;Cognitive Dysfunction;Probucol," Family history of one or more parents or multiple siblings who developed Alzheimer-like dementia, as established by review of history and/or medical records, and by responses to a brief questionnaire describing characteristics of the relatives' condition"
NCT02707458,Phase 1/Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,Apr-16,Alzheimer Disease;Cognitive Dysfunction;Probucol, Aged 60+. May be aged 55-59 only if at least one parent or sibling experienced onset of Alzheimer's dementia at an age no more than 15 years beyond the prospective participant's current age
NCT02707458,Phase 1/Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,Apr-16,Alzheimer Disease;Cognitive Dysfunction;Probucol, At least six years of formal education
NCT02707458,Phase 1/Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,Apr-16,Alzheimer Disease;Cognitive Dysfunction;Probucol, Sufficient fluency in spoken and written English and/or French to participate in study visits and in psychometric testing
NCT02707458,Phase 1/Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,Apr-16,Alzheimer Disease;Cognitive Dysfunction;Probucol," A collateral respondent available to provide information on the cognitive and health status of the participant, and to assist with monitoring of study interventions, if needed"
NCT02707458,Phase 1/Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,Apr-16,Alzheimer Disease;Cognitive Dysfunction;Probucol, Willingness to undergo four lumbar punctures for collection of CSF
NCT02707458,Phase 1/Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,Apr-16,Alzheimer Disease;Cognitive Dysfunction;Probucol, Affirmation of prior informed consent to undergo genetic testing for APOE and other known or suspected AD risk factors
NCT02707458,Phase 1/Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,Apr-16,Alzheimer Disease;Cognitive Dysfunction;Probucol," Ability and intention to participate in study visits per protocol, in the opinion of a study physician"
NCT02707458,Phase 1/Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,Apr-16,Alzheimer Disease;Cognitive Dysfunction;Probucol," Willingness to limit use of over-the-counter or prescription medicines (e.g., tricyclic antidepressants, anti-histamines) known to prolong QTc interval, or to potentiate the tendency of probucol to prolong this interval, in the opinion of a study physician"
NCT02707458,Phase 1/Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,Apr-16,Alzheimer Disease;Cognitive Dysfunction;Probucol," If on a statin or other lipid lowering drug that, in the opinion of a study physician, can safely be co-administered with probucol, willingness to remain on a stable dose of this medication during the entire trial period."
NCT02707458,Phase 1/Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,Apr-16,Alzheimer Disease;Cognitive Dysfunction;Probucol, Provision of informed consent for this trial.
NCT02707978,Phase 2,Alzheimer Disease,"Tammie L. S. Benzinger, MD, PhD",unknown,"Alzheimer Disease;Dementia;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain","Male or female participants, at least 18 years of age."
NCT02707978,Phase 2,Alzheimer Disease,"Tammie L. S. Benzinger, MD, PhD",unknown,"Alzheimer Disease;Dementia;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain","Clinically diagnosed with frontotemporal dementia (FTD), or a carrier of a mutation known to cause FTD (with or without symptoms); or a normal control."
NCT02707978,Phase 2,Alzheimer Disease,"Tammie L. S. Benzinger, MD, PhD",unknown,"Alzheimer Disease;Dementia;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain","Participant is able and willing to undergo testing (MRI or CT, PET, radioactive tracer injection, LP; for those unable to undergo an MRI, CT will be used to generate regions-of-interest)."
NCT02707978,Phase 2,Alzheimer Disease,"Tammie L. S. Benzinger, MD, PhD",unknown,"Alzheimer Disease;Dementia;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain",Pre-menopausal women will have a negative a urine pregnancy test within 24 hours of T807 drug administration.
NCT02719327,Phase 2/Phase 3,Alzheimer's Disease,VA Office of Research and Development,unknown,Alzheimer Disease;Eicosapentaenoic acid ethyl ester, United States Veteran eligible for VA care
NCT02719327,Phase 2/Phase 3,Alzheimer's Disease,VA Office of Research and Development,unknown,Alzheimer Disease;Eicosapentaenoic acid ethyl ester," Age 50-75 years, inclusive"
NCT02719327,Phase 2/Phase 3,Alzheimer's Disease,VA Office of Research and Development,unknown,Alzheimer Disease;Eicosapentaenoic acid ethyl ester, Cognitively healthy
NCT02727699,Phase 2,"Dementia, Alzheimer Type",Actinogen Medical,unknown,Alzheimer Disease;Dementia,Males and females aged 50 years or older at the time of informed consent.
NCT02727699,Phase 2,"Dementia, Alzheimer Type",Actinogen Medical,unknown,Alzheimer Disease;Dementia,Female Subjects:
NCT02727699,Phase 2,"Dementia, Alzheimer Type",Actinogen Medical,unknown,Alzheimer Disease;Dementia,"Post menopausal women, defined as no menses for 12 months without an alternative medical cause. If there is any concern about the menopausal status of a prospective female subject, a follicle stimulating hormone test (FSH) should be requested to confirm post-menopausal status. Post menopausal women confirmed by FSH level greater than  40 mIU (milli-international units per milliliter) /mL, will be confirmed by central laboratory."
NCT02727699,Phase 2,"Dementia, Alzheimer Type",Actinogen Medical,unknown,Alzheimer Disease;Dementia,"Women of childbearing potential (WOCBP) must have a negative pregnancy test at Screening and Baseline, and be willing to use highly effective methods of contraception from the Screening visit until 3 months after last dose of study drug. If re-test is required, a local urine pregnancy test will be performed at Baseline to determine if the subject can continue to randomisation."
NCT02727699,Phase 2,"Dementia, Alzheimer Type",Actinogen Medical,unknown,Alzheimer Disease;Dementia,"Are permanently sterile or have had a hysterectomy, bilateral salpingectomy or bilateral oophorectomy."
NCT02727699,Phase 2,"Dementia, Alzheimer Type",Actinogen Medical,unknown,Alzheimer Disease;Dementia,Women must not be breastfeeding.
NCT02727699,Phase 2,"Dementia, Alzheimer Type",Actinogen Medical,unknown,Alzheimer Disease;Dementia,Male Subjects:
NCT02727699,Phase 2,"Dementia, Alzheimer Type",Actinogen Medical,unknown,Alzheimer Disease;Dementia,"Who are sexually active, fertile men must use highly effective methods of contraception from Day 1 until 3 months after last dose of study drug if their partners are WOCBP."
NCT02727699,Phase 2,"Dementia, Alzheimer Type",Actinogen Medical,unknown,Alzheimer Disease;Dementia,Who are permanently sterile or have had bilateral orchiectomy.
NCT02727699,Phase 2,"Dementia, Alzheimer Type",Actinogen Medical,unknown,Alzheimer Disease;Dementia,"Diagnosis of mild dementia due to Alzheimer's disease (AD) with increased level of certainty (provided by evidence of clinical deterioration within the 6 months preceding Screening, as assessed by the investigator) as determined by the National Institute of Ageing (NIA) and the Alzheimer's Association (AA) workgroup."
NCT02727699,Phase 2,"Dementia, Alzheimer Type",Actinogen Medical,unknown,Alzheimer Disease;Dementia,Mild dementia due to probable AD with Mini-Mental Status Examination (MMSE) 20 to 26 (inclusive).
NCT02727699,Phase 2,"Dementia, Alzheimer Type",Actinogen Medical,unknown,Alzheimer Disease;Dementia,Clinical Dementia Rating Scale (CDR) Global Score of 0.5 to 1.0.
NCT02727699,Phase 2,"Dementia, Alzheimer Type",Actinogen Medical,unknown,Alzheimer Disease;Dementia,"A brain magnetic resonance imaging (MRI) or computed tomography (CT) scan in the 12 months preceding Screening that in the investigator's opinion is consistent with AD as the principle aetiology of the dementia with no other clinically significant abnormality, e.g. another principle underlying aetiology of the subject's dementia, or a lesion which could affect cognition e.g. a brain tumour or large stroke."
NCT02727699,Phase 2,"Dementia, Alzheimer Type",Actinogen Medical,unknown,Alzheimer Disease;Dementia,On stable dose of acetylcholinesterase (AChEI) and/or memantine (at least 3 months prior to Screening) OR treatment-nave. Initiating AChEIs or memantine during the study will not be permitted.
NCT02727699,Phase 2,"Dementia, Alzheimer Type",Actinogen Medical,unknown,Alzheimer Disease;Dementia,"Apart from a clinical diagnosis of mild dementia due to AD, the subject must be in good health as determined by the investigator, based on medical history and screening assessments."
NCT02727699,Phase 2,"Dementia, Alzheimer Type",Actinogen Medical,unknown,Alzheimer Disease;Dementia,"Has a consenting study partner who, in the investigator's judgement, has frequent and sufficient contact with the subject to be able to provide accurate information as to the subject's cognitive and functional abilities. The study partner must be available to provide information to the investigator and study site staff about the subject and agrees to attend all study site visits in person for scale completion. A study partner should be available for the duration of the study. The measure of adequate availability will be at the investigator's discretion."
NCT02727699,Phase 2,"Dementia, Alzheimer Type",Actinogen Medical,unknown,Alzheimer Disease;Dementia,Must be willing and able to comply with the requirements of the protocol and must be available to complete the study.
NCT02727699,Phase 2,"Dementia, Alzheimer Type",Actinogen Medical,unknown,Alzheimer Disease;Dementia,Must satisfy a medical examiner about their fitness to participate in the study.
NCT02727699,Phase 2,"Dementia, Alzheimer Type",Actinogen Medical,unknown,Alzheimer Disease;Dementia,Must provide written informed consent to participate in the study.
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant," Diagnosis of probable Alzheimer's disease based on either a) the National Institute on Aging - Alzheimer's Association (NIA-AA) criteria or b) the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, (DSM-5) criteria for AD."
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant," Have sleep complaints that meet DSM-5 criteria for a diagnosis of insomnia (e.g., difficulty initiating or maintaining sleep, and/or early morning awakenings with inability to return to sleep for at least 3 nights per week for  the past 3 months prior to study start, despite adequate opportunity for sleep) based on the investigator's judgment and by the participant's sleep history, as assessed by the sleep items on the Insomnia Diagnostic Interview and Sleep History assessments."
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant, Be willing to stay overnight in a sleep laboratory and must be willing to stay in bed for at least 8 hours for PSG testing
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant, Regular bedtime is between 8 pm and 1 am and is willing to maintain it for the duration of the trial
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant, Be able and willing to wear an activity/sleep watch on the wrist throughout the day and night
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant," Based on the investigator's judgment the participant should: a) be able to speak, read, and understand the language of the trial staff and the informed consent form; b) possess the ability to respond verbally to questions, follow instructions, and complete study assessments; c) be able to adhere to dose and visit schedules."
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant," Have a reliable and competent trial partner (e.g., spouse, family member, or other caregiver) who:"
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant," a) Signs their own informed consent, after the trial has been explained to them, and before Screening assessments;"
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant, b) Is not diagnosed with dementia;
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant," c) Resides with the participant overnight and has a close relationship with the participant (defined as daily face-to-face contact, at least 15 waking hours a week for at least 3 months prior to Visit 1);"
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant, d) Accompanies the participant to and from trial visits and stays overnight at the sleep laboratory for the 3 PSG visits;
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant," e) Assumes responsibility for trial medication procedures (e.g., witnessing and/or helping to administer trial medication, assessing compliance), for completion of the sleep e-diary each morning, and oversight of the activity/sleep watch worn throughout the trial;"
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant, f) Answers questions regarding the trial partner's sleep quality and trial partner's distress related to the subject's behaviors.
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant," If female, not of childbearing potential as indicated by one of the following: has reached natural menopause, defined as:"
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant, a) 45 years of age with either: 12 months of spontaneous amenorrhea OR 6 months of spontaneous amenorrhea with serum follicle stimulating hormone (FSH) levels greater than  40 IU/L as determined by the central laboratory
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant, b) has had a hysterectomy;
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant, c) has had bilateral tubal ligation; or
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant, d) has had a bilateral oophorectomy (with or without a hysterectomy) and greater than 6 weeks have passed since the surgery
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant, Be willing to provide a blood sample for Apolipoprotein E (APOE) genotyping
NCT02756858,Phase 2,Alzheimer's Disease,Anavex Life Sciences Corp.,Mar-16,Alzheimer Disease," Previous exposure to ANAVEX2-73 via participation in Phase 2a Study of ANAVEX2-73 Adaptive-Trial-Design With Repeated Doses, MTD Finding, Pharmacodynamic and Bioavailability Evaluation in Patients With Mild to Moderate Alzheimer's Disease With a 12-Month Open Label Follow-Up Period (ANAVEX2-73-002)"
NCT02760602,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Jun-16,Alzheimer Disease, Has a diagnosis by the study investigator of a clinical syndrome of cognitive impairment consistent with prodromal AD per International Working Group (IWG) diagnostic criteria or mild cognitive impairment (MCI) due to AD per National Institute on Aging-Alzheimer's Association (NIA-AA) diagnostic criteria.
NCT02760602,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Jun-16,Alzheimer Disease, Scores 17-28 on Montreal Cognitive Assessment (MoCA) at screening.
NCT02760602,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Jun-16,Alzheimer Disease, Scores less than 27 on free recall cutoff score from the Free and Cued Selective Reminding Test (FCSRT) (Picture version) at screening.
NCT02760602,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Jun-16,Alzheimer Disease, Scores 4 on Modified Hachinski Ischemia Scale (MHIS).
NCT02760602,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Jun-16,Alzheimer Disease, Scores greater than 0 on the Functional Activities Questionnaire (FAQ).
NCT02760602,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Jun-16,Alzheimer Disease, Has a florbetapir positron emission tomography (PET) scan or cerebrospinal fluid (CSF) result at screening consistent with the presence of amyloid pathology.
NCT02783573,Phase 3,Alzheimer's Disease,AstraZeneca,unknown,Alzheimer Disease;Dementia, Participant must meet the National Institute on Aging (NIA) and the Alzheimer's Association (AA) (NIA-AA) criteria for probable AD dementia.
NCT02783573,Phase 3,Alzheimer's Disease,AstraZeneca,unknown,Alzheimer Disease;Dementia, MMSE score of 20 to 26 inclusive at screening visit.
NCT02783573,Phase 3,Alzheimer's Disease,AstraZeneca,unknown,Alzheimer Disease;Dementia," For a diagnosis of mild AD dementia, participant must have a CDR global score of 0.5 or 1, with the memory box score 0.5 at screening."
NCT02783573,Phase 3,Alzheimer's Disease,AstraZeneca,unknown,Alzheimer Disease;Dementia, Evidence of amyloid pathology.
NCT02783573,Phase 3,Alzheimer's Disease,AstraZeneca,unknown,Alzheimer Disease;Dementia, The participant must have a reliable study partner with whom he/she cohabits or has regular contact.
NCT02791191,Phase 2,Alzheimer's Disease,Eli Lilly and Company,unknown,Alzheimer Disease;Dementia;Disease Progression, Present with mild AD dementia based on the National Institute on Aging (NIA) and the Alzheimer's Association (AA) disease diagnostic criteria as determined by a qualified clinician approved by the Sponsor or designee.
NCT02791191,Phase 2,Alzheimer's Disease,Eli Lilly and Company,unknown,Alzheimer Disease;Dementia;Disease Progression, Mini-Mental State Examination score of 20 to 26 inclusive at screening visit.
NCT02791191,Phase 2,Alzheimer's Disease,Eli Lilly and Company,unknown,Alzheimer Disease;Dementia;Disease Progression, Has a florbetapir PET scan consistent with the presence of amyloid pathology at screening.
NCT02792257,Phase 2,Alzheimer's Disease,Johns Hopkins University,unknown,Alzheimer Disease;Psychomotor Agitation;Dronabinol,Diagnosis of Dementia due to AD
NCT02792257,Phase 2,Alzheimer's Disease,Johns Hopkins University,unknown,Alzheimer Disease;Psychomotor Agitation;Dronabinol,"Presence of Agit-AD as defined by the provisional criteria from the International Psychogeriatric Association (IPA). The definition requires the presence of cognitive impairment, evidence of emotional distress, one of three observable types of behavior (excessive motor activity, verbal aggression, physical aggression), requires that the behavior cause excess disability, and notes that the behaviors cannot be solely attributable to another disorder such as psychiatric illness, medical illness, or effects of substance use."
NCT02792257,Phase 2,Alzheimer's Disease,Johns Hopkins University,unknown,Alzheimer Disease;Psychomotor Agitation;Dronabinol,Clinically significant severity of agitation defined by NPI-C Agitation or NPI-C Aggression greater than  4.
NCT02792257,Phase 2,Alzheimer's Disease,Johns Hopkins University,unknown,Alzheimer Disease;Psychomotor Agitation;Dronabinol,"Able to give informed consent, or deemed to lack such capacity by clinical team and legally authorized representative consents."
NCT02792257,Phase 2,Alzheimer's Disease,Johns Hopkins University,unknown,Alzheimer Disease;Psychomotor Agitation;Dronabinol,"Must be fluent in English and/or Spanish (includes reading, writing, and speech)"
NCT02792257,Phase 2,Alzheimer's Disease,Johns Hopkins University,unknown,Alzheimer Disease;Psychomotor Agitation;Dronabinol,"Must be admitted to clinical sites associated with McLean Hospital, Johns Hopkins University, and Miami Jewish Health Services as an inpatient/long term care resident during the study duration (3 weeks) OR be able to travel to these locations to enroll as an outpatient."
NCT02792257,Phase 2,Alzheimer's Disease,Johns Hopkins University,unknown,Alzheimer Disease;Psychomotor Agitation;Dronabinol,Must be 60-95 years old
NCT02792257,Phase 2,Alzheimer's Disease,Johns Hopkins University,unknown,Alzheimer Disease;Psychomotor Agitation;Dronabinol,Must begin enrollment in study within one week of being determined eligible
NCT02795780,Phase 2,Alzheimer's Disease,Avid Radiopharmaceuticals,Aug-16,Alzheimer Disease, Confirmatory cohort subjects who completed the 18F-AV-1451-A05 (NCT02016560) study
NCT02817906,Phase 3,"Agitation in Dementia, Including Alzheimer's Disease","Intra-Cellular Therapies, Inc.",unknown,Alzheimer Disease;Dementia;Psychomotor Agitation, Clinical diagnosis of probable Alzheimer's disease
NCT02817906,Phase 3,"Agitation in Dementia, Including Alzheimer's Disease","Intra-Cellular Therapies, Inc.",unknown,Alzheimer Disease;Dementia;Psychomotor Agitation, Clinically significant symptoms of agitation secondary to probable Alzheimer's disease
NCT02817906,Phase 3,"Agitation in Dementia, Including Alzheimer's Disease","Intra-Cellular Therapies, Inc.",unknown,Alzheimer Disease;Dementia;Psychomotor Agitation, Able to attend outpatient clinic visits with primary caregiver
NCT02831283,Phase 2,Alzheimer's Disease,William Charles Kreisl,Jun-16,Alzheimer Disease;Inflammation,Age 60 and older.
NCT02831283,Phase 2,Alzheimer's Disease,William Charles Kreisl,Jun-16,Alzheimer Disease;Inflammation,"Meet criteria for either a) amnestic mild cognitive impairment (single or mixed domain) or mild Alzheimer's disease, or b) have no cognitive impairment based on history, exam, neuropsychological testing, and consensus diagnosis. MCI and mild AD patients must have Clinical Dementia Rating scale score of 0.5 or 1. Unimpaired subjects must have Clinical Dementia Rating scale score of 0."
NCT02831283,Phase 2,Alzheimer's Disease,William Charles Kreisl,Jun-16,Alzheimer Disease;Inflammation,Subjects unable to provide informed consent must have a surrogate decision maker
NCT02831283,Phase 2,Alzheimer's Disease,William Charles Kreisl,Jun-16,Alzheimer Disease;Inflammation,Written and oral fluency in English or Spanish.
NCT02831283,Phase 2,Alzheimer's Disease,William Charles Kreisl,Jun-16,Alzheimer Disease;Inflammation,Able to participate in all scheduled evaluations and to complete all required tests and procedures.
NCT02831283,Phase 2,Alzheimer's Disease,William Charles Kreisl,Jun-16,Alzheimer Disease;Inflammation,"In the opinion of the investigator, the subject must be considered likely to comply with the study protocol and to have a high probability of completing the study."
NCT02833792,Phase 2,Alzheimer Dementia,"Stemedica Cell Technologies, Inc.",unknown,Alzheimer Disease;Dementia,Males or females between 55-80 years of age.
NCT02833792,Phase 2,Alzheimer Dementia,"Stemedica Cell Technologies, Inc.",unknown,Alzheimer Disease;Dementia,"Diagnosed with mild to moderate dementia for at least 3 months prior to enrollment, based on the National Institute of Neurological and Communicative"
NCT02833792,Phase 2,Alzheimer Dementia,"Stemedica Cell Technologies, Inc.",unknown,Alzheimer Disease;Dementia,Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINDS-ADRDA) Alzheimer's criteria.
NCT02833792,Phase 2,Alzheimer Dementia,"Stemedica Cell Technologies, Inc.",unknown,Alzheimer Disease;Dementia,MMSE between 12-24 (inclusive) at time of enrollment.
NCT02833792,Phase 2,Alzheimer Dementia,"Stemedica Cell Technologies, Inc.",unknown,Alzheimer Disease;Dementia,Amyloid-positive florbetapir PET scan.
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia,Signed an Institutional Review Board (IRB) approved informed consent document indicating that they understand the purpose of and procedures required by the study protocol and are willing to participate in the study and comply with all its procedures and restrictions. Informed consent must be obtained from the patient and/or a designated representative prior to initiating screening procedures to evaluate their eligibility for the study.
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia,Aged 50 - 79 years inclusive.
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia,Meet the diagnosis of probable AD consistent with:
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia, Revised National Institute on Aging-Alzheimer's Association (NIA-ADA) criteria and
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia, Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria.
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia,Of mild to moderate severity: Mini-Mental Status Exam (MMSE) score 10 - 24 inclusive.
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia,Rosen-Modified Hachinski Ischemia Score of 4.
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia,Have a suitable caregiver to supervise the at-home administration of study drugs and observe for AEs.
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia,"Treated with donepezil 10 mg/day (given once daily) for at least 4 weeks just prior to study entry and to have safely tolerated, as judged clinically by the investigator."
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia,"Patients must be in generally good health as indicated by their medical history and physical examination, vital signs, electrocardiogram (ECG), and standard laboratory tests."
NCT02880956,Phase 2,Alzheimer's Disease,AbbVie,unknown,Alzheimer Disease;Tilavonemab," Subject who meets the National Institute on Aging and the Alzheimer's Association (NIA-AA) clinical criteria for mild cognitive impairment or probable AD, and have:"
NCT02880956,Phase 2,Alzheimer's Disease,AbbVie,unknown,Alzheimer Disease;Tilavonemab, Clinical Dementia Rating (CDR)-Global Score of 0.5
NCT02880956,Phase 2,Alzheimer's Disease,AbbVie,unknown,Alzheimer Disease;Tilavonemab," Mini-Mental State Examination (MMSE) score of 22 to 30, inclusive"
NCT02880956,Phase 2,Alzheimer's Disease,AbbVie,unknown,Alzheimer Disease;Tilavonemab, Repeatable Battery for the Assessment of Neuropsychological Status-Delayed Memory Index (RBANS - DMI) score of 85 or lower
NCT02880956,Phase 2,Alzheimer's Disease,AbbVie,unknown,Alzheimer Disease;Tilavonemab, Subject has a positive amyloid Positron Emission Tomography (PET) scan.
NCT02880956,Phase 2,Alzheimer's Disease,AbbVie,unknown,Alzheimer Disease;Tilavonemab, Subject has a Modified Hachinski Ischemic Scale (MHIS) score of  4.
NCT02880956,Phase 2,Alzheimer's Disease,AbbVie,unknown,Alzheimer Disease;Tilavonemab," The subject has an identified, reliable, study partner (e.g., family member)."
NCT02880956,Phase 2,Alzheimer's Disease,AbbVie,unknown,Alzheimer Disease;Tilavonemab," If using medications to treat symptoms related to AD, doses must be stable for at least 12 weeks prior to randomization."
NCT02884492,Phase 2,Alzheimer's Disease,William Charles Kreisl,unknown,Alzheimer Disease,Age 50 and older.
NCT02884492,Phase 2,Alzheimer's Disease,William Charles Kreisl,unknown,Alzheimer Disease,"Meet criteria for either a) amnestic mild cognitive impairment (single or mixed domain) or mild Alzheimer's disease, or b) have no cognitive impairment, based on history, exam, neuropsychological testing, and consensus diagnosis. MCI and mild AD patients must have Clinical Dementia Rating scale score of 0.5 or 1. Unimpaired subjects must have Clinical Dementia Rating scale score of 0."
NCT02884492,Phase 2,Alzheimer's Disease,William Charles Kreisl,unknown,Alzheimer Disease,Subjects unable to provide informed consent must have a surrogate decision maker.
NCT02884492,Phase 2,Alzheimer's Disease,William Charles Kreisl,unknown,Alzheimer Disease,Written and oral fluency in English or Spanish.
NCT02884492,Phase 2,Alzheimer's Disease,William Charles Kreisl,unknown,Alzheimer Disease,Able to participate in all scheduled evaluations and to complete all required tests and procedures.
NCT02884492,Phase 2,Alzheimer's Disease,William Charles Kreisl,unknown,Alzheimer Disease,"In the opinion of the investigator, the subject must be considered likely to comply with the study protocol and to have a high probability of completing the study."
NCT02886494,Phase 2,Alzheimer's Disease or Vascular Dementia,Charsire Biotechnology Corp.,unknown,"Alzheimer Disease;Dementia;Dementia, Vascular",With either gender aged at least 40 years old
NCT02886494,Phase 2,Alzheimer's Disease or Vascular Dementia,Charsire Biotechnology Corp.,unknown,"Alzheimer Disease;Dementia;Dementia, Vascular",With a diagnosis of one of the following disease i. Vascular dementia according to the NINDS-AIREN International Workshop criteria or ii. Alzheimer's disease according to the NIAAA criteria iii.  Mixed  dementia (possible Alzheimer's disease with cerebrovascular disease) according to the NIAAA criteria
NCT02886494,Phase 2,Alzheimer's Disease or Vascular Dementia,Charsire Biotechnology Corp.,unknown,"Alzheimer Disease;Dementia;Dementia, Vascular", Note:
NCT02886494,Phase 2,Alzheimer's Disease or Vascular Dementia,Charsire Biotechnology Corp.,unknown,"Alzheimer Disease;Dementia;Dementia, Vascular",NINDS-AIREN: National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherche et l'Enseignement en Neurosciences
NCT02886494,Phase 2,Alzheimer's Disease or Vascular Dementia,Charsire Biotechnology Corp.,unknown,"Alzheimer Disease;Dementia;Dementia, Vascular",NIAAA: National Institute on Aging-Alzheimer's Association
NCT02886494,Phase 2,Alzheimer's Disease or Vascular Dementia,Charsire Biotechnology Corp.,unknown,"Alzheimer Disease;Dementia;Dementia, Vascular",With mild-to-moderate dementia (score of the Mini-Mental State Examination (MMSE) defined as between 10 to 24 and score of ADAS-Cog as at least 12)
NCT02886494,Phase 2,Alzheimer's Disease or Vascular Dementia,Charsire Biotechnology Corp.,unknown,"Alzheimer Disease;Dementia;Dementia, Vascular","Able to read, write, communicate, and understand cognitive testing instructions"
NCT02886494,Phase 2,Alzheimer's Disease or Vascular Dementia,Charsire Biotechnology Corp.,unknown,"Alzheimer Disease;Dementia;Dementia, Vascular","Having a responsible caregiver who spends at least 4 hours daily with the patient. The caregiver will accompany the patient to all study visits, , supervise administration of study drug, and be able to assess the patient's condition"
NCT02886494,Phase 2,Alzheimer's Disease or Vascular Dementia,Charsire Biotechnology Corp.,unknown,"Alzheimer Disease;Dementia;Dementia, Vascular",Patients and the responsible caregiver willing and able to provide written informed consent form
NCT02907567,Phase 1/Phase 2,Alzheimer's Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Willing and able to provide written informed consent prior to initiation of any study-related procedures. For subjects unable to provide written consent, consent will be provided by the Person Responsible per local regulations."
NCT02907567,Phase 1/Phase 2,Alzheimer's Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Men and women, 50-80 years in age inclusively with a diagnosis of mild to moderate Alzheimer's disease according to the 2011 NIA-AA. Women must be neither pregnant nor nursing, and are either surgically sterile, postmenopausal or premenopausal using an acceptable method of contraception."
NCT02907567,Phase 1/Phase 2,Alzheimer's Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Previous decline in cognition for more than six months.
NCT02907567,Phase 1/Phase 2,Alzheimer's Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Neuroimaging (MRI) obtained within the previous 6 months or during screening, consistent with the clinical diagnosis of Alzheimer's disease."
NCT02907567,Phase 1/Phase 2,Alzheimer's Disease,Cognition Therapeutics,unknown,Alzheimer Disease,MMSE 18-26 inclusive.
NCT02907567,Phase 1/Phase 2,Alzheimer's Disease,Cognition Therapeutics,unknown,Alzheimer Disease,No active depression and a Geriatric Depression Score (GDS) of less than  6.
NCT02907567,Phase 1/Phase 2,Alzheimer's Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Modified Hachinski Ischemia score  4.
NCT02907567,Phase 1/Phase 2,Alzheimer's Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Formal education of eight or more years.
NCT02907567,Phase 1/Phase 2,Alzheimer's Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Living at home or in a community setting (assisted living) without continuous nursing care. Each subject must have a reliable caregiver who sees them at least 3 times weekly, can oversee the administration of study drug, and is willing and able to participate in all clinic visits and some study procedures. Responsible caregiver must provide written informed consent to participate."
NCT02907567,Phase 1/Phase 2,Alzheimer's Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Concurrent use of acetylcholinesterase inhibitors or memantine must be stable for 90 days prior to screening and not expected to change.
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,"Age 60-85, all races/ethnicities, and both sexes are eligible."
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,"a) A positive family history of dementia defined as having at least one first-degree relative with a history of AD or other type of dementia,or b) having subjective cognitive decline."
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,Mini-Mental State Exam (MMSE)  26 to exclude gross dementia.
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,"Must lead a sedentary lifestyle defined by not having an  active  rating on Rapid Assessment of Physical Activity (RAPA), i.e., score below 6 on RAPA."
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,"a) Individuals treated for HTN with 110  SBP  130 mmHg; or b) Individuals with SBP greater than  130 and SBP less than  180 (If an individual, not treated for HTN, has a SBP  125 mmHg, consider rescreening after 24 hours)."
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,Willingness to be randomized into the treatment groups and ability to return to clinic for follow-up visits over 24 months.
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,"Fluency in English, adequate visual and auditory acuity to allow neuropsychological testing."
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,Participants must have a regular healthcare provider.
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,Physical ability to undergo exercise training; able to walk 10 minutes without pain.
NCT02916056,Phase 3,Alzheimer's Disease,vTv Therapeutics,unknown,Alzheimer Disease, Successful completion of Study TTP488-301 through the Month 18 Visit without ongoing serious adverse events or history of serious adverse drug reactions during study TTP488-301.
NCT02916056,Phase 3,Alzheimer's Disease,vTv Therapeutics,unknown,Alzheimer Disease, Patients must enroll in the present study within 7 days of completion of study TTP488-301.
NCT02916056,Phase 3,Alzheimer's Disease,vTv Therapeutics,unknown,Alzheimer Disease," Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally authorized representative) and caregiver/informant has been informed of all pertinent aspects of the study. Participants must be able to provide assent (where this is in accordance with local laws, regulations and ethics committee policy) and assent may be re-evaluated during the study at regular intervals."
NCT02916056,Phase 3,Alzheimer's Disease,vTv Therapeutics,unknown,Alzheimer Disease," Participants and caregiver/informants who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures."
NCT02916056,Phase 3,Alzheimer's Disease,vTv Therapeutics,unknown,Alzheimer Disease," The subject must have a reliable caregiver/informant with regular contact (i.e., 10 hours a week as combination of face-to-face visits and telephone contact acceptable) who will facilitate the subject's full participation in the study. Caregivers/informant must have sufficient subject interaction to be able to provide meaningful input into the rating scales administered in this study where caregiver/informant input is required, in particular the CDR and evidence of this should be documented in source documentation. Participants who reside in assisted living facilities are permitted provided that they meet caregiver/informant criteria."
NCT02916056,Phase 3,Alzheimer's Disease,vTv Therapeutics,unknown,Alzheimer Disease," Participants and caregiver/informants must be able to read, write, and speak the language in which psychometric tests are provided with visual and auditory acuity (corrected) sufficient to allow for accurate psychometric testing."
NCT02916056,Phase 3,Alzheimer's Disease,vTv Therapeutics,unknown,Alzheimer Disease, Subject must be able to ingest oral medications.
NCT02925650,Phase 1/Phase 2,Alzheimer's Disease,Annovis Bio Inc.,unknown,Alzheimer Disease;Phenserine,Male or female aged 55 to 85 years (inclusive).
NCT02925650,Phase 1/Phase 2,Alzheimer's Disease,Annovis Bio Inc.,unknown,Alzheimer Disease;Phenserine,"Female participants must be post-menopausal for at least 2 consecutive years or surgically sterile (bilateral tubal ligation, hysterectomy or bilateral oophorectomy) for at least 6 months prior to screening."
NCT02925650,Phase 1/Phase 2,Alzheimer's Disease,Annovis Bio Inc.,unknown,Alzheimer Disease;Phenserine,Female participants will be given a urine pregnancy test at the screening visit for which they should test negative.
NCT02925650,Phase 1/Phase 2,Alzheimer's Disease,Annovis Bio Inc.,unknown,Alzheimer Disease;Phenserine,Diagnosis of amnestic MCI or probable mild AD according to the core clinical criteria outlined in the NIA-AA Guidelines.
NCT02925650,Phase 1/Phase 2,Alzheimer's Disease,Annovis Bio Inc.,unknown,Alzheimer Disease;Phenserine,MMSE score between the range of 21 to 27.
NCT02925650,Phase 1/Phase 2,Alzheimer's Disease,Annovis Bio Inc.,unknown,Alzheimer Disease;Phenserine,CDR score of 0.5 or 1.0.
NCT02925650,Phase 1/Phase 2,Alzheimer's Disease,Annovis Bio Inc.,unknown,Alzheimer Disease;Phenserine,"A score on the Logical Memory II subscale (Delayed Paragraph Recall, Paragraph A only) from the Wechsler Memory Scale-Revised within the following education-adjusted ranges:"
NCT02925650,Phase 1/Phase 2,Alzheimer's Disease,Annovis Bio Inc.,unknown,Alzheimer Disease;Phenserine, Less than or equal to 11 for 16 or more years of education
NCT02925650,Phase 1/Phase 2,Alzheimer's Disease,Annovis Bio Inc.,unknown,Alzheimer Disease;Phenserine, Less than or equal to 9 for 8-15 years of education
NCT02925650,Phase 1/Phase 2,Alzheimer's Disease,Annovis Bio Inc.,unknown,Alzheimer Disease;Phenserine, Less than or equal to 6 for 0-7 years of education
NCT02925650,Phase 1/Phase 2,Alzheimer's Disease,Annovis Bio Inc.,unknown,Alzheimer Disease;Phenserine,"To qualify for entry, subjects will have CSF A42 levels that are consistent with Alzheimer's disease as measured via mass spectrometry by C2N."
NCT02925650,Phase 1/Phase 2,Alzheimer's Disease,Annovis Bio Inc.,unknown,Alzheimer Disease;Phenserine,General cognition and functional performance sufficiently preserved that the subject can provide written informed consent.
NCT02925650,Phase 1/Phase 2,Alzheimer's Disease,Annovis Bio Inc.,unknown,Alzheimer Disease;Phenserine,A minimum of 6 years of education or good work history.
NCT02925650,Phase 1/Phase 2,Alzheimer's Disease,Annovis Bio Inc.,unknown,Alzheimer Disease;Phenserine,"Study partner is available who has frequent contact with the subject (e.g. average of 10 hours per week or more), and can accompany the subject to most visits to answer questions about the subject. Study partner (or other individual) should also oversee study drug administration if needed to ensure compliance with dose regimen."
NCT02925650,Phase 1/Phase 2,Alzheimer's Disease,Annovis Bio Inc.,unknown,Alzheimer Disease;Phenserine,No evidence of current suicidal ideation or previous suicide attempt in the past month as evaluated in the Columbia Suicide Severity Rating Scale.
NCT02925650,Phase 1/Phase 2,Alzheimer's Disease,Annovis Bio Inc.,unknown,Alzheimer Disease;Phenserine,"MRI scan within the 12 months prior to screening without evidence of infection, infarction, or other focal lesions and without clinical symptoms suggestive of intervening neurological disease. Lacunes that are not believed to contribute to the subject's cognitive impairment are permissible. If there is no MRI available within a 12-month timeframe, then an MRI must be performed as part of the screening procedures for eligibility."
NCT02925650,Phase 1/Phase 2,Alzheimer's Disease,Annovis Bio Inc.,unknown,Alzheimer Disease;Phenserine,"Stability of permitted medications for 4 weeks prior to baseline. NOTE: Cholinesterase inhibitors and or memantine are allowable only if stable for 12 weeks prior to screen. If taking Aricept (donepezil), no more than 10 mg/day is permitted during the course of the study."
NCT02925650,Phase 1/Phase 2,Alzheimer's Disease,Annovis Bio Inc.,unknown,Alzheimer Disease;Phenserine,Adequate visual and hearing ability (physical ability to perform all the study assessments).
NCT02925650,Phase 1/Phase 2,Alzheimer's Disease,Annovis Bio Inc.,unknown,Alzheimer Disease;Phenserine,"Good general health with no disease expected to interfere with the study. Subjects may have common age-related disorders (i.e., hypertension, type II diabetes, dyslipidemia, and hypothyroidism) as long as these disorders are being controlled by diet or medication."
NCT02925650,Phase 1/Phase 2,Alzheimer's Disease,Annovis Bio Inc.,unknown,Alzheimer Disease;Phenserine,Must speak English fluently.
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,Age  50
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,Fluent in English
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,Biomarker confirmed AD with CSF level of Abeta42 less than 600ng/mL
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,Able to ingest oral medications
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,Diagnosis of mild to moderate AD according to dementia criteria outlined by McKhann et al.
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,Neuroimaging (MRI or CT) consistent with the diagnosis of AD within the past year
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,MMSE between 17 and 24 (inclusive) at screening
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,Modified Hachinski score  4
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,"QTc interval 350-460ms, inclusive"
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,Caregiver/study partner to accompany participant to all visits and have direct contact with the participant greater than  2 days/week
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,Written informed consent
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,Capability and willingness to comply with all study criteria
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,Supervision available for study medication
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,Stable medical conditions for 3 months prior to screening visit
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,Stable medications for 4 weeks prior to screening visit
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,Able to complete baseline assessments
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,"Minimum of 6 years of education, or work history sufficient to exclude mental retardation"
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,"Stable use of cholinesterase inhibitors and memantine (U.S. FDA-approved medications for patients with probable AD), vitamin E (up to 400 IU daily), estrogens, aspirin (81-300 mg daily), and cholesterol-lowering agents for 3 months prior to screening is allowed."
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,"Clinical laboratory values within normal limits or, if abnormal, must be judged to be clinically insignificant by the investigator"
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease, Core Study
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease, Mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia including
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease,Mini Mental State Examination score equal to or greater than 24
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease,Clinical Dementia Rating (CDR) global score of 0.5
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease,CDR Memory Box score of 0.5 or greater
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease, Impaired episodic memory confirmed by a list learning task
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease, Positive biomarker for brain amyloid pathology as indicated by either amyloid positron emission tomography or cerebrospinal fluid AD assessment or both
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease, Extension Phase
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease,  Participants who complete the Core Study
NCT02972658,Phase 3,Alzheimer's Disease,AstraZeneca,unknown,Alzheimer Disease;Dementia, Participants previously enrolled in AMARANTH (NCT02245737) who meet eligibility criteria for delayed-start I8D-MC-AZFD.
NCT02992132,Phase 2,Agitation and Aggression in Alzheimer's Disease,ACADIA Pharmaceuticals Inc.,Nov-16,Alzheimer Disease;Psychomotor Agitation;Aggression;Pimavanserin,"Male or female, 50 years of age or older"
NCT02992132,Phase 2,Agitation and Aggression in Alzheimer's Disease,ACADIA Pharmaceuticals Inc.,Nov-16,Alzheimer Disease;Psychomotor Agitation;Aggression;Pimavanserin,Can understand the nature of the trial and protocol requirements and provide signed informed consent
NCT02992132,Phase 2,Agitation and Aggression in Alzheimer's Disease,ACADIA Pharmaceuticals Inc.,Nov-16,Alzheimer Disease;Psychomotor Agitation;Aggression;Pimavanserin," from patient, if deemed competent to provide consent"
NCT02992132,Phase 2,Agitation and Aggression in Alzheimer's Disease,ACADIA Pharmaceuticals Inc.,Nov-16,Alzheimer Disease;Psychomotor Agitation;Aggression;Pimavanserin, from an appropriate person (e.g. patient's Legally Authorized Representative (LAR) with the patient's assent) if patient is deemed not competent to provide informed consent.
NCT02992132,Phase 2,Agitation and Aggression in Alzheimer's Disease,ACADIA Pharmaceuticals Inc.,Nov-16,Alzheimer Disease;Psychomotor Agitation;Aggression;Pimavanserin,Has a diagnosis of probable AD according to the National Institute on Aging-Alzheimer's Association (NIA-AA) guidelines
NCT02992132,Phase 2,Agitation and Aggression in Alzheimer's Disease,ACADIA Pharmaceuticals Inc.,Nov-16,Alzheimer Disease;Psychomotor Agitation;Aggression;Pimavanserin,Meets criteria for agitation according to the International Psychogeriatric Association (IPA) guidelines
NCT02992132,Phase 2,Agitation and Aggression in Alzheimer's Disease,ACADIA Pharmaceuticals Inc.,Nov-16,Alzheimer Disease;Psychomotor Agitation;Aggression;Pimavanserin,Lives at home or in an assisted living or care facility (but has the capacity to visit the clinic as an outpatient). Subjects must have been at their current location for at least 3 weeks prior to Screening and plan to remain at the same location for the duration of the trial.
NCT02992132,Phase 2,Agitation and Aggression in Alzheimer's Disease,ACADIA Pharmaceuticals Inc.,Nov-16,Alzheimer Disease;Psychomotor Agitation;Aggression;Pimavanserin,Has a designated study partner/caregiver who is in contact with the patient at least 3 times a week on 3 separate days
NCT02992132,Phase 2,Agitation and Aggression in Alzheimer's Disease,ACADIA Pharmaceuticals Inc.,Nov-16,Alzheimer Disease;Psychomotor Agitation;Aggression;Pimavanserin,"Female patients must be of non-childbearing potential or must agree to use an acceptable method of contraception or abstinence , for at least 1 month prior to randomization, during the study, and 1 month following completion of the study"
NCT02992132,Phase 2,Agitation and Aggression in Alzheimer's Disease,ACADIA Pharmaceuticals Inc.,Nov-16,Alzheimer Disease;Psychomotor Agitation;Aggression;Pimavanserin,The patient and caregiver are willing and able to participate in all schedule evaluations and complete all required tests
NCT03024944,Phase 2,Alzheimer Dementia,Columbia University,unknown,Dementia;Alzheimer Disease;Diabetes Mellitus," All persons who have undergone magnetic resonance imaging (MRI) and amyloid PET already, or those who prospectively are deemed eligible for the parent study covered under protocol AAAQ2950, will be approached for participation."
NCT03038035,Phase 2,Alzheimer Disease,"National University Hospital, Singapore",Dec-16,Alzheimer Disease," Male or female, age 50 years"
NCT03038035,Phase 2,Alzheimer Disease,"National University Hospital, Singapore",Dec-16,Alzheimer Disease," Diagnosed with probable AD according to NINCDS-ADRDA criteria,"
NCT03038035,Phase 2,Alzheimer Disease,"National University Hospital, Singapore",Dec-16,Alzheimer Disease," MMSE score of 10 to 24,"
NCT03038035,Phase 2,Alzheimer Disease,"National University Hospital, Singapore",Dec-16,Alzheimer Disease," Receiving the same AChEI or Memantine for the past 6 months prior to screening and on a stable dose for the past 4 months (stable dose is defined as 5 to 10mg/day for Donepezil, 3, 4.5 or 6 mg twice daily for rivastigmine capsules, 4.6 or 9.5 mg for rivastigmine transdermal patch once daily, 8 or 12 mg twice daily for galantamine tablets, 16 to 24 mg once daily for galantamine capsules XL, 10 mg OD or 10 mg BD for Memantine)"
NCT03038035,Phase 2,Alzheimer Disease,"National University Hospital, Singapore",Dec-16,Alzheimer Disease, Patient or legal representative is able to provide informed consent
NCT03044249,Phase 2,Alzheimer Dementia,Mediti Pharma Inc.,unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Psychotic Disorders;Mental Disorders;Aggression," Females must be of non-childbearing potential, defined as women greater than or equal to () 60 years of age, postmenopausal women 50 and less than (less than ) 60 years of age who have had a cessation of menses for at least 12 months, or women who are congenitally or surgically sterile"
NCT03044249,Phase 2,Alzheimer Dementia,Mediti Pharma Inc.,unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Psychotic Disorders;Mental Disorders;Aggression," Males must agree to use 2 forms of highly effective birth control with female partners of childbearing potential while enrolled in the study, and for at least 28 days following the last dose"
NCT03044249,Phase 2,Alzheimer Dementia,Mediti Pharma Inc.,unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Psychotic Disorders;Mental Disorders;Aggression, Ambulatory (with or without walking device) with a stable gait
NCT03044249,Phase 2,Alzheimer Dementia,Mediti Pharma Inc.,unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Psychotic Disorders;Mental Disorders;Aggression, Have a Mini-Mental State Examination (MMSE) score of 10 to 24
NCT03044249,Phase 2,Alzheimer Dementia,Mediti Pharma Inc.,unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Psychotic Disorders;Mental Disorders;Aggression," Meet clinical criteria for one of the following disorders: dementia associated with Parkinson's disease, dementia with Lewy bodies, possible or probable Alzheimer's disease, frontotemporal degeneration spectrum disorders, vascular dementia"
NCT03044249,Phase 2,Alzheimer Dementia,Mediti Pharma Inc.,unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Psychotic Disorders;Mental Disorders;Aggression, Able to communicate verbally
NCT03044249,Phase 2,Alzheimer Dementia,Mediti Pharma Inc.,unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Psychotic Disorders;Mental Disorders;Aggression," Have an NPI score of 4 on either individual item (delusions or hallucinations) or 6 on the Psychosis Subscale (combined delusions and hallucinations), or an NPI score of 4 on agitation/aggression domain"
NCT03044249,Phase 2,Alzheimer Dementia,Mediti Pharma Inc.,unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Psychotic Disorders;Mental Disorders;Aggression," Have a reliable caregiver who provides written informed consent to participate and who is in frequent contact with the patient (defined as spending at least 4 hours/day at least 4 days/week with the patient and who is knowledgeable about the patient's daytime and nighttime behaviors). The caregiver must be able to communicate with site personnel, and opinion of the investigator, must understand the written protocol-specified questionnaires. If a caregiver cannot continue, one replacement caregiver will be allowed if the above criterion is met"
NCT03044249,Phase 2,Alzheimer Dementia,Mediti Pharma Inc.,unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Psychotic Disorders;Mental Disorders;Aggression," Must be on a stable dose of cholinesterase inhibitor and/or memantine, if applicable"
NCT03044249,Phase 2,Alzheimer Dementia,Mediti Pharma Inc.,unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Psychotic Disorders;Mental Disorders;Aggression," If taking antipsychotic drugs or any drug intended to treat psychosis, must be on a stable treatment regimen for 1 month prior to the study"
NCT03044249,Phase 2,Alzheimer Dementia,Mediti Pharma Inc.,unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Psychotic Disorders;Mental Disorders;Aggression, Have venous access sufficient to allow for blood sampling per the protocol
NCT03044249,Phase 2,Alzheimer Dementia,Mediti Pharma Inc.,unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Psychotic Disorders;Mental Disorders;Aggression, Have clinical laboratory test results within normal reference range for the population or investigative site
NCT03044249,Phase 2,Alzheimer Dementia,Mediti Pharma Inc.,unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Psychotic Disorders;Mental Disorders;Aggression, Are capable of participating in all study assessments
NCT03044249,Phase 2,Alzheimer Dementia,Mediti Pharma Inc.,unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Psychotic Disorders;Mental Disorders;Aggression, Are able and willing to provide consent (patients and caregivers)
NCT03055741,Phase 2,Mild-moderate Alzheimer's Disease,"Daehwa Pharmaceutical Co., Ltd.",unknown,Alzheimer Disease;Donepezil,55 and 85 years of age
NCT03055741,Phase 2,Mild-moderate Alzheimer's Disease,"Daehwa Pharmaceutical Co., Ltd.",unknown,Alzheimer Disease;Donepezil,Patient who was diagnosed mild to moderate Alzheimer's disease by National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association(NINCDS-ADRDA) or National Institute on Aging-Alzheimer's Association(NIAAA)
NCT03055741,Phase 2,Mild-moderate Alzheimer's Disease,"Daehwa Pharmaceutical Co., Ltd.",unknown,Alzheimer Disease;Donepezil,Korean Mini-Mental State Examination(K-MMSE) score 15 to 26
NCT03055741,Phase 2,Mild-moderate Alzheimer's Disease,"Daehwa Pharmaceutical Co., Ltd.",unknown,Alzheimer Disease;Donepezil,Patient who maintained on donepezil without dose escalation or reduction for at least during 3 months before screening (visit 1)
NCT03055741,Phase 2,Mild-moderate Alzheimer's Disease,"Daehwa Pharmaceutical Co., Ltd.",unknown,Alzheimer Disease;Donepezil,Clinical Dementia Rating(CDR) score 0.5 to 2.0 at screening (visit 1)
NCT03055741,Phase 2,Mild-moderate Alzheimer's Disease,"Daehwa Pharmaceutical Co., Ltd.",unknown,Alzheimer Disease;Donepezil,Written informed consent voluntarily
NCT03055741,Phase 2,Mild-moderate Alzheimer's Disease,"Daehwa Pharmaceutical Co., Ltd.",unknown,Alzheimer Disease;Donepezil,Patient who has a relative/caregiver who support the information of patient's status
NCT03055741,Phase 2,Mild-moderate Alzheimer's Disease,"Daehwa Pharmaceutical Co., Ltd.",unknown,Alzheimer Disease;Donepezil,Patient who are deemed adequate to participate in the clinical trial by the investigator
NCT03055741,Phase 2,Mild-moderate Alzheimer's Disease,"Daehwa Pharmaceutical Co., Ltd.",unknown,Alzheimer Disease;Donepezil,Infertility or patients and his/her spouse consent with contraception during the study period
NCT03062449,Phase 2,Alzheimer Disease,Aleksandra Stark,unknown,Alzheimer Disease,Diagnosis of early stage Alzheimer's disease as scored by the ClinicalDementia Rating Scale score of 0.5 -1.0 within the 6 months prior to study enrollment.
NCT03062449,Phase 2,Alzheimer Disease,Aleksandra Stark,unknown,Alzheimer Disease,Participants able to provide informed consent.
NCT03062449,Phase 2,Alzheimer Disease,Aleksandra Stark,unknown,Alzheimer Disease,Participants taking NMDA receptor antagonist medications or acetylcholinesterase inhibitor medications must be on a stable dose of these medications for at least 30 days prior to enrolling in this clinical trial.
NCT03062449,Phase 2,Alzheimer Disease,Aleksandra Stark,unknown,Alzheimer Disease,Participants able to consume study gummy chews throughout the course of the clinical trial.
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease,Men and women (non-childbearing potential) with a diagnosis of Alzheimer's disease according to McKhann (2011) criteria
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease,Age 50-85 years (50-80 in Czech Republic)
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease,"MRI or CT assessment within six months before baseline, corroborating the clinical diagnosis of AD and excluding other potential causes of dementia, especially cerebrovascular lesions (see exclusion criteria, number 3)"
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease,"CSF AD specific biomarker profile; positive, defined as CSF A42 less than  550 ng l-1 or an A 40/42 ratio less than  0.89"
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease,Mild to moderate stage of Alzheimer's disease according to MMSE  18 and  26
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease,Absence of major depressive disease according to GDS of less than  5
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease,Modified Hachinski Ischemic Scale  4
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease,Formal education for eight or more years
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease,Previous decline in cognition for more than six months as documented in patient medical records
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease,A caregiver available and living in the same household or interacting with the patient a sufficient time each week (in Czech Republic: providing personal care for the patient during at least 10 hours per week ) and available if necessary to assure administration of drug
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease,Patients living at home or nursing home setting without continuous nursing care
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease,General health status acceptable for a participation in a 6-month clinical trial
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease,Ability to swallow capsules
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease,Stable pharmacological treatment of any other chronic condition for at least one month prior to screening
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease,"Stable treatment with one of the acetylcholinesterase inhibitors donepezil (Aricept ), galantamine (Razadyne), or rivastigmine (Exelon) or the partial NMDA receptor antagonist with memantine (Namenda) at least 3-months before baseline Visit or Combination of both treatments mentioned above"
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease,No regular intake of prohibited medications as noted in Section 11.8 of the protocol
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease,"Signed informed consent by the patient, examined and verified to be mentally capable by an independent physician, prior to the initiation of any study specific procedure. Signed consent of the caregiver (see inclusion criteria 10)."
NCT03075241,Phase 3,Alzheimer's Disease,Brasilia University Hospital,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Zolpidem, 55 years of age or older
NCT03075241,Phase 3,Alzheimer's Disease,Brasilia University Hospital,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Zolpidem, Diagnosis of probable Alzheimer's disease (AD) by National Institute of Neurological and Communicative Disorders and Stroke / the Alzheimer's Disease and Related Disorders Association Criteria
NCT03075241,Phase 3,Alzheimer's Disease,Brasilia University Hospital,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Zolpidem, Hachinski Ischemia Scale less than 5
NCT03075241,Phase 3,Alzheimer's Disease,Brasilia University Hospital,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Zolpidem, Mini-Mental State Examination score of 0 to 26
NCT03075241,Phase 3,Alzheimer's Disease,Brasilia University Hospital,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Zolpidem, Actigraph evidence of a mean time immobile of less than 7 hours per night based on at least 7 nights of complete actigraph data collected over a single week
NCT03075241,Phase 3,Alzheimer's Disease,Brasilia University Hospital,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Zolpidem," Four-week history of sleep disorder behaviors, occurring at least once weekly, as reported by the caregiver using the Neuropsychiatric Inventory (NPI) Nighttime Behavior scale"
NCT03075241,Phase 3,Alzheimer's Disease,Brasilia University Hospital,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Zolpidem, Sleep disturbance observed was not present before the diagnosis of AD
NCT03075241,Phase 3,Alzheimer's Disease,Brasilia University Hospital,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Zolpidem," Other co-morbidities, especially delirium, depression, chronic pain and medication use may be present, but do not cooperate in the primary symptoms"
NCT03075241,Phase 3,Alzheimer's Disease,Brasilia University Hospital,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Zolpidem, Computed tomography or magnetic resonance imaging since the onset of memory problems showing no more than 1 lacunar infract in a nonstrategic area and no clinical events suggestive of stroke or other intracranial disease or normal
NCT03075241,Phase 3,Alzheimer's Disease,Brasilia University Hospital,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Zolpidem, Stable medications for 4 weeks prior to the screening visit
NCT03075241,Phase 3,Alzheimer's Disease,Brasilia University Hospital,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Zolpidem, Having a mobile upper extremity to which to attach an actigraph
NCT03075241,Phase 3,Alzheimer's Disease,Brasilia University Hospital,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Zolpidem," Residing with a responsible spouse, family member, or professional caregiver who is present during the night and would agree to assume the role of the principle caregiver for the 3-week protocol"
NCT03075241,Phase 3,Alzheimer's Disease,Brasilia University Hospital,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Zolpidem, Ability to ingest oral medication and participate in all scheduled evaluations
NCT03090516,Phase 2/Phase 3,Alzheimer's,The First Affiliated Hospital with Nanjing Medical University,unknown,Alzheimer Disease;Donepezil,"All patients were diagnosed with dementia caused by AD in 2011, the latest diagnostic criteria for Alzheimer's disease (NIA-AA), according to the patient's clinical and cranial imaging findings"
NCT03090516,Phase 2/Phase 3,Alzheimer's,The First Affiliated Hospital with Nanjing Medical University,unknown,Alzheimer Disease;Donepezil,Improved Hachinski ischemic scale score less than 4
NCT03090516,Phase 2/Phase 3,Alzheimer's,The First Affiliated Hospital with Nanjing Medical University,unknown,Alzheimer Disease;Donepezil,All patients underwent head CT and / or MRI examinations and laboratory tests to rule out other causes of dementia
NCT03090516,Phase 2/Phase 3,Alzheimer's,The First Affiliated Hospital with Nanjing Medical University,unknown,Alzheimer Disease;Donepezil,"MMSE(High school24,Primary school20;illiteracy17)"
NCT03090516,Phase 2/Phase 3,Alzheimer's,The First Affiliated Hospital with Nanjing Medical University,unknown,Alzheimer Disease;Donepezil,CDR 1-2
NCT03090516,Phase 2/Phase 3,Alzheimer's,The First Affiliated Hospital with Nanjing Medical University,unknown,Alzheimer Disease;Donepezil,"The subjects and nurses signed informed consent, and the nursing staff were able to take responsibility for the supervision of the participants"
NCT03090516,Phase 2/Phase 3,Alzheimer's,The First Affiliated Hospital with Nanjing Medical University,unknown,Alzheimer Disease;Donepezil,The subjects were stable
NCT03090516,Phase 2/Phase 3,Alzheimer's,The First Affiliated Hospital with Nanjing Medical University,unknown,Alzheimer Disease;Donepezil,"Cooperate, willing to complete all parts of the research, and have the ability to complete the study alone or with the help of the nursing staff"
NCT03090516,Phase 2/Phase 3,Alzheimer's,The First Affiliated Hospital with Nanjing Medical University,unknown,Alzheimer Disease;Donepezil,"To cooperate with the study, do not live alone, such as living alone should keep in touch with the nurse every day."
NCT03101085,Phase 1/Phase 2,Alzheimer Disease,Russell Swerdlow,unknown,Alzheimer Disease;Equol, Have a diagnosis of Alzheimer's Disease (AD)
NCT03101085,Phase 1/Phase 2,Alzheimer Disease,Russell Swerdlow,unknown,Alzheimer Disease;Equol, Have a study partner who has a close relationship with the participant and will attend study visits with the participant
NCT03101085,Phase 1/Phase 2,Alzheimer Disease,Russell Swerdlow,unknown,Alzheimer Disease;Equol, Do not possess an Alkylphenol ethoxylates 4 (APOE4) variant of the APOE gene
NCT03101085,Phase 1/Phase 2,Alzheimer Disease,Russell Swerdlow,unknown,Alzheimer Disease;Equol, Speak English as their primary language
NCT03101085,Phase 1/Phase 2,Alzheimer Disease,Russell Swerdlow,unknown,Alzheimer Disease;Equol, Have not had any medication changes within the past 30 days
NCT03114657,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Weight between 40 and 120 kilograms (Kg) inclusive
NCT03114657,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Availability of a person (referred to as the  caregiver ) who in the investigator's judgment:
NCT03114657,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Has frequent and sufficient contact with the participant to be able to provide accurate information regarding the participant's cognitive and functional abilities, agrees to provide information at clinic visits (which require partner input for scale completion), signs the necessary consent form, and has sufficient cognitive capacity to accurately report upon the participant's behavior and cognitive and functional abilities"
NCT03114657,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Fluency in the language of the tests used at the study site
NCT03114657,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Adequate visual and auditory acuity, in the investigator's judgment, sufficient to perform the neuropsychological testing (eye glasses and hearing aids are permitted)"
NCT03114657,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Evidence of the AD pathological process, by a positive amyloid assessment either on cerebrospinal fluid (CSF) amyloid beta 1-42 levels as measured on the Elecsys beta-amyloid(1-42) test system or amyloid PET scan by qualitative read by the core/central PET laboratory"
NCT03114657,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Demonstrated abnormal memory function at screening (up to 4 weeks before screening begins) or screening (FCSRT cueing index =less than 0.67 AND free recall =less than 27)
NCT03114657,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Screening mini mental state examination (MMSE) score of greater than or equal to (greater than =) 22 points and Clinical Dementia Rating-Global Score (CDR-GS) of 0.5 or 1.0
NCT03114657,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Meets National Institute on Aging/Alzheimer's Association (NIAAA) core clinical criteria for probable AD dementia or prodromal AD (consistent with the NIAAA diagnostic criteria and guidelines for mild cognitive impairment (MCI)
NCT03114657,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," If receiving symptomatic AD medications, the dosing regimen must have been stable for 3 months prior to screening"
NCT03114657,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Participant must have completed at least 6 years of formal education after the age of 5 years
NCT03116126,Phase 3,Alzheimer Disease,Imperial College London,unknown,Alzheimer Disease;Guanfacine, Outpatients
NCT03116126,Phase 3,Alzheimer Disease,Imperial College London,unknown,Alzheimer Disease;Guanfacine, NINCDS/ADRDA criteria for probable AD
NCT03116126,Phase 3,Alzheimer Disease,Imperial College London,unknown,Alzheimer Disease;Guanfacine, MMSE at assessment = 10-30
NCT03116126,Phase 3,Alzheimer Disease,Imperial College London,unknown,Alzheimer Disease;Guanfacine, Identified informant to accompany patient at all visits
NCT03116126,Phase 3,Alzheimer Disease,Imperial College London,unknown,Alzheimer Disease;Guanfacine," Stable dose of donepezil, galantamine or rivastigmine for preceding 12 weeks"
NCT03117738,Phase 1/Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease, Male or female subjects aged 50 and above at the time of signing the Informed Consent form
NCT03117738,Phase 1/Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease, Subjects who can understand and provide written informed consent (assent)
NCT03117738,Phase 1/Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease, Subjects who have diagnosis of probable mild-to-moderate Alzheimer disease according to NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke; Alzheimer's Disease and Related Disorders Association) criteria
NCT03117738,Phase 1/Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease, Subjects who have MMSE Score of 16 to 26 at screening
NCT03117738,Phase 1/Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease," Subjects who are taking FDA-approved AD medications (donepezil, galantamine, memantine, rivastigmine or their combinations) treatment on a stable dosage for at least 3 months prior to screening."
NCT03117738,Phase 1/Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease," Subjects who have one (or more) identified adult caregiver who is able to read, understand, and speak the designated language at the study site; either lives with the subject or sees the subject for 2 hours/day 4 days/week; and agrees to accompany the subject to each study visit"
NCT03117738,Phase 1/Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease, Subjects who have a designated study partner who will accompany the subject to all clinic visits and participate in the subject's clinical assessments
NCT03118947,Phase 2,Agitation and Aggression in Alzheimer's Disease,ACADIA Pharmaceuticals Inc.,unknown,Alzheimer Disease;Psychomotor Agitation;Aggression;Pimavanserin,Must complete the Week 12 visit in Study ACP-103-032 while continuing to take his/her assigned dose of blinded study drug
NCT03118947,Phase 2,Agitation and Aggression in Alzheimer's Disease,ACADIA Pharmaceuticals Inc.,unknown,Alzheimer Disease;Psychomotor Agitation;Aggression;Pimavanserin,Can understand the nature of the trial and protocol requirements and provide signed informed consent
NCT03118947,Phase 2,Agitation and Aggression in Alzheimer's Disease,ACADIA Pharmaceuticals Inc.,unknown,Alzheimer Disease;Psychomotor Agitation;Aggression;Pimavanserin," from patient, if deemed competent to provide consent"
NCT03118947,Phase 2,Agitation and Aggression in Alzheimer's Disease,ACADIA Pharmaceuticals Inc.,unknown,Alzheimer Disease;Psychomotor Agitation;Aggression;Pimavanserin, from an appropriate person (e.g. patient's Legally Authorized Representative (LAR) with the patient's assent) if patient is deemed not competent to provide informed consent.
NCT03118947,Phase 2,Agitation and Aggression in Alzheimer's Disease,ACADIA Pharmaceuticals Inc.,unknown,Alzheimer Disease;Psychomotor Agitation;Aggression;Pimavanserin,Lives at home or in an assisted living or care facility (but has the capacity to visit the clinic as an outpatient)
NCT03118947,Phase 2,Agitation and Aggression in Alzheimer's Disease,ACADIA Pharmaceuticals Inc.,unknown,Alzheimer Disease;Psychomotor Agitation;Aggression;Pimavanserin,Has a designated study partner/caregiver who is in contact with the patient at least 3 times a week on 3 separate days
NCT03118947,Phase 2,Agitation and Aggression in Alzheimer's Disease,ACADIA Pharmaceuticals Inc.,unknown,Alzheimer Disease;Psychomotor Agitation;Aggression;Pimavanserin,"Female patients must be of non-childbearing potential or must agree to use an acceptable method of contraception or abstinence, during the study, and 1 month following completion of the study"
NCT03118947,Phase 2,Agitation and Aggression in Alzheimer's Disease,ACADIA Pharmaceuticals Inc.,unknown,Alzheimer Disease;Psychomotor Agitation;Aggression;Pimavanserin,The patient and caregiver are willing and able to participate in all schedule evaluations and complete all required tests
NCT03131453,Phase 2/Phase 3,Alzheimers Disease,Novartis Pharmaceuticals,unknown,Alzheimer Disease;CNP520," consent to receive disclosure of their risk estimates to develop clinical symptoms of AD based on their APOE genotype and, if Heterozygotes, evidence of elevated brain amyloid."
NCT03131453,Phase 2/Phase 3,Alzheimers Disease,Novartis Pharmaceuticals,unknown,Alzheimer Disease;CNP520," Male or female, age 60 to 75 years inclusive. Females must be considered post-menopausal and not of child bearing potential"
NCT03131453,Phase 2/Phase 3,Alzheimers Disease,Novartis Pharmaceuticals,unknown,Alzheimer Disease;CNP520, Cognitively unimpaired as evaluated by memory tests performed at screening.
NCT03131453,Phase 2/Phase 3,Alzheimers Disease,Novartis Pharmaceuticals,unknown,Alzheimer Disease;CNP520, Participant's willingness to have a study partner.
NCT03131453,Phase 2/Phase 3,Alzheimers Disease,Novartis Pharmaceuticals,unknown,Alzheimer Disease;CNP520," Carrier of at least one APOE4 gene if Heterozygotes, elevated brain amyloid (as measured by CSF Abeta or amyloid PET imaging)."
NCT03184467,Phase 2,Alzheimer Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,55 to 85 years of age
NCT03184467,Phase 2,Alzheimer Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,A patient who satisfies diagnostic criteria for dementia in DSM-IV
NCT03184467,Phase 2,Alzheimer Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Probable Alzheimer's disease in NINCDS-ADRDA
NCT03184467,Phase 2,Alzheimer Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,K-MMSE  19 at screening and randomization visit
NCT03184467,Phase 2,Alzheimer Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,GDS 5~6 stage
NCT03184467,Phase 2,Alzheimer Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,MRI or CT scan within 12 months prior to screening visit that proves Alzheimer's disease without any other disease that may cause dementia
NCT03184467,Phase 2,Alzheimer Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,A patient taking stable doses of donepezil for more than 3 months before screening visit
NCT03184467,Phase 2,Alzheimer Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,A patient who are able to visit a hospital (including inpatient and outpatient based) and receive cognitive and other tests
NCT03184467,Phase 2,Alzheimer Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"A patient with a caregiver who can accompany all visits and supervise the subject's compliance with the procedures and study drug prescribed in the protocol, and provide detailed information about the patient"
NCT03184467,Phase 2,Alzheimer Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Written informed consent by a patient or legal representative
NCT03186989,Phase 1/Phase 2,Mild Alzheimer's Disease,"Ionis Pharmaceuticals, Inc.",unknown,Alzheimer Disease," Males or females aged 50-74 years, inclusive, at the time of informed consent"
NCT03186989,Phase 1/Phase 2,Mild Alzheimer's Disease,"Ionis Pharmaceuticals, Inc.",unknown,Alzheimer Disease," Diagnosed with mild Alzheimers disease, including CSF biomarkers consistent with this diagnosis"
NCT03186989,Phase 1/Phase 2,Mild Alzheimer's Disease,"Ionis Pharmaceuticals, Inc.",unknown,Alzheimer Disease, Body Mass Index BMI  18 and  35 kg/m2 and total body weight greater than  50 kg (110 lbs)
NCT03186989,Phase 1/Phase 2,Mild Alzheimer's Disease,"Ionis Pharmaceuticals, Inc.",unknown,Alzheimer Disease," Able and willing to meet all study requirements, including toleration for MRI scans, blood draws and lumbar punctures, travel to Study Center and participation in all procedures and measurements at study visits"
NCT03186989,Phase 1/Phase 2,Mild Alzheimer's Disease,"Ionis Pharmaceuticals, Inc.",unknown,Alzheimer Disease," Have a trial partner who is reliable, competent and at least 18 years of age, is willing to accompany the patient to select trial visits and to be available to the Study Center by phone if needed"
NCT03186989,Phase 1/Phase 2,Mild Alzheimer's Disease,"Ionis Pharmaceuticals, Inc.",unknown,Alzheimer Disease, Reside within 4 hours travel of the Study Center
NCT03186989,Phase 1/Phase 2,Mild Alzheimer's Disease,"Ionis Pharmaceuticals, Inc.",unknown,Alzheimer Disease, Must have completed the Treatment Evaluation and Post-Treatment Periods in Part 1
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil,Age of 50 to 85 as of the date of informed consent
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil,Clinical diagnosis of probable Alzheimer's disease according to Diagnostic and Statistical Manual of Mental Disorders 4th Edition (DSM-IV) and National Institute of Neurological and Communicative Disorders and Strokes; Alzheimer's disease and Related Disorders Association (NINCDS-ADRDA)
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil,Mini Mental Status Examination (MMSE) score 10 to 26 at screening
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil,"Global Clinical Dementia Rating (CDR) score 0.5, 1 or 2 at screening"
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil,Capable of performing procedures for cognitive and other tests
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil,Subject who meets any of the following as of the date of informed consent
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil, No past treatment with donepezil (nave patient)
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil, Ongoing treatment with donepezil 10mg/day for the past 3 months
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil, Ongoing treatment with donepezil 5mg/day for the past 3 months
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil,The subject or his/her representative must voluntarily decide to participate in the study and provide written informed consent.
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil,"The subject must have a reliable caregiver who regularly contacts the subject and is available to accompany the subject for on-site visits. (Note: A caregiver is defined as someone who has regular contact with the subject [i.e., an average of approximately 10 or more hours per week], must be able to oversee subject's compliance with the study treatment and to report on the patient's status and must be able to accompany the subject to all study visits.)"
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,"Able to provide written informed consent in accordance with federal, local and institutional guidelines. For subjects unable to provide written consent, consent will be provided by the Person Responsible per local regulations."
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,"Age 65 years, or 55 years if they have been diagnosed by a psychiatrist or neurologist with dementia, or if they have a validated previous positive amyloid PET scan."
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,Weight between 40 and 120 kg
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,Have an available caregiver
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,Have  6 years of education (any) and able to follow testing instructions.
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,Have visual and auditory acuity sufficient to perform neuropsychological testing.
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,"Have prior evidence of AD pathology, by a positive amyloid assessment, or amyloid PET scan."
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,Demonstrate abnormal memory function in the last 6 months or at screening: International Shopping List Test (ISLT) greater than 1.5 SD below the age adjusted mean
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,Subjective or clinical history of retrospective cognitive decline 6 months
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,"Evidence of mild symptomatology, as defined by a screening MMSE score of  20 points"
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,Meet National Institute on Ageing/Alzheimer's Association Diagnostic Guidelines for Alzheimer's Disease (NIAAA) research criteria for mAD or pAD
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,"If receiving medication for symptomatic AD, have a stable dosing regimen for 3 months prior to screening."
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,Females of Child Bearing Potential (FCBP) must have confirmed negative serum pregnancy test within the 21 days prior to randomization.
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,FCBP and male subjects who are sexually active with FCBP must agree to use highly effective contraception during the study and until 90 days after the last dose of treatment (for sexually active male participants whose partners are FCBP) or until 30 days after the last dose of treatment (for women of childbearing potential participants).
NCT03250741,Phase 2,Alzheimer Disease,I.R.C.C.S. Fondazione Santa Lucia,unknown,Alzheimer Disease;Rotigotine,The patient (or if applicable the legally acceptable representative if different from the responsible caregiver) and the responsible caregiver have signed the Informed Consent Form.
NCT03250741,Phase 2,Alzheimer Disease,I.R.C.C.S. Fondazione Santa Lucia,unknown,Alzheimer Disease;Rotigotine,"The patient has probable AD, diagnosed according to National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria."
NCT03250741,Phase 2,Alzheimer Disease,I.R.C.C.S. Fondazione Santa Lucia,unknown,Alzheimer Disease;Rotigotine,"The patient is a man or woman, aged  85 years."
NCT03250741,Phase 2,Alzheimer Disease,I.R.C.C.S. Fondazione Santa Lucia,unknown,Alzheimer Disease;Rotigotine,The patient has a Clinical Dementia Rating (CDR) total score of 0.5 or 1 (mild) and MMSE score of 20-26 (inclusive) at Screening.
NCT03250741,Phase 2,Alzheimer Disease,I.R.C.C.S. Fondazione Santa Lucia,unknown,Alzheimer Disease;Rotigotine,"Has at least one identified adult caregiver who is able to provide meaningful assessment of changes in subject behavior and function over time and provide information on safety and tolerability, and is able to verify daily compliance with study drug"
NCT03250741,Phase 2,Alzheimer Disease,I.R.C.C.S. Fondazione Santa Lucia,unknown,Alzheimer Disease;Rotigotine,"The patient has been treated with acetylcholinesterase inhibitor (AChEI), i.e., donepezil, galantamine, or rivastigmine, at the time of Screening"
NCT03250741,Phase 2,Alzheimer Disease,I.R.C.C.S. Fondazione Santa Lucia,unknown,Alzheimer Disease;Rotigotine, For at least 3 months
NCT03250741,Phase 2,Alzheimer Disease,I.R.C.C.S. Fondazione Santa Lucia,unknown,Alzheimer Disease;Rotigotine, The current dosage regimen and must have remained stable for  8 weeks
NCT03250741,Phase 2,Alzheimer Disease,I.R.C.C.S. Fondazione Santa Lucia,unknown,Alzheimer Disease;Rotigotine, It must be planned that the dosage regimen will remain stable throughout participation in the study
NCT03283059,Phase 3,Alzheimer Disease,Shanghai Mental Health Center,unknown,Alzheimer Disease;Donepezil,"Age 50-85 years (including 50 and 85 years old), male or female;"
NCT03283059,Phase 3,Alzheimer Disease,Shanghai Mental Health Center,unknown,Alzheimer Disease;Donepezil,Diagnose probable AD in accordance with the National Institute Aging and Alzheimer's Association (NIA-AA) (2011);
NCT03283059,Phase 3,Alzheimer Disease,Shanghai Mental Health Center,unknown,Alzheimer Disease;Donepezil,"Mild-to-moderate AD patients, MMSE 11-26 (including 11 and 26, primary school education subjects from 11 to 22);"
NCT03283059,Phase 3,Alzheimer Disease,Shanghai Mental Health Center,unknown,Alzheimer Disease;Donepezil,Hachinski Incheinic Score (HIS) less than 4 points;
NCT03283059,Phase 3,Alzheimer Disease,Shanghai Mental Health Center,unknown,Alzheimer Disease;Donepezil,Hamilton depression scale /17 Version (HAMD) score less than 10 points;
NCT03283059,Phase 3,Alzheimer Disease,Shanghai Mental Health Center,unknown,Alzheimer Disease;Donepezil,"Memory decline at least 12 months, and the decline is progressive;"
NCT03283059,Phase 3,Alzheimer Disease,Shanghai Mental Health Center,unknown,Alzheimer Disease;Donepezil,Brain MRI examination was done within 6 months before screening;
NCT03283059,Phase 3,Alzheimer Disease,Shanghai Mental Health Center,unknown,Alzheimer Disease;Donepezil,Neurological examination had no obvious signs (except due to AD disease or peripheral injury);
NCT03283059,Phase 3,Alzheimer Disease,Shanghai Mental Health Center,unknown,Alzheimer Disease;Donepezil,"Females were postmenopausal (menopause beyond 24 weeks), or accepted the surgical sterilization, or women of childbearing age agreed to take effective contraceptive measures during the study. Women of childbearing age or menopausal time shorter than 24 weeks must do the urine pregnancy test and results to be negative during the screening period;"
NCT03283059,Phase 3,Alzheimer Disease,Shanghai Mental Health Center,unknown,Alzheimer Disease;Donepezil,"Subjects should have stable and reliable caregivers, or have frequent contact with caregivers (at least 4 days per week, at least 2 hours per day), caregivers will help patients to participate in the study. Caregivers must accompany the subjects in the study visit to provide valuable information for the NPI, ADCS-ADL and CIBIC-plus scales assessments;"
NCT03283059,Phase 3,Alzheimer Disease,Shanghai Mental Health Center,unknown,Alzheimer Disease;Donepezil,"Subjects have at least primary school education level, and have the ability to complete the determination of cognitive ability assessments and other tests;"
NCT03283059,Phase 3,Alzheimer Disease,Shanghai Mental Health Center,unknown,Alzheimer Disease;Donepezil,The participants and legal guardian must sign informed consent.
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Men or women between the ages of 60 and 85 years of age at the time of consent
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Patients with gradual and progressive change in memory function for a period equal to or greater than six months
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Patients who have a Mini Mental State Examination (MMSE) score in the 20-27 range
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Patients who are willing to undergo a PET scan using flortaucipir F 18
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Patients who give informed consent or have a legally authorized representative (LAR) to consent for enrollment
NCT03363269,Phase 2,Alzheimer Disease,IlDong Pharmaceutical Co Ltd,unknown,Alzheimer Disease,Patient diagnosed with dementia of Alzheimer's type according to DSM-IV criteria and probable Alzheimer's disease according to the NINCDS-ADRDA
NCT03363269,Phase 2,Alzheimer Disease,IlDong Pharmaceutical Co Ltd,unknown,Alzheimer Disease,modified Hachinski Ischemia Scale score of less than or equal to 4
NCT03363269,Phase 2,Alzheimer Disease,IlDong Pharmaceutical Co Ltd,unknown,Alzheimer Disease,Mini-Mental State Examination score 16 to 26 and Clinical Dementia Rating-Global Scale score 0.5 to 1
NCT03363269,Phase 2,Alzheimer Disease,IlDong Pharmaceutical Co Ltd,unknown,Alzheimer Disease,Amyloid postivie PET image (BAPL score 2 or 3)
NCT03363269,Phase 2,Alzheimer Disease,IlDong Pharmaceutical Co Ltd,unknown,Alzheimer Disease,Patients who have not received AChE inhibitors or NMDA antagonist at least for 3 months prior to the screening visit
NCT03367403,Phase 2,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease, Gradual and progressive change in memory function reported by participants or informants for  6 months.
NCT03367403,Phase 2,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease, MMSE score of 20 to 28 (inclusive) at baseline or an acceptable historical flortaucipir PET scan within 6 months prior to baseline that meets the central read criteria.
NCT03367403,Phase 2,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease, Meet 18F flortaucipir PET scan eligibility criteria.
NCT03367403,Phase 2,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease, Meet 18F florbetapir PET scan (central read) eligibility criteria.
NCT03373604,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,Age 50 and older.
NCT03373604,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,Meet criteria for either
NCT03373604,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,"amnestic mild cognitive impairment (MCI) (single or mixed domain) or mild Alzheimer's disease (AD), or"
NCT03373604,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,"have no cognitive impairment, based on history, exam, neuropsychological testing, and consensus diagnosis. MCI and mild AD patients must have Clinical Dementia Rating scale score of 0.5 or 1. Unimpaired subjects must have Clinical Dementia Rating scale score of 0."
NCT03373604,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,Subjects unable to provide informed consent must have a surrogate decision maker.
NCT03373604,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,Written and oral fluency in English or Spanish.
NCT03373604,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,Able to participate in all scheduled evaluations and to complete all required tests and procedures.
NCT03373604,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,"In the opinion of the investigator, the subject must be considered likely to comply with the study protocol and to have a high probability of completing the study."
NCT03393520,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation, Diagnosis of probable Alzheimer's Disease (AD) according to the 2011 National Institute on Aging-Alzheimer's Association (NIA-AA) working groups criteria
NCT03393520,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation," Participants with clinically significant, moderate/severe agitation at the time of screening and for at least 2 weeks prior to baseline that interferes with their daily routine and for which a prescription medication has been indicated, in the opinion of the investigator"
NCT03393520,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation, The diagnosis of agitation must meet the provisional consensus definition of agitation in participants with cognitive disorders developed by the International Psychogeriatric Association (IPA) Agitation Definition Work Group.
NCT03393520,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation, A Clinical Global Impression of Severity of Illness scale for Agitation (CGIS-Agitation) score of  4 (moderately ill) at screening and baseline
NCT03393520,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation," Participants must have a reliable caregiver who is able and willing to comply with study procedures, including not administering any prohibited medications during the course of the study."
NCT03393520,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation," Caregiver who is able and willing to comply with all required study procedures. In order to qualify as a reliable informant (i.e., caregiver) capable of assessing changes in participant's condition during the study, the individual must spend a minimum of 2 hours per day for 4 days per week with the participant."
NCT03402503,Phase 2,Alzheimer Disease,IntelGenx Corp.,unknown,Alzheimer Disease;Montelukast, Mild to moderate Alzheimer's Disease.
NCT03402503,Phase 2,Alzheimer Disease,IntelGenx Corp.,unknown,Alzheimer Disease;Montelukast, MMSE score of 14 - 22
NCT03402503,Phase 2,Alzheimer Disease,IntelGenx Corp.,unknown,Alzheimer Disease;Montelukast, CT or MRI within 18 months prior to screening indicating clinical phenotype of Alzheimer's Disease
NCT03402503,Phase 2,Alzheimer Disease,IntelGenx Corp.,unknown,Alzheimer Disease;Montelukast," Treated daily with donepezil, rivastigmine or galantamine for  3 months"
NCT03402503,Phase 2,Alzheimer Disease,IntelGenx Corp.,unknown,Alzheimer Disease;Montelukast, All other medications for chronic conditions should have been at a stable dose for at least 2 weeks prior to first dose.
NCT03402503,Phase 2,Alzheimer Disease,IntelGenx Corp.,unknown,Alzheimer Disease;Montelukast," No clinically meaningful abnormalities on electrocardiogram (ECG), physical examination and clinical laboratory tests"
NCT03402659,Phase 2,Alzheimer Disease,EIP Pharma Inc,unknown,Alzheimer Disease,"Men and women age 55 to 85 years, inclusive."
NCT03402659,Phase 2,Alzheimer Disease,EIP Pharma Inc,unknown,Alzheimer Disease,Willing and able to provide informed consent.
NCT03402659,Phase 2,Alzheimer Disease,EIP Pharma Inc,unknown,Alzheimer Disease,"Must have mild cognitive impairment (MCI) or mild AD with evidence of progression ( Mild-AD ), as defined by the following:"
NCT03402659,Phase 2,Alzheimer Disease,EIP Pharma Inc,unknown,Alzheimer Disease,"CDR-Global Score of 0.5 or 1.0, with CDR memory subscore of at least 0.5."
NCT03402659,Phase 2,Alzheimer Disease,EIP Pharma Inc,unknown,Alzheimer Disease,"MMSE score ranging from 20 to 28, inclusive."
NCT03402659,Phase 2,Alzheimer Disease,EIP Pharma Inc,unknown,Alzheimer Disease,"Positive biomarker for AD, as defined by a CSF A1-42R below the threshold and phospho-tau above the threshold for the assay utilized in the study and assessed by the central laboratory."
NCT03402659,Phase 2,Alzheimer Disease,EIP Pharma Inc,unknown,Alzheimer Disease,Computed tomography (CT) or magnetic resonance imaging (MRI) findings within 2 years of Screening that are compatible with AD and no other pathologic processes that might potentially account for the subject's cognitive impairment.
NCT03402659,Phase 2,Alzheimer Disease,EIP Pharma Inc,unknown,Alzheimer Disease,"If the subject is taking a single drug for AD (e.g., donepezil or other cholinesterase inhibitors or memantine; dual therapy is excluded), he/she has been on a stable dose for at least 2 months prior to baseline, and the dose must remain unchanged during the study unless required for management of adverse events (AEs)."
NCT03402659,Phase 2,Alzheimer Disease,EIP Pharma Inc,unknown,Alzheimer Disease,Adequate visual and auditory abilities to perform all aspects of the cognitive and functional assessments.
NCT03402659,Phase 2,Alzheimer Disease,EIP Pharma Inc,unknown,Alzheimer Disease,Must have reliable informant or caregiver.
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine, For AD subject
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,Newly diagnosed (less than  12 months) early-to-mild Alzheimer's disease as classified by a Mini-Mental State Examination (MMSE) Score of 25-18 reconfirmed at screening
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,"AD diagnosis confirmed by recommended examinations in accordance with German DGN (Deutsche Gesellschaft fr Neurologie)/DGPPN (Deutsche Gesellschaft fr Psychiatrie und Psychotherapie,Psychosomatik und Nervenheilkunde) S3 Guideline  Dementia  and to standard at the clinical unit by:"
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine, psychometric and cognitive tests
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine, lumbar puncture in subjects with uncertain AD diagnosis following central nervous system (CNS) imaging
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine," Clinical Dementia Rating (global CDR) is 0.5 or 1. Memory box score must be at least 0.5. Isolated or predominant episodic memory deficit, manifested as memory performance in the Logical Memory subscale (Delayed Paragraph Recall) from the Wechsler Memory Scale-III 1 below age adjusted norms, according to hospital standard)"
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,AD subject has full legal competence according to investigator opinion
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,Ability to comply with requirements or cognitive and other testing for the entire length of the trial available
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine, For healthy volunteer
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,"Subject is a non-demented volunteer, based on the assessment of medical history, physical examination and clinically laboratory data at screening as determined by the Investigator"
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine, For AD subject and healthy volunteer
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,Age greater than  55 - less than  75 years
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,Written informed consent to participate within this trial
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,"Subject is on stable dose for at least 3 month prior to screening when receiving protocol-allowed concomitant medications at screening (e.g. acetylcholinesterase inhibitors, NMDA (N-methyl-D-aspartate) receptor antagonists)"
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,"For subject receiving anticholinergic agents, oral corticosteroids, propranolol, clonidine, antihistamines other than cetirizin and EBSTEL a washout period of 4 weeks prior to screening must be completed. Concerning anticholinergic agents in Group 1a: only for high- to medium-potency anticholinergic agents a washout period of 4 weeks prior to screening must be completed."
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,"Post-menopausal females (post menopausal amenorrhea for at least 2 years or surgically sterilized (hysterectomy), tubal ligation is not acceptable)"
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,"Male subjects with reproductive potential, and have not been surgically sterilized, that have been informed and agreed to that he and his partner must use a highly effective method of contraception (Pearl Index less than 1%) such as implants, injectables, combined oral contraceptives, or hormonal intrauterine devices (IUDs), or refrain from sexual intercourse during the trial and until 3 months after completion of the trial"
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,Good general health with no additional disease states that could interfere with the trial due to the investigator's assessment
NCT03435861,Phase 2,Alzheimer Disease,"University Hospital, Toulouse",unknown,Infectious Encephalitis;Alzheimer Disease;Encephalitis;Inflammation," A group of 40 AD patients at an early stage (prodromal) will be recruited. Patient's recruitment will follow the most recent research criteria for AD in its  typical form  (Dubois, Feldman et al. 2014):"
NCT03435861,Phase 2,Alzheimer Disease,"University Hospital, Toulouse",unknown,Infectious Encephalitis;Alzheimer Disease;Encephalitis;Inflammation, Age 50 - 90 (inclusive)
NCT03435861,Phase 2,Alzheimer Disease,"University Hospital, Toulouse",unknown,Infectious Encephalitis;Alzheimer Disease;Encephalitis;Inflammation, Willing and able to provide informed consent
NCT03435861,Phase 2,Alzheimer Disease,"University Hospital, Toulouse",unknown,Infectious Encephalitis;Alzheimer Disease;Encephalitis;Inflammation," Objective memory impairment corroborated by level of performance on a standardized memory test (Free and Cued Selective Reminding test, (Grober, Hall et al. 2008)) less than  -1.5 DS according to established norms and"
NCT03435861,Phase 2,Alzheimer Disease,"University Hospital, Toulouse",unknown,Infectious Encephalitis;Alzheimer Disease;Encephalitis;Inflammation, Documented cerebral amyloidopathy using CSF analysis or PET amyloid imaging and
NCT03435861,Phase 2,Alzheimer Disease,"University Hospital, Toulouse",unknown,Infectious Encephalitis;Alzheimer Disease;Encephalitis;Inflammation," Early stage of the disease (Mini Mental State Examination greater than  20) (Folstein, Robins et al. 1983)."
NCT03446001,Phase 3,Alzheimer Disease,TauRx Therapeutics Ltd,unknown,Alzheimer Disease;Methylene Blue," Diagnosis of Alzheimer's Disease (AD), encompassing probable AD and mild cognitive impairment due to AD (MCI-AD) based on the 2011 National Institute on Aging and Alzheimer's Association (NIA/AA) criteria"
NCT03446001,Phase 3,Alzheimer Disease,TauRx Therapeutics Ltd,unknown,Alzheimer Disease;Methylene Blue, Documented PET scan that is positive for amyloid
NCT03446001,Phase 3,Alzheimer Disease,TauRx Therapeutics Ltd,unknown,Alzheimer Disease;Methylene Blue," Mini-Mental State Examination (MMSE) score of 16-27 (inclusive), subject to stratification requirements"
NCT03446001,Phase 3,Alzheimer Disease,TauRx Therapeutics Ltd,unknown,Alzheimer Disease;Methylene Blue," Global Clinical Dementia Rating (CDR) of 0.5 to 2 (if 0.5, including a score of greater than 0 in one of the functional domains: Community Affairs, Home and Hobbies, or Personal Care)"
NCT03446001,Phase 3,Alzheimer Disease,TauRx Therapeutics Ltd,unknown,Alzheimer Disease;Methylene Blue, Age less than 90 years
NCT03446001,Phase 3,Alzheimer Disease,TauRx Therapeutics Ltd,unknown,Alzheimer Disease;Methylene Blue," Females must be surgically sterile, have undergone bilateral tubal occlusion / ligation, be post-menopausal, or use adequate contraception"
NCT03446001,Phase 3,Alzheimer Disease,TauRx Therapeutics Ltd,unknown,Alzheimer Disease;Methylene Blue," Subject, and/or, in the case of reduced decision-making capacity, legally acceptable representative(s) consistent with local and national law is/are able to read, understand, and provide written informed consent in the designated language of the study site"
NCT03446001,Phase 3,Alzheimer Disease,TauRx Therapeutics Ltd,unknown,Alzheimer Disease;Methylene Blue," Has one or more identified adult study partner who either lives with the subject or has sufficient contact to provide assessment of changes in subject behavior and function over time and information on safety and tolerability; is willing to provide written informed consent for his/her own participation; is able to read, understand, and speak the designated language(s) at the study site; agrees to accompany the subject to each study visit; and is able to verify daily compliance with study drug"
NCT03446001,Phase 3,Alzheimer Disease,TauRx Therapeutics Ltd,unknown,Alzheimer Disease;Methylene Blue, Must not be taking an acetylcholinesterase inhibitor and/or memantine for at least 60 days at the time of the Baseline assessments
NCT03446001,Phase 3,Alzheimer Disease,TauRx Therapeutics Ltd,unknown,Alzheimer Disease;Methylene Blue, Able to comply with the study procedures in the view of the Investigator
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,Patients with gradual and progressive change in memory function reported by the patient or informant for 6 months
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,Patients who have a mini-mental status exam (MMSE) score between 20-28 inclusive
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,Patients who are willing to undergo a PET scan using flortaucipir F 18
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,Patients who give informed consent or have a legally authorized representative (LAR) available to consent at the time of enrollment
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,A study partner who must be available if the patient enters the treatment trial
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,Subjects between 55 and 85 years old (inclusive) in good general health:
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,Willing and able to consent and participate for the duration of the study
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,Have eighth-grade education or good work history sufficient to exclude mental retardation
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,Have visual and auditory acuity adequate for neuropsychological testing
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,Have proficient fluency of the native local language to participate in all the neuropsychological test assessments
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,"Have a study partner who has sufficient contact with the subject to be able to provide assessment of memory changes, who can accompany the subject to all the clinic visits for the duration of each visit, and who is able to provide an independent evaluation of the subject's functioning"
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,Have MCI due to AD as defined by all of the following criteria and consistent with the National Institute on Aging-Alzheimer's Association criteria:
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,MMSE scores between 24 and 30 (inclusive; exceptions may be made for subjects with less than 8 years of education at the discretion of the sponsor)
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,A memory complaint reported by the subject or his/her study partner
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,Evidence of lower memory performance based on delayed recall in the International Shopping List Test (ISLT)
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,A clinical dementia rating (CDR) score of 0.5 with a memory box score of 0.5
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,Essentially preserved activities of daily living
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,"Cognitive decline not primarily caused by vascular, traumatic, or medical problems (alternative causes of cognitive decline are ruled out)"
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,Permitted medications:
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,"With potential pro-cognitive effects, such as cholinesterase inhibitors and memantine, must be at a stable dose for 3 months prior to screening and remain stable throughout the study; estrogen replacement therapy, Ginkgo biloba, and vitamin E must be at a stable dose for 4 weeks prior to screening and remain stable throughout the study"
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,"Other psychotropics, such as antidepressants and antipsychotics, must be at a stable dose for 3 months prior to screening and remain stable throughout the study"
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,Willing and able to undergo imaging procedures:
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,A Positron Emission Tomography (PET) scan with Florbetaben(an 18F isotope diagnostic agent) or documented evidence of an amyloid positive PET scan.
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction," The Florbetaben scan performed at baseline must be read by a qualified physician with experience in reading amyloid PET scans, and it should be consistent with the presence of amyloid plaques."
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,Repeated MRI scans (3 Tesla) with no contraindications to MRI. MRI scan results are consistent with the diagnosis of amnestic MCI due to Alzheimer's disease with no clinically significant findings of non-AD pathology that could account for the observed cognitive impairment.
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,Willing to allow collection of blood for apolipoprotein E (ApoE) genotyping.
NCT03491150,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Previous participation in Study BN29552 or BN29553 and completion of the Week 105 visit.
NCT03491150,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Able to provide written informed consent by the patient or legally authorized representative, if required."
NCT03491150,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Every effort to have the same caregiver participate throughout the duration of the OLE (Open Label Extension) study who also participated in Study BN29552 or BN29553.
NCT03491150,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Willingness and ability to complete all aspects of the study [including MRI (Magnetic Resonance Imaging), lumbar puncture [if applicable], and PET (Positron Emission Tomography) imaging [if applicable]."
NCT03491150,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Adequate visual and auditory acuity, in the investigator's judgment, sufficient to perform the neuropsychological testing."
NCT03491150,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a protocol approved contraceptive method and agreement to refrain from donating eggs for at least 8 weeks after last dose.
NCT03491150,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a protocol approved contraceptive method for at least 8 weeks after last dose.
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease, Participants may be included in the study only if they meet all of the following criteria:
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Men, and women of non-childbearing potential, 50-85 years of age inclusively, with a diagnosis of mild to moderate Alzheimer's disease according to the 2011 NIA-AA criteria and at least a 6 month decline in cognitive function documented in the medical record."
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Non-childbearing potential for women is defined as postmenopausal [last natural menses greater than 24 months; in women under age 55, menopausal status will be documented with serum follicle stimulating hormone (FSH) test] or undergone a documented bilateral tubal ligation or hysterectomy."
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Male participants who are sexually active with a woman of child-bearing potential must agree to use condoms during the trial and for 3 months after last dose unless the woman is using an acceptable means of birth control. Acceptable forms of birth control include abstinence, birth control pills, or any double combination of: intrauterine device (IUD), male or female condom, diaphragm, sponge, and cervical cap."
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Neuroimaging (MRI) obtained during screening consistent with the clinical diagnosis of Alzheimer's disease and without findings of significant exclusionary abnormalities (see exclusion criteria, number 3)."
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,MMSE 18-26 inclusive
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"A positive amyloid (Pittsburgh imaging compound B) scan at screening, or history of a positive amyloid scan prior to study entry, or prior lumbar puncture with a CSF Abeta concentration consistent with Alzheimer's disease."
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Formal education of eight or more years.
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Must have a caregiver who sees them at least 10 hours per week, oversees the administration of study drug, and is willing and able to oversee administration of study medication and participate in all clinic visits and some study assessments. The caregiver must provide written informed consent to participate in the study."
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Living at home or in the community (assisted living acceptable)
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Able to swallow CT1812 capsules.
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Stable pharmacological treatment of any other chronic conditions for at least 30 days prior to screening.
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Capable of providing either written informed consent or oral assent to the study procedures and for use of protected health information [Health Insurance Portability and Accountability Act (HIPAA) Authorization, if applicable]. If the Participant can provide only assent, their legally authorized representative also must provide written informed consent. Written informed consent also shall be obtained from the responsible caregiver. All consent processes must be undertaken in the presence of a witness and prior to any study procedures."
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Must consent to apolipoprotein E (ApoE) genotyping.
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Generally healthy with mobility (ambulatory or ambulatory-aided, i.e., walker or cane), vision and hearing (hearing aid permissible) sufficient for compliance with testing procedures."
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Able to complete all screening evaluations.
NCT03503331,Phase 2,Alzheimer Disease,University of Alabama at Birmingham,unknown,Alzheimer Disease,Enrollment in the UAB-ADC study under a separate IRB-approved research protocol (IRB-300000169).
NCT03503331,Phase 2,Alzheimer Disease,University of Alabama at Birmingham,unknown,Alzheimer Disease,Negative urine or serum B-hCG test within 2 days of [C-11]PiB administration in women of child bearing potential. Women who are post-menopausal with at least 1 year since last menses or documented surgical sterilization will not require pregnancy testing.
NCT03518073,Phase 2,Alzheimer Disease (AD),Eli Lilly and Company,unknown,Alzheimer Disease, Participants must have gradual and progressive change in memory function for greater than 6 months.
NCT03518073,Phase 2,Alzheimer Disease (AD),Eli Lilly and Company,unknown,Alzheimer Disease, Participants must have a family member or close friend who is with you at least 10 hours per week and can attend study appointments.
NCT03520998,Phase 2,Mild to Moderate Alzheimer Disease,"Alkahest, Inc.",unknown,Alzheimer Disease, Diagnosis of probable AD based upon the National Institute on Aging-Alzheimer's Association (NIA-AA) Criteria
NCT03520998,Phase 2,Mild to Moderate Alzheimer Disease,"Alkahest, Inc.",unknown,Alzheimer Disease, MMSE Score 12-24 inclusive
NCT03520998,Phase 2,Mild to Moderate Alzheimer Disease,"Alkahest, Inc.",unknown,Alzheimer Disease, Modified Hachinski Ischemia Scale (MHIS) score of  4
NCT03520998,Phase 2,Mild to Moderate Alzheimer Disease,"Alkahest, Inc.",unknown,Alzheimer Disease, Provided a signed and dated informed consent form (either the subject and/or subject's legal representative as well as the trial partner)
NCT03531710,Phase 2,Alzheimer's Disease,United Neuroscience Ltd.,unknown,Alzheimer Disease, Patients who participated in V203-AD trial without major safety concerns;
NCT03531710,Phase 2,Alzheimer's Disease,United Neuroscience Ltd.,unknown,Alzheimer Disease, Stable doses of permitted medications for 3 months before screening;
NCT03531710,Phase 2,Alzheimer's Disease,United Neuroscience Ltd.,unknown,Alzheimer Disease, With a caregiver;
NCT03531710,Phase 2,Alzheimer's Disease,United Neuroscience Ltd.,unknown,Alzheimer Disease, Other inclusion criteria apply
NCT03533257,Phase 2,Alzheimer Disease,Amylyx Pharmaceuticals Inc.,unknown,Alzheimer Disease;Ursodoxicoltaurine;4-phenylbutyric acid,"Ages 55-89, inclusive, male or female"
NCT03533257,Phase 2,Alzheimer Disease,Amylyx Pharmaceuticals Inc.,unknown,Alzheimer Disease;Ursodoxicoltaurine;4-phenylbutyric acid,"Diagnosis of  Probable Alzheimer's Disease  or Mild Cognitive Impairment (amnestic or amnestic plus other) with biomarkers that suggest intermediate or high likelihood that the syndrome is due to AD, according to 2011 NIA-AA Workgroup criteria"
NCT03533257,Phase 2,Alzheimer Disease,Amylyx Pharmaceuticals Inc.,unknown,Alzheimer Disease;Ursodoxicoltaurine;4-phenylbutyric acid,MoCA 8 - 26 inclusive
NCT03533257,Phase 2,Alzheimer Disease,Amylyx Pharmaceuticals Inc.,unknown,Alzheimer Disease;Ursodoxicoltaurine;4-phenylbutyric acid,Able to read and write in English sufficiently to complete all study procedures
NCT03533257,Phase 2,Alzheimer Disease,Amylyx Pharmaceuticals Inc.,unknown,Alzheimer Disease;Ursodoxicoltaurine;4-phenylbutyric acid,Geriatric Depression Scale less than 7
NCT03533257,Phase 2,Alzheimer Disease,Amylyx Pharmaceuticals Inc.,unknown,Alzheimer Disease;Ursodoxicoltaurine;4-phenylbutyric acid,Willing and able to complete all assessments and study procedures
NCT03533257,Phase 2,Alzheimer Disease,Amylyx Pharmaceuticals Inc.,unknown,Alzheimer Disease;Ursodoxicoltaurine;4-phenylbutyric acid,"Not pregnant, lactating or of child-bearing potential (women must be greater than 2 years post-menopausal or surgically sterile)"
NCT03533257,Phase 2,Alzheimer Disease,Amylyx Pharmaceuticals Inc.,unknown,Alzheimer Disease;Ursodoxicoltaurine;4-phenylbutyric acid,Study partner with at least two days per week with contact with patient willing to accompany patient to visits and complete partner study forms
NCT03533257,Phase 2,Alzheimer Disease,Amylyx Pharmaceuticals Inc.,unknown,Alzheimer Disease;Ursodoxicoltaurine;4-phenylbutyric acid,No known hypersensitivity to Tauroursodeoxycholic acid or Phenylbutyrate
NCT03533257,Phase 2,Alzheimer Disease,Amylyx Pharmaceuticals Inc.,unknown,Alzheimer Disease;Ursodoxicoltaurine;4-phenylbutyric acid,"Must have a previous biomarker supportive of AD as the underlying pathology of cognitive decline, which could include amyloid PET, CSF AD biomarkers, FDG-PET, or vMRI scan"
NCT03533257,Phase 2,Alzheimer Disease,Amylyx Pharmaceuticals Inc.,unknown,Alzheimer Disease;Ursodoxicoltaurine;4-phenylbutyric acid,"If on cholinesterase inhibitor and/or memantine, doses are stable for 3 months prior to baseline"
NCT03542656,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage"," Ageabove 20 years old with ICH or AD, or control subjects."
NCT03542656,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage", Patient agrees to participate in the study and receive cerebral amyloid PET and MRI SWI and perfusion studies.
NCT03548584,Phase 3,Alzheimer Dementia,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Brexpiprazole, Subjects with a diagnosis of probable Alzheimer's disease.
NCT03548584,Phase 3,Alzheimer Dementia,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Brexpiprazole, Subjects with a diagnosis of agitation
NCT03548584,Phase 3,Alzheimer Dementia,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Brexpiprazole," Subjects with a MMSE score of 5 to 22, inclusive, at screening and baseline visits."
NCT03548584,Phase 3,Alzheimer Dementia,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Brexpiprazole," Subjects with a previous MRI or CT scan of the brain, that was performed after the onset of symptoms of dementia, with findings consistent with a diagnosis of Alzheimer's disease."
NCT03548584,Phase 3,Alzheimer Dementia,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Brexpiprazole, Subjects who are residing at their current location for at least 28 days before screening and are expected to remain at the same location for the duration of the trial.
NCT03548584,Phase 3,Alzheimer Dementia,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Brexpiprazole, Institutionalized subjects with an identified caregiver who has sufficient contact (minimum of 2 hours per day for 4 days per week) to describe the subject's symptoms and has direct observation of the subject's behavior. Non-institutionalized subjects may not be living alone and must have an identified caregiver who has sufficient contact (minimum of 2 hours per day for 4 days per week) to describe the subject's symptoms and has direct observation of the subject's behavior.
NCT03548584,Phase 3,Alzheimer Dementia,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Brexpiprazole, Subjects with onset of symptoms of agitation at least 2 weeks prior to screening visit.
NCT03548584,Phase 3,Alzheimer Dementia,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Brexpiprazole, Subjects will and able to discontinue all prohibited concomitant medications to meet protocol required washouts prior to and during the trial period.
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Written informed consent from caregiver and subject (if possible) or legally acceptable representative if different from caregiver
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Male and female subjects 55-85 years of age inclusive
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Cognitive deficit present for at least 2 years that meet the diagnostic criteria for probable Alzheimer's dementia. The diagnosis must be confirmed at the time of the screening visit
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,MMSE-2 score of 4-15 inclusive (applies to Screening Visit only)
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Patients must be able to perform at least one item on the SIB and may not have a SIB score greater than 93 at screening
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"Neuroimaging computerized tomography (CT) or Magnetic Resonance Imaging (MRI) within the last 24 months consistent with a diagnosis of probable AD without any other clinically significant co-morbid pathologies. If there has been a significant change in the subject's clinical status since the last imaging study that is not consistent with progression of the subject's AD, an imaging study should be performed to confirm eligibility"
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Reliable caregiver(s) or informant(s) who attends the subject at least an average of 3 hours or more per day for 3 or more days per week and who will agree to accompany the subject to the clinic visits and reliably complete the caregiver questions
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Adequate vision and motor function to comply with testing
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"If taking an approved cholinesterase inhibitor for treatment of Alzheimer's disease, must be on a stable dose for at least 3 months prior to entry into study and the dose must not change during the study unless a change is required due to an adverse effect of the prescribed medication or a clinically significant change in the patient's status"
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Subjects who are memantine nave or have been off memantine for at least 30 days prior to initial treatment with study drug
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Subjects on neuroleptic medications must be on a stable dose for 4 weeks (dose adjustments will be permitted)
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Females participating in the study must meet one the following criteria:
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"Surgically sterilized (e.g., hysterectomy, bilateral oophorectomy or tubal ligation) for at least 6 months or postmenopausal (postmenopausal females must have no menstrual bleeding for at least 1 year) or"
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"If not postmenopausal, agree to use a double method of contraception, one of which is a barrier method (e.g., intrauterine device plus condom, spermicidal gel plus condom) 30 days prior to dosing until 30 days after last dose and have negative human chorionic gonadotropin (-hCG) test for pregnancy at screening"
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Males who have not had a vasectomy must use appropriate contraception methods (barrier or abstinence) from 30 days prior to dosing until 30 days after last dose
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,In the opinion of the PI subjects should be in reasonably good health over the last 6 months and any chronic disease should be stable -
NCT03594123,Phase 3,Alzheimer's Disease,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Alzheimer Disease;Dementia;Psychomotor Agitation;Brexpiprazole, Subject must have participated in the 331-14-213 study.
NCT03594123,Phase 3,Alzheimer's Disease,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Alzheimer Disease;Dementia;Psychomotor Agitation;Brexpiprazole," Subject must have an identified caregiver who has contact, at a minimum of 2 hours per day, 4 days per week to describe the subject's symptoms and can observe subject behavior."
NCT03613844,Phase 2,Brain DHA Delivery and Alzheimer's Disease Risk,University of Southern California,unknown,Alzheimer Disease, Age:  55 and  80
NCT03613844,Phase 2,Brain DHA Delivery and Alzheimer's Disease Risk,University of Southern California,unknown,Alzheimer Disease," At least one dementia risk factor (obesity, education years, hypertension, hyperlipidemia)"
NCT03613844,Phase 2,Brain DHA Delivery and Alzheimer's Disease Risk,University of Southern California,unknown,Alzheimer Disease, Mini-Mental State Examination (MMSE)  25
NCT03613844,Phase 2,Brain DHA Delivery and Alzheimer's Disease Risk,University of Southern California,unknown,Alzheimer Disease, Logical Memory II delayed recall score  6 and  18 .
NCT03620981,Phase 2/Phase 3,Agitation Associated With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Co., Ltd.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Brexpiprazole, Patients who satisfy both of the following diagnostic criteria:
NCT03620981,Phase 2/Phase 3,Agitation Associated With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Co., Ltd.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Brexpiprazole,Diagnosis of  Dementia due to Alzheimer's Disease  according to DSM-5.
NCT03620981,Phase 2/Phase 3,Agitation Associated With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Co., Ltd.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Brexpiprazole,Diagnosis of  Probable Alzheimer's Disease  according to NINCDS-ADRDA.
NCT03620981,Phase 2/Phase 3,Agitation Associated With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Co., Ltd.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Brexpiprazole, Hospitalized patients or care facility patients or care at home patients
NCT03620981,Phase 2/Phase 3,Agitation Associated With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Co., Ltd.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Brexpiprazole, Patients with an MMSE score of 1 to 22
NCT03620981,Phase 2/Phase 3,Agitation Associated With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Co., Ltd.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Brexpiprazole, Patients who have the agitation defined according to the  Consensus provisional definition of agitation in cognitive disorders  from the International Psychogeriatric Association (IPA)
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,Subjects must be diagnosed with probable AD in accordance with the National Institute on Aging and Alzheimer's Association (NIA-AA) (2011) criteria.
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,Subjects must have a Mini-Mental State Examination (MMSE) score of 15 and 26 at screening and baseline.
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,Subjects must have a brain magnetic resonance imaging (MRI) scan that is consistent with a clinical diagnosis of probable AD.
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,Subjects should not have received A-based or tau-based treatment for AD.
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,"Subjects who were previously treated with Acetyl cholinesterase inhibitor (AChEI) or memantine, must have been off of the therapy for at least 3 months prior to baseline assessments. Subjects who have been taking AChEI or memantine for 7 days may be considered for enrollment in this study."
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,"For subjects who are currently receiving other non-excluded prescription or over-the-counter medications that might affect cognitive function (eg, non-anticholinergic antidepressants, atypical antipsychotics, non-benzodiazepine anxiolytics, soporifics, centrally acting anticholinergic antihistamines, centrally acting anticholinergic antispasmodics):"
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease, Treatment must be at a stable dose for 1 month prior to randomization and throughout the duration of the study.
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease, Treatment given intermittently and on a short-term basis must not be administered within 5 half-lives prior to the screening of neurocognitive assessments.
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,"Subjects must be male or female between 50 years to 85 years of age (inclusive), at screening."
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,"Female subjects must be post-menopausal for at least 2 consecutive years or surgically sterile (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy) for at least 6 months prior to screening."
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,"Male subjects with partners of reproductive potential must agree to use a reliable means of contraception (eg, minimum condom + spermicide) during the study and 30 days after discontinuing the study drug."
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,"Subjects must have a reliable caregiver with contact at least 3 times per week (combination of face to face visits and telephone contact acceptable). The caregiver must be able to oversee the subject's compliance with study drug and participate in the subject's clinical assessment, to provide meaningful input into the NPI, ADCS-ADL, and CIBIC+."
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,Subjects (or subject's legally authorized representatives and their caregivers) must be able to provide informed consent.
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,"Subjects (and their caregivers) must be able to read, write, speak, and understand English to ensure compliance with cognitive testing and study visit procedures."
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,Subjects (and their caregivers) must be willing and able to comply with the protocol's requirements.
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,"Subjects must weigh between 45 kg and 90 kg (inclusive), at screening."
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,"Subjects must be in general good health in the opinion of the Investigator, based on medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG) in triplicate, and clinical laboratory values."
NCT03625622,Phase 2,Mild to Moderate Alzheimer's Disease,"AriBio Co., Ltd.",unknown,Alzheimer Disease,Male or female subjects aged 55-80 years at the time of signing the Informed Consent Form.
NCT03625622,Phase 2,Mild to Moderate Alzheimer's Disease,"AriBio Co., Ltd.",unknown,Alzheimer Disease,Subjects (or subject's legally acceptable representative) and caregiver(s) who can sign an Informed Consent to participate in the study. Same caregiver(s) must assist the subject throughout the entire duration of the study.
NCT03625622,Phase 2,Mild to Moderate Alzheimer's Disease,"AriBio Co., Ltd.",unknown,Alzheimer Disease,"Subjects who have a diagnosis of probable Alzheimer's disease according to the NIA-AA (National Institute of Aging and Alzheimer's Associations, 2011) criteria with mild to moderate dementia (stage 4 - 5) at screening."
NCT03625622,Phase 2,Mild to Moderate Alzheimer's Disease,"AriBio Co., Ltd.",unknown,Alzheimer Disease,Subjects who have mild-to-moderate cognitive impairment with MMSE Score of 16-26 at screening.
NCT03625622,Phase 2,Mild to Moderate Alzheimer's Disease,"AriBio Co., Ltd.",unknown,Alzheimer Disease,Subjects who have an MRI (either 1.5T or 3T) or CT scan performed after onset of symptoms and prior to randomization with findings consistent with the diagnosis of dementia due to Alzheimer's disease and without any other clinically significant comorbid pathologies.
NCT03625622,Phase 2,Mild to Moderate Alzheimer's Disease,"AriBio Co., Ltd.",unknown,Alzheimer Disease,"Subjects who have one (or more) identified adult study partner(s) who, in the opinion of the investigator, has sufficient contact with and knowledge about the subject as to be able to report knowledgeably about the subject's safety, compliance and adherence, cognition, function, and behavior."
NCT03656042,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Lenograstim,Subject with age of at lease 50 years old and no more than 85 years old
NCT03656042,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Lenograstim,Subject diagnosed of Alzheimer's disease; based on the criteria of The Diagnostic and Statistical Manual of Mental Disorders (DSM)- for dementia and those of National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer's Dementia and Related Disorder Association (NINCDS - ADRDA) and within 12-months CT/MRI brain scan supporting evidences.
NCT03656042,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Lenograstim,Subject with Mini-Mental Examination (MMSE) scores of 12 to 26 (inclusive).
NCT03656042,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Lenograstim,Subject with Clinical Dementia Rating (CDR) score of 1 (mild) or 2 moderate).
NCT03656042,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Lenograstim,Subject with Modified Hachinski Ischemic score of 4.
NCT03656042,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Lenograstim,Subject with a Hamilton Psychiatric Rating Scale for Depression score of 12.
NCT03656042,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Lenograstim,Female subject with child-bearing potential agrees to take reliable contraceptive method during the participation of the study (Females with no child-bearing potential have to be surgically sterilized or at least 2 years after post-menopausal).
NCT03656042,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Lenograstim,Subject and subject's legally acceptable representative have given written informed consent.
NCT03656042,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Lenograstim,A reliable caregiver is sufficiently familiar with the subject (as determined by the investigator) and is willing to provide accurate data.
NCT03691519,Phase 3,Alzheimer Disease,"University Hospital, Toulouse",unknown,Alzheimer Disease;Cognitive Dysfunction, RBC DHA/EPA index  4.83% with at least one of the following criteria:
NCT03691519,Phase 3,Alzheimer Disease,"University Hospital, Toulouse",unknown,Alzheimer Disease;Cognitive Dysfunction," subjective memory complaint,"
NCT03691519,Phase 3,Alzheimer Disease,"University Hospital, Toulouse",unknown,Alzheimer Disease;Cognitive Dysfunction, family history of Alzheimer's disease;
NCT03691519,Phase 3,Alzheimer Disease,"University Hospital, Toulouse",unknown,Alzheimer Disease;Cognitive Dysfunction, Mini-Mental State Examination (MMSE) score  24;
NCT03691519,Phase 3,Alzheimer Disease,"University Hospital, Toulouse",unknown,Alzheimer Disease;Cognitive Dysfunction," Have a study partner that is willing to participate as a source of information and has at least weekly contact with the participant (contact can be in person, via telephone or electronic communication);"
NCT03691519,Phase 3,Alzheimer Disease,"University Hospital, Toulouse",unknown,Alzheimer Disease;Cognitive Dysfunction, Sufficient vision and hearing to complete study protocol procedures based on medical judgment;
NCT03691519,Phase 3,Alzheimer Disease,"University Hospital, Toulouse",unknown,Alzheimer Disease;Cognitive Dysfunction, Have general health status that will not interfere with the ability to complete the study;
NCT03691519,Phase 3,Alzheimer Disease,"University Hospital, Toulouse",unknown,Alzheimer Disease;Cognitive Dysfunction, Willing and able to participate and to give written consent to comply with study procedures;
NCT03691519,Phase 3,Alzheimer Disease,"University Hospital, Toulouse",unknown,Alzheimer Disease;Cognitive Dysfunction, Covered by a health insurance system.
NCT03712787,Phase 2,Alzheimer's Disease,AbbVie,unknown,Alzheimer Disease;Tilavonemab," All subjects with early AD who complete Study M15-566 (NCT02880956), meet all inclusion criteria, and do not meet any exclusion criteria are eligible for enrollment"
NCT03712787,Phase 2,Alzheimer's Disease,AbbVie,unknown,Alzheimer Disease;Tilavonemab, Subject was compliant during participation in Study M15-566 (NCT02880956)
NCT03712787,Phase 2,Alzheimer's Disease,AbbVie,unknown,Alzheimer Disease;Tilavonemab," Subject has an identified, reliable study partner who has frequent contact with the subject and who will provide information as to the subject's cognitive and functional abilities"
NCT03724942,Phase 3,Agitation Associated With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Co., Ltd.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Brexpiprazole," Patients who completed the double-blind treatment period for 10 weeks and all observation, examination and evaluation at Week 10 of the double-blind trial."
NCT03724942,Phase 3,Agitation Associated With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Co., Ltd.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Brexpiprazole, Patients whose caregiver can properly collect the necessary information.
NCT03744312,Phase 1/Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease;Inflammation,Age 50 and older
NCT03744312,Phase 1/Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease;Inflammation,"Meet criteria for either a) amnestic mild cognitive impairment or Alzheimer's disease, or b) have no cognitive impairment"
NCT03744312,Phase 1/Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease;Inflammation,"If you are unable to provide informed consent, you must have a surrogate decision maker and be able to verbally assent to the study procedures"
NCT03744312,Phase 1/Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease;Inflammation,Written and oral fluency in English
NCT03744312,Phase 1/Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease;Inflammation,Able to participate in all scheduled evaluations and to complete all required tests and procedures.
NCT03744312,Phase 1/Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease;Inflammation,"In the opinion of the investigator, you must be considered likely to comply with the study protocol and to have a high probability of completing the study."
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, Ages greater than = 50 and less than = 85 years
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, Informed consent form (ICF) signed by the subject or legally acceptable representative.
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, Clinical diagnosis of dementia due to possible or probable Alzheimer's disease
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, Mini-Mental State Examination score greater than = 16 and less than = 24 at screening
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease," If female, postmenopausal for at least 1 year"
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease," Patient living at home, senior residential setting, or an institutional setting without the need for continuous (i.e. 24-hour) nursing care"
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, General health status acceptable for participation in the study
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, Fluency (oral and written) in English or Spanish
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease," If receiving memantine, rivastigmine, galantamine or an AChEI, receiving a stable dose for at least 3 months (90 days) before screening and with continuous dosing for at least 3 months. If receiving donepezil, receiving any dose lower than 23 mg once daily."
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, The patient is a non-smoker for at least 12 months.
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, The patient or legal representative must agree to comply with the drawing of blood samples and with a lumbar puncture and the drawing of cerebrospinal fluid samples.
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, The patient has a ratio of total tau/Abeta42 in cerebrospinal fluid greater than = 0.30.
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, Patient has a caregiver or legal representative responsible for administering the drug and recording the time.
NCT03752463,Phase 2,Alzheimer Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease, Clinical diagnosis of Alzheimer's disease
NCT03752463,Phase 2,Alzheimer Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease, MMSE between 10-26
NCT03752463,Phase 2,Alzheimer Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease, CDR 1
NCT03765762,Phase 2,Severe Alzheimer Disease,"Alkahest, Inc.",unknown,Alzheimer Disease, Diagnosis of probable AD according to the National Institute on Aging-Alzheimer's Association (NIA-AA) Criteria
NCT03765762,Phase 2,Severe Alzheimer Disease,"Alkahest, Inc.",unknown,Alzheimer Disease, MMSE Score 0-10 inclusive
NCT03765762,Phase 2,Severe Alzheimer Disease,"Alkahest, Inc.",unknown,Alzheimer Disease, Modified Hachinski Ischemia Scale (MHIS) score of 4 or less
NCT03765762,Phase 2,Severe Alzheimer Disease,"Alkahest, Inc.",unknown,Alzheimer Disease, Provided a signed and dated informed consent form (either the subject and/or subject's legal representative)
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease," Patients aged 60 to 85 years, inclusive, with a NIA-AA diagnosis of mild cognitive impairment (MCI) due to AD or early stage mild dementia due to AD. AD diagnosis should be made by an appropriately qualified medical specialist and AD pathology should be confirmed by either:"
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease,Historical records of amyloid CSF assessment or
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease,Historical records of amyloid PET scan or
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease,"If neither historical records are available, then AD pathological diagnosis confirmation should be offered at screening:"
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease, i. CSF collection or ii. Amyloid PET iii. Past medical records of MRI or CT are optional.
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease," Mini Mental State Examination (MMSE) score between 20-28, inclusive."
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease, Free Recall score 17 or Total Recall score less than 40 on the Free and Cued Selective Reminding Test (FCSRT).
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease," Participants are either outpatients, or residents of an assisted-living facility. Participant has a designated study partner, who spends at least 10hrs per week with the participant, in order that assessments e.g. carer burden instruments are completed with true knowledge of the participant."
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease," No suicidal ideation of type 4 or 5 in the Columbia Suicide Severity Rating Scale (C-SSRS) in the past 3 months (i.e. active suicidal thought(s) with intent but without specific plan, or active suicidal thought(s) with plan and intent) OR suicidal behavior in the past 2 years (i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior)."
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease," Confirmation from the participant that, if of childbearing potential is not pregnant through urine pregnancy testing."
NCT03790982,Phase 2,Alzheimer's Disease,Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease," Men and women, 50-75 years of age."
NCT03790982,Phase 2,Alzheimer's Disease,Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease, Formal education of five or more years.
NCT03790982,Phase 2,Alzheimer's Disease,Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease, Diagnosed of probable AD in accordance with the NINCDS/ADRDA criteria (2011).
NCT03790982,Phase 2,Alzheimer's Disease,Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease, Mild or moderate AD subjects: MMSE Score of 15-26 and CDR Score  0.5 (CDR memory score  0.5).
NCT03790982,Phase 2,Alzheimer's Disease,Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease," Subjects must have a brain magnetic resonance imaging (MRI) scan that is consistent with a clinical diagnosis of probable AD. Brain atrophy and medial temporal lobe atrophy visual assessment scale MTA grading greater than 2 points. Mild white matter degeneration may occur, but Fazekas less than or equal to 2 points and supratentorial lacunar infarction lesions less than or equal to 3 points."
NCT03790982,Phase 2,Alzheimer's Disease,Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease, The total score of modified Hachinski ischemia scale (MHIS)  4.
NCT03790982,Phase 2,Alzheimer's Disease,Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease, Hamilton depression scale (HAMD) has a total score  17.
NCT03801642,Phase 1/Phase 2,Alzheimer Disease,"Jeff Burns, MD",unknown,Alzheimer Disease;Dapagliflozin,Provision of informed consent prior to any study specific procedures.
NCT03801642,Phase 1/Phase 2,Alzheimer Disease,"Jeff Burns, MD",unknown,Alzheimer Disease;Dapagliflozin,Have a diagnosis of probable AD per McKhann et al. criteria
NCT03801642,Phase 1/Phase 2,Alzheimer Disease,"Jeff Burns, MD",unknown,Alzheimer Disease;Dapagliflozin,Have a body mass index (BMI) 23
NCT03801642,Phase 1/Phase 2,Alzheimer Disease,"Jeff Burns, MD",unknown,Alzheimer Disease;Dapagliflozin,Age 50-85
NCT03801642,Phase 1/Phase 2,Alzheimer Disease,"Jeff Burns, MD",unknown,Alzheimer Disease;Dapagliflozin,Have a Mini Mental Status Exam (MMSE) score of 15-26 (inclusive) at screening visit
NCT03801642,Phase 1/Phase 2,Alzheimer Disease,"Jeff Burns, MD",unknown,Alzheimer Disease;Dapagliflozin,"Have a reliable and competent study partner who is willing to accompany the participant to all study visits, monitor compliance of study medication administration, and observe/report any changes in the participant's health throughout the study duration"
NCT03801642,Phase 1/Phase 2,Alzheimer Disease,"Jeff Burns, MD",unknown,Alzheimer Disease;Dapagliflozin,Are on stable doses of concurrent medications for at least 4 weeks prior to the screening visit
NCT03801642,Phase 1/Phase 2,Alzheimer Disease,"Jeff Burns, MD",unknown,Alzheimer Disease;Dapagliflozin,Speaks English as his/her primary language.
NCT03801642,Phase 1/Phase 2,Alzheimer Disease,"Jeff Burns, MD",unknown,Alzheimer Disease;Dapagliflozin,"Females of child-bearing potential (i.e., pre-menopausal) must have a negative urine pregnancy test at the screening visit and must agree to use of contraception throughout the trial and for 30 days after the last dose of study medication. The approved methods of contraception are abstinence, the consistent use of an approved oral contraceptive (birth control pill or  the pill ), an intrauterine device (IUD), hormonal implants, contraceptive injection, double barrier method (diaphragm with spermicidal gel or condom with contraceptive foam)."
NCT03806478,Phase 2,Alzheimer Disease 3,Aphios,unknown,Alzheimer Disease;Dementia, Males and Females ages greater than  50 years of age at screening visit
NCT03806478,Phase 2,Alzheimer Disease 3,Aphios,unknown,Alzheimer Disease;Dementia, Probable Alzheimer's Disease according to National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association(NINCDS-ADRDA) and Diagnostic Statistical Manual (DSM) IV-V criteria
NCT03806478,Phase 2,Alzheimer Disease 3,Aphios,unknown,Alzheimer Disease;Dementia, Clinical Dementia Rating Scale (CDR) global score greater than  1.0 at the time of screening
NCT03806478,Phase 2,Alzheimer Disease 3,Aphios,unknown,Alzheimer Disease;Dementia," Mini-Mental Status Examination score of 22-30 at screening visit CT or MRI of brain, within 12 months prior to randomization, compatible with a diagnosis of Probable Alzheimer's Disease"
NCT03806478,Phase 2,Alzheimer Disease 3,Aphios,unknown,Alzheimer Disease;Dementia," Physical examination, laboratory data and electrocardiogram results from screening visit must be normal or abnormal findings must be judged not to be clinically significant"
NCT03806478,Phase 2,Alzheimer Disease 3,Aphios,unknown,Alzheimer Disease;Dementia," Ability to walk, at least with an assistive device"
NCT03806478,Phase 2,Alzheimer Disease 3,Aphios,unknown,Alzheimer Disease;Dementia, Vision and hearing sufficient to comply with testing
NCT03806478,Phase 2,Alzheimer Disease 3,Aphios,unknown,Alzheimer Disease;Dementia," Informed consent from patient, or legal guardian (if applicable) and a caregiver"
NCT03806478,Phase 2,Alzheimer Disease 3,Aphios,unknown,Alzheimer Disease;Dementia, Living outside an institutional facility
NCT03806478,Phase 2,Alzheimer Disease 3,Aphios,unknown,Alzheimer Disease;Dementia, Must have at least 1 informant/study partner
NCT03817684,Phase 2,Alzheimer's Disease,Tetra Discovery Partners,unknown,Alzheimer Disease,"Males or females between the ages of 55 and 85 years with a clinical diagnosis of early stage AD, defined according to the following criteria assessed during Screening and at Baseline :"
NCT03817684,Phase 2,Alzheimer's Disease,Tetra Discovery Partners,unknown,Alzheimer Disease,"Clinical Dementia Rating (CDR) score of 0.5 or 1, with Memory Box score of 0.5 or greater"
NCT03817684,Phase 2,Alzheimer's Disease,Tetra Discovery Partners,unknown,Alzheimer Disease,MMSE score of 20 or greater
NCT03817684,Phase 2,Alzheimer's Disease,Tetra Discovery Partners,unknown,Alzheimer Disease,"RBANS DMI score  85 Note: PET imaging for amyloid is not required for diagnosis, which will be made on clinical grounds."
NCT03817684,Phase 2,Alzheimer's Disease,Tetra Discovery Partners,unknown,Alzheimer Disease,Currently receiving a stable (at least 2 months) dose regimen of donepezil or another cholinesterase inhibitor for treatment of Alzheimer's disease. Doses of these drugs may not be changed during the trial.
NCT03817684,Phase 2,Alzheimer's Disease,Tetra Discovery Partners,unknown,Alzheimer Disease, Note: Memantine is not permitted during the trial and must be discontinued at least 3 weeks prior to Baseline.
NCT03817684,Phase 2,Alzheimer's Disease,Tetra Discovery Partners,unknown,Alzheimer Disease,Modified Hachinski Ischemia score less than  4.
NCT03817684,Phase 2,Alzheimer's Disease,Tetra Discovery Partners,unknown,Alzheimer Disease,"Body mass index (BMI) less than  38 kg/m2, inclusive, and body weight of greater than 48 kg (105 pounds) at screening."
NCT03817684,Phase 2,Alzheimer's Disease,Tetra Discovery Partners,unknown,Alzheimer Disease,"Female subjects must be at least two years post-menopausal (subjected reported menopausal status), surgically sterile (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy at least 6 months prior to first study drug administration), or willing to either (1) utilize hormonal contraception plus one barrier method or (2) use two barrier methods of contraception (e.g. diaphragm and spermicide) from initial screening until one month after taking the final dose. An intrauterine device (IUD) is considered a barrier method of contraception in this study. Male subjects must be willing to inform female partners of their participation in the study and must agree to use adequate contraceptive methods (vasectomy performed at least 6 months prior to first study drug administration, or use at least one barrier method of birth control)."
NCT03817684,Phase 2,Alzheimer's Disease,Tetra Discovery Partners,unknown,Alzheimer Disease,"Able to understand and comply with the study procedures, voluntarily agree to participate in this study, and provide written informed consent prior to start of any study-specific procedures."
NCT03817684,Phase 2,Alzheimer's Disease,Tetra Discovery Partners,unknown,Alzheimer Disease,"All subjects must have a caregiver who is willing and able to ensure compliance with study medications, visits, and study procedures."
NCT03828747,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, National Institute on Aging/Alzheimer's Association core clinical criteria for probable AD dementia
NCT03828747,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," Evidence of the AD pathological process, by a positive amyloid assessment either on CSF A1-42 as measured on Elecsys -Amyloid(1-42) Test System OR amyloid PET scan"
NCT03828747,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," AD dementia of moderate severity, as defined by a screening MMSE score of 16-21 points, inclusive, and a CDR-GS of 1 or 2"
NCT03828747,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," Availability of a person with sufficient contact with the participant to be able to provide accurate information on the participant's cognitive, behavioral and functional ability"
NCT03856359,Phase 2,Alzheimer's Disease,Duke University,unknown,Alzheimer Disease;Rifaximin,"  Probable Alzheimer's Disease (National Institute of Neurological Disorders and Stroke (NINDS) criteria), mild to moderate severity"
NCT03856359,Phase 2,Alzheimer's Disease,Duke University,unknown,Alzheimer Disease;Rifaximin, Ages 55-85; both genders
NCT03856359,Phase 2,Alzheimer's Disease,Duke University,unknown,Alzheimer Disease;Rifaximin, Mini Mental State Exam (MMSE) scores 10-23
NCT03856359,Phase 2,Alzheimer's Disease,Duke University,unknown,Alzheimer Disease;Rifaximin, Willing and able to comply with all scheduled clinic visits.
NCT03856359,Phase 2,Alzheimer's Disease,Duke University,unknown,Alzheimer Disease;Rifaximin, Stable medical health
NCT03856359,Phase 2,Alzheimer's Disease,Duke University,unknown,Alzheimer Disease;Rifaximin, Has a family or professional caregiver who has regular contact with subject
NCT03856359,Phase 2,Alzheimer's Disease,Duke University,unknown,Alzheimer Disease;Rifaximin, Ability to consent or legal guardian who can consent
NCT03856359,Phase 2,Alzheimer's Disease,Duke University,unknown,Alzheimer Disease;Rifaximin, Living at home or in a facility
NCT03856359,Phase 2,Alzheimer's Disease,Duke University,unknown,Alzheimer Disease;Rifaximin, On no AD therapies or on stable (2 months) concurrent AD therapies
NCT03867253,Phase 2,Mild to Moderate Alzheimer's Disease,Oryzon Genomics S.A.,unknown,Alzheimer Disease, Probable Alzheimer's Disease (AD) diagnosed according to National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria
NCT03867253,Phase 2,Mild to Moderate Alzheimer's Disease,Oryzon Genomics S.A.,unknown,Alzheimer Disease, MMSE score at Screening and Baseline Visits of at least 16 and not greater than 26
NCT03867253,Phase 2,Mild to Moderate Alzheimer's Disease,Oryzon Genomics S.A.,unknown,Alzheimer Disease, Evidence of the AD pathophysiological process indicated by decreased levels of amyloid antigen binding (AB) and increased levels of total Tau protein or phospho-Tau protein in cerebrospinal fluid (CSF)
NCT03867253,Phase 2,Mild to Moderate Alzheimer's Disease,Oryzon Genomics S.A.,unknown,Alzheimer Disease," Outpatient consulting a general practitioner, or a psychiatrist/neurologist/geriatrician"
NCT03867253,Phase 2,Mild to Moderate Alzheimer's Disease,Oryzon Genomics S.A.,unknown,Alzheimer Disease, Knowledgeable and reliable close relative/caregiver who will accompany the patient to all clinic visits during the study
NCT03867253,Phase 2,Mild to Moderate Alzheimer's Disease,Oryzon Genomics S.A.,unknown,Alzheimer Disease, Daily treatment with the same acetylcholinesterase inhibitor on a stable dose
NCT03867253,Phase 2,Mild to Moderate Alzheimer's Disease,Oryzon Genomics S.A.,unknown,Alzheimer Disease," Fertile male and female must use highly effective contraception, from the Screening Visit until 90 days after last dose."
NCT03867253,Phase 2,Mild to Moderate Alzheimer's Disease,Oryzon Genomics S.A.,unknown,Alzheimer Disease," Signed informed consent by patient (or legal representative, if applicable) and a close relative/caregiver prior to the initiation of any study specific procedure"
NCT03903211,Phase 2,Alzheimer Disease,Jae Seung Kim,unknown,Alzheimer Disease;Cognitive Dysfunction,General Subject Inclusion Criteria
NCT03903211,Phase 2,Alzheimer Disease,Jae Seung Kim,unknown,Alzheimer Disease;Cognitive Dysfunction," In order to be eligible for participation in this trial, the subject must:"
NCT03903211,Phase 2,Alzheimer Disease,Jae Seung Kim,unknown,Alzheimer Disease;Cognitive Dysfunction, Be  40 and less than  85 years of age at the Screening Visit.
NCT03903211,Phase 2,Alzheimer Disease,Jae Seung Kim,unknown,Alzheimer Disease;Cognitive Dysfunction," Be able to read at a 6th grade level or equivalent, (as determined by the investigator, and must have a history of academic achievement and/or employment sufficient to exclude mental retardation.)"
NCT03903211,Phase 2,Alzheimer Disease,Jae Seung Kim,unknown,Alzheimer Disease;Cognitive Dysfunction," Be able to speak, read, hear, and understand the language of the trial staff, and the informed consent form, and possess the ability to respond verbally to questions, follow instructions, and complete questionnaires and detailed neuropsychological test."
NCT03903211,Phase 2,Alzheimer Disease,Jae Seung Kim,unknown,Alzheimer Disease;Cognitive Dysfunction," Have results of clinical laboratory tests/physical examination, vital signs, and ECG within normal limits (at 90 days prior to [18F]PI-2620 positron emission computed tomography) or clinically acceptable to the investigator at screening."
NCT03903211,Phase 2,Alzheimer Disease,Jae Seung Kim,unknown,Alzheimer Disease;Cognitive Dysfunction," If female, not be of childbearing potential as indicated by one of the following"
NCT03903211,Phase 2,Alzheimer Disease,Jae Seung Kim,unknown,Alzheimer Disease;Cognitive Dysfunction," Each subject (or legal representative) must sign the informed consent form in accordance with local requirements after the scope and nature of the investigation have been explained to them, and before screening assessments."
NCT03903211,Phase 2,Alzheimer Disease,Jae Seung Kim,unknown,Alzheimer Disease;Cognitive Dysfunction,Cognitively normal individuals
NCT03903211,Phase 2,Alzheimer Disease,Jae Seung Kim,unknown,Alzheimer Disease;Cognitive Dysfunction,Subjects with Mild Cognitive Impairment
NCT03903211,Phase 2,Alzheimer Disease,Jae Seung Kim,unknown,Alzheimer Disease;Cognitive Dysfunction,Subjects with Alzheimer Disease
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"Male or female participants 55 to 85 years of age, inclusive, at the time of signing the informed consent."
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Diagnosis of probable AD based on NINCDS-ADRDA criteria.
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Diagnosis of dementia based on DSM-V criteria.
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Moderate dementia as evidenced by MMSE score 10 to less than 20 at screening.
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Magnetic resonance imaging or CT within 12 months prior to randomization with findings consistent with AD and without any other disease that may cause dementia.
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"If receiving an FDA-approved medication for AD (ie, donepezil, galantamine, rivastigmine, memantine, or memantine/donepezil combination product) must be on a stable dose for at least 3 months prior to screening visit."
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"If receiving an OTC supplement for cognition (eg, gingko biloba, omega-3 polyunsaturated fatty acid, vitamin E, curcumin) must be taking a stable dose for at least 3 months prior to screening visit."
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"Able to visit the study center and undergo cognitive, functional, and other tests specified in the protocol."
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Has a caregiver who:
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease, Agrees to accompany the participant to all study visits and able to supervise the participant's compliance with the study procedures and provide detailed information about the participant.
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease," Either lives with the participant or sees the participant on average for 1 hours/day 3 days/week, or in the Investigator's opinion, the extent of contact is sufficient to provide meaningful assessment of changes in participant behavior and function over time and provide information on safety and tolerability."
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease," Is able to read, understand, and speak the designated language at the study center."
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease, Caregiver must be cognitively able to fulfill the requirements of the study.
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,A male participant must agree to use a highly effective contraception as detailed in Appendix 4 of this protocol during the treatment period and for at least 3 months after the last dose of study treatment and refrain from donating sperm during this period.
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"A female participant is eligible to participate if she is not pregnant (see Appendix 4), not breastfeeding, and at least one of the following conditions applies:"
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease, Not a woman of childbearing potential (WOCBP) as defined in Appendix 4. OR
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease, A WOCBP who agrees to follow the contraceptive guidance in Appendix 4 during the treatment period and for at least 3 months after the last dose of study treatment.
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,A WOCBP must have a negative serum pregnancy test (beta human chorionic gonadotropin [-hCG]) at screening and a negative urine pregnancy test at Visit 2 before randomization.
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Written informed consent provided by participant or legal representative and caregiver prior to any study-specific procedures.
NCT03969732,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage", ICH
NCT03969732,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage",Ageabove 20 years old.
NCT03969732,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage",Evidence of intraparenchymal hemorrhage on CT or MRI.
NCT03969732,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage","Patient agrees to participate in the study and receive neurophsychological examinations, genetic and biochemical markers test, MRI and PET imaging."
NCT03969732,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage", AD
NCT03969732,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage",Ageabove 20 years old.
NCT03969732,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage",Patients who fulfills the clinical criteria of possible or probable Alzheimer's disease (AD).51
NCT03969732,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage","Patient agrees to participate in the study and receive neurophsychological examinations, genetic and biochemical markers test, MRI and PET imaging."
NCT03969732,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage", Control
NCT03969732,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage",Ageabove 20 years old.
NCT03969732,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage","Patient agrees to participate in the study and receive neurophsychological examinations, genetic and biochemical markers test, MRI and PET imaging."
NCT03977584,Phase 2,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Enrolled in main Study NCT01998841 (GN28352).
NCT03980730,Phase 2,Alzheimer Disease,vTv Therapeutics,unknown,Alzheimer Disease;Glucose Intolerance, Diagnosis of probable Alzheimer Disease (AD) with documented evidence of progression of disease
NCT03980730,Phase 2,Alzheimer Disease,vTv Therapeutics,unknown,Alzheimer Disease;Glucose Intolerance," Mini Mental State Examination (MMSE) score of 21-26, inclusive"
NCT03980730,Phase 2,Alzheimer Disease,vTv Therapeutics,unknown,Alzheimer Disease;Glucose Intolerance, Clinical Dementia Rating global score of 0.5 or 1
NCT03980730,Phase 2,Alzheimer Disease,vTv Therapeutics,unknown,Alzheimer Disease;Glucose Intolerance, Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog14) of 10 or more
NCT03980730,Phase 2,Alzheimer Disease,vTv Therapeutics,unknown,Alzheimer Disease;Glucose Intolerance, Brain magnetic resonance imaging (MRI) consistent with the diagnosis of probable AD
NCT03980730,Phase 2,Alzheimer Disease,vTv Therapeutics,unknown,Alzheimer Disease;Glucose Intolerance, Concurrent use of cholinesterase inhibitor or memantine with stable dose for at least 2 months prior to screening
NCT03980730,Phase 2,Alzheimer Disease,vTv Therapeutics,unknown,Alzheimer Disease;Glucose Intolerance," Hemoglobin A1c (HbA1c) 6.5% - 9.5%, inclusive"
NCT03980730,Phase 2,Alzheimer Disease,vTv Therapeutics,unknown,Alzheimer Disease;Glucose Intolerance, Caregiver willing to participate and be able to attend clinic visits with patient
NCT03980730,Phase 2,Alzheimer Disease,vTv Therapeutics,unknown,Alzheimer Disease;Glucose Intolerance, Ability to ingest oral medications
NCT03991988,Phase 2,Alzheimer Disease,Emory University,unknown,Alzheimer Disease;Montelukast,Age: 50 years or older
NCT03991988,Phase 2,Alzheimer Disease,Emory University,unknown,Alzheimer Disease;Montelukast,MCI group will be defined based on:
NCT03991988,Phase 2,Alzheimer Disease,Emory University,unknown,Alzheimer Disease;Montelukast, (i) Subjective memory concern;
NCT03991988,Phase 2,Alzheimer Disease,Emory University,unknown,Alzheimer Disease;Montelukast," (ii) Abnormal memory function documented using the Logical Memory subscale (Delayed Paragraph Recall, Paragraph A only) from the Wechsler Memory Scale-Revised (the maximum score is 25): [less than 11 for 16 or more years of education; less than 9 for 8-15 years of education; less than 6 for less than 7 years of education];"
NCT03991988,Phase 2,Alzheimer Disease,Emory University,unknown,Alzheimer Disease;Montelukast, (iii) Montreal Cognitive Assessment (MoCA) less than  26;
NCT03991988,Phase 2,Alzheimer Disease,Emory University,unknown,Alzheimer Disease;Montelukast, (iv) Clinical Dementia Rating scale /Memory box score=0.5;
NCT03991988,Phase 2,Alzheimer Disease,Emory University,unknown,Alzheimer Disease;Montelukast, (v) General functional performance sufficiently preserved (Functional Assessment Questionnaire 5).
NCT03991988,Phase 2,Alzheimer Disease,Emory University,unknown,Alzheimer Disease;Montelukast,Early AD dementia group will be defined based on:
NCT03991988,Phase 2,Alzheimer Disease,Emory University,unknown,Alzheimer Disease;Montelukast, (i) Subjective memory concern;
NCT03991988,Phase 2,Alzheimer Disease,Emory University,unknown,Alzheimer Disease;Montelukast," (ii) Abnormal memory function documented using the Logical Memory subscale (Delayed Paragraph Recall, Paragraph A only) from the Wechsler Memory Scale-Revised (the maximum score is 25): [less than 11 for 16 or more years of education; less than 9 for 8-15 years of education; less than 6 for less than 7 years of education];"
NCT03991988,Phase 2,Alzheimer Disease,Emory University,unknown,Alzheimer Disease;Montelukast, (iii) Montreal Cognitive Assessment (MoCA) less than 26;
NCT03991988,Phase 2,Alzheimer Disease,Emory University,unknown,Alzheimer Disease;Montelukast, (iv) Clinical Dementia Rating scale/Memory box score 1 or 2;
NCT03991988,Phase 2,Alzheimer Disease,Emory University,unknown,Alzheimer Disease;Montelukast, (v) Early AD dementia defined as Functional Assessment Staging Test (FAST) of 4 or 5
NCT04004702,Phase 2,Alzheimer Disease,Walter Reed National Military Medical Center,unknown,Alzheimer Disease;Epilepsy;Levetiracetam, Meet the National Institute of Aging-Alzheimer's Association criteria for probable AD
NCT04004702,Phase 2,Alzheimer Disease,Walter Reed National Military Medical Center,unknown,Alzheimer Disease;Epilepsy;Levetiracetam, Twelve-item Neuropsychiatric Inventory with score 4 or greater
NCT04004702,Phase 2,Alzheimer Disease,Walter Reed National Military Medical Center,unknown,Alzheimer Disease;Epilepsy;Levetiracetam, MMSE less than 26
NCT04004702,Phase 2,Alzheimer Disease,Walter Reed National Military Medical Center,unknown,Alzheimer Disease;Epilepsy;Levetiracetam," Stable doses current medications, including acetylcholinesterase inhibitors if applicable, for at least 4 weeks prior to trial entry"
NCT04004702,Phase 2,Alzheimer Disease,Walter Reed National Military Medical Center,unknown,Alzheimer Disease;Epilepsy;Levetiracetam," Reliable caregiver willing and available to assist with medication administration, outcome measures"
NCT04004702,Phase 2,Alzheimer Disease,Walter Reed National Military Medical Center,unknown,Alzheimer Disease;Epilepsy;Levetiracetam, MRI completed with no evidence of potential seizure focus as outlined in the exclusion criteria
NCT04063124,Phase 1/Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Dasatinib;Quercetin,Age 65 years or above.
NCT04063124,Phase 1/Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Dasatinib;Quercetin,Clinical diagnosis of AD (MoCA 10-20 and Clinical Dementia Rating Scale/CDR = 1) on a stable dose of cholinesterase inhibitors for at least three months
NCT04063124,Phase 1/Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Dasatinib;Quercetin,Body Mass Index (BMI) within range of 19 - 35 kg/ m2
NCT04063124,Phase 1/Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Dasatinib;Quercetin,"Labs: Normal blood cell counts without clinically significant excursions (WBCs: 4,500-10,500 cells/mcL; absolute neutrophil count: 1,800-8,700 cells/mcL; platelets: 140-450 K/uL; hemoglobin 12.0-17.5 grams/dL); liver and renal function (AST 10-40 IU/L, total bilirubin 0.1-1.4 mg/dl); cholesterol (less than 240 mg/dl), triglycerides (less than 300 mg/dl), and glucose control (HbA1c less than  7%). PT/PTT/INR within normal limits"
NCT04063124,Phase 1/Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Dasatinib;Quercetin,Participants must be accompanied by a Legally Authorized Representative designated to sign informed consent and to provide study partner reported outcomes at all remaining visits
NCT04063124,Phase 1/Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Dasatinib;Quercetin,Participants must have no plans to travel over the next 4-5 months that interfere with study visits following consent
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,Each subject must be  55 to  85 years of age at the screening visit.
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,Each subject must have a diagnosis of probable AD dementia according to National Institute on Aging-Alzheimer's Association (NIA-AA) criteria.
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,Each subject must have a Mini-Mental State Examination (MMSE) score  15 and  26 at the screening visit.
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,Each subject must have a Magnetic Resonance Imaging (MRI) scan performed during the screening period that is consistent with a diagnosis of AD.
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,"Each subject must have a positive amyloid Positron Emission Tomography (PET) scan, either performed during the screening period, or previously performed provided that the scan and result are considered acceptable by the investigator."
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,"If the subject is receiving a cholinesterase inhibitor (donepezil, rivastigmine, or galantamine) and/or memantine, the dose must have been stable for at least 12 weeks before the screening visit, and the subject must be willing to remain on the same dose for the duration of the trial."
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,"Each subject must have a study partner who is reliable and competent. The study partner must have a close relationship with the subject, have face to face contact at least 3 days/week for a minimum of 6 waking hours/week, and be willing to accompany the subject to all required study visits."
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,"Each subject must have no clinically significant abnormal laboratory test results [complete blood count (CBC), prothrombin time (PT)/international normalized ratio (INR), activated partial thromboplastin time (APTT), comprehensive metabolic panel (CMP), thyroid stimulating hormone (TSH), and vitamin B12 level] at the screening visit."
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,Each subject must have results of a physical and neurological examination and vital signs within normal limits or clinically acceptable to the investigator at the screening visit.
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,"If female, the subject must be postmenopausal defined as: No menses for 12 or more months without an alternative medical cause OR permanently surgically sterile (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy)."
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, Ages greater than = 50 and less than = 85 years
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, Informed consent form (ICF) signed by the subject or legally acceptable representative.
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, Clinical diagnosis of dementia due to possible or probable Alzheimer's disease
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, Mini-Mental State Examination score greater than = 16 and less than = 26 at screening
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease," If female, postmenopausal for at least 1 year"
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease," Patient living at home, senior residential setting, or an institutional setting without the need for continuous (i.e. 24-h) nursing care"
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, General health status acceptable for participation in the study
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, Fluency (oral and written) in English or Spanish
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease," If receiving memantine, rivastigmine, galantamine or an AChEI, receiving a stable dose for at least 3 months. If receiving donepezil, any dose lower than 23 mg once daily."
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, The patient is a non-smoker for at least 3 years.
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, The patient or legal representative must agree to comply with the drawing of blood samples and with a lumbar puncture and the drawing of cerebrospinal fluid samples.
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, The patient has a ratio of total tau/A42 in cerebrospinal fluid greater than = 0.28.
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, Patient has a caregiver or legal representative responsible for administering the drug and recording the time.
NCT04169126,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction, 1.1 All subjects
NCT04169126,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,Age between 55-80 years
NCT04169126,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,Written informed consent must be obtained before any assessment is performed.
NCT04169126,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,"Female subjects must be documented by medical records or physician's note to be either surgically sterile (by means of hysterectomy, bilateral oophorectomy, or tubal ligation) or post-menopausal for at least 1 year or, if they are of child-bearing potential, must commit to use a barrier contraception method for the duration of the study."
NCT04169126,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,"Male subjects and their partners of childbearing potential must commit to the use of two methods of contraception, one of which is a barrier method for male subjects for the study duration."
NCT04169126,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,Male subjects must not donate sperm for the study duration.
NCT04169126,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,Willing to undergo repeated MRIs and at least two PET scans.
NCT04169126,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction, 1.2 Patient with Prodromal AD or AD dementia
NCT04169126,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,Patients fulfill the criteria of prodromal AD or AD dementia based on IWG-2 criteria
NCT04169126,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,Able to provide written informed consent with reliable carer in AD population. The participant should have reading ability OR 6/more years of formal education OR with working experiences.
NCT04169126,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction, 1.3 Cognitive normal control
NCT04169126,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,"Cognitive unimpaired individual is defined as normal control in this study. Cognitive un-impaired normal control is defined as cognitive performance in the non-impaired range for that individual, defined as not mild cognitive impairment or demented)."
NCT04169126,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,The normal control should have their clinical dementia rating score 0
NCT04169126,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,Cognitive Ability Screening Instrument (CASI) scores rated greater than 50 percentile.
NCT04174287,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Amyloidosis, All the participants must meet the following criteria:
NCT04174287,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Amyloidosis,Age between 55-80 years.
NCT04174287,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Amyloidosis,Patients population: Diagnosed as prodromal AD or mild AD dementia based on IWG-2 criteria.
NCT04174287,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Amyloidosis,"Normal control population: Cognitive unimpaired individual is defined as normal control in this study. Cognitive un-impaired normal control is defined as cognitive performance in the non-impaired range for that individual, defined as not mild cognitive impairment or demented. The normal control should have their clinical dementia rating score 0 AND Cognitive Ability Screening Instrument (CASI) scores rated greater than 50 percentile."
NCT04174287,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Amyloidosis,Able to provide written informed consent with reliable caregiver in AD population. The participant should have reading ability OR 6/more years of formal education OR with working experiences.
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,"Subjects between the ages of 50 and 85 (inclusive) at the time of Screening Visit 1. Subjects 86 to 90 years of age (inclusive) can be enrolled, provided that the Medical Monitor reviews the subject's medical condition during the screening process and approves enrolment."
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,"Dementia of mild to moderate severity, as classified by MMSE score between 14 to 26, inclusive, at Screening Visit 1."
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,Meets diagnostic clinical criteria of probable Alzheimer's dementia according to the National Institute on Aging and the Alzheimer's Association (NIA-AA) [25].
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,Magnetic resonance imaging prior to Visit 3 (Baseline) compatible with a diagnosis of probable AD.
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,"Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) brain scan showing a pattern typical for AD according to central PET reader (with areas of glucose hypometabolism in posterior cingulate, temporal, parietal, and/or prefrontal cortices, as per criteria in imaging manual)."
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,Confirmed APOE negative genotype result obtained by the central laboratory prior to Screening Visit 2 or documented prior to screening.
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,"Subjects taking the following cholinesterase inhibitors (ChEI): donepezil, galantamine, or rivastigmine; and/or GV-971, and/or memantine and/or other agents which may impact cognition (e.g., Souvenaid, NeuroAidTM, Cerefolin, Gingko biloba, etc) are eligible for enrolment:"
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,If the subject has been taking such medication(s)/products for 3 months or more at Screening Visit 1.
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,If the current dosage regimen is within the approved dose range.
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,The daily dose has remained unchanged for at least 6 weeks prior to screening.
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,If the dose is not expected to change during trial participation.
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,Tacrine use is not allowed.
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,"In the opinion of the Investigator, the subject's medical condition, except for dementia, has been stable for at least 3 consecutive months prior to Screening Visit 1."
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,"Subjects do not have active suicidal thoughts (answers 'yes' to questions 4 or 5, on the Columbia-Suicide Severity Rating Scale [C-SSRS]) within 6 months preceding Screening Visit 2 or Visit 3 (Baseline). Additionally, subjects have no active history of suicide attempt in the previous 2 years or more than 1 lifetime suicide attempt, nor are they at serious suicidal risk, in the opinion of the Investigator."
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,The subject is able to comply with protocol testing and procedures for the entire length of the trial.
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,"Has a permanent caregiver (subject's caregiver is not expected to change during the trial) who is willing to attend all visits, oversee the subject's compliance with protocol-specified procedures and IP administration, and report on subject's status. Caregiver must have, in the opinion of the Investigator, enough contact with the subject to be able to perform the duties described above."
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,"The subject and caregiver are, in the Investigator's judgement, proficient in the language in which the trial assessments will be completed, and have hearing, vision and physical abilities adequate to perform assessments (corrective aids allowed)."
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,"Subject and caregiver must provide full written informed consent prior to the performance of any protocol-specified procedure; or if subject is unable to provide informed consent due to cognitive status, provision of informed consent by cognitively intact legally acceptable representative (where this is in accordance with local laws, regulations and ethics committee policy)."
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,Subject is able to ingest oral medication.
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,Subject is able to tolerate a 5 g dose of tricaprilin (formulated as 12.5 g of AC-SD-03) as per sentinel dose challenge at Visit 3 (Baseline).
NCT04229927,Phase 3,Moderate-to-severe Alzheimer's Disease,"Hyundai Pharmaceutical Co., LTD.",unknown,Alzheimer Disease," A voluntary, written informed consent from the patient or the patients representative."
NCT04229927,Phase 3,Moderate-to-severe Alzheimer's Disease,"Hyundai Pharmaceutical Co., LTD.",unknown,Alzheimer Disease, Male or female patients  45 years of age as of the date of informed consent.
NCT04229927,Phase 3,Moderate-to-severe Alzheimer's Disease,"Hyundai Pharmaceutical Co., LTD.",unknown,Alzheimer Disease, Diagnosed with probable AD according to the National Institute on Aging-Alzheimer's Association [NIA-AA (2011)] criteria.
NCT04229927,Phase 3,Moderate-to-severe Alzheimer's Disease,"Hyundai Pharmaceutical Co., LTD.",unknown,Alzheimer Disease, MMSE score of  5 and  20 during screening period.
NCT04229927,Phase 3,Moderate-to-severe Alzheimer's Disease,"Hyundai Pharmaceutical Co., LTD.",unknown,Alzheimer Disease, CDR-GS of 2 ~ 3 or GDS of 4 ~ 7 during screening period.
NCT04229927,Phase 3,Moderate-to-severe Alzheimer's Disease,"Hyundai Pharmaceutical Co., LTD.",unknown,Alzheimer Disease," Ongoing cholinesterase inhibitor therapy with stable dose of 10 mg/day donepezil hydrochloride for more than 12 weeks (inclusive) prior to screening, and can continue this therapy until randomization without any change in the dosage regimen of donepezil hydrochloride."
NCT04249869,Phase 1/Phase 2,Alzheimer Disease,"Taipei Veterans General Hospital, Taiwan",unknown,Alzheimer Disease,Aged over 65 years old regardless of gender.
NCT04249869,Phase 1/Phase 2,Alzheimer Disease,"Taipei Veterans General Hospital, Taiwan",unknown,Alzheimer Disease,Under the subject's and caregiver's willing and agreement.
NCT04249869,Phase 1/Phase 2,Alzheimer Disease,"Taipei Veterans General Hospital, Taiwan",unknown,Alzheimer Disease,"According to DSM5 (American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing), was diagnosis of mild to moderate Alzheimer's type dementia;"
NCT04249869,Phase 1/Phase 2,Alzheimer Disease,"Taipei Veterans General Hospital, Taiwan",unknown,Alzheimer Disease,MMSE score between 14 and 26;
NCT04249869,Phase 1/Phase 2,Alzheimer Disease,"Taipei Veterans General Hospital, Taiwan",unknown,Alzheimer Disease,"Under standard treatment regularly over 3 months. (Includes Acetylcholinesterase inhibitor, NMDA receptor antagonist, and antipsychotics, antidepressants, mood stabilizer, and anxiolytic agents)"
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease," Have a reliable caregiver, an identified adult who, in the opinion of the investigator has sufficient contact to knowledgeably report on the subject's daily cognition, function, behavior, safety, compliance and adherence. Same caregiver(s) must assist the subject throughout the duration of the trial."
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease, Have a clinical diagnosis of mild-to-moderate AD (Stage 4 or 5) according to the NIA-AA (National Institute of Aging - Alzheimer's Association) criteria at screening
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease, Meet criteria for mild-to-moderate cognitive impairment with Mini-Mental State Examination (MMSE) score of 14 through 26 at the screening visit.
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease, Neuroimaging evidence consistent with the diagnosis of AD
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease, Modified Hachinski less than /= 4 at screening
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease, Clinical Dementia Rating is 0.5 to 2.0 at screening and Clinical Dementia Rating - Sum of Boxes is  3 at screening
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease, Visual and auditory acuity adequate for neuropsychological testing
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease, No evidence of hepatic impairment or renal insufficiency
NCT04305210,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease, Patient with probable AD (Appendix I) Inclusion criteria
NCT04305210,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease,Age ranges from 45~90 years
NCT04305210,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease,Patients fulfill the criteria of probable AD (DSM IV and NINCDS-ADRDA)
NCT04305210,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease,Mild cognitive impairment to moderate dementia (CDR: 0.5 to 2.0 or MMSE: 10-25)
NCT04305210,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease,Female subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception after the final study
NCT04305210,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease, Patient with amnestic MCI due to AD criteria (Appendix II: criteria proposed by world ADNI) Inclusion criteria
NCT04305210,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease,Age ranges from 45~90 years
NCT04305210,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease,Patients fulfill the criteria of aMCI (The early aMCI and late aMCI were proposed by world ADNI)
NCT04305210,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease,"Amnestic mild cognitive impairment (CDR: 0.5 or MMSE: 26-30, with logical memory greater than =7)"
NCT04305210,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease,Female subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception after the final study
NCT04305210,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease," Patients with probable FTD (Appendix III) 1, 2, 3 Inclusion criteria"
NCT04305210,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease,Age ranges from 45~90 years
NCT04305210,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease,Patients fulfill the criteria of probable FTD
NCT04305210,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease,Mild cognitive impairment to moderate dementia (CDR: 0.5 to 2.0 or MMSE: 10-25)
NCT04305210,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease,Female subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception after the final study
NCT04305210,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease, Healthy control Inclusion criteria
NCT04305210,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease,Age ranges from 45~90 years
NCT04305210,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease,Normal cognitive function (CDR: 0 or MMSE: 26-30)
NCT04305210,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease,Female subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception after the final study
NCT04309253,Phase 2,"Vascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal Dementia",Chang Gung Memorial Hospital,unknown,"Alzheimer Disease;Dementia;Tauopathies;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain;Plaque, Amyloid;Cognitive Dysfunction","Inclusion criteria for VCI (Group A, n=80)"
NCT04309253,Phase 2,"Vascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal Dementia",Chang Gung Memorial Hospital,unknown,"Alzheimer Disease;Dementia;Tauopathies;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain;Plaque, Amyloid;Cognitive Dysfunction", Males or females with age greater than = 20 years old.
NCT04309253,Phase 2,"Vascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal Dementia",Chang Gung Memorial Hospital,unknown,"Alzheimer Disease;Dementia;Tauopathies;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain;Plaque, Amyloid;Cognitive Dysfunction", Patients fulfill the AHA/ASA criteria for vascular cognitive impairment.
NCT04309253,Phase 2,"Vascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal Dementia",Chang Gung Memorial Hospital,unknown,"Alzheimer Disease;Dementia;Tauopathies;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain;Plaque, Amyloid;Cognitive Dysfunction", Provision of signed informed consent from the subject and the subject's legally authorized representative or caregiver (if applicable).
NCT04309253,Phase 2,"Vascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal Dementia",Chang Gung Memorial Hospital,unknown,"Alzheimer Disease;Dementia;Tauopathies;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain;Plaque, Amyloid;Cognitive Dysfunction"," The subject has an appropriate caregiver capable of accompanying the subject, if necessary."
NCT04309253,Phase 2,"Vascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal Dementia",Chang Gung Memorial Hospital,unknown,"Alzheimer Disease;Dementia;Tauopathies;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain;Plaque, Amyloid;Cognitive Dysfunction","Inclusion criteria for AD / MCI (Group B, n=80)"
NCT04309253,Phase 2,"Vascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal Dementia",Chang Gung Memorial Hospital,unknown,"Alzheimer Disease;Dementia;Tauopathies;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain;Plaque, Amyloid;Cognitive Dysfunction", Males or females with age greater than = 20 years old.
NCT04309253,Phase 2,"Vascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal Dementia",Chang Gung Memorial Hospital,unknown,"Alzheimer Disease;Dementia;Tauopathies;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain;Plaque, Amyloid;Cognitive Dysfunction", Patients fulfill the National Institute on Aging (NIA) - Alzheimer's Association Diagnostic Guidelines.
NCT04309253,Phase 2,"Vascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal Dementia",Chang Gung Memorial Hospital,unknown,"Alzheimer Disease;Dementia;Tauopathies;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain;Plaque, Amyloid;Cognitive Dysfunction", Provision of signed informed consent from the subject and the subject's legally authorized representative or caregiver (if applicable).
NCT04309253,Phase 2,"Vascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal Dementia",Chang Gung Memorial Hospital,unknown,"Alzheimer Disease;Dementia;Tauopathies;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain;Plaque, Amyloid;Cognitive Dysfunction"," The subject has an appropriate caregiver capable of accompanying the subject, if necessary."
NCT04309253,Phase 2,"Vascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal Dementia",Chang Gung Memorial Hospital,unknown,"Alzheimer Disease;Dementia;Tauopathies;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain;Plaque, Amyloid;Cognitive Dysfunction","Inclusion criteria for FTD (Group C, n=30)"
NCT04309253,Phase 2,"Vascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal Dementia",Chang Gung Memorial Hospital,unknown,"Alzheimer Disease;Dementia;Tauopathies;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain;Plaque, Amyloid;Cognitive Dysfunction", Males or females with age greater than = 20 years old.
NCT04309253,Phase 2,"Vascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal Dementia",Chang Gung Memorial Hospital,unknown,"Alzheimer Disease;Dementia;Tauopathies;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain;Plaque, Amyloid;Cognitive Dysfunction", Patients fulfill the criteria of probable FTD.
NCT04309253,Phase 2,"Vascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal Dementia",Chang Gung Memorial Hospital,unknown,"Alzheimer Disease;Dementia;Tauopathies;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain;Plaque, Amyloid;Cognitive Dysfunction", Provision of signed informed consent from the subject and the subject's legally authorized representative or caregiver (if applicable).
NCT04309253,Phase 2,"Vascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal Dementia",Chang Gung Memorial Hospital,unknown,"Alzheimer Disease;Dementia;Tauopathies;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain;Plaque, Amyloid;Cognitive Dysfunction"," The subject has an appropriate caregiver capable of accompanying the subject, if necessary."
NCT04309253,Phase 2,"Vascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal Dementia",Chang Gung Memorial Hospital,unknown,"Alzheimer Disease;Dementia;Tauopathies;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain;Plaque, Amyloid;Cognitive Dysfunction","Inclusion criteria for normal control (Group D, n=30)"
NCT04309253,Phase 2,"Vascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal Dementia",Chang Gung Memorial Hospital,unknown,"Alzheimer Disease;Dementia;Tauopathies;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain;Plaque, Amyloid;Cognitive Dysfunction", Males or females with age greater than = 20 years old.
NCT04309253,Phase 2,"Vascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal Dementia",Chang Gung Memorial Hospital,unknown,"Alzheimer Disease;Dementia;Tauopathies;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain;Plaque, Amyloid;Cognitive Dysfunction", Provision of signed informed consent.
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,Male or female aged 55 to 80 years old (inclusive)
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,Diagnosis of probable AD dementia based on National Institute on Aging and Alzheimer's Association (NIA/AA) AD Dementia diagnostic criteria
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,Mild AD as assessed by Mini Mental State Examination (MMSE) score between 18 to 26 at Screening Visit (inclusive)
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,Tau positive as evaluated by Tau PET using 18F-PI-2620 and assessment of tracer uptake in the medial temporal lobe and any cortical regions associated with Alzheimer's disease.
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,Geriatric Depression Scale score of  6 (on the staff administered short form)
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,Magnetic resonance imaging (MRI) or computerized tomography (CT) scan performed within the past 2 years that has confirmed no findings inconsistent with a diagnosis of AD
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,Subjects or his/her caregiver and/or legally authorized representative must have signed and dated an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written Informed Consent Form (ICF)
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,"Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, and other requirements of the study"
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,"Must have one caregiver who, in the investigator's judgment, has frequent and sufficient contact with the subject (at least 10 hours/week) and is able to provide accurate information about the subject's cognitive and functional abilities; the caregiver must agree to, accompany the subject to clinic visits and/or be available by phone at designated times to provide information to the investigator and study staff about the subject, attend in person clinic visits that require partner input for scale completion, and must agree to monitor the subject's administration of any prescribed medications"
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,"Female must either be post menopausal (no menstrual period for greater than 1 year), or surgically sterilized (by hysterectomy, bilateral oophorectomy, or bilateral tubal ligation)."
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,"Males who are sexually active and whose partners are females of childbearing potential must agree to use condoms from screening through 90 days after administration of the last dose of IMP; their partners must be willing to use a medically acceptable method of contraception (a barrier method, intrauterine device, or hormonal contraception) from screening through 90 days after administration of the last dose of IMP"
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,Must consent to Apolipoprotein E (ApoE) genotyping; the subject's ApoE status may be disclosed to him/her at the investigator's discretion -
NCT04314934,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease, Previous completion of participation in the ANAVEX2-73-AD-004 double-blind study.
NCT04314934,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease," Participants may be either outpatients, or residents of an assisted-living facility."
NCT04314934,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease," Participants must have a designated study partner, who spends at least 10hrs per week with the participant, in order that assessments e.g. carer burden instruments are completed with true knowledge of the participant."
NCT04314934,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease," No suicidal ideation of type 4 or 5 in the Columbia Suicide Severity Rating Scale (C-SSRS) in the past 3 months (i.e. active suicidal thought(s) with intent but without specific plan, or active suicidal thought(s) with plan and intent) OR suicidal behavior in the past 2 years (i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior)."
NCT04314934,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease," Confirmation from the participant that, if of childbearing potential is not pregnant through urine pregnancy testing."
NCT04339413,Phase 3,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Part 1: Participants who completed the open-label extensions (OLEs) of studies WN25203 or WN28745 will be eligible to participate in Part 1 of the study
NCT04339413,Phase 3,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Part 2: All participants who have completed Week 104 visit in Part 1 will be eligible for Part 2 of the study
NCT04339413,Phase 3,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, For Part 1 and Part 2:
NCT04339413,Phase 3,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of less than 1% per year during the treatment period and for at least 16 weeks after the last dose of study drug
NCT04339413,Phase 3,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Agreement to not donate blood or blood products for transfusion for the duration of the study and for 1 year after final dose of study drug
NCT04339413,Phase 3,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Availability of a person ('caregiver') who in the investigator's judgement, has frequent and sufficient contact with the participant"
NCT04374253,Phase 3,Alzheimer Disease,Hoffmann-La Roche,unknown,"Alzheimer Disease;Antibodies, Monoclonal"," Completed Study WN29922 or WN39658, either its double-blind part or OLE part, and did not discontinue study drug early"
NCT04374253,Phase 3,Alzheimer Disease,Hoffmann-La Roche,unknown,"Alzheimer Disease;Antibodies, Monoclonal", The participant should be capable of completing assessments either alone or with the help of the caregiver
NCT04374253,Phase 3,Alzheimer Disease,Hoffmann-La Roche,unknown,"Alzheimer Disease;Antibodies, Monoclonal", Availability of a person (referred to as the  caregiver )
NCT04374253,Phase 3,Alzheimer Disease,Hoffmann-La Roche,unknown,"Alzheimer Disease;Antibodies, Monoclonal"," For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception methods with a failure rate of less than 1% per year (bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices) during the treatment period and for at least 16 weeks after the final dose of gantenerumab"
NCT04374253,Phase 3,Alzheimer Disease,Hoffmann-La Roche,unknown,"Alzheimer Disease;Antibodies, Monoclonal", Agreement not to donate blood or blood products for transfusion for the duration of the study and for 1 year after final dose of study drug
NCT04408755,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation, Participants with a diagnosis of probable Alzheimer's disease according to the 2011 Neuropsychiatric Inventory Agitation/Aggression (NPI-AA) working groups criteria
NCT04408755,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation," Participants with clinically significant, moderate-to-severe agitation for at least 2 weeks prior to Screening that interferes with daily routine per the Investigator's judgment"
NCT04408755,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation, Participants who require pharmacotherapy for the treatment of agitation per the Investigator's judgment after an evaluation of reversible factors and a course of nonpharmacological interventions
NCT04408755,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation, Diagnosis of agitation must meet the International Psychogeriatric Association (IPA) provisional definition of agitation.
NCT04408755,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation," Participants meeting an additional predetermined blinded eligibility criterion, which will remain blinded to the clinical study site Investigators and staff"
NCT04408755,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation," Participants with a reliable caregiver who is able and willing to comply with all study procedures, including adherence to administering study drug and not administering any prohibited medications during the course of the study, and who spends a minimum of 2 hours per day for 4 days per week with the participant"
NCT04437511,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease, Gradual and progressive change in memory function reported by participants or informants for  6 months
NCT04437511,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease, MMSE score of 20 to 28 (inclusive) at baseline
NCT04437511,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease, Meet 18F flortaucipir PET scan (central read) criteria - does not apply to safety cohort
NCT04437511,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease, Meet 18F florbetapir PET scan (central read) criteria
NCT04437511,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease, Have a study partner who will provide written informed consent to participate
NCT04464564,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation, Participants with a diagnosis of probable Alzheimer's disease according to the 2011 Neuropsychiatric Inventory Agitation/Aggression (NPI-AA) working groups criteria
NCT04464564,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation," Participants with clinically significant, moderate-to-severe agitation for at least 2 weeks prior to Screening that interferes with daily routine per the Investigator's judgment"
NCT04464564,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation, Participants who require pharmacotherapy for the treatment of agitation per the Investigator's judgment after an evaluation of reversible factors and a course of nonpharmacological interventions
NCT04464564,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation, Diagnosis of agitation must meet the International Psychogeriatric Association (IPA) provisional definition of agitation.
NCT04464564,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation," Participants meeting an additional predetermined blinded eligibility criterion, which will remain blinded to the clinical study site Investigators and staff"
NCT04464564,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation," Participants with a reliable caregiver who is able and willing to comply with all study procedures, including adherence to administering study drug and not administering any prohibited medications during the course of the study, and who spends a minimum of 2 hours per day for 4 days per week with the participant"
NCT04482413,Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease;Donepezil, Male or female patients aged 50 and above at the time of signing the Informed Consent Form
NCT04482413,Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease;Donepezil, Patients who can understand and provide written informed consent (assent)
NCT04482413,Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease;Donepezil, Patients who have a diagnosis of probable mild Alzheimer's Disease(AD) according to the National Institute of Neurological and Communicative Disorders and Stroke; Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria within one year of the start of treatment
NCT04482413,Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease;Donepezil, Patients who have an MMSE Score of 20 to 24 at baseline
NCT04482413,Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease;Donepezil," Patients who have not taken any FDA-approved AD medication (donepezil, galantamine, memantine, rivastigmine or any combination) since their AD diagnosis"
NCT04482413,Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease;Donepezil," Patients who have one (or more) identified adult caregiver (study partner) who is able to read, understand, and speak the designated language at the study site; who either lives with the subject or sees the subject for 2 hours/day 4 days/week; and who agrees to accompany the subject to each study visit and to participate in the subject's clinical assessments"
NCT04482413,Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease;Donepezil," Patients who have a diagnosis of probable mild AD according to concentration of biomarkers in CSF (Amyloid beta 42, t-tau and p-tau)"
NCT04520412,Phase 3,Alzheimer Disease,"Green Valley (Shanghai) Pharmaceuticals Co., Ltd.",unknown,Alzheimer Disease, Mild to moderate AD per NIA-AA.
NCT04520412,Phase 3,Alzheimer Disease,"Green Valley (Shanghai) Pharmaceuticals Co., Ltd.",unknown,Alzheimer Disease, History of cognitive and functional decline over at least 1 year.
NCT04520412,Phase 3,Alzheimer Disease,"Green Valley (Shanghai) Pharmaceuticals Co., Ltd.",unknown,Alzheimer Disease, MMSE scores between 11 and 24 (inclusive) at baseline.
NCT04520412,Phase 3,Alzheimer Disease,"Green Valley (Shanghai) Pharmaceuticals Co., Ltd.",unknown,Alzheimer Disease, Brain MRI scan show the highest possibility of AD.
NCT04520412,Phase 3,Alzheimer Disease,"Green Valley (Shanghai) Pharmaceuticals Co., Ltd.",unknown,Alzheimer Disease, Have a study partner/caregiver.
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Written informed consent from caregiver and subject (if possible) or legally acceptable representative if different from caregiver
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Male and female subjects 55-85 years of age inclusive
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Cognitive deficit present for at least 2 years that meet the diagnostic criteria for probable Alzheimer's dementia. The diagnosis must be confirmed at the time of the screening visit
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,MMSE-2 score of 10-18 inclusive (applies to Screening Visit only)
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Patients must have a baseline SIB total score of at least 60 and may not have a SIB score greater than 93 at screening
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"Neuroimaging computerized tomography (CT) or Magnetic Resonance Imaging (MRI) within the last 24 months consistent with a diagnosis of probable AD without any other clinically significant co-morbid pathologies. If there has been a significant change in the subject's clinical status since the last imaging study that is not consistent with progression of the subject's AD, an imaging study should be performed to confirm eligibility"
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Reliable caregiver(s) or informant(s) who attends the subject at least an average of 3 hours or more per day for 3 or more days per week and who will agree to accompany the subject to the clinic visits and reliably complete the caregiver questions
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Adequate vision and motor function to comply with testing
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"If taking an approved cholinesterase inhibitor for treatment of Alzheimer's disease, must be on a stable dose for at least 3 months prior to entry into study and the dose must not change during the study unless a change is required due to an adverse effect of the prescribed medication or a clinically significant change in the patient's status"
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Subjects who are memantine nave or have been off memantine for at least 90 days prior to initial treatment with study drug
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Subjects on neuroleptic medications must be on a stable dose for 4 weeks at screening (dose adjustments will be permitted if medically necessary at the discretion of the PI)
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Females participating in the study must meet one the following criteria:
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"Surgically sterilized (e.g., hysterectomy, bilateral oophorectomy or tubal ligation) for at least 6 months or postmenopausal (postmenopausal females must have no menstrual bleeding for at least 1 year) or"
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"If not postmenopausal, agree to use a double method of contraception, one of which is a barrier method (e.g., intrauterine device plus condom, spermicidal gel plus condom) 30 days prior to dosing until 30 days after last dose and have negative human chorionic gonadotropin (-hCG) test for pregnancy at screening"
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Males who have not had a vasectomy must use appropriate contraception methods (barrier or abstinence) from 30 days prior to dosing until 30 days after last dose
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,In the opinion of the PI subjects should be in reasonably good health over the last 6 months and any chronic disease should be stable -
NCT04552795,Phase 1/Phase 2,"Alzheimer Disease, Early Onset","Bess Frost, PhD",unknown,Alzheimer Disease;Lamivudine,Aged 50-99 years
NCT04552795,Phase 1/Phase 2,"Alzheimer Disease, Early Onset","Bess Frost, PhD",unknown,Alzheimer Disease;Lamivudine,"Clinical diagnosis of early Alzheimer's disease (Clinical Dementia Rating (CDR) = 0.5, Mini-Mental State Exam (MMSE) = 24-30)"
NCT04552795,Phase 1/Phase 2,"Alzheimer Disease, Early Onset","Bess Frost, PhD",unknown,Alzheimer Disease;Lamivudine,"If using drugs to treat symptoms related to Alzheimer's disease, doses must be stable for at least eight weeks prior to screening visit 1"
NCT04552795,Phase 1/Phase 2,"Alzheimer Disease, Early Onset","Bess Frost, PhD",unknown,Alzheimer Disease;Lamivudine,"Labs: Adequate blood cell counts (white blood cells: 4,000-111,000 cells per microliter (cells/mcL); absolute neutrophil count: 1,800-8,700 cells/mcL; platelets: 120-500 K/L; hemoglobin 12.0-17.5 grams/dL); LFT's within 2x normal value; creatinine clearance test (CrCl)  50 mL/min; cholesterol (260 mg/dl), triglycerides 400 mg/dl), and glucose control (HbA1c  8%). Prothrombin time/partial thromboplastin time/international normalized ratio (PT/PTT/INR) within normal limits"
NCT04552795,Phase 1/Phase 2,"Alzheimer Disease, Early Onset","Bess Frost, PhD",unknown,Alzheimer Disease;Lamivudine,Body mass index (BMI) within range of 19 - 35 kg/m2
NCT04552795,Phase 1/Phase 2,"Alzheimer Disease, Early Onset","Bess Frost, PhD",unknown,Alzheimer Disease;Lamivudine,Must have a reliable informant or caregiver
NCT04552795,Phase 1/Phase 2,"Alzheimer Disease, Early Onset","Bess Frost, PhD",unknown,Alzheimer Disease;Lamivudine,Participants must have no plans to travel that interfere with study visits
NCT04570085,Phase 3,Alzheimer Disease,"University Hospital, Lille",unknown,Alzheimer Disease;Caffeine, Age  50 at screening
NCT04570085,Phase 3,Alzheimer Disease,"University Hospital, Lille",unknown,Alzheimer Disease;Caffeine," Probable Alzheimer dementia according to the criteria of the National Institute on Aging-Alzheimer's Association; diagnosis must be supported by brain imaging (CT or MRI) and blood test (including ionogram, kidney and liver function, calcemia, CRP, TSH, B12 vitamins and folates) performed in routine care"
NCT04570085,Phase 3,Alzheimer Disease,"University Hospital, Lille",unknown,Alzheimer Disease;Caffeine, MMSE score 16
NCT04570085,Phase 3,Alzheimer Disease,"University Hospital, Lille",unknown,Alzheimer Disease;Caffeine," Presence of an informant and caregiver, living with the patient"
NCT04570085,Phase 3,Alzheimer Disease,"University Hospital, Lille",unknown,Alzheimer Disease;Caffeine, IAChE and/or Memantine treatment non-compulsory ; If implemented it must be effective and stable for 2 months before the selection visit and must remain stable for the duration of the study
NCT04576793,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,Age 50 to 75 years at time of screening.
NCT04576793,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,"At screening, must have no cognitive impairment, or meet criteria for amnestic Alzheimer's disease, posterior cortical atrophy, or logopenic variant primary progressive aphasia. Diagnoses will be made based on history, exam, neuropsychological testing, brain MRI, and consensus diagnosis."
NCT04576793,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,Patients must have Clinical Dementia Rating scale score of 0.5 or 1 at enrollment. Controls must have Clinical Dementia Rating scale score of 0 at enrollment.
NCT04576793,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,Subjects unable to provide informed consent must have a surrogate decision maker.
NCT04576793,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,Written and oral fluency in English.
NCT04576793,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,Able to participate in all scheduled evaluations and to complete all required tests and procedures.
NCT04576793,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,"In the opinion of the PI, the subject must be considered likely to comply with the study protocol and to have a high probability of completing the study."
NCT04592341,Phase 2,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Probable Alzheimer's Disease (AD) dementia or prodromal AD.
NCT04592341,Phase 2,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Availability of a reliable study partner (non-professional caregiver) who accepts to participate in study procedure throughout the study duration
NCT04592341,Phase 2,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," The participant should be capable of completing all aspects of study assessments including MRI, clinical genotyping, and PET imaging, either alone or with the help of the study partner (non-professional caregiver)."
NCT04592341,Phase 2,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Adequate visual and auditory acuitysufficient to perform the neuropsychological testing (eye glasses and hearing aids are permitted).
NCT04592341,Phase 2,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Evidence of AD pathological process, as confirmed by amyloid PET scan by qualitative read by the core/central PET laboratory."
NCT04592341,Phase 2,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Prodromal or mild symptomatology, as defined by a screening Mini-Mental State Examination (MMSE) score greater than /=22 and Clinical Dementia Rating global score (CDR-GS) of 0.5 or 1.0, as well as a clinical dementia rating (CDR) memory domain score greater than /=0.5."
NCT04592341,Phase 2,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," If the participant is receiving symptomatic AD medications, a stable dosing regimen for at least 3 months prior to screening and until start of study treatment."
NCT04592341,Phase 2,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Agreement not to donate blood or blood products for transfusion for the duration of the study and for 1 year after final dose of study drug.
NCT04592341,Phase 2,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Agreement not to participate in other research studies for the duration of this trial, unless these are related Roche-sponsored non-interventional studies."
NCT04592341,Phase 2,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods hat result in a failure rate of less than  1% per year during the treatment period and for at least 16 weeks after the final dose of study drug.
NCT04592874,Phase 2,Alzheimer Disease,Alector Inc.,unknown,Alzheimer Disease, Diagnosis of Early AD including evidence of brain amyloidosis by CSF or PET
NCT04592874,Phase 2,Alzheimer Disease,Alector Inc.,unknown,Alzheimer Disease," MMSE score  22 points, CDR Global Score of 0.5 - 1.0, and RBANS score on the DMI 85."
NCT04592874,Phase 2,Alzheimer Disease,Alector Inc.,unknown,Alzheimer Disease, Study partner who consents to study participation and who cares for/visits the participant at least 10 hours a week
NCT04592874,Phase 2,Alzheimer Disease,Alector Inc.,unknown,Alzheimer Disease," Written informed consent must be obtained and documented (from the participant or, where jurisdictions allow it, from their legal decision maker)."
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction, I. Vascular cognitive impairment patients:
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,Age older than 20 years.
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,Clinical diagnosis:
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,"At least one obstacle to executive function, attention, memory, language and visual space function."
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,Affected activities of daily living.
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,Brain MRI showing cerebrovascular disease.
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,Patient agrees to participate in the study and is willing to receive 11C-PiB PET.
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction, II. Alzheimer's disease (AD) patients:
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,Age older than 20 years.
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,Clinical diagnosis:
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,"Amnesia or non-amnesia (language, visual space, executive ability) performance."
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,Affected activities of daily living.
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,Patient agrees to participate in the study and is willing to receive 11C-PiB PET.
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction, III. Normal controls:
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,Age older than 20 years.
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,No neurological or psychiatric history.
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,Patient agrees to participate in the study and is willing to receive 11C-PiB PET.
NCT04623242,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal", Between 18-80 years of age
NCT04623242,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal", Individuals who know they have an Alzheimer's disease-causing mutation or are unaware of their genetic status and have dominantly inherited Alzheimer's disease (DIAD) mutation in their family.
NCT04623242,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal", Are within -15 to + 10 years of the predicted or actual age of cognitive symptom onset.
NCT04623242,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal"," Cognitively normal or with mild cognitive impairment or mild dementia, Clinical Dementia Rating (CDR) of 0-1 (inclusive)"
NCT04623242,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal", Fluency in DIAN-TU trial approved language and evidence of adequate premorbid intellectual functioning
NCT04623242,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal"," Able to undergo Magnetic Resonance Imaging (MRI), Lumbar Puncture (LP), Positron Emission Tomography (PET), and complete all study related testing and evaluations."
NCT04623242,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal"," For women of childbearing potential, if partner is not sterilized, subject must agree to use effective contraceptive measures (hormonal contraception, intra-uterine device, sexual abstinence, barrier method with spermicide)."
NCT04623242,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal", Adequate visual and auditory abilities to perform all aspects of the cognitive and functional assessments.
NCT04623242,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal"," Has a Study Partner who in the investigator's judgment is able to provide accurate information as to the subject's cognitive and functional abilities, who agrees to provide information at the study visits which require informant input for scale completion."
NCT04629495,Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Cognitive Dysfunction;Sirolimus,Both genders and all ethnic groups
NCT04629495,Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Cognitive Dysfunction;Sirolimus,Ages 55 to 89 years
NCT04629495,Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Cognitive Dysfunction;Sirolimus,"Diagnosis of MCI or AD (Mini Mental Status Examination (MMSE): 18-30; Clinical Dementia Rating Scale (CDR) = 0.5 - 1; California Verbal Learning Test III (CVLT-III) Delayed Recall 16% based on age-adjusted norms, clinician approval)"
NCT04629495,Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Cognitive Dysfunction;Sirolimus,Amyloid positivity based on Amyloid PET Imaging
NCT04629495,Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Cognitive Dysfunction;Sirolimus,Labs: Normal blood cell counts without clinically significant excursions; normal liver and renal function; and glucose control (HbA1c less than  6.5%). Fasting lipid panel and prothrombin time/prothrombin time test/international normalized ration (PT/PTT/INR) within normal limits
NCT04629495,Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Cognitive Dysfunction;Sirolimus,A legally authorized representative (LAR) designated to sign informed consent (if necessary) must attend the Screening visit and accompany the participant to all remaining visits to provide reported outcomes
NCT04629495,Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Cognitive Dysfunction;Sirolimus,"Stable dose of AD medications (Donepezil, rivastigmine, Memantine, galantamine) for at least three months is allowed"
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant, Male or female.
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant, Any race or ethnicity.
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant, Participants must be age 65 years and able to sign informed consent.
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant, PET PIB standard uptake value ratio (SUVR) between greater than 1.42 to less than 3.
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant, Clinical Dementia Rating (CDR) 0.
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant, Willing and able to undergo study procedures.
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant, Capacity to give informed consent and follow study procedures.
NCT04661280,Phase 3,"Alzheimer Disease, Early Onset",Assistance Publique - Hpitaux de Paris,unknown,Alzheimer Disease;Donepezil, Diagnosis of Alzheimer's disease according to the IWG-2 criteria.
NCT04661280,Phase 3,"Alzheimer Disease, Early Onset",Assistance Publique - Hpitaux de Paris,unknown,Alzheimer Disease;Donepezil, Age  50 years.
NCT04661280,Phase 3,"Alzheimer Disease, Early Onset",Assistance Publique - Hpitaux de Paris,unknown,Alzheimer Disease;Donepezil," Absence of legal protection measures (guardianship, curatorship)."
NCT04661280,Phase 3,"Alzheimer Disease, Early Onset",Assistance Publique - Hpitaux de Paris,unknown,Alzheimer Disease;Donepezil, MMSE score  10 at inclusion.
NCT04661280,Phase 3,"Alzheimer Disease, Early Onset",Assistance Publique - Hpitaux de Paris,unknown,Alzheimer Disease;Donepezil, abnormal values for A42 in the CSF or A40 / A42 ratio.
NCT04661280,Phase 3,"Alzheimer Disease, Early Onset",Assistance Publique - Hpitaux de Paris,unknown,Alzheimer Disease;Donepezil, abnormal values for phosphorylated Tau in CSF
NCT04661280,Phase 3,"Alzheimer Disease, Early Onset",Assistance Publique - Hpitaux de Paris,unknown,Alzheimer Disease;Donepezil, Presence of a family carer or a person at home who can ensure compliance with treatment if MMSE score less than 20.
NCT04661280,Phase 3,"Alzheimer Disease, Early Onset",Assistance Publique - Hpitaux de Paris,unknown,Alzheimer Disease;Donepezil, French native speaker.
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,Male or female subject aged 60 to 85 y at Screening (V1). 2. Has mild to moderate probable AD as defined by all of the following criteria:
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,"Meets the National Institute on Aging and Alzheimer's Association (NIA-AA, 2011) criteria of all cause dementia and probable AD."
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,"Has a Clinical Dementia Rating (CDR) (Section 8.1.6) Standard Global Score of 1 to 2, inclusive (mild to moderate)."
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,"Has a MMSE score of 14 and 24 at both Screening and Baseline visits. The difference in scores between Screening and Baseline must be less than  3 points (i.e., the difference must not exceed 3 points). (Section 8.1.5)"
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,Has an historical MRI or CT scan of the brain on file no earlier than AD diagnosis that fails to exhibit features of another potential pathobiology that could better account for the cognitive disorder.
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,Historical evidence of impairment on a mental status exam or documented prior diagnosis of or treatment for dementia from a health care professional.
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,Has a modified Hachinski Ischemic Scale (Section 8.1.8) score of 4 at Screening (V1).
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,"If taking an anticholinesterase inhibitor (AChEI) (e.g., donepezil, galantamine, rivastigmine) and/or memantine at Screening (V1):"
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,"Must have been taking the medication(s) for 3 mo, and"
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,Current dose regimen and form must have remained stable for 6 wk and must remain stable throughout participation in the study.
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease, NOTE: Subjects not being treated with an AChEI and/or memantine at Screening (V1) may also be enrolled if initiation of an AChEI and/or memantine is not planned for the time period during which the subject will be participating in this study.
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease, NOTE: Dosage changes during the study due to clinical deterioration should be discussed with the Medical Monitor prior to being implemented.
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,"If taking medications for glycemic control at the time of Screening (V1), must be stable on the current dose regimen and form for 3 mo prior to randomization and must remain stable throughout participation in the study."
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,Females taking hormone replacement therapy (HRT) must have maintained a stable regimen for at least two years prior to randomization and agree to continue the regimen until completing the final safety assessment in Week 30 at the end of the study.
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,Must meet one of the following criteria:
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,"Females: Surgically sterilized (e.g., hysterectomy, bilateral oophorectomy, or tubal ligation) for at least 6 mo prior to Screening (V1) or postmenopausal (postmenopausal females must have no menstrual bleeding for at least 1 y; if needed, the Investigator may confirm menopausal status through an FSH assessment at Screening [V1]). 6.8.1"
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,"Males: Vasectomized. If not vasectomized, must use an appropriate contraception method as noted in Section 6.8.1."
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,"Must provide voluntary written informed consent prior to Screening (V1). If the subject is unable to provide informed consent due to cognitive status, the subject must provide assent and a legally authorized representative provides full written informed consent on behalf of the subject."
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,"Willing to allow collection of blood for ApoE genotyping. 11. Able to comply with the study procedures, in the opinion of the Investigator."
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,"Has a primary caregiver/study partner willing to accept responsibility for supervising the treatment (e.g., administering study drug), accompanying the subject to clinic visits and assessing the condition of the subject throughout the study in accordance with all protocol requirements. The primary caregiver/study partner must be willing to sign the caregiver ICF."
NCT04693520,Phase 2,Early Alzheimer's Disease,Alzheon Inc.,unknown,Alzheimer Disease,"Age between 50 and 80 years, inclusive."
NCT04693520,Phase 2,Early Alzheimer's Disease,Alzheon Inc.,unknown,Alzheimer Disease,"Early Alzheimer's Disease (AD): a diagnosis of Probable AD Dementia or Mild Cognitive Impairment (MCI) due to AD in accordance with the National Institute on Aging-Alzheimer's Association (NIA-AA) Working Group Criteria [Albert et al, 2011; McKhann et al, 2011]."
NCT04693520,Phase 2,Early Alzheimer's Disease,Alzheon Inc.,unknown,Alzheimer Disease,One of the following apolipoprotein E (APOE) genotypes - either APOE4/4 (homozygous) or APOE3/4 (heterozygous).
NCT04693520,Phase 2,Early Alzheimer's Disease,Alzheon Inc.,unknown,Alzheimer Disease,"MMSE score 22 to 30 inclusive; Clinical Dementia Rating (CDR)-Global Score of 0.5 or 1.0, and CDR Memory Box Score of  0.5."
NCT04693520,Phase 2,Early Alzheimer's Disease,Alzheon Inc.,unknown,Alzheimer Disease,Documented confirmation of AD diagnosis by either positive amyloid positron emission tomography (PET) or positive CSF AD signature. Subjects without documented positive AD biomarker status must have a positive CSF biomarker result from a sample provided at screening.
NCT04693520,Phase 2,Early Alzheimer's Disease,Alzheon Inc.,unknown,Alzheimer Disease,Stable doses of acetylcholinesterase for the duration of the study are allowed.
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Women of non-childbearing potential and men, aged 50 to 85 years, inclusive, with a diagnosis of mild to moderate Alzheimer's disease according to the 2018 NIA-AA criteria and at least a 6-month history of decline in cognitive function documented in the medical record."
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease," i) Non-childbearing potential for women is defined as postmenopausal (last menses greater than 24 months) or undergone a documented bilateral tubal ligation or hysterectomy. If last menses less than 24 months, a serum follicle stimulating hormone (FSH) value confirming post-menopausal status may be used."
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease," ii) Male participants who are sexually active with a woman of child-bearing potential must agree to use condoms during the study and for 3 months after last dose. Female partners should also consider using an acceptable means of birth control, though it is not mandatory. Acceptable forms of birth control include abstinence, birth control pills, or any double combination of: intrauterine device (IUD), male or female condom, diaphragm, sponge, and cervical cap."
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"CSF positive for amyloid beta (as defined in the study manual). Historical CSF results will be considered provided the results are consistent with the CSF amyloid beta threshold required for inclusion and following discussion with the medical monitor; however, an LP is still required as part of screening procedures"
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Neuroimaging (MRI) consistent with the clinical diagnosis of Alzheimer's disease and without findings of significant exclusionary abnormalities (see Section 9.3 exclusion criteria no. 4). An historical MRI, up to 1 year prior to screening, may be used as long as there have been no interval clinical neurologic events that may suggest a change in the MRI scan."
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,MMSE 18-26 inclusive.
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Geriatric Depression Scale (GDS)  6 with no active depression (see Section 9.3 exclusion criteria no. 6).
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Formal education of 8 or more years.
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Participants must have a caregiver/study partner who in the opinion of the site's Principal Investigator, has contact with the study participant for a sufficient number of hours per week to provide informative responses on the protocol assessments, oversee the administration of study drug, and is willing and able to participate in all study site visits and some study assessments. The caregiver/ study partner must provide written informed consent to participate in the study."
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Participants living at home or in the community (assisted living acceptable).
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Participants must have no known history of difficulty swallowing capsules.
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Stable pharmacological treatment of any other chronic conditions for at least 30 days prior to screening.
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Must consent to apolipoprotein E (APOE) genotyping.
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Participants shall be generally healthy with mobility (ambulatory or ambulatory-aided, ie, walker or cane), vision and hearing (hearing aid permissible) sufficient for compliance with testing procedures."
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Must be able to complete all screening evaluations.
NCT04770220,Phase 3,Early Alzheimer's Disease,Alzheon Inc.,unknown,Alzheimer Disease, Clinical diagnosis of MCI or Mild Dementia due to AD consistent with the National Institute on Aging-Alzheimer's Association (NIA-AA) Working Group Criteria.
NCT04770220,Phase 3,Early Alzheimer's Disease,Alzheon Inc.,unknown,Alzheimer Disease, Homozygous for the 4 allele of the apolipoprotein E gene (APOE4/4).
NCT04770220,Phase 3,Early Alzheimer's Disease,Alzheon Inc.,unknown,Alzheimer Disease, MMSE score at Screening of 22 to 30 (inclusive).
NCT04770220,Phase 3,Early Alzheimer's Disease,Alzheon Inc.,unknown,Alzheimer Disease, CDR - Global score of 0.5 or 1 and CDR Memory Box Score of  0.5.
NCT04770220,Phase 3,Early Alzheimer's Disease,Alzheon Inc.,unknown,Alzheimer Disease, RBANS delayed memory index score  85.
NCT04770220,Phase 3,Early Alzheimer's Disease,Alzheon Inc.,unknown,Alzheimer Disease, Evidence of progressive memory loss over the last 12 months per investigator assessment
NCT04777396,Phase 3,Early Alzheimer's Disease,Novo Nordisk A/S,unknown,Alzheimer Disease," Male or female, aged 55-85 years (both inclusive) at the time of signing informed consent."
NCT04777396,Phase 3,Early Alzheimer's Disease,Novo Nordisk A/S,unknown,Alzheimer Disease, MCI (mild cognitive impairment) or mild dementia of the Alzheimer's type according to the NIA-AA (National Institute of Aging-Alzheimer's Association) 2018 criteria.
NCT04777396,Phase 3,Early Alzheimer's Disease,Novo Nordisk A/S,unknown,Alzheimer Disease," CDR (Clinical Dementia Rating) global score of 0.5 and CDR of 0.5 or more in at least one of the three instrumental activities of daily living categories (personal care, home  and  hobbies, community affairs) Or CDR global score of 1.0"
NCT04777396,Phase 3,Early Alzheimer's Disease,Novo Nordisk A/S,unknown,Alzheimer Disease, RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) delayed memory index score of below or equal to 85
NCT04777396,Phase 3,Early Alzheimer's Disease,Novo Nordisk A/S,unknown,Alzheimer Disease, MMSE (Mini-Mental State Examination) greater than or equal to 22
NCT04777396,Phase 3,Early Alzheimer's Disease,Novo Nordisk A/S,unknown,Alzheimer Disease," Amyloid positivity established with either amyloid PET (positron emission tomography), CSF (cerebrospinal fluid) A1-42 or CSF A1-42/A1-40 ."
NCT04777396,Phase 3,Early Alzheimer's Disease,Novo Nordisk A/S,unknown,Alzheimer Disease," If receiving an approved Alzheimer's disease treatment (such as acetylcholinesterase inhibitors, memantine or aducanumab) the dose must have been stable for at least 3 months prior to screening and should not be changed during the trial unless medically necessary."
NCT04777409,Phase 3,Early Alzheimers Disease,Novo Nordisk A/S,unknown,Alzheimer Disease," Male or female, aged 55-85 years (both inclusive) at the time of signing informed consent."
NCT04777409,Phase 3,Early Alzheimers Disease,Novo Nordisk A/S,unknown,Alzheimer Disease, MCI (mild cognitive impairment) or mild dementia of the Alzheimer's type according to the NIA-AA (National Institute of Aging-Alzheimer's Association) 2018 criteria.
NCT04777409,Phase 3,Early Alzheimers Disease,Novo Nordisk A/S,unknown,Alzheimer Disease," CDR (Clinical Dementia Rating) global score of 0.5 and CDR of 0.5 or more in at least one of the three instrumental activities of daily living categories (personal care, home  and  hobbies, community affairs) Or CDR global score of 1.0"
NCT04777409,Phase 3,Early Alzheimers Disease,Novo Nordisk A/S,unknown,Alzheimer Disease, RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) delayed memory index score of below or equal to 85
NCT04777409,Phase 3,Early Alzheimers Disease,Novo Nordisk A/S,unknown,Alzheimer Disease, MMSE (Mini-Mental State Examination) greater than or equal to 22
NCT04777409,Phase 3,Early Alzheimers Disease,Novo Nordisk A/S,unknown,Alzheimer Disease," Amyloid positivity established with either amyloid PET (positron emission tomography), CSF (cerebrospinal fluid) A1-42 or CSF A1-42/A1-40."
NCT04777409,Phase 3,Early Alzheimers Disease,Novo Nordisk A/S,unknown,Alzheimer Disease," If receiving an approved Alzheimer's disease treatment (such as acetylcholinesterase inhibitors, memantine or aducanumab) the dose must have been stable for at least 3 months prior to screening and should not be changed during the trial unless medically necessary."
NCT04784416,Phase 2,Alzheimer Disease,NYU Langone Health,unknown,Alzheimer Disease;Cognitive Dysfunction,Able to give written informed consent and follow study procedures.
NCT04784416,Phase 2,Alzheimer Disease,NYU Langone Health,unknown,Alzheimer Disease;Cognitive Dysfunction,Age  65 years and  85 years.
NCT04784416,Phase 2,Alzheimer Disease,NYU Langone Health,unknown,Alzheimer Disease;Cognitive Dysfunction,"Meets the Petersen MCI criteria for Amnestic MCI (single and multiple domain) with a Clinical Dementia Rating (CDR) between 0.5 to 1, and a Functional Assessment Staging (FAST) of 1-3."
NCT04784416,Phase 2,Alzheimer Disease,NYU Langone Health,unknown,Alzheimer Disease;Cognitive Dysfunction,"Consents to permit and identifies a willing informed relative, family member, or spouse for study staff to interview to confirm subject reports as per UDS 3.0 guidelines."
NCT04784416,Phase 2,Alzheimer Disease,NYU Langone Health,unknown,Alzheimer Disease;Cognitive Dysfunction,Have at least a high school diploma / 12 years education
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,Men and women of age 55 years and older at the time of enrollment
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,"Clinical diagnosis of symptomatic probable AD (MMSE 26 to 15 or Short Test of Mental Status 31 to 15 inclusive and/or Clinical Dementia Rating Scale/CDR = 0.5 to 2, inclusive)"
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,"Not on cholinesterase inhibitors or memantine; or if on cholinesterase inhibitors and/or memantine, on a stable dose for at least three months"
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,Body Mass Index (BMI) within range of 19 - 50 kg/ m2
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,Participants must be accompanied by a LAR designated to sign informed consent and to provide study partner reported outcomes at all visits
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,Participants must have no plans to travel over the ~3 months between Visits 3 and 14 that interfere with study visits
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,Tau positivity by brain PET imaging
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,"Adequate blood counts i.e. platelets greater than  50,000 per microliter; HB greater than  9/dL, and ANC greater than  1000 per microliter"
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,Availability and consent from a LAR.
NCT04786223,Phase 2,Alzheimer Disease,Val Lowe,unknown,Alzheimer Disease;Dementia, Males or females 60 years of age or older.
NCT04786223,Phase 2,Alzheimer Disease,Val Lowe,unknown,Alzheimer Disease;Dementia," Meet the requirements for one of the four groups (CU A-, CU A+, MCI A+, AD A+)."
NCT04786223,Phase 2,Alzheimer Disease,Val Lowe,unknown,Alzheimer Disease;Dementia, Undergoing neurologic evaluation procedures with cognitive testing in the MCSA or - ADRC for a minimum of about 3 years.
NCT04786223,Phase 2,Alzheimer Disease,Val Lowe,unknown,Alzheimer Disease;Dementia, All participants must have had an amyloid PiB PET scan and MRI brain scan within the previous 6 months.
NCT04786223,Phase 2,Alzheimer Disease,Val Lowe,unknown,Alzheimer Disease;Dementia, Capacity to sign consent or have a legally authorized representative to sign the consent.
NCT04798989,Phase 2,Alzheimer's Disease With Vascular Pathology,Cyclerion Therapeutics,unknown,Alzheimer Disease,"Provide written informed consent prior to the performance of any protocol-specified procedure or, if unable to provide informed consent due to cognitive status, provides assent to participate, with a legally authorized representative (LAR) providing written informed consent on behalf of the participant."
NCT04798989,Phase 2,Alzheimer's Disease With Vascular Pathology,Cyclerion Therapeutics,unknown,Alzheimer Disease,60 years of age or older
NCT04798989,Phase 2,Alzheimer's Disease With Vascular Pathology,Cyclerion Therapeutics,unknown,Alzheimer Disease,Meets core clinical criteria for probable AD dementia according to the 2011 National Institute on Aging-Alzheimer's Associated guidelines. Can be based on medical history.
NCT04798989,Phase 2,Alzheimer's Disease With Vascular Pathology,Cyclerion Therapeutics,unknown,Alzheimer Disease,Mini-Mental State Examination (MMSE) score of 20 to 26 (inclusive)
NCT04798989,Phase 2,Alzheimer's Disease With Vascular Pathology,Cyclerion Therapeutics,unknown,Alzheimer Disease,Confirmation of AD pathophysiology
NCT04798989,Phase 2,Alzheimer's Disease With Vascular Pathology,Cyclerion Therapeutics,unknown,Alzheimer Disease,At least 2 cardiovascular risk factors per protocol criteria
NCT04798989,Phase 2,Alzheimer's Disease With Vascular Pathology,Cyclerion Therapeutics,unknown,Alzheimer Disease,Magnetic resonance imaging (MRI) scan (existing MRI obtained 6 months before Screening is acceptable) findings of mild-to-moderate subcortical small-vessel disease
NCT04798989,Phase 2,Alzheimer's Disease With Vascular Pathology,Cyclerion Therapeutics,unknown,Alzheimer Disease,"If receiving concomitant or chronic medication(s), has had no change for 4 weeks before study drug initiation and has no plans to alter the regimen(s) during the study"
NCT04798989,Phase 2,Alzheimer's Disease With Vascular Pathology,Cyclerion Therapeutics,unknown,Alzheimer Disease,"If male, agrees to refrain from donating sperm from the Screening visit through 90 days after taking the final study drug dose"
NCT04798989,Phase 2,Alzheimer's Disease With Vascular Pathology,Cyclerion Therapeutics,unknown,Alzheimer Disease,"If male, agrees to use protocol-specified, effective contraception methods from the signing of the informed consent form (ICF) until 90 days after taking the final study drug dose."
NCT04798989,Phase 2,Alzheimer's Disease With Vascular Pathology,Cyclerion Therapeutics,unknown,Alzheimer Disease,"If female, is postmenopausal/not of reproductive potential defined per protocol"
NCT04798989,Phase 2,Alzheimer's Disease With Vascular Pathology,Cyclerion Therapeutics,unknown,Alzheimer Disease,"Agrees to the study procedures, including undergoing lumbar puncture for cerebrospinal fluid (CSF) samples"
NCT04804241,Phase 2,Alzheimer Disease,"University of California, Davis",unknown,Alzheimer Disease;Cognitive Dysfunction, Age 55-85
NCT04804241,Phase 2,Alzheimer Disease,"University of California, Davis",unknown,Alzheimer Disease;Cognitive Dysfunction, Fluent in either English or Spanish
NCT04804241,Phase 2,Alzheimer Disease,"University of California, Davis",unknown,Alzheimer Disease;Cognitive Dysfunction, Willing to be randomized to active drug (10 mg Senicapoc) vs. placebo (3:1 ratio)
NCT04804241,Phase 2,Alzheimer Disease,"University of California, Davis",unknown,Alzheimer Disease;Cognitive Dysfunction, Clinical Dementia Rating (CDR) global score of 1 or 0.5
NCT04804241,Phase 2,Alzheimer Disease,"University of California, Davis",unknown,Alzheimer Disease;Cognitive Dysfunction, Education adjusted scores between 15-28 on the Montreal Cognitive Assessment (MoCA) at the Screening visit.
NCT04804241,Phase 2,Alzheimer Disease,"University of California, Davis",unknown,Alzheimer Disease;Cognitive Dysfunction," A consensus clinical diagnosis of either amnestic Mild Cognitive Impairment (MCI) or mild AD dementia. Diagnoses are made by a comprehensive case conference review for all participants in the ADRC longitudinal cohort and all CADC referrals, resulting in a consensus diagnosis made according to current research criteria. For patients referred from other clinics, the case will be reviewed by a study physician and neuropsychologist and only patients who satisfy criteria for probable AD (McKhann et al 1984) or amnestic MCI (Petersen et al 2004) will be eligible for enrollment."
NCT04804241,Phase 2,Alzheimer Disease,"University of California, Davis",unknown,Alzheimer Disease;Cognitive Dysfunction, Vision (with or without correction) of at least 20/50 for distant vision
NCT04804241,Phase 2,Alzheimer Disease,"University of California, Davis",unknown,Alzheimer Disease;Cognitive Dysfunction," All participants will need a study partner informant who has at least 6 hours of contact per week with the participant. The study partners are used to help answer questions on the subject's behalf, since many of them will be impaired and may need assistance with providing accurate information. The study partners are not asked to provide any opinions or judgements about the subjects."
NCT04804241,Phase 2,Alzheimer Disease,"University of California, Davis",unknown,Alzheimer Disease;Cognitive Dysfunction, For Females of childbearing potential: Must agree to practice a highly effective method of contraception throughout the study until completion of the Week 78 follow up visit. Highly effective methods of contraception are those that alone or in combination result in a failure rate of less than 1% per year when used correctly and consistently.
NCT04842552,Phase 3,Alzheimer Disease,Shahid Sadoughi University of Medical Sciences and Health Services,unknown,Alzheimer Disease;Hydralazine, Diagnoses of Alzheimer's disease according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria.
NCT04842552,Phase 3,Alzheimer Disease,Shahid Sadoughi University of Medical Sciences and Health Services,unknown,Alzheimer Disease;Hydralazine," Presence of a caregiver (friend or relative) who can assume responsibility for medication administrations, accompany the patient to all visits, and rate patient's condition."
NCT04842552,Phase 3,Alzheimer Disease,Shahid Sadoughi University of Medical Sciences and Health Services,unknown,Alzheimer Disease;Hydralazine, Written informed consent form from both the patient (or surrogate) and caregiver.
NCT04842552,Phase 3,Alzheimer Disease,Shahid Sadoughi University of Medical Sciences and Health Services,unknown,Alzheimer Disease;Hydralazine, A Mini-Mental State Examination score between 12 and 26 inclusive.
NCT04842552,Phase 3,Alzheimer Disease,Shahid Sadoughi University of Medical Sciences and Health Services,unknown,Alzheimer Disease;Hydralazine," Prescription of donepezil (5-10mg/d), rivastigmine (3-6mg/d), galantamine or galantamine ER (8-16mg/d) for a minimum of 4 weeks prior to randomization."
NCT04842552,Phase 3,Alzheimer Disease,Shahid Sadoughi University of Medical Sciences and Health Services,unknown,Alzheimer Disease;Hydralazine, Agreement not to take hydralazine.
NCT04842552,Phase 3,Alzheimer Disease,Shahid Sadoughi University of Medical Sciences and Health Services,unknown,Alzheimer Disease;Hydralazine, Age 49 and over.
NCT04871074,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease, Cognitively unimpaired adults-
NCT04871074,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease, Aged 55 - 89
NCT04871074,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease, Normal cognition (results of most recent testing with the source cohort indicate the participant is cognitively unimpaired as judged by consensus or expert review)
NCT04871074,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease, In good general health with no conditions/medications affecting cognition or imaging
NCT04871074,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease," Willing to undergo [C-11]UCB-J, [C-11]PiB, and [F-18]MK6240 PET scans"
NCT04871074,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease, An adequate MRI exam within 12 months prior to baseline. An MRI will be performed if not already available.
NCT04871074,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease, Mild dementia and amnestic Mild Cognitive Impairment-
NCT04871074,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease, Aged 50 years or older
NCT04871074,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease, Abnormal cognitive status of MCI or dementia as judged by consensus or expert review using NIA-AA 2018 criteria
NCT04871074,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease, MCI's must be affected in the memory domain but may also have other affected domains
NCT04871074,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease," Willing to undergo [C-11]UCB-J, [C-11]PiB, and [F-18]MK6240 PET scans"
NCT04871074,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease, An adequate MRI exam within 12 months prior to baseline. This MRI exam will come from ADRC/WRAP studies. Clinical MRI's (ones obtained outside of the research program) will not be adequate. An MRI will be performed if not already available from within the research program.
NCT04886063,Phase 2,Alzheimer Disease,Athira Pharma,unknown,Alzheimer Disease, Subject has completed the Week 26 visit of either of the two blinded parent studies (ATH-1017-AD-0201 or ATH-1017-AD-0202).
NCT04886063,Phase 2,Alzheimer Disease,Athira Pharma,unknown,Alzheimer Disease," Reliable and capable support person/caregiver who is willing to accept responsibility for supervising the daily treatment or, if required, administering study drug."
NCT04886063,Phase 2,Alzheimer Disease,Athira Pharma,unknown,Alzheimer Disease," Subject capable of giving signed informed consent, or by a legally acceptable representative."
NCT04886063,Phase 2,Alzheimer Disease,Athira Pharma,unknown,Alzheimer Disease, Subjects must be in generally good health.
NCT04886063,Phase 2,Alzheimer Disease,Athira Pharma,unknown,Alzheimer Disease," Male subjects and their partners must agree to continue to use a double-barrier method of contraception during the study, including the follow-up period, unless the partner is not of childbearing potential."
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim," Males or females between age 60 and 80 years, inclusive, at time of consent."
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim," Have a dedicated partner/caregiver informant who is in the company of the participant at least 12 hours a week, who can accompany them to scheduled visits, and who is able to provide accurate reporting upon the behavioral, cognitive and functional abilities of the participant."
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim, Be physically able to participate with adequate visual acuity and auditory discrimination.
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim, Be willing / able to provide written informed consent or assent.
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim," Must reside within a proximity of the study site that will not preclude their regularly-scheduled participation in the trial, as well as a catchment area for local lab blood draws (i.e. central contracted laboratory)."
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim," Meet criteria for probable AD dementia according to the National Institute of Aging - Alzheimer's Association (NIA-AA) 2018 core research criteria, and have the following at screening:"
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim, A diagnosis of mild AD or moderate AD.
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim, MoCA score of 10-22 inclusive.
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim, Have positive biomarker for brain amyloid pathology as shown by CSF assay for AD assessment.
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim," If receiving anti-dementia treatment (i.e. AChEI), be on stable treatment for at least 2 months (i.e., cholinesterase inhibitor and/or Memantine) before initial screening visit."
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim, Be stable on all other medications for at least 30 days prior to initial screening visit.
NCT04926272,Phase 2,Alzheimer's Disease,First Affiliated Hospital of Fujian Medical University,unknown,Alzheimer Disease, Patients or their families complain of significant memory impairment;
NCT04926272,Phase 2,Alzheimer's Disease,First Affiliated Hospital of Fujian Medical University,unknown,Alzheimer Disease," Objective memory impairment (e.g., tests of article identification, recall, delayed memory);"
NCT04926272,Phase 2,Alzheimer's Disease,First Affiliated Hospital of Fujian Medical University,unknown,Alzheimer Disease, Meets Alzheimer's criteria for DSMIV and NINCDS-ADRDA;
NCT04926272,Phase 2,Alzheimer's Disease,First Affiliated Hospital of Fujian Medical University,unknown,Alzheimer Disease, Be able to obtain complete diagnosis and treatment records and be able to carry out long-term follow-up;
NCT04926272,Phase 2,Alzheimer's Disease,First Affiliated Hospital of Fujian Medical University,unknown,Alzheimer Disease, Signed written consent.
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction,"Male or female, age 18 to 80 years at the time of informed consent"
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction,"Individuals who are confirmed to be mutation positive for presenilin 1 (PSEN1), amyloid precursor protein (APP), or presenilin 2 (PSEN2) gene that is associated with DIAD"
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction,Clinical Dementia Rating - Sum of Boxes (CDR-SB) score 5 to 12 at Screening
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction,Evidence of positive amyloid status based on historical or screening amyloid PET
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction,"Able to undergo magnetic resonance imaging (MRI), lumbar puncture (LP), PET, and complete all study-related testing and evaluations"
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction,"Has a study partner who in the investigator's judgment is able to provide accurate information as to the participant's cognitive and functional abilities, who agrees to provide information at the study visits which require informant input for scale completion"
NCT04983368,Phase 1/Phase 2,Alzheimer's Disease,Actinogen Medical,unknown,Alzheimer Disease;Cognitive Dysfunction,Male or female aged 50 to 80
NCT04983368,Phase 1/Phase 2,Alzheimer's Disease,Actinogen Medical,unknown,Alzheimer Disease;Cognitive Dysfunction,"Body mass index 17.5 to less than  35 kg/m2, inclusive at the time of screening"
NCT04983368,Phase 1/Phase 2,Alzheimer's Disease,Actinogen Medical,unknown,Alzheimer Disease;Cognitive Dysfunction,Mini-Mental State Score of  25 points at screening
NCT04983368,Phase 1/Phase 2,Alzheimer's Disease,Actinogen Medical,unknown,Alzheimer Disease;Cognitive Dysfunction,Must provide written informed consent
NCT05006599,Phase 2,"Alzheimer Disease, Early Onset",Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc",Age 55 to 85 (inclusive)
NCT05006599,Phase 2,"Alzheimer Disease, Early Onset",Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc",Fluent in English
NCT05006599,Phase 2,"Alzheimer Disease, Early Onset",Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc",Cognitively normal or diagnosis of amnestic mild cognitive impairment (aMCI) or mild Alzheimer's disease (AD)
NCT05006599,Phase 2,"Alzheimer Disease, Early Onset",Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc",Amyloid positive by positron emission tomography (PET) or cerebrospinal fluid (CSF) criteria
NCT05006599,Phase 2,"Alzheimer Disease, Early Onset",Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc",Stable medical condition for 3 months prior to screening visit
NCT05006599,Phase 2,"Alzheimer Disease, Early Onset",Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc",Stable medications for 4 weeks prior to the screening and study visits (exceptions may be made on a case by case basis by the study physician)
NCT05006599,Phase 2,"Alzheimer Disease, Early Onset",Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc","Clinical laboratory values must be within normal limits or, if abnormal, must be judged to be clinically insignificant by the study physician"
NCT05026866,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease, A Telephone Interview for Cognitive Status - modified (TICS-M) score reflective of intact cognitive functioning.
NCT05026866,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease, Has a phosphorylated tau (P-tau) result consistent with the presence of amyloid and early-tau pathology.
NCT05026866,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease," Has a reliable study partner and backup study partner familiar with overall function and behavior, such as day-to-day activities and cognitive abilities."
NCT05026866,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease," Have adequate literacy, vision, and hearing for neuropsychological testing at screening."
NCT05026866,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease, Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
NCT05026866,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease," Female participants include those who are infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation), congenital anomaly such as Mullerian agenesis; or post menopausal (women 55 or older not on hormone therapy and had at least 12 months of spontaneous amenorrhea; or with a diagnosis of menopause prior to starting hormone replacement therapy."
NCT05063539,Phase 2,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease, Gradual and progressive change in memory function reported by participants or informants for  6 months
NCT05063539,Phase 2,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease, MMSE score of 22 to 30 (inclusive) at baseline
NCT05063539,Phase 2,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease," CDR global score of 0.5 to 1.0 (inclusive), with a memory box score 0.5."
NCT05063539,Phase 2,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease, Meet 18F flortaucipir positron emission tomography (PET) scan (central analysis) criteria
NCT05063539,Phase 2,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease, Have a study partner who will provide written informed consent to participate
NCT05063851,Phase 2,Alzheimer Disease,University of Virginia,unknown,Alzheimer Disease;Memantine,Be between the age of 57 and 62 years at time of informed consent.
NCT05063851,Phase 2,Alzheimer Disease,University of Virginia,unknown,Alzheimer Disease;Memantine,Have a positive family history for dementia (minimum of 1 first degree relative).
NCT05063851,Phase 2,Alzheimer Disease,University of Virginia,unknown,Alzheimer Disease;Memantine,Previously known or documented heterozygote or homozygote ApoE 4 allele.
NCT05063851,Phase 2,Alzheimer Disease,University of Virginia,unknown,Alzheimer Disease;Memantine,Be able to read and write and must have adequate hearing and visual acuity to complete the psychometric tests.
NCT05063851,Phase 2,Alzheimer Disease,University of Virginia,unknown,Alzheimer Disease;Memantine,"Be otherwise healthy for their age group or medically stable with or without medication on the basis of physical examination, medical history, vital signs, and 12-lead ECG performed at screening or at baseline."
NCT05063851,Phase 2,Alzheimer Disease,University of Virginia,unknown,Alzheimer Disease;Memantine,Have Montreal Cognitive Assessment (MOCA) score of 27 or above.
NCT05063851,Phase 2,Alzheimer Disease,University of Virginia,unknown,Alzheimer Disease;Memantine,"Have a creatinine clearance (CrCl), estimated using the Cockcroft-Gault formula, greater or equal to 30 mL/minute."
NCT05074498,Phase 1/Phase 2,Alzheimer's Disease,"TrueBinding, Inc.",unknown,Alzheimer Disease," Body weight of  50 kilograms (kg) and body mass index (BMI) between 18 and 35 kg/meters squared (m^2), inclusive"
NCT05074498,Phase 1/Phase 2,Alzheimer's Disease,"TrueBinding, Inc.",unknown,Alzheimer Disease, Mini-Mental State Examination (MMSE) score of 24 or less
NCT05074498,Phase 1/Phase 2,Alzheimer's Disease,"TrueBinding, Inc.",unknown,Alzheimer Disease, Must be ambulatory
NCT05074498,Phase 1/Phase 2,Alzheimer's Disease,"TrueBinding, Inc.",unknown,Alzheimer Disease, Clinical diagnosis of Alzheimer's Disease (AD) consistent with the following:
NCT05074498,Phase 1/Phase 2,Alzheimer's Disease,"TrueBinding, Inc.",unknown,Alzheimer Disease,"Probable AD, according to National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA)"
NCT05074498,Phase 1/Phase 2,Alzheimer's Disease,"TrueBinding, Inc.",unknown,Alzheimer Disease,"Meets the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) - Criteria for Major Neurocognitive Disorder (previously dementia)"
NCT05081219,Phase 2,Alzheimer Disease,Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc;Empagliflozin",Age 55 to 85 (inclusive)
NCT05081219,Phase 2,Alzheimer Disease,Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc;Empagliflozin",Fluent in English
NCT05081219,Phase 2,Alzheimer Disease,Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc;Empagliflozin",Cognitively normal or diagnosis of amnestic mild cognitive impairment (aMCI) or mild Alzheimer's disease (AD)
NCT05081219,Phase 2,Alzheimer Disease,Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc;Empagliflozin",Amyloid positive by positron emission tomography (PET) or cerebrospinal fluid (CSF) criteria
NCT05081219,Phase 2,Alzheimer Disease,Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc;Empagliflozin",Stable medical condition for 3 months prior to screening visit
NCT05081219,Phase 2,Alzheimer Disease,Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc;Empagliflozin",Stable medications for 4 weeks prior to the screening and study visits (exceptions may be made on a case by case basis by the study physician)
NCT05081219,Phase 2,Alzheimer Disease,Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc;Empagliflozin","Clinical laboratory values must be within normal limits or, if abnormal, must be judged to be clinically insignificant by the study physician"
NCT05108922,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease;Cognitive Dysfunction, Gradual and progressive change in memory function reported by the participant or informant for 6 months.
NCT05108922,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease;Cognitive Dysfunction, Meet florbetapir F18 PET scan criteria.
NCT05108922,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease;Cognitive Dysfunction, A Clinical Dementia Rating (CDR)-Global Score of 0.5 or 1.
NCT05108922,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease;Cognitive Dysfunction, Must consent to apolipoprotein E (ApoE) genotyping
NCT05108922,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease;Cognitive Dysfunction, Must have a mini mental state examination (MMSE) score between 20 and 30
NCT05108922,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease;Cognitive Dysfunction," Have a study partner who will provide written informed consent to participate, is in frequent contact with the participant (defined as at least 10 hours per week), and will accompany the participant to study visits or be available by telephone at designated times."
NCT05108922,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease;Cognitive Dysfunction," Have adequate literacy, vision, and hearing for neuropsychological testing in the opinion of the investigator at the time of screening."
NCT05108922,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease;Cognitive Dysfunction, Women not of childbearing potential may participate
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease, 1- Diagnosis of dementia due to AD
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease, 2- Meet the National Institute of Aging-Alzheimer's Association (NIA-AA) core clinical criteria for dementia due to AD
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease, 3- Have a global CDR score of 0.5 to 1.0 and a CDR Memory Box score of 0.5 or greater at Screening and Baseline
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease, 4- Have an MMSE score greater than or equals to 20 at Screening and less than or equals to 27 at Screening and Baseline
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease," 5- Have a positive amyloid PET (visual reading) or positivity threshold of CSF A[1-42] less than  660ng/ml or ptau/A[1-42] greater than 0.09 using INNOTEST Enzyme-Linked ImmunoAssay (ELISA) technique (Fujirebio, Ghent, Belgium)."
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease," 6- QTc (corrected Q wave to the end of the T wave) interval 350-480 ms, inclusive for both men and women"
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease, 7- English or Spanish fluency
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease, 8- Report a history of subjective memory decline with gradual onset and slow progression over the last 1 year before Screening; must be corroborated by an informant
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease, 9- Positive biomarker for brain amyloid pathology as indicated by at least 1 of the following:
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,PET assessment of imaging agent uptake into brain
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,"CSF assessment of A[1-42] or ptau/A[1-42] NOTE: To confirm eligibility, a positive amyloid result is needed in only 1 of the 2 procedures, including PET or CSF measurement."
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease," 10- Male or female subjects aged 55 and  85 years, at the time of informed consent (IC)"
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease, 11- Body mass index (BMI) greater than 17 and less than 35 at Screening
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease," 12- If receiving an approved AD treatment, such as acetylcholinesterase inhibitors (AChEIs), or memantine, or both for AD, must be on a stable dose for at least 12 weeks prior to Baseline. Treatment-nave subjects for AD can be entered into the study. Unless otherwise stated, subjects must have been on stable doses of all other (i.e., non-AD-related) permitted concomitant medications for at least 4 weeks prior to Baseline."
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease," 13- Have an identified study partner. The study partner must provide separate written IC. In addition, this person must be willing and able to provide follow-up information on the subject throughout the course of the study. This person must, in the opinion of the investigator, spend sufficient time with the subject on a regular basis such that the study partner can reliably fulfill the study requirements. A permanent study partner need not be living in the same residence with the subject. For such a study partner not residing with the subject, the investigator has to be satisfied that the subject can contact the study partner readily during the times when the study partner is not with the subject. Study partners need to participate in person for visits where clinical assessment of CDR (global and CDR-SB), ADAS-Cog, ADCS-ADL-MCI and NPI."
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease," 14- Provide written IC. If a subject lacks capacity to consent in the investigator's opinion, the subject's assent should be obtained, if required in accordance with local laws, regulations and customs, plus the written IC of a legal representative should be obtained."
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease, 15- Willing and able to comply with all aspects of the protocol.
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease, Biomarker Sub-study
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease," NOTE: Subjects may consent to either one or both the PET and CSF assessments, but to confirm eligibility, a positive amyloid result is needed in only 1 of the 2 procedures (Amyloid PET (via visual reading) or CSF assessment). The historical imaging data and CSF assessment results must be made available to the sponsor or medical monitor to confirm amyloid positivity and eligibility."
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease," Historical PET and CSF assessments will ONLY be used for determination of eligibility. However, subjects who enroll in the biomarker sub study MUST participate in one or more of the amyloid and tau PET, vMRI and CSF assessments according to the Assessments Schedule in the sponsor protocol."
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease," Patients may use any amyloid PET tracer to prove eligibility, but they must use only the sponsor provided tracer at Baseline and End of Treatment- unless the same tracer was used within 12 months from Baseline and the data can be provided to the investigator and the subject has not participated in any subsequent anti-amyloid study or treatment."
NCT05161715,Phase 2,Early Alzheimer's Disease,NewAmsterdam Pharma,unknown,Alzheimer Disease, men  and  women 50-75 years
NCT05161715,Phase 2,Early Alzheimer's Disease,NewAmsterdam Pharma,unknown,Alzheimer Disease, post-menopausal or women not of child-bearing potential
NCT05161715,Phase 2,Early Alzheimer's Disease,NewAmsterdam Pharma,unknown,Alzheimer Disease, diagnosis of Alzheimer's disease based on National Institute for Aging:
NCT05161715,Phase 2,Early Alzheimer's Disease,NewAmsterdam Pharma,unknown,Alzheimer Disease, Biomarker classification A+T+N+ or A+T+N-
NCT05161715,Phase 2,Early Alzheimer's Disease,NewAmsterdam Pharma,unknown,Alzheimer Disease, Clinical Stage 3 or 4 with Clinical Dementia Rating score greater than /= 0.5  and  less than /= 1; mini-mental state examination (MMSE) score greater than /=20
NCT05161715,Phase 2,Early Alzheimer's Disease,NewAmsterdam Pharma,unknown,Alzheimer Disease, Have an APOE genotype of E4/E4 or E3/E4
NCT05161715,Phase 2,Early Alzheimer's Disease,NewAmsterdam Pharma,unknown,Alzheimer Disease, not on or on stabilized AD medication
NCT05161715,Phase 2,Early Alzheimer's Disease,NewAmsterdam Pharma,unknown,Alzheimer Disease, Patient  and  study partner willing to sign consent
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Male or female participants 55 to 85 years of age (both inclusive) at the time of signing the informed consent.
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"Diagnosis of probable AD based on NINCDS-ADRDA criteria as determined by a neurologist, geriatrician, psychiatrist, or clinician approved by the Sponsor or designee."
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Mild or moderate dementia as evidenced by MMSE score 13 to 24 at screening (Visit 1).
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Imaging studies (MRI or CT) within 2 years prior to screening that has findings consistent with AD and without any other disease that may cause dementia.
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,An A PET scan or CSF examination performed within 2 years prior to screening with results consistent with the presence of amyloid pathology.
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"If receiving an approved medication for AD (ie, donepezil, galantamine, rivastigmine, memantine, or memantine/donepezil combination product), must be on the medication with a stable dose for at least 12 weeks before the screening visit (dosing should remain stable throughout the study)."
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"If receiving an OTC supplement for cognition (eg, gingko biloba, omega-3 polyunsaturated fatty acid, vitamin E, curcumin), must not be exceeding the recommended dose for at least 12 weeks prior to screening visit."
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"Able to visit the study center and undergo cognitive, functional, and other tests specified in the protocol."
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Has a caregiver who:
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease, Agrees to accompany the participant to all study visits and able to supervise the participant's compliance with the study procedures and provide detailed information about the participant.
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease," Either lives with the participant or sees the participant on average for 1 hour/day 3 days/week, or in the Investigator's opinion, the extent of contact is sufficient to provide meaningful assessment of changes in participant behavior and function over time and provide information on safety and tolerability."
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease," Is able to read, understand, and speak the designated language at the study center."
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease, Caregiver must be cognitively able to fulfill the requirements of the study.
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,A male participant must agree to use a highly effective contraception method as detailed in Protocol Appendix 3 during the treatment period and for at least 3 months after the last dose of study treatment and refrain from donating sperm during this period.
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:"
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease, Not a woman of childbearing potential as defined in Protocol Appendix 3. OR
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease, A WOCBP who agrees to use a highly effective contraception method as detailed in Appendix 3 during the treatment period and for at least 3 months after the last dose of study treatment.
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"A WOCBP must have a negative serum pregnancy test (beta-human chorionic gonadotropin [-hCG]) at screening (Visit 1) and a negative urine pregnancy test at Visit 2 before randomization, and must use medically accepted means of contraception throughout the study."
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Written informed consent provided by participant (or legal representative) and caregiver prior to any study-specific procedures.
NCT05194163,Phase 2,Alzheimer Disease,Neurokine Therapeutics,unknown,Alzheimer Disease,"Signed informed consent from subject (or legally authorized representative, LAR) and study partner."
NCT05194163,Phase 2,Alzheimer Disease,Neurokine Therapeutics,unknown,Alzheimer Disease,"Male or female, age 50 to 90 inclusive."
NCT05194163,Phase 2,Alzheimer Disease,Neurokine Therapeutics,unknown,Alzheimer Disease,"Have a study partner who is able to accompany the subject, has frequent contact with subject."
NCT05194163,Phase 2,Alzheimer Disease,Neurokine Therapeutics,unknown,Alzheimer Disease,Meet criteria for Alzheimer's Disease by NIAA-AA criteria.
NCT05194163,Phase 2,Alzheimer Disease,Neurokine Therapeutics,unknown,Alzheimer Disease,Must speak English fluently.
NCT05194163,Phase 2,Alzheimer Disease,Neurokine Therapeutics,unknown,Alzheimer Disease,Must have education of at least 8 years.
NCT05194163,Phase 2,Alzheimer Disease,Neurokine Therapeutics,unknown,Alzheimer Disease,Must have adequate hearing and visual abilities.
NCT05194163,Phase 2,Alzheimer Disease,Neurokine Therapeutics,unknown,Alzheimer Disease,MMSE score of 14 to 28.
NCT05194163,Phase 2,Alzheimer Disease,Neurokine Therapeutics,unknown,Alzheimer Disease,Clinical Dementia Rating (CDR) Global score of 0.5 to 2.0 inclusive.
NCT05194163,Phase 2,Alzheimer Disease,Neurokine Therapeutics,unknown,Alzheimer Disease,Absence of suicidal ideation for at least 1 year.
NCT05194163,Phase 2,Alzheimer Disease,Neurokine Therapeutics,unknown,Alzheimer Disease,Absence of medical conditions that could affect ability to participate in study.
NCT05194163,Phase 2,Alzheimer Disease,Neurokine Therapeutics,unknown,Alzheimer Disease,"MRI within 1 year of screening, not showing clinically significant structural lesions. Subjects without available MRI within 1 year, must have an MRI performed for eligibility."
NCT05194163,Phase 2,Alzheimer Disease,Neurokine Therapeutics,unknown,Alzheimer Disease,Stable neuropsychiatric medications for at least 2 months prior to screening.
NCT05194163,Phase 2,Alzheimer Disease,Neurokine Therapeutics,unknown,Alzheimer Disease,"If female, must not be of childbearing potential, as defined by being postmenopausal (more than 1 year without periods) or surgically sterile for at least 6 months prior to screening."
NCT05194163,Phase 2,Alzheimer Disease,Neurokine Therapeutics,unknown,Alzheimer Disease,"If male, must agree to use contraception if with a potentially childbearing partner."
NCT05227820,Phase 2,Alzheimer Disease,Neurological Associates of West Los Angeles,unknown,Alzheimer Disease;Dementia," Cognitive decline with Clinical Dementia Rating (CDR) score of 0.5 to 1, suggesting mild cognitive impairment to mild dementia."
NCT05227820,Phase 2,Alzheimer Disease,Neurological Associates of West Los Angeles,unknown,Alzheimer Disease;Dementia, Participants must be between the ages of 50-89
NCT05227820,Phase 2,Alzheimer Disease,Neurological Associates of West Los Angeles,unknown,Alzheimer Disease;Dementia, Primary cognitive complaint must be memory Impairment without movement or psychiatric explanation/diagnosis
NCT05227820,Phase 2,Alzheimer Disease,Neurological Associates of West Los Angeles,unknown,Alzheimer Disease;Dementia, Participants must show at least one abnormal imaging biomarker and none of the exclusion criteria below.
NCT05233774,Phase 2,Mild Alzheimer's Disease,Longeveron Inc.,unknown,Alzheimer Disease, Provide written informed consent.
NCT05233774,Phase 2,Mild Alzheimer's Disease,Longeveron Inc.,unknown,Alzheimer Disease, Be 60 - 85 years of age at signing of the Informed Consent Form.
NCT05233774,Phase 2,Mild Alzheimer's Disease,Longeveron Inc.,unknown,Alzheimer Disease, Clinical diagnosis of mild Alzheimer's disease in accordance with the NIA-AA criteria at the time of enrollment.
NCT05233774,Phase 2,Mild Alzheimer's Disease,Longeveron Inc.,unknown,Alzheimer Disease, MMSE score of 19 - 23.
NCT05233774,Phase 2,Mild Alzheimer's Disease,Longeveron Inc.,unknown,Alzheimer Disease, Body weight of 40 - 150 kg.
NCT05233774,Phase 2,Mild Alzheimer's Disease,Longeveron Inc.,unknown,Alzheimer Disease, Has an adult caregiver who meets all of the following criteria.
NCT05233774,Phase 2,Mild Alzheimer's Disease,Longeveron Inc.,unknown,Alzheimer Disease,Provides written informed consent to participate on the trial (reporting on patient observations).
NCT05233774,Phase 2,Mild Alzheimer's Disease,Longeveron Inc.,unknown,Alzheimer Disease,"Either lives with the patient, or sees the patient for at least 2 hours/day for at least 3 days/week."
NCT05233774,Phase 2,Mild Alzheimer's Disease,Longeveron Inc.,unknown,Alzheimer Disease,"Is willing and able to participate in the study, and agrees to accompany the patient to each study visit."
NCT05233774,Phase 2,Mild Alzheimer's Disease,Longeveron Inc.,unknown,Alzheimer Disease,"Is able to read, understand, and speak the designated language at the study site."
NCT05233774,Phase 2,Mild Alzheimer's Disease,Longeveron Inc.,unknown,Alzheimer Disease, Brain MRI consistent with AD.
NCT05233774,Phase 2,Mild Alzheimer's Disease,Longeveron Inc.,unknown,Alzheimer Disease," A PET scan using an FDA-approved tracer (e.g., AMYViD, Vizamyl, or Neuraceq) consistent with the diagnosis of AD. A prior positive PET scan will be allowed with Sponsor approval."
NCT05233774,Phase 2,Mild Alzheimer's Disease,Longeveron Inc.,unknown,Alzheimer Disease," Living in the community, includes assisted living facilities (but excluding long-term care nursing facilities)."
NCT05239390,Phase 2,Alzheimer Disease,The Israeli Medical Center for Alzheimer's,unknown,Alzheimer Disease;Dronabinol, Male or female aged greater than 60 to less than 85 years inclusive.
NCT05239390,Phase 2,Alzheimer Disease,The Israeli Medical Center for Alzheimer's,unknown,Alzheimer Disease;Dronabinol, Patients diagnosed according to the NINCDS criteria for AD (possible and probable).
NCT05239390,Phase 2,Alzheimer Disease,The Israeli Medical Center for Alzheimer's,unknown,Alzheimer Disease;Dronabinol, MMSE less than 24 at the time of screening.
NCT05239390,Phase 2,Alzheimer Disease,The Israeli Medical Center for Alzheimer's,unknown,Alzheimer Disease;Dronabinol, Patients who in the opinion of the investigators need medication to control agitation or whose current anti-agitation medication is ineffective or poorly tolerated
NCT05239390,Phase 2,Alzheimer Disease,The Israeli Medical Center for Alzheimer's,unknown,Alzheimer Disease;Dronabinol, Patients who have been taking stable dose concomitant medications for at least 1 week.
NCT05239390,Phase 2,Alzheimer Disease,The Israeli Medical Center for Alzheimer's,unknown,Alzheimer Disease;Dronabinol, Only individuals who have a legally appointed guardian who can sign Informed Consent Form (ICF)
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Male or female aged 60 85 years (inclusive).
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Participant is an outpatient living at home or in an assisted living facility and is willing to attend all planned visits during the study.
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia," The participant has a study partner (who is not expected to change during the study) who will accompany the patient to the clinic, and/or be available by telephone at designated times, monitor administration of prescribed medications, control the minimum 2 hour daily light exposure requirement. The study partner must, in the opinion of the investigator, have enough contact with the participant to be able to perform the duties described above."
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Signed informed consent from the patient who has the capacity to provide informed consent as judged by the study investigator
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Signed informed consent from the study partner.
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia," Meets NIA AA research criteria for probable AD (McKhann, Knopman et al. 2011)."
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Patient has a clearly documented history of cognitive decline over at least 12 months.
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia," Patient has MRI/CT scan, performed within 12 months before Screening, with findings consistent with the diagnosis of AD without any other clinically significant comorbid pathologies as detailed in Appendix 3."
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, MMSE score of 20 26 (inclusive) at Screening and stability of MMSE - no more than three-point change on successive screening and baseline visits before randomization.
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Patient has a CDR GS of 0.5 1 (mild dementia) at Screening.
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia," Patients taking acetylcholinesterase inhibitors and or memantine for the treatment of AD may be enrolled if the patient has been taking such medication for at least 6 months before Visit 2 (Baseline) and is stable on any dose for the last 4 months prior to Baseline, and if the dose is not expected to change during study participation."
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia," Patients not receiving acetylcholinesterase inhibitors may be enrolled but must be stable off acetylcholinesterase inhibitors for at least 3 months before Baseline, and agreeable to not starting throughout the first 26 weeks of the trial."
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Patient has a negative drug screen (benzodiazepines or opiates) at Screening.
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Female patients must have had last natural menstruation  24 months before Screening OR be surgically sterile.
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia," Male patients and their female spouse/partners who are of childbearing potential must agree to use highly effective methods of contraception, consisting of 2 forms of birth control (at least one of which must be a barrier method) starting at Screening, throughout the study and for 90 days post last dose, OR be surgically sterile."
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Patients who are taking medications for non excluded concurrent medical conditions should be on a stable dose for at least 4 weeks before Screening. Patients taking allowed antidepressants (see Section 12.9) should be on a stable dose for at least 3 months before Screening and throughout the study
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Patient has ability and commitment to spend at least 2 hours per day exposed to daylight (preferably outside but can be next to a window if weather or personal situation does not permit).
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia," Participant and study partner have the ability to read and write in English or Spanish and have hearing, vision, and physical abilities adequate to perform assessments (corrective aids allowed)."
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Participant and study partner are fully vaccinated for COVID 19 including booster doses as indicated (6 months post second dose).
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease,"Age 50 to 85 years old (including 50 and 85 years old), male or female;"
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease,Meet the diagnostic criteria of  likely ad dementia  of the National Institute on aging Alzheimer's disease association (NIA-AA) (2011);
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease,"The subjects are primary school graduates / graduates and above, and have the ability to complete the cognitive ability test and other tests specified in the program;"
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease,Memory loss lasted for at least 6 months and tended to worsen gradually;
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease,Subjects with mild or moderate illness: 11  MMSE  26;
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease,Total score of Clinical Dementia Rating Scale (CDR):
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease, Mild dementia: CDR = 1.0; Moderate dementia: CDR = 2.0;
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease,The total score of Hachinski scale(HIS)  4;
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease,The total score of Hamilton Depression Scale (HAMD 17 item version) is  10;
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease,There was no obvious positive sign in nervous system examination;
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease,"Coronal scanning of head MRI in screening stage: the MTA grade of medial temporal lobe atrophy visual assessment scale is grade 2 or higher, and the signal changes of T2 FLAIR sequence in coronal position of hippocampus. If the subject can provide the head MRI film that meets the requirements within 1 month before screening, it can be used as the basis for enrollment without repeated shooting; If the researcher cannot judge whether the subject's condition has changed, the coronal MRI scan of the head before enrollment can be added;"
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease,"The subjects should have stable and reliable caregivers, who will take care of them at least 3 days a week and at least 2 hours a day. The caregivers will accompany the subjects to participate in the whole process of the study. Caregivers must accompany the subjects to the study visit and assist the investigator in completing the Neuropsychiatric Inventory (NPI), Alzheimer's Disease Collaborative Study-Ability of Daily Living Scale (ADCS-ADL), and Clinician Interview Based Impression of Severity (CIBIC -plus), and other scale scores;"
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease,"Agree to participate and sign the informed consent form by the legal guardian. Due to the subject's limited cognitive ability and other reasons, the subject's signature is allowed to be left blank, and the reason is explained. In addition, the legal guardian shall sign the reason statement, and the legal guardian shall sign the informed consent."
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease,Meet the criteria of AD in traditional Chinese medicine.
NCT05291234,Phase 1/Phase 2,Alzheimer's Disease (AD),AbbVie,unknown,Alzheimer Disease, Diagnosis of Stage 3 or Stage 4 Alzheimer's disease (AD) based on the 2018 National Institute on Aging (NIA)-Alzheimer's Association (AA) Research Framework Criteria.
NCT05291234,Phase 1/Phase 2,Alzheimer's Disease (AD),AbbVie,unknown,Alzheimer Disease," Mini-Mental State Examination (MMSE) score of 20 to 28, inclusive, at Screening."
NCT05291234,Phase 1/Phase 2,Alzheimer's Disease (AD),AbbVie,unknown,Alzheimer Disease, Plasma A42/A40 value consistent with increased likelihood of positive amyloid positron emission tomography (PET).
NCT05291234,Phase 1/Phase 2,Alzheimer's Disease (AD),AbbVie,unknown,Alzheimer Disease, Amyloid PET scan results consistent with amyloid pathology.
NCT05291234,Phase 1/Phase 2,Alzheimer's Disease (AD),AbbVie,unknown,Alzheimer Disease, Stage B: Participants must have a study partner who spends a minimum average of 10 hours per week with the participant.
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Subjects aged  55 to  85 years
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Subjects who meet the DSM-IV criteria for diagnosing dementia
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Subjects who are clinically diagnosed with probable Alzheimer's disease as defined in the NINCDS-ADRDA criteria
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Subjects with a K-MMSE score  19 at the screening visit
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Subjects with GDS (Global Deterioration Scale) grade 5 to 6
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Subjects who have no other diseases to cause dementia other than AD as a result of MRI or CT scan within 12 months from the screening visit
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Subjects who are taking donepezil alone or donepezil and memantine in combination at a stable dose without a dose change over 3 months before screening
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Subjects who are not illiterate
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Subjects who can walk with or without assist device to visit hospitals or clinics to undergo cognitive tests and other tests
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"Subjects with caregiver who can accompany all visits with the subjects as scheduled for this trial, supervise subject's compliance for the tests and examination process and provide information about the subject's indications, and who give written consent"
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Subjects and/or caregivers who voluntarily agreed in written to participate in the clinical trial
NCT05307692,Phase 2,Alzheimer Disease,"Janssen Research &amp; Development, LLC",unknown,Alzheimer Disease, Participant has received a diagnosis of probable Alzheimer Disease (AD) (Diagnostic and Statistical Manual of Mental Disorders-5 [DSM-5]) with the following characteristics at screening: Clinical Dementia Rating (CDR) global score greater than or equal to (greater than =) 2; Mini-Mental State Examination (MMSE) total score of 10 to 24 (inclusive)
NCT05307692,Phase 2,Alzheimer Disease,"Janssen Research &amp; Development, LLC",unknown,Alzheimer Disease, Participant meets the criteria of a syndrome diagnosis of agitation based on International Psychogeriatric Association (IPA) consensus clinical and research definition of agitation in cognitive disorders for at least 2 weeks before screening
NCT05307692,Phase 2,Alzheimer Disease,"Janssen Research &amp; Development, LLC",unknown,Alzheimer Disease, Participant meets the criteria of Neuropsychiatric Inventory (NPI-12) Agitation/Aggression (A/A) domain score greater than = 4 with frequency score greater than = 2 at screening and baseline with no more than 35 percent (%) of improvement in NPI-12 A/A domain score from the screening to baseline assessments
NCT05307692,Phase 2,Alzheimer Disease,"Janssen Research &amp; Development, LLC",unknown,Alzheimer Disease, Female participants must be postmenopausal before study entry (amenorrhea for at least 12 months)
NCT05307692,Phase 2,Alzheimer Disease,"Janssen Research &amp; Development, LLC",unknown,Alzheimer Disease, Body Mass Index (BMI) within the range 18-40 kilograms per square meter (kg/m^2) (inclusive)
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone,"Age 55-80 years (both inclusive), male or female."
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone,Body mass index between 18.5 to 30.0 kg/m2 (both inclusive).
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone,Should meet the criteria for early clinical stage Alzheimer's Disease (AD) according to the National Institute on Aging and Alzheimer's Association (NIA-AA) criteria research framework:
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone,"Gradual and progressive change in memory function reported by patient or informant over more than 6 months,"
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone,"Clinical syndrome of Mild Cognitive Impairment (MCI) due to AD or mild AD dementia,"
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone,"An Mini-Mental State Exam (MMSE) score  20 at screening,"
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone,Biomarker classification according to the Amyloid/Tau/Neurodegeneration (ATN) as A+T+N+ or A+T+N- based upon:
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone," (i) Cerebrospinal fluid (CSF) profile consistent with AD (an A42 concentration of less than 1000 pg/mL AND phosphorylated tau (p-tau) greater than 19 pg/mL, or a ratio of p-tau/A42 of 0.020) taken during the screening period prior to the day of the first dose of study medication, or"
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone," (ii) Documented evidence of a CSF profile consistent with AD obtained with the previous 12 months, or"
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone, (iii) Documented amyloid positron emission tomography (PET) scan evidence acquired within the previous 12 months.
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone,"A reliable and competent trial partner/caregiver who can assist and witness dosing and is willing to accompany the patient to all visits. The trial partner/caregiver should understand the nature of the trial and adhere to trial requirements (e.g., visit schedules, evaluations) and confirm this by co-signing the informed consent of the patient or signing of a separate informed consent of the partner/caregiver according to the local requirements."
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone,"If a patient is taking medication, supplements or vitamins, the dose must be stable for at least the last 3 months before screening, and the patient must be willing to remain on the same dose for the duration of the trial."
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone,"A male patient abstains from sexual intercourse, or is vasectomized (greater than  6 months), or will use a condom with spermicide during sexual intercourse during the trial and for three months after participation in the trial and will abstain from sperm donation during the trial and for three months after participation in the trial."
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone,A female patient should not be of reproductive potential:
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone, A female patient who is not of reproductive potential is defined as one who:
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone,"Has reached natural menopause (defined as 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone [FSH] levels in the postmenopausal range as determined by the local laboratory, or 12 months of spontaneous amenorrhea);"
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone,Is 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy; or
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone,"Has undergone bilateral tubal ligation. Spontaneous amenorrhea does not include cases for which there is an underlying disease that causes amenorrhea (e.g., anorexia nervosa)."
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone,Capable of providing informed consent and complying with trial procedures.
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,"Have a study partner/caregiver who, in the Investigator's judgment, has frequent and sufficient face-to-face contact with the participant (approximately 10 hours per week or more) and consents to attend all study visits, assist in ensuring compliance with all study requirements and procedures, and provide input into assessments of cognitive performance and functioning in daily activities throughout the full duration of the participant's involvement in the study."
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,Signed informed consent from:
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,The participant or person responsible/guardian
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,The participant's study partner/caregiver
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,"Men and women, 50 to 85 years (inclusive) of age."
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,"Gradual and progressive change in cognitive performance has been observed for  6 months not associated with a specific event or medical condition e.g., head trauma, stroke, cardiac arrest, cerebrovascular disease, epilepsy, alcohol abuse, etc."
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,Capable of completing study assessments either alone or with assistance from the study partner.
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,Mini-mental status examination (MMSE) score  16 and  27 at screening.
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,Modified Hachinski Score  4 at screening.
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,Body Mass Index (BMI) between 20 kg/m2 and 32 kg/m2 (inclusive)
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,"Clinical Dementia Rating (CDR) global score of 0.5, 1.0, or 2.0 at screening."
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,Clinical Dementia Rating - Sum of Boxes (CDR-SB) score  0.5 at screening.
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,"Documentation of results for either CSF A42, CSF A42/A40 ratio, or brain imaging with PET (amyloid or tau) that was consistent with a diagnosis of AD within 12 months of screening."
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,Stable doses of all concomitant medications for at least 30 days prior to the baseline visit.
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,"For participants taking cholinesterase inhibitors and/or memantine, documentation of stable use for at least 12 weeks is required prior to screening."
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,Negative serum beta-human chorionic gonadotropin (-hCG) pregnancy result at the screening visit for female participants of childbearing potential.
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,Willingness to comply with sexual abstinence or contraception guidelines of this study.
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,"Willingness and ability to complete all study procedures, including brain magnetic resonance imaging (MRI), lumbar puncture, clinical genotyping, and brain positron emission tomography (PET)."
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,Participant and study partner/caregiver must be fluent in the English language for both reading and speaking.
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,Participant and study partner/caregiver must be fully vaccinated as per local regulations for COVID-19 at least 2 weeks prior to screening.
NCT05336695,Phase 1/Phase 2,Dementia of Alzheimer Type,Massachusetts General Hospital,unknown,Alzheimer Disease;Dementia, Age between 55 and 90 years
NCT05336695,Phase 1/Phase 2,Dementia of Alzheimer Type,Massachusetts General Hospital,unknown,Alzheimer Disease;Dementia, Ability to provide informed consent
NCT05336695,Phase 1/Phase 2,Dementia of Alzheimer Type,Massachusetts General Hospital,unknown,Alzheimer Disease;Dementia, Specific to healthy volunteers: no history of ADRD
NCT05336695,Phase 1/Phase 2,Dementia of Alzheimer Type,Massachusetts General Hospital,unknown,Alzheimer Disease;Dementia," Specific to ADRD subjects: clinical diagnosis of AD - either amnestic or atypical, clinical severity ranging from MCI to moderate dementia (CDR 0.5-2.0), MMSE score greater than or equal to 15 and/or MOCA greater than or equal to 12"
NCT05336695,Phase 1/Phase 2,Dementia of Alzheimer Type,Massachusetts General Hospital,unknown,Alzheimer Disease;Dementia, Specific to BAnD subjects: referred through the Brain Aging and Dementia (BAnD) research registry
NCT05345509,Phase 1/Phase 2,Alzheimer Disease,"Inventage Lab., Inc.",unknown,Alzheimer Disease;Donepezil," Healthy male or female, 18 and 55 years of age, non-smokers or occasional smokers (defined as smoking less than 10 cigarettes or nicotine equivalent per week, and willing to abstain from smoking during confinement at the study site)."
NCT05345509,Phase 1/Phase 2,Alzheimer Disease,"Inventage Lab., Inc.",unknown,Alzheimer Disease;Donepezil, Body mass index (BMI) 18.0 and 32.0 kg/m2 and body weight 55.0 kg for males and 50.0 kg for females.
NCT05345509,Phase 1/Phase 2,Alzheimer Disease,"Inventage Lab., Inc.",unknown,Alzheimer Disease;Donepezil, Male subjects who are sexually active with a same-sex partner must be willing to use a condom until study exit.
NCT05345509,Phase 1/Phase 2,Alzheimer Disease,"Inventage Lab., Inc.",unknown,Alzheimer Disease;Donepezil, Male and female subjects who practice abstinence from sexual intercourse as a usual and preferred lifestyle.
NCT05345509,Phase 1/Phase 2,Alzheimer Disease,"Inventage Lab., Inc.",unknown,Alzheimer Disease;Donepezil," Willing to abstain from use of non-steroidal anti-inflammatory drugs (NSAIDs) including ibuprofen, naproxen, aspirin, meloxicam, etc. from screening until study exit."
NCT05345509,Phase 1/Phase 2,Alzheimer Disease,"Inventage Lab., Inc.",unknown,Alzheimer Disease;Donepezil, Willing and able to provide written informed consent after the nature of the study has been explained and prior to the commencement of any protocol specific study procedures.
NCT05363293,Phase 1/Phase 2,Alzheimer's Disease,"Alzamend Neuro, Inc.",unknown,Alzheimer Disease, Availability of medical history to provide information about the cognitive and functional level of the participant and of a qualified source such as the caregiver willing and able to provide information about the cognitive and functional level of the participant
NCT05363293,Phase 1/Phase 2,Alzheimer's Disease,"Alzamend Neuro, Inc.",unknown,Alzheimer Disease, Males (non-vasectomized and vasectomized) must agree to use barrier contraception during the study until after Study Day 42
NCT05363293,Phase 1/Phase 2,Alzheimer's Disease,"Alzamend Neuro, Inc.",unknown,Alzheimer Disease, Females must meet criteria if childbearing for contraception or be non-childbearing
NCT05363293,Phase 1/Phase 2,Alzheimer's Disease,"Alzamend Neuro, Inc.",unknown,Alzheimer Disease, Clinical diagnosis of dementia (neurocognitive disorder) by a qualified clinician based on the DSM-V criteria:
NCT05363293,Phase 1/Phase 2,Alzheimer's Disease,"Alzamend Neuro, Inc.",unknown,Alzheimer Disease," Considered AD Stage 2, 3, or 4 based on the FDA classification"
NCT05363293,Phase 1/Phase 2,Alzheimer's Disease,"Alzamend Neuro, Inc.",unknown,Alzheimer Disease," Mini-Mental State Examination (MMSE) score between 16 and 26, inclusive, at Screening"
NCT05363293,Phase 1/Phase 2,Alzheimer's Disease,"Alzamend Neuro, Inc.",unknown,Alzheimer Disease, Patient's health is judged adequate to participate in this clinical study by the Investigator
NCT05393388,Phase 3,Alzheimer Disease,University of Pennsylvania,unknown,Alzheimer Disease;Cognitive Dysfunction,Males and females African Americans  65 years of age.
NCT05393388,Phase 3,Alzheimer Disease,University of Pennsylvania,unknown,Alzheimer Disease;Cognitive Dysfunction,"Part of the ABCD2 longitudinal cohort, protocol 844047, of the PMC/ADCC with consensus conference designation of normal cognition."
NCT05393388,Phase 3,Alzheimer Disease,University of Pennsylvania,unknown,Alzheimer Disease;Cognitive Dysfunction,ABCD2 longitudinal visit must be completed or scheduled to be completed within 180 days prior to the 18F-Flortaucipir TAU PET scan.
NCT05393388,Phase 3,Alzheimer Disease,University of Pennsylvania,unknown,Alzheimer Disease;Cognitive Dysfunction,"A brain MRI must be performed within 180 days prior to their study 18F-Flortaucipir TAU PET scan date and be deemed of adequate quality that the scan may be used for study analysis, including 3T high-resolution imaging of medial temporal lobe structures."
NCT05393388,Phase 3,Alzheimer Disease,University of Pennsylvania,unknown,Alzheimer Disease;Cognitive Dysfunction,An amyloid PET scan completed or scheduled within 180 days of their study 18F-Flortaucipir scan date.
NCT05393388,Phase 3,Alzheimer Disease,University of Pennsylvania,unknown,Alzheimer Disease;Cognitive Dysfunction,Women must be post-menopausal or surgically sterile.
NCT05397639,Phase 3,Alzheimer's Type Dementia,Suven Life Sciences Limited,unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;1-((2-bromophenyl)sulfonyl)-5-methoxy-3-((4-methyl-1-piperazinyl)methyl)-1H-indole dimesylate monohydrate, Has a diagnosis of dementia of the Alzheimer's type according to the National Institute on Aging-Alzheimer's Association (NIA-AA) criteria.
NCT05397639,Phase 3,Alzheimer's Type Dementia,Suven Life Sciences Limited,unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;1-((2-bromophenyl)sulfonyl)-5-methoxy-3-((4-methyl-1-piperazinyl)methyl)-1H-indole dimesylate monohydrate, Has confirmed agitation using the IPA Consensus Provisional Definition of Agitation in Cognitive Disorders.
NCT05397639,Phase 3,Alzheimer's Type Dementia,Suven Life Sciences Limited,unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;1-((2-bromophenyl)sulfonyl)-5-methoxy-3-((4-methyl-1-piperazinyl)methyl)-1H-indole dimesylate monohydrate, Has a score between 8 and 24 (both inclusive) on Mini-Mental State Examination (MMSE).
NCT05413655,Phase 2,Alzheimer Disease,Excelsior,unknown,Alzheimer Disease, Aged 50-80 years.
NCT05413655,Phase 2,Alzheimer Disease,Excelsior,unknown,Alzheimer Disease," Clinical diagnosis of probable mild Alzheimer disease dementia based on National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA criteria, 2011)"
NCT05413655,Phase 2,Alzheimer Disease,Excelsior,unknown,Alzheimer Disease, Last time (which must be within 3 months ) of Mini Mental State Exam (MMSE) between 10-26.
NCT05413655,Phase 2,Alzheimer Disease,Excelsior,unknown,Alzheimer Disease, Last time (which must be within 3 months) of Clinical Dementia Rating (CDR) score of
NCT05413655,Phase 2,Alzheimer Disease,Excelsior,unknown,Alzheimer Disease," Physically healthy and all laboratory assessments (including hematology, chemistry, urinalysis and electrocardiograph) are within normal range or meet the following criteria:"
NCT05413655,Phase 2,Alzheimer Disease,Excelsior,unknown,Alzheimer Disease," AST, ALT level  upper limit of normal"
NCT05413655,Phase 2,Alzheimer Disease,Excelsior,unknown,Alzheimer Disease, Creatine Kinase (CK) concentration more than 3 times upper limit of normal
NCT05413655,Phase 2,Alzheimer Disease,Excelsior,unknown,Alzheimer Disease, Serum creatinine level  upper limit of normal
NCT05413655,Phase 2,Alzheimer Disease,Excelsior,unknown,Alzheimer Disease, HbA1c more than 8.0
NCT05413655,Phase 2,Alzheimer Disease,Excelsior,unknown,Alzheimer Disease," Complaints of subjective memory impairment and cognitive disturbances by patients themselves or caregivers, including memory loss and at least one of the following cognitive disturbances: language, perceptual skills, attention, constructive abilities, orientation, problem solving, functional abilities."
NCT05413655,Phase 2,Alzheimer Disease,Excelsior,unknown,Alzheimer Disease, Cognitive deficits caused impairment in social or occupational function.
NCT05413655,Phase 2,Alzheimer Disease,Excelsior,unknown,Alzheimer Disease, Disease progression with gradual and continued decline from a previous level of functioning.
NCT05413655,Phase 2,Alzheimer Disease,Excelsior,unknown,Alzheimer Disease," Female subjects must be of non-childbearing potential (greater than 1 year without menstrual period in the absence of hormone replacement therapy) or surgically sterile. If pre-menopausal or menopausal for 1 year or less, must have a negative pregnancy test and must not be lactating at screening visit. Female subjects of childbearing potential and who are sexually active are required to practice adequate methods of birth control. Male subjects who are sexually active will also be required to use an adequate form of birth control."
NCT05413655,Phase 2,Alzheimer Disease,Excelsior,unknown,Alzheimer Disease, Has sufficient education equivalent to elementary education to communicate effectively and were capable of completing the assessments of the study.
NCT05423522,Phase 2,Alzheimer's Disease,Medesis Pharma SA,unknown,Alzheimer Disease, Male and female patients between 50 and 90 years inclusive;
NCT05423522,Phase 2,Alzheimer's Disease,Medesis Pharma SA,unknown,Alzheimer Disease, Sufficient clinical and paraclinical information for the diagnosis of AD according to the international diagnosis criteria from McKhann G. M. et al. 2011;
NCT05423522,Phase 2,Alzheimer's Disease,Medesis Pharma SA,unknown,Alzheimer Disease, Patient presents clinically significant behavioral and psychological symptoms of dementia (BPSD) requiring medication in the opinion of the study physician;
NCT05423522,Phase 2,Alzheimer's Disease,Medesis Pharma SA,unknown,Alzheimer Disease, Mild to-severe AD with a Minimal Mental State Examination (MMSE) score from 10 to 26 included;
NCT05423522,Phase 2,Alzheimer's Disease,Medesis Pharma SA,unknown,Alzheimer Disease," Symptomatic treatments of AD (acetylcholinesterase inhibitors and memantine) and psychotics drugs (benzodiazepines, antidepressants, anxiolytics, neuroleptics) are allowed but need to be maintained during at least 4 weeks before inclusion and during the follow-up;"
NCT05423522,Phase 2,Alzheimer's Disease,Medesis Pharma SA,unknown,Alzheimer Disease, Female patient of childbearing potential must be willing to use an efficient birth control method during the study and until 5 days after the end of the treatment.
NCT05423522,Phase 2,Alzheimer's Disease,Medesis Pharma SA,unknown,Alzheimer Disease," A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state ( 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus, tubal ligation)."
NCT05423522,Phase 2,Alzheimer's Disease,Medesis Pharma SA,unknown,Alzheimer Disease," The following are acceptable contraceptive methods: - Established use of oral, injected, or implanted hormonal methods of contraception - Intrauterine system or placement of an intrauterine device - Double barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam, gel, film, cream, or suppository True abstinence [periodic abstinence (e.g., calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception]"
NCT05423522,Phase 2,Alzheimer's Disease,Medesis Pharma SA,unknown,Alzheimer Disease, Male patient must be willing to use male contraception (condom) during the study;
NCT05423522,Phase 2,Alzheimer's Disease,Medesis Pharma SA,unknown,Alzheimer Disease," Patient must have availability of a person ( study partner  or caregiver) who has frequent and sufficient contact with the patient, can provide accurate information regarding the patient's behavior, cognitive, and functional abilities as well as his/her health throughout the study, and agrees to provide information at investigational site visits;"
NCT05423522,Phase 2,Alzheimer's Disease,Medesis Pharma SA,unknown,Alzheimer Disease," Patient is willing and able to give informed consent. If the study patient is not competent, a legally authorized representative must provide informed consent on his/her behalf, and the patient must provide assent;"
NCT05423522,Phase 2,Alzheimer's Disease,Medesis Pharma SA,unknown,Alzheimer Disease, Patient affiliated to French social security;
NCT05423522,Phase 2,Alzheimer's Disease,Medesis Pharma SA,unknown,Alzheimer Disease," Patient is willing to and can comply with the study protocol requirements, in the opinion of the investigator."
NCT05463731,Phase 3,Alzheimer's Disease,Eli Lilly and Company,unknown,Alzheimer Disease, Gradual and progressive change in cognitive function 6 months prior to screening.
NCT05463731,Phase 3,Alzheimer's Disease,Eli Lilly and Company,unknown,Alzheimer Disease, A Mini-Mental (MMSE) score of 20 to 28 (inclusive) at screening.
NCT05463731,Phase 3,Alzheimer's Disease,Eli Lilly and Company,unknown,Alzheimer Disease, Has a P-tau result consistent with the presence of amyloid pathology.
NCT05463731,Phase 3,Alzheimer's Disease,Eli Lilly and Company,unknown,Alzheimer Disease, Has an amyloid PET scan result consistent with the presence of brain amyloid pathology.
NCT05463731,Phase 3,Alzheimer's Disease,Eli Lilly and Company,unknown,Alzheimer Disease, Have a reliable study partner who will provide written informed consent to participate and is in frequent contact with the participant.
NCT05463731,Phase 3,Alzheimer's Disease,Eli Lilly and Company,unknown,Alzheimer Disease," Have adequate literacy, vision, and hearing for the neuropsychological testing in the opinion of the investigator at the time of screening."
NCT05463731,Phase 3,Alzheimer's Disease,Eli Lilly and Company,unknown,Alzheimer Disease, Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.
NCT05463731,Phase 3,Alzheimer's Disease,Eli Lilly and Company,unknown,Alzheimer Disease, Males and females will be eligible for this study.
NCT05463731,Phase 3,Alzheimer's Disease,Eli Lilly and Company,unknown,Alzheimer Disease, Women not of childbearing potential (WNOCBP) may participate in this trial.
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2, Patients aged greater than  18
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2, Age of disease onset less than  70 years
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2, Clinical and biological diagnosis of AD based on
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2, Progressive amnestic syndrome associated or not with other cognitive impairments
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2, Biological criteria: CSF biomarkers suggestive of AD.
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2," Brain MRI congruent with the diagnosis, left to the appreciation of the investigator"
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2, CDR (Clinical Dementia Rating Scale) = 0.5 or 1
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2," If patients have an antidepressant or acetylcholinesterase inhibitors treatment, patients must be treated with stable doses of treatment for at least 3 months before inclusion."
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2," Have a caregiver who provides a separate written informed consent to participate. If a caregiver/study informant cannot continue, one replacement is allowed."
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2, Have adequate vision and hearing for neuropsychological testing in the opinion of the investigator.
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2, Have given written informed consent approved by the ethical review board (ERB) governing the site.
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2, The patient has to have a French social security number and be fluent and literate in French.